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ABSTRACT 
 
Aim:  To explore potential methods of increasing cervical screening coverage.  
 
Methods: Cervical screening defaulters in Dumfries and Galloway were identified in 2012, split 
into a control (N=64) and 7 intervention groups who were offered multiple screening options 
including self-collecting a vaginal sample at home. Self-samples were tested for high-risk 
human papillomavirus (HPV). A total of 3323 were invited to request a kit and 492 were sent a 
kit directly. Women who declined screening were asked to complete a questionnaire. 
Colposcopy referrals from defaulters were audited to identify changes over time. Defaulters 
attending the hospital smear clinic were questioned to ascertain barriers to cervical screening.  
 
Results: Among seven intervention groups the proportion responding varied between 32% 
(25%-38%) and 14% (11%-17%) compared to 6% among controls. One hundred and thirty 
women were HPV positive on self-sample, 8 of whom had CIN2+ diagnosed. A significantly 
higher number of defaulters were referred to colposcopy in June-December 2012 (n=51) than in 
the same period in 2011 (n=17; OR=3.8, 2.1-6.9). Defaulting was more commonly attributed to 
practical (112/155=72%) than attitudinal barriers (23/115=15%) (RR=4.9, 3.3-8.0). 
 
Conclusions: Practical barriers are often the cause of women not attending for cervical 
screening and offering more options, particularly the option of self-sampling at home, increases 
screening coverage.  
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1.1. INTRODUCTION 
 
Cervical cancer prevention 
Each year in the UK about 2800 women are diagnosed with cervical cancer and 1000 die from 
the disease (Aapro, Fabi et al. 2010; NHSCSP 2011). Most women who develop cancer have 
not been screened regularly. According to a national audit in England (NHSCSP 2011), the 
majority (1345/1896=71%) of cervical cancer cases diagnosed in younger (<50 year old) women 
were those who hadn’t had a screening test in the previous three and a half years. The three 
and a half yearly screening coverage in the 25-49 year group in England had been between 
69% and 74% during this period (NHSCSP 2012). National audit reports from other countries 
also revealed that most women who developed cervical cancer were overdue for screening 
(Bergstrom, Sparen et al. 1999; Bos, Rebolj et al. 2006; Andrae, Kemetli et al. 2008). In high-
income countries, more than half of the women who were diagnosed with cervical cancer had 
never had a Pap test or were infrequently screened (van der Graaf, Zielhuis et al. 1988; 
National Institutes of Health 1996; Sasieni, Cuzick et al. 1996; Bekkers, Massuger et al. 2004; 
Bekkers, Meijer et al. 2006; Ingemann-Hansen, Lidang et al. 2008). 
 
Although routine cervical screening represents an effective tool in the early detection of cervical 
cancer, it remains underused by some women. A declining trend seen in the Scottish cervical 
smear uptake rate from 81% in 2003 to 71% in 2013 (ISD Scotland 2013), appears alarming.  
 
Fig 1.1.1 Trends seen in Scotland’s cervical screening coverage (ISD Scotland 2013) 
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More worryingly, the cervical cancer mortality rate in the UK has remained static at around 1000 
per year since 2006 (Fig 1.1.2). These trends are unlikely to improve unless different strategies 
are adopted (Giorgi Rossi, Marsili et al. 2011).  
 
Fig 1.1.2 Cervical cancer mortality rate in UK (per 100,000) (CRUK 2014) 
 
Cervical cancer is potentially one of the most preventable cancers (IARC 2005). The benefits of 
cervical screening are conferred on those who are actually screened. Despite the known value 
of cervical screening, a significant number of women do not avail themselves of the procedure 
(Anttila, Ronco et al. 2004). 
 
Potential ways of reducing cervical cancer mortality 
Whilst cervical cancer is the third most common cancer diagnosed in women in the world, it is 
ranked number 12 in the UK (Fig 1.1.3.a). Although cervical cancer is the fourth most common 
cause of cancer deaths in women in the world, it is ranked number 16 in the UK (Fig 1.1.3.b). 
 
 
 
17 
 
Fig 1.1.3: (a) The ten most commonly diagnosed cancers (b) The ten most common cancer 
deaths in females worldwide 2008 [with comparison to UK 2008] (Cancer Research UK 1 2013) 
  
 
 
This mortality difference is mainly due to the rapid decline in the incidence of cervical cancer 
seen over the past 3 decades. However, the cervical cancer mortality rate in the UK remained 
static around 1000 deaths per year from 2006 to 2011 (Fig 1.1.2). A similar trend is seen in the 
incidence of cervical cancer over a decade (Fig 1.1.4). Hopefully, the HPV vaccination which 
began in 2008 will ameliorate this situation in the future.  
 
Fig 1.1.4: European age-standardised incidence rates per 100,000 population, females, Great 
Britain. (Cancer Research UK 2014) 
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Although relatively low numbers of new cervical cancer cases (802/3107=26%) are diagnosed 
after the age of 60 years (Fig 1.1.5 and Table 1.1.1), the majority of deaths (545/956=57%) 
occurred in this age group (Fig 1.1.6 and Table 1.1.1). The high mortality to incidence ratio 68% 
(545/802) reflects the poor prognosis owing to the advanced stage at disease presentation. 
Cervical screening currently stops at the age of 58-64 in the UK.  
 
Fig 1.1.5: Average number of new cases per year [and age-specific incidence rates per 100,000 
population, females, UK] (Cancer Research UK 2014) 
 
Fig 1.1.6: Average number of deaths per year [and age-specific mortality rates per 100,000 
population, females, UK] (Cancer Research UK 2014) 
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Table 1.1.1: Average number of new cases per year [and age-specific incidence rates per 
100,000 population, females, UK] and average number of deaths* per year [and age-specific 
mortality rates** per 100,000 population, females, UK]  (Cancer Research UK 1 2013) 
 
 
About half of cervical cancer deaths in the recent past in the UK occurred after the screening 
has stopped. It is very unlikely that women after the age of 60 years have acquired new HPV 
infections. However, virtually all of these cancers were caused by persistent HPV infection. 
Therefore, it seems vital to recognise women with persistent cervical/genital HPV infection, 
before women ‘retire’ from cervical screening, in order to reduce this high number of cervical 
cancer deaths in the elderly.   
 
Barriers to get screened 
Evidence suggests that practical issues such as difficulty gaining access to a female smear 
taker, communication barriers, inaccessible locations, unfavourable appointment times, physical 
disability, previous bad experience, work and family commitments affected women’s decision 
making more than attitudinal barriers (Waller, Bartoszek et al. 2009). Offering more flexible and 
convenient cervical screening options such as self-collection for Human Papillomavirus (HPV) 
testing might increase the screening coverage (Bais, van Kemenade et al. 2007; Giorgi Rossi, 
Marsili et al. 2011; Virtanen, Anttila et al. 2011).  
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Anatomy of the cervix 
The uterine cervix is also called the neck of the womb. It is the part of the female genitalia 
between the uterine body (corpus) and the vagina (Fig 1.1.7). Cylindrical in shape, the cervix 
consists of two major parts: the ectocervix and the endocervix. The ectocervix is dome shape 
when seen through the vagina. The endocervix is the middle canal-like portion which opens into 
the uterus though the internal os. The size, shape and the colour of the cervix depend on a 
woman’s age, hormonal state and whether or not she has given birth. A non-pregnant cervix is 
smooth, firm in consistency, pink in colour, cylindrical in shape and measures approximately 2-
3cm in diameter and 3-4cm in length. 
 
Fig 1.1.7: Female reproductive organs  
 
Figure courtesy of Dellaesque Photography, London 
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Cervical neoplasia 
Cancer affecting the cervix is one of the most common female cancers. It is the second most 
common female cancer in women in developing countries (International Agency for Research 
on Cancer (IARC) 2004). Cervical cancer is estimated to cause one death every two minutes 
worldwide. Virtually all (>99%) cervical cancer is caused by the persistent Human 
Papillomavirus (HPV) infection (Walboomers, Jacobs et al. 1999; Cogliano, Baan et al. 2005). 
The viral oncogenic process is well understood (zur Hausen 1991; Bosch, Manos et al. 1995). 
Whilst most cervical cancers are squamous carcinomas, about 20% are adenocarcinomas 
(NHSCSP 2011).  Whilst squamous carcinomas are known to originate from the squamous 
epithelium which is the lining of the ectocervix, adenocarcinomas originate from the columnar 
epithelium, which is the lining of the endocervical canal.  
 
Fig 1.1.8: Cervical squamo-columnar junction and transformation zone  
 
Figure courtesy of Merck & Co., Inc.  
 
Hallmark of screening  
The anatomical junction between the endocervical columnar epithelium and the ectocervical 
squamous epithelium is called the squamo-columnar junction (SCJ, Fig 1.1.8), where these two 
epithelia merge. Anatomical location of the SCJ on the cervix changes over the course of 
reproductive life of a woman, as the cervix has to adapt to various unique functions such as 
acting as the gateway for the sperm to enter the womb and acting as a barrier to 
microorganisms.  The zone between the original SCJ and the new SCJ is called the 
transformation zone (TZ). Cells of the new SCJ are most susceptible for HPV induced neoplasia 
(cancer and pre-cancer).  The transformation zone is the most vulnerable area of the cervix for 
developing cervical cancer. Therefore, colposcopy examination of the SCJ and the TZ remains 
the mainstay of making a clinical diagnosis of cervical neoplasia. This allows the colposcopist to 
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obtain directed biopsies from target lesions which enable the making of a definitive histological 
diagnosis. Similarly, proper sampling of SCJ and the TZ is essential for a cervical smear 
(cytology) test, but it is not essential when screening for HPV infection alone. However, isolation 
of HPV in a cervical sample would be a better surrogate marker of disease presence. If HPV 
screen positive women were to go through a secondary screening test (e.g. cervical cytology) 
prior to the diagnostic test (colposcopy), then proper cervical sampling would become a less 
important requirement in HPV screening.  
 
Conventional Pap smear screening 
A conventional method of cervical screening is the Pap smear test. Obtaining cervical scrapes 
with a wooden spatula to make a smear of cells on a glass slide to be examined under a light 
microscope after staining was the basis of the conventional Pap smear test. Sensitivity of 
recognising hgCIN of the Pap smear test varies, but is generally about 50%. The sensitivity of 
the Pap test of 55.4% (95% CI= 33.6-77.2; P=0.01) was significantly lower than the sensitivity of 
the HPV test of 94.6% (95% CI= 84.2 -100)) in a randomised controlled study involving over 
10,000 participants (Mayrand, Duarte-Franco et al. 2007) when a result of ASCUS, AGC or 
worse was considered positive to detect CIN2+. However, the sensitivity of the Pap test 
depends on the quality of the test which involves several steps, sampling, processing and 
interpretation. A recent study reported that the relative sensitivity of HPV testing was 3.4 times 
greater (2.4-4.9) than the conventional Pap smear for detecting hgCIN (Lazcano-Ponce, Lorincz 
et al. 2011). Poor quality Pap smears could confound this higher relative sensitivity ratio.  
 
Liquid based cytology (LBC) screening 
In the UK, the conventional Pap smear was replaced by liquid based cytology which seemingly 
has a higher sensitivity (60-65%) for detecting hgCIN, although this has never been shown in a 
controlled trial. LBC had reduced the unsatisfactory test results to 2-3% (Health and Social Care 
Information Centre 2013). The fundamental difference between the conventional Pap smear test 
and LBC is the suspension of the cytology sample in a liquid preservative medium and making a 
thin film of cells on a slide. The ratio of sensitivity and specificity for CIN2 or worse of liquid-
based relative to conventional cytology was calculated using pooled data from 9 studies (Arbyn, 
Bergeron et al. 2008). The ratio of sensitivity was 1.03 (95%CI= 0.97–1.09), p=0.002. Crude 
ratios of the odds of test positivity rates of liquid-based (n=49,222) compared with conventional 
cytology (n=40,562) for atypical squamous cells of undetermined significance or more severe 
was 0.95 (95%CI= 0.82-1.10) and the major advantage of liquid-based cytology was that it 
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resulted in fewer unsatisfactory tests (OR= 0.30, 95% CI= 0.23-0.38) (Siebers, Klinkhamer et al. 
2008).  
 
Specificity between the conventional and liquid based cytology is generally comparable and 
higher than that of the HPV testing. The specificity of the Pap test for detecting hgCIN 96.8% 
(95% CI, 96.3-97.3) was slightly higher than the specificity of the HPV test 94.1% (95% CI, 93.4-
94.8), P<0.001) in the trial that reported Pap sensitivity of 55% (Mayrand, Duarte-Franco et al. 
2007). The ratio of specificity between the HPV test and the Pap test was 0.91 (95%CI= 0.84–
0.98), p<0.001 when the cut off was atypical squamous cells of undetermined significance or 
more severe (Arbyn, Bergeron et al. 2008).  
 
The relative sensitivity of HPV screening in clinician versus self-collected samples   
Numerous reports show that more hgCIN are identified in women when primary cytological 
screening is replaced by primary high-risk Human Papillomavirus (hrHPV) testing in cervical 
samples (Wright, Schiffman et al. 2004; Meijer, Berkhof et al. 2009; Anttila, Kotaniemi-Talonen 
et al. 2010; Ronco, Giorgi-Rossi et al. 2010). Sensitivities of detecting hgCIN between the HPV 
screening in self collected vaginal samples and standard liquid based cytology (LBC) are 
comparable (Lazcano-Ponce, Lorincz et al. 2011; Rijkaart, Berkhof et al. 2012). HPV screening 
in vaginal samples has a better sensitivity for the detection of high grade cervical intra-epithelial 
neoplasia or worse (CIN 2+), than the conventional Pap smear test (Lazcano-Ponce, Lorincz et 
al. 2011). A recent randomized trial in Mexican women of low socioeconomic status (Lazcano-
Ponce, Lorincz et al. 2011) demonstrated self-sampling for HPV to be 3.4 times more sensitive 
than the conventional Pap smear test in detecting CIN2+. Hence, self-sampling for HPV testing 
appears to be more sensitive than the LBC for detecting high-grade CIN.  
 
There is a high level of concordance between the clinician and self-collected samples for 
cervical HPV detection (Brink, Meijer et al. 2006). A meta-analysis of pooled data demonstrated 
concordance of 87% (0.82-0.91) with kappa 0.66 (0.56-0.76) between the clinician and self-
collected samples for HPV detection (Petignat, Faltin et al. 2007). 
 
Strategies that could increase the specificity of cervical screening 
Secondary screening strategies such as genotyping for high-risk HPV types (Franceschi, Cuzick 
et al. 2009), short-interval repeat HPV testing (Gyllensten, Sanner et al. 2011), p16 testing 
(Samarawardana, Dehn et al. 2010; Jentschke, Lange et al. 2013), p16/Ki-67 double-staining 
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(Yoshida, Sano et al. 2011), DNA methylation techniques (Sun, Reimers et al. 2011; 
Snellenberg, De Strooper et al. 2012; Wentzensen, Sun et al. 2012; Lorincz, Brentnall et al. 
2013; Mirabello, Schiffman et al. 2013), VIA (Sankaranarayanan, Esmy et al. 2007), LBC 
(Rijkaart, Berkhof et al. 2012; Rijkaart, Berkhof et al. 2012) and HPV mRNA detection (Rijkaart, 
Heideman et al. 2012; Chambers, Millan et al. 2013) were used in conjunction to increase the 
specificity of cervical samples.  
 
Triaging self-collected HPV positive women to colposcopy  
It is possible to apply some of these triaging methods to self-collected vaginal samples 
(Yoshida, Sano et al. 2011) (Jentschke, Lange et al. 2013). Reflex cytology of HPV positive is 
possible for cervical samples, but it is not an appropriate option for self-collected specimens. 
Among women older than 35 years, primary HPV DNA screening with cytology triage was more 
specific than conventional screening (Leinonen, Nieminen et al. 2009). Triaging high risk HPV-
positive women with cytology, followed by repeat cytology testing yielded a high NPV and 
modest colposcopy referral rate and appeared to be the most feasible management strategy out 
of 14 different triaging strategies evaluated (Rijkaart, Berkhof et al. 2012). The specificity can be 
increased by the cytology triage of cervical samples (Gok, Heideman et al. 2010). A vast 
majority (684/757= 90%) of women who were screened positive for HPV self-testing studies 
attended subsequent follow-up (Gok, Heideman et al. 2010). 
 
The principles of triaging vaginal HPV positives are similar to that of the cervical HPV positives, 
as long as the sample used to triage is a cervical sample. The main aim of triaging HPV 
positives is to increase the specificity of the screening test. It is important to pick up a good 
positive surrogate marker of cervical disease as the triaging method. The most reliable method 
would be to test a cervical sample, aiming to identify one or more surrogate markers of cervical 
neoplasia.. A vast majority of vaginal HPV positives attended for a cervical smear in many 
reported studies. In a large community-based self-sampling study conducted in The Netherlands 
(Gok, Heideman et al. 2010), 27% out of 27,792 women who did not go for their routine smears, 
self-obtained a vaginal specimen for HPV testing, at home. Ninety percent (684/757) of HPV 
positive women attended subsequent smear test. Similar HPV+ follow-up smear uptake was 
reported from the same study group in another large scale, population based study in The 
Netherlands which recruited 26,409 defaulters(Gok, van Kemenade et al. 2012).  All HPV 
positives 8/8 (100%) had a smear test in the Szarewski 2011 study (Szarewski, Cadman et al. 
2011). A lower proportion 7/10 (70%) of HPV positives had a smear in the Darlin 2013 study 
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(Darlin, Borgfeldt et al. 2013). It was probably the lowest in a study based in France where 
116/283= 41% came for cytology follow-up. Women who were living in the Bouches du Rhone 
area and had not had a Pap test in the previous 2 years who did not respond to the first 
invitation were the target population of this study. A shorter screening interval may have 
contributed to lower attendance at the follow-up visit. Another French study (Tamalet, Le 
Retraite et al. 2013) had a follow-up rate of 43/62= 69%. In France, about 40% of women aged 
25-65 years do not participate in regular screening.  
 
 
Recognising specific molecular markers in the self-collected material is another way of 
increasing the specificity. Isolation of HPV 16 in self-collected samples could increase the 
specificity (Daponte, Pournaras et al. 2006). Molecular markers indicative of active HPV disease 
is another approach (Yoshida, Sano et al. 2011), however, poor cellularity is an important 
limitation. The feasibility of identification of cyclin-dependent kinase inhibitor 2A protein [p16 
(INK4a)] on self-collected cervico-vaginal lavage samples to improve specificity was evaluated 
in 140 women (Jentschke, Lange et al. 2013).   Whilst 27 (19%) physician-collected samples 
were p16 (INK4a) ELISA positive, only one (1%) vaginal lavage sample self-collected with the 
Delphi screener was positive. Another study comparing HPV mRNA with HPV DNA testing 
found mRNA testing to increase the specificity of vaginal self-sampling slightly (93.0% [91.8, 
94.0] vs 90.5% [89.1, 91.7]) for identical levels of sensitivities of 62.5% [35.4, 84.8] to detect 
CIN3+ (Nieves, Enerson et al. 2013).  
 
The low specificity of an HPV DNA test may lead to psychological distress, emotional distress, 
social distress, increased frequency of follow-up and most importantly, the possibility of over 
treatment (Leinonen, Nieminen et al. 2009). Specificity of HPV screening for detection of hgCIN 
is lower compared with conventional cytology (Cuzick, Clavel et al. 2006; Shi, Belinson et al. 
2009; Ronco, Giorgi-Rossi et al. 2010). The lower specificity observed in younger women may 
be explained by the high prevalence of transient HPV infections. It is suggested that women 
who  have tested positive for hrHPV but negative for cytology should have co-testing in 1 year 
intervals (Bulkmans, Berkhof et al. 2007; Naucler, Ryd et al. 2007). This strategy may reduce 
the number of colposcopy referrals (Cuzick, Arbyn et al. 2008; Franco, Mahmud et al. 2009; 
Zhao, Florea et al. 2010). 
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Acceptability of self-sampling  
The acceptability of self-sampling has been evaluated in many studies. Self-sampling has been 
generally well accepted. Acceptability rates of 75% (Jones, Wiegerinck et al. 2008), 86% 
(Safaeian, Kiddugavu et al. 2007), 88% (Nobbenhuis, Helmerhorst et al. 2002) and 93% 
(Dzuba, Diaz et al. 2002) have been reported. The majority of women found self-sampling 
devices easy to use, less embarrassing, more relaxed and more comfortable than clinician 
sampling.  Although women’s response to self-sampling was generally positive, many were 
uncertain whether they had collected an adequate sample (Nobbenhuis, Helmerhorst et al. 
2002; Barata, Mai et al. 2008). A large proportion of women from Indian and African-Caribbean 
ethnic groups living in Manchester who self-collected were concerned about doing the test 
properly (Forrest, McCaffery et al. 2004). A lack of understanding about the difference in 
principles of cytology screening and HPV screening could have played a part in this. Cultural 
and religious beliefs do not appear to have been barriers in accepting self-sampling for HPV 
screening (Howard, Lytwyn et al. 2009; Barbee, Kobetz et al. 2010). Overall, most studies 
showed that women preferred self-collection over clinician collection, suggesting that self-
sampling has the potential to increase the population coverage (Dzuba, Diaz et al. 2002; Jones, 
Wiegerinck et al. 2008). 
 
Self-sampling uptake may depend on many factors such as,  
a) overall smear coverage of the population 
b) duration since the last smear test  
c) age and attitude of the defaulter  
d) reason for defaulting  
e) method and the quality of the information provided 
f) type of self-sampling device 
g) method, the way (how much the woman like the test) and time of approach 
h) how cumbersome was the consent procedure 
i) planned method of follow-up 
j) trustworthiness of the service provider  
k) how strong is the existing evidence to convince defaulters  
l) availability of someone familiar who had experienced this (recommendation by a peer or 
family member who has done self-sampling) 
m) availability of self-sampling at a different time when circumstances had been changed as 
some defaulters may take a long time to decide and may need to be reminded 
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The potential for self-sampling to increase the screening coverage   
Offering self-sampling to screening programme defaulters is known to increase the population’s 
screening coverage. All nonparticipants in organized cervical cancer screening in 2008 in 
Espoo, Finland were randomized to receive a self-sampling kit (n=1,130) or a reminder letter 
(n=3,030) (Virtanen, Anttila et al. 2011). The screening participation rate in the self-sampling 
arm, 30%, was significantly higher than in the reminder letter arm, 26%. The screening 
coverage rose significantly after the two interventions from 64% to 75%. The same research 
group’s larger study randomized 8699 defaulters to receive either a self-sampling kit (2,397 
women) or an extra invitation (6,302 women) (Virtanen, Nieminen et al. 2011).  The adjusted 
relative risk for taking up a screening test was 1.21 (95% CI: 1.13–1.30) when self-sampling 
was offered as the second intervention in comparison to sending a cytology reminder letter. 
Total attendance increased from 65% to 76% by self-sampling and from 65% to 74% with a 
reminder letter. Combining the interventions (a reminder letter and then self-sampling) 
increased total attendance from 63% to 78%.  
 
The evidence supporting clinical applications of self-sampling  
Offering self-sampling has been shown to be superior to a routine recall invitation for LBC in re-
attracting defaulters into the screening program in developed countries (Virtanen, Anttila et al. 
2011). Additionally, self-testing has been shown to facilitate access to cervical screening for 
women in low resource areas (Lazcano-Ponce, Lorincz et al. 2011) (Belinson, Du et al. 2011) 
(Belinson, Du et al. 2012).  
 
According to a recently published review (Snijders, Verhoef et al. 2013), which included studies 
published between January 1992 and January 2012, comparing clinical accuracy of HPV testing 
on self-sampled material with that of cytology or HPV testing on clinician-taken samples, hrHPV 
testing on self-samples appeared to be at least as, if not more, sensitive for detecting CIN2+ as 
cytology on clinician collected cervical samples.  
 
According to the first published systematic review and meta-analysis to determine the accuracy 
of testing for HPV DNA in urine in detecting cervical HPV in sexually active women (Pathak, 
Dodds et al. 2014), testing urine for HPV seems to have good accuracy for the detection of 
cervical HPV. Urine detection of high risk HPV had a pooled sensitivity of 77% (68% to 84%) 
and specificity of 88% (58% to 97%). The authors concluded that when cervical HPV detection 
is considered difficult, urine testing should be regarded as an acceptable alternative. 
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LITERATURE REVIEW  
a) Search strategy  
 
Key words and Medical Subject Headings (MeSH) used:  
Human Papillomavirus, papillomavirus infections, HPV testing, HPV test*,self-
test*, self-testing, self-sample, self-sample*, self-collect*, physician-collect*, 
physician taken, clinician collect*, clinician obtained, provider-obtained, home 
testing, auto-test, vaginal smear, unscreened, under screened, non-attendance, 
non-compliance, patient compliance, patient participation, screening coverage, 
uptake rate, cervix, cervical cancer prevention, cervical screening, HPV 
screening, smear test, Pap test, liquid based cytology and cytology. Cervical 
neoplasms, uterine cervix carcinoma, cervical intraepithelial neoplasia and 
cervical carcinoma in-situ. Various combinations of search words/*stems were 
used to search titles and abstracts. Relevant author names were also searched.  
 
Databases: PubMed database was searched through EndNoteX5 software. 
Evidence published in the last 2 decades (from 1990) was focussed on. Only 
evidence published in the English language was included.  
 
Moreover, abstract books of the 2011 International Papillomavirus Conference 
held in Germany (17-22 Sep), EUROGIN 2012 (Prague 8-11 July) and EUROGIN 
2013 (Florence 3-6 Nov) were searched manually. Reports of the National 
Cervical Screening Programme were accessed manually. Research of some 
dedicated study groups and author names were also searched. References of 
relevant publications were also retrieved.  
 
Inclusion criteria: Studies in which the HPV testing has been carried out as a 
part of cervical screening or understanding the natural history of the cervical 
disease. Relevant systematic reviews and meta-analysis were also included.  
 
Exclusion criteria: Studies in which HPV testing had been carried out for 
purposes other than cervical screening, e.g. to determine the HPV prevalence in 
male partners of sexually active women or other HPV related diseases.  
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Over 600 abstracts were reviewed. Manuscripts of relevant abstracts were 
retrieved.  
 
b) Themes under which the literature review was organised  
 
1. Is self-sampling for HPV testing an effective screening strategy?  
2. Could self-sampling increase the cervical screening participation in high 
income countries?  
3. Reasons for non-participation of cervical screening programmes. 
4. Different self-sampling kits used. 
 
 
 
1.2 Is self-sampling for HPV testing an effective screening strategy?  
 
HPV screening in self collected vaginal samples 
 
Early research on self-sampling was mainly based on women attending colposcopy clinics. The 
primary aim of most of these studies was to demonstrate the concordance between the clinician 
collected and self-collected samples for HPV screening. Almost all of these studies used 
colposcopic diagnosis as the reference standard although positive lesions were confirmed by 
histology (biopsies were not taken when the cervix was colposcopically normal).  
 
In one study, the overall agreement between self-collected and clinician-collected samples was 
92%; however among HPV-positive specimens, the HPV agreement was only 39% (Harper, 
Hildesheim et al. 1999). In another, the HPV prevalence in the vagina (21%) was slightly higher 
than the cervix (18%), when a swab was used for self-collection (Bidus, Zahn et al. 2005) in 
women younger than 50 years. The prevalence was similar (10% vs 9%) in women over 50 
years old. A study was conducted to compare time of clearance of specific HPV types between 
clinician collected lavage and self-collected sampling in a cohort of 537 women (Moscicki, 
Widdice et al. 2010). Both samples were obtained every 4 months at alternate 2-month 
windows. Findings suggest that self-collected vaginal swabs reveal similar natural histories of 
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HPV compared to clinician collected lavage specimens making self-testing a feasible method for 
repeated HPV DNA detection. 
 
In a population based study which included 878 sexually active Brazilian women aged 15-69 
years (Ogilvie, Patrick et al. 2005), the hrHPV prevalence was 34% in self- collected Digene 
brush samples, compared with 29% among clinician collected samples. In 82 (9%) participants, 
the self-collected sample tested positive for HPV HC II, whereas the clinician collected sample 
tested negative. Conversely, 35 (4%) patients tested positive in clinician collected samples and 
negative in their self-collected samples (kappa=0.7). All 878 participants underwent colposcopy. 
Biopsy was taken as indicated (n=63). Of 9 cases of histologically-confirmed, high-grade 
squamous intraepithelial lesion, self-collected and clinician collected samples missed one each.  
 
Self-collected dry samples appear as good as wet sample for HPV screening (Stainier and 
Cornelis 1998; Cambronne and Schneewind 2002; Darlin, Borgfeldt et al. 2013). The FTA Elute 
cartridge, which does not require any liquid preservative transport medium (Cambronne and 
Schneewind 2002; Geraets, van Baars et al. 2013; Guan, Gravitt et al. 2013) appears to be a 
promising method of specimen transport, if cervical cancer screening programs consider using 
the use of self-collected specimen for HPV testing.  
 
Some studies correlated the clinical performance between the self-collected vaginal samples 
and clinician collected cervical cytology samples. Studies conducted by (Wright, Denny et al. 
2000; Belinson, Qiao et al. 2003) (Belinson, Qiao et al. 2001) and (Salmeron, Lazcano-Ponce et 
al. 2003) had a large number of participants (1365-8497). All 1997 women in Belinson’s 2001 
study had undergone colposcopy. The Dacron swab was used as the self-sampler except in 
Belinson’s 2003 study which used a vaginal conical (cytology) brush. This study was the only 
study which used liquid based cytology for cytology screening. The other 3 studies used 
conventional smears where the specimen was collected with a spatula. The sensitivity of the 
cytology screening arm was less than that of the HPV screening arm in all studies.  
 
However, diagnostic accuracy of HPV screening between the clinician collected samples for 
detecting high grade pre-cancer has been the focus of some researchers. The number of 
participants in most of these studies was 200 or less (Morrison, Goldberg et al. 1992; Morrison, 
Goldberg et al. 1992; Sellors, Lorincz et al. 2000; Harper, Noll et al. 2002; Nobbenhuis, 
Helmerhorst et al. 2002; Kahn, Slap et al. 2004; Brink, Meijer et al. 2006; Castle, Aftab et al. 
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2006; Daponte, Pournaras et al. 2006; Seo, Song et al. 2006; Szarewski, Cadman et al. 2007; 
Dijkstra, Heideman et al. 2012; Jentschke, Soergel et al. 2013). Some studies had 200-300 
participants (Hillemanns, Kimmig et al. 1999; Gravitt, Lacey et al. 2001; Lorenzato, Singer et al. 
2002; Garcia, Barker et al. 2003; Khanna, Mishra et al. 2007; Twu, Yen et al. 2011). All of these 
large studies used the Hybrid Capture II (HC2) for detecting high risk HPV DNA.  
 
The HC2 test was the most commonly used HPV DNA test. It was the DNA test of choice for 
cervical samples (Nieminen, Vuorma et al. 2004). It performed consistently well (Gage, 
Partridge et al. 2011; Arbyn, Roelens et al. 2013). However, the HPV detection was 17% lower 
in self collected specimen in comparison to clinician collected cervical samples when HC2 had 
been used (Belinson, Hu et al. 2010). A total of 397 out of 2,625 women tested positive for 
hrHPV with HC2 in any of 5 samples obtained. All hrHPV positive samples were also tested with 
the Linear Array (a PCR based) assay. Of 47 women with CIN 2+, HC2 was positive in 
(46/47=98%) of endocervical and (38/47=81%) of self-collected specimens. Seven out of 9 
women with CIN2+ and a negative self-collected HC2 tests were positive for hrHPV by the 
Linear Array on the self-collected sample. According to expert opinion (Arbyn, Verdoodt et al. 
2014), PCR based tests are preferred as the test of choice for self-collected samples. It would 
be interesting to know sensitivity data of self-sampling trials, if PCR based tests were used as 
the reference standard rather than signal amplification tests such as HC2 or Cervista. Self-
sampling trials which used multiple HPV tests (Belinson, Du et al. 2011) provide some 
supporting evidence for this.  
 
Based on the evidence built on the women referred to colposcopy, large scale population-based 
studies were carried out.  
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Table 1.2.1: Applied, clinical research carried out in normal screening population in low and 
medium income countries to evaluate the feasibility of self-sampling.  
Study  Country  n  
(age group)  
Self-sampling 
Device  
HPV test  
(Salmeron, Lazcano-
Ponce et al. 2003) 
Mexico 7868 
(15-85) 
Dacron swab 
(self), Conical 
brush (clinician) 
HC2 
(Qiao, Sellors et al. 
2008)  
China 2,530  
(30-54) 
QIAGEN conical 
brush 
cHPV 
(Belinson, Du et al. 
2011) 
China  2,653  
(16-54) 
QIAGEN conical 
brush 
HC2 
(Lazcano-Ponce, 
Lorincz et al. 2011) 
Mexico 22,102  
(25-65) 
Digene conical 
brush 
HC2 
(Nieves, Enerson et 
al. 2013) 
Mexico 2,049  
(30-50) 
POI/NIH 
sampler   
HC2 
AHPV 
(Sankaranarayanan, 
Nene et al. 2009) 
India 34,126  
(30-59) 
Digene conical 
brush 
HC2 
(Bhatla, Dar et al. 
2009) 
India  546 
(>30) 
Digene conical 
brush 
HC2 
(Sowjanya, Paul et 
al. 2009) 
India 432 Digene cervical 
sampler  
HC2 
PCR 
(Chang, Tseng et al. 
2002) 
Taiwan 1194 ?Dacron swab  HC2 
Abbreviations: cHPV= careHPV test; AHPV= Aptima HPV DNA test.  
 
The Digene/QIAGEN conical brush was the self-sampler used in all except 2 studies in (Table 
1.2.1). The other 2 studies used swabs. Two studies were on a much larger scale, including 
over 34,000 (Sankaranarayanan, Nene et al. 2009) and 22,000 (Lazcano-Ponce, Lorincz et al. 
2011) participants. The former study was designed to have 80% power at the 5% significance 
level to detect a 50% reduction in cumulative mortality rate from cervical cancer within 15 years 
of enrollment between one of the arms and the control group.  
 
The latter targeted a sample size of 9500 women per group (initial refusal rate of up to 25% 
predicted) providing 85% power to show a 40% difference (two-sided alpha of 0·05) between 
groups. The study was aiming to assess relative detection rates, relative sensitivity (ratio of the 
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relative detection rates), positive predictive value for CIN 1–3 and invasive cervical cancer in the 
HPV group versus the cytology group. They reported that HPV testing of self-collected samples 
had a relative sensitivity of 3·4-times greater (95% CI, 2·4–4·9) than cytology for detection of 
CIN 2 or worse; it detected 41·1 times (95% CI, 15·2–111·2) more CIN 1; 3·6 times (95% CI, 
2·2–6·0) more CIN 2; 2·4 times (95% CI, 1·1–5·1) more CIN 3; and 4·2 times (95% CI, 1·9–9·2) 
more invasive cancer than did cytology. A sample was taken from the ectocervix with an Ayre 
wooden spatula, and specimens from the endocervical canal taken with a cytobrush were 
smeared onto one slide and sent to one diagnostic reference centre in each state. Only 
38/11,054 (0.3%) Pap smears were reported positive, over 10 times lower than cervical cytology 
results in the UK (NHSCSP 2012; Health and Social Care Information Centre 2013). Whilst 4 
CIN1, 20 CIN2, 10 CIN3 and 8 cancers diagnosed had a positive cytology result, 137 CIN1, 60 
CIN2, 20 CIN3 and 28 cancers diagnosed had a positive HPV result. It appears that the poor 
sensitivity of the conventional cervical smear may have contributed to such a high relative 
sensitivity of HPV screening rather than exceptionally high quality of HPV screening methods.  
 
The HC2 test was used to test self-collected samples, except in one study which used careHPV 
(cHPV), a new test (careHPV; QIAGEN, Gaithersburg, MD, USA) developed to detect 14 hrHPV 
to screen women in developing regions. The careHPV test is broadly based on the HC2 test 
with some important differences. The assay time is 2.5 h or less, compared with up to 6 h for 
HC2. The careHPV collection medium, unlike other collection media, contains no toxic 
chaotropic salts, but rather contains non-toxic surfactants and is specifically formulated for 
absorbing cervical specimens from the collection brush without any requirement for extended 
mechanical shaking. All 2388 women were assessed by visual inspection with acetic acid (VIA), 
Digene High-Risk HPV HC2 DNA Test (HC2), liquid-based cytology (LBC), and colposcopy with 
directed biopsy and endocervical curettage as necessary(Qiao, Sellors et al. 2008). Of note, 
441 women with negative colposcopy, but unsatisfactory or abnormal cytology or who were 
positive on HC2 or the new careHPV test, were recalled for a second colposcopy, four-quadrant 
cervical biopsies, and endocervical curettage. The sensitivities and specificities for detecting 
CIN2+ (n=70) of the careHPV test were 90·0% (95% CI 83·0–97·0) and 84·2% (82·7–85·7), 
respectively, on cervical specimens, and 81·4% (72·3–90·5) and 82·4% (80·8–83·9), 
respectively, on vaginal specimens; compared with VIA 41·4% (29·9–53·0) and 94·5% (93·6–
95·4). It appears that the careHPV test is a good HPV test for low-resourced settings.  
 
34 
 
One study (Nieves, Enerson et al. 2013) used a HPV mRNA - Aptima HPV test (AHPV), 
reporting the sensitivity of LBC (>ASCUS), HC2 and AHPV for CIN3+ (n=16) in clinician 
collected sample as 88%, 100%, and 100%, respectively. The specificity of LBC (>ASCUS), 
HC2, and AHPV for CIN3+ was 94%, 92%, and 94%, respectively. The sensitivity of vaginal 
self-collected samples for CIN3+ was very low 63% (95%CI= 35.4, 84.8) in self-collected 
vaginal samples in HC2 as well as in AHPV. The specificity of vaginal samples was significantly 
higher in the AHPV test 93.0 (95%CI= 91.8, 94.0) in comparison to the HC2 test 91% (95%CI= 
89.1, 91.7). It appears that HPV mRNA testing gives a more specific result than HC2 without 
compromising its sensitivity. Sensitivity of LBC which was carried out in a center in the USA was 
higher than that of self-samples for HPV testing.  
 
HPV screening in urine samples 
 
Urine is essentially a self-collected sample. Urine sample collection is used routinely for 
molecular testing in the diagnosis of the most common sexually transmitted infection (STI), for 
example, infections with Chlamydia trachomatis (Carder, Robinson et al. 1999) and Neisseria 
gonorrhoeae. Self-sampling for STI has increased patient acceptance of STI screening tests in 
the UK, which lead to development of the national Chlamydia Screening Programme in England 
www.chlamydiascreening.nhs.uk. Similarly, a urine-based assay designed for the detection of 
HPV DNA has been utilized previously in groups at high-risk of infection, such as subjects 
infected with HIV. Willingness to access self-collected tests for STIs (85%) and HIV (87%) was 
high (Saunders, Mercer et al. 2012).  
 
Some principles of HPV screening and Chlamydia screening appear similar, as both infect the 
female genital tract, particularly the cervix in a similar way, although the treatments vary. 
Sensitivities of detecting Chlamydia by Cobas 4800 PCR method (Roche diagnostics, USA) are 
comparable between urine (Carder, Robinson et al. 1999), self-collected vaginal and clinician-
collected cervical samples, all of which are over 90% (manufacture’s literature). A urine sample 
is probably the most easily self-collected biological sample, worldwide. In a colposcopy clinic 
based study (Sellors, Lorincz et al. 2000), almost all respondents (126/128= 98%) deemed urine 
sampling acceptable, 93% (118/127) found vulvar sampling acceptable, and 88% (112/127) 
found vaginal sampling acceptable. Therefore, it is worth exploring clinical applications of HPV 
screening in urine samples in terms of preventing cervical cancer as clinician sampling or 
vaginal self-sampling may not be acceptable for some communities in the world.  
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Table 1.2.2 Studies evaluated the clinical applications of HPV screening in urine samples 
Author, year Country  Subjects, age 
(scatter) 
Amplification/ primers hrHPV DNA positive  
(Sellors, 
Lorincz et al. 
2000) 
Canada 200 women with 
abnormal cytology 
32 (SD=9) 
HC II; PCR 
consensus HPV L1 
primers and β-globins 
30% (43/142) No 
HSIL 
45% (26/58) HSIL 
(Stanczuk, 
Kay et al. 
2003) 
Zimbab
we  
43 women with 
cancer  
44 (24-70) 
Conventional nested 
PCR, degenerated 
nested primers 
72% (31/43) cancer  
(Daponte, 
Pournaras et 
al. 2006) 
Greece 77 women with 
abnormal cervical 
cytology 
PCR & commercial 
multiplex assay 
32% (25/77) overall 
45% (13/29) HSIL 
88% (8/9) cancer  
(Gupta, Arora 
et al. 2006) 
India 30 women with 
cancer & 30 healthy 
controls 42 
HPV-L1 consensus 
primer & in-house 
beta-globin primers 
27% (8/30) control 
82% (23/28) cancer   
 
(Manhart, 
Holmes et al. 
2006) 
USA 3262 sexually active 
women 
(18-25) 
PCR,MY09/MY11/ 
HMB01 & PC04/ 
GH20 β-globin 
29% (934/3262) 
overall 
(Alameda, 
Bellosillo et 
al. 2007) 
Spain 50 women referred 
to gynae clinic  
36 (28-55) 
In-house or 
commercial PCR 
MY09/MY11 
6% (1/36) LSIL 
82% (10/14) HSIL 
(Feng, 
Hawes et al. 
2007) 
Senegal 129 women with 
cervical biopsies 
 47 (SD=11) 
PCR MY09/MY11/ 
HMB01 & PC04/ 
GH20 β-globin 
11% (2/19) No CIN 
44% (4/9) CIN1 
59% (17/29) CIN2+ 
70% (50/72)cancer 
(Song, Lee et 
al. 2007) 
Korea 89/100 women with 
cervical biopsies 
and cervical swabs  
45 (26-77) 
PCR –based DNA 
microarray system- 
HPV DNA chip 
13% (3/23) cervicitis 
62% (26/42) HGCIN 
71% (17/24) cancer 
(Payan, 
Ducancelle et 
al. 2007) 
France 333 women referred 
to Gynaecology 
Real-time PCR. 
Mx4000 (Stratagene) 
vs LightCycler 
(Roche) 
37% (66/177) overall 
in urine, 
45% (150/333) in 
cervix (k=93%) 
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(Daponte, 
Tsezou et al. 
2008) 
Greece  100 women with 
abnormal cytology & 
HPV-16 positive 
Classic PCR & QRT 
PCR 
33% (16/49) LSIL 
72% (26/36) HSIL 
87% (13/15) cancer  
(Fambrini, 
Penna et al. 
2008) 
Italy  52 HG-CIN before 
CO2 conization  
38 (18-59) 
PCR kit Bioline  81% (42/52) HGCIN 
Relative sensitivity 
(urine vs cervix) 
96.6% 
Payan et al. 
2009 
France 1,169 women 
refusing smears 
(25-65) 
Real-time PCR 19% (222/1169) 
overall 
(O'Leary, 
Sinka et al. 
2011) 
Scotlan
d 
2575 unvaccinated 
school girls 
(11-18) 
HPV Inno-LiPA 
(PCR) 
weighted prevalence 
1% (11-14 years)  
15% (16-18 years) 
 
(Cuschieri, 
Nandwani et 
al. 2011) 
Scotlan
d 
90 women attending 
at drop-in sexual 
health clinic  
(16-25) 
PCR based assay  Relative sensitivity 
(urine vs cervix) 
90.5% (79.3-96.9) 
Relative specificity 
67.6% (50.2–82.0%) 
(Mendez, 
Romaguera 
et al. 2013) 
USA 52 women attending 
Gyne clinic  
(21-60) 
Linear Array (PCR) 
 
42% (22/52) urine 
67% (35/52) cervix 
(Kavanagh, 
Sinka et al. 
2013)  
Scotlan
d 
 378 Screening 
defaulters were sent 
urine collection kits 
(20-21) 
Digene HPV 
Genotyping RH test  
GP5 + 6+ primers 
weighted prevalence 
32% (adjusted OR= 
0.33 (95%CI: 
0.25,0.44) 
(Tanzi, 
Bianchi et al. 
2013)  
Italy  107 women 
attending STD clinic 
(22-70) 
PCR based assay 
(RFLP for typing). 
MY09/11primers 
65% (69/107) 
95% CI: 55-73%. 
Relative sensitivity 
(urine vs cervix) 
98.6% (93.1–99.9%) 
Relative specificity 
97.4% (87.7–99.9) 
Abbreviations: STD= sexually transmitted disease. 
 
Table 1.2.2 summarises studies evaluating HPV testing of urine samples. All except one study 
(Sellors, Lorincz et al. 2000) used a PCR based assay. High risk HPV was detected by HC 2 in 
the self-collected vaginal samples of 50/58 (86.2%), in the self-collected vulvar samples of 
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36/58 (62.1%), and in the self-collected urine samples of 26/58 (44.8%) and physician collected 
cervical samples of 57/58 (98.3%) in this study.  
 
Urine is a diluted specimen, not only are HPV DNA levels in urine low, but also it contains 
polymerase chain reaction (PCR) inhibitors (Khan, Kangro et al. 1991) such as urea and nitrites. 
Moreover, HPV DNA levels can be affected by bacterial contamination and endonucleases that 
could be found in urine specimen (Carder, Robinson et al. 1999; Milde, Haas-Rochholz et al. 
1999). All these factors can potentially reduce the sensitivity of the test.  
 
Seven studies in the Table 1.2.2 contain urine HPV prevalence data in women with high grade 
cervical lesion and ones without. I have carried out a meta-analysis of these data (Fig 1.2.1). It 
computes that the relative risk of HG HPV to be found in urine samples of women with a high 
grade CIN lesion is 2.4 (95CI, 1.9-3.0).  
 
Fig 1.2.1: Urine HPV positivity in women with high grade CIN 
 
 
Although the genomic DNA found in urine samples appears to be very low (Payan, Ducancelle 
et al. 2007; Mendez, Romaguera et al. 2013), detection is possible, if the highly effective PCR-
based method, restriction fragment length polymorphism (RFLP) has been used with a newly 
designed specific primer set (Tanzi, Bianchi et al. 2013). The restriction fragment length 
polymorphism (RFLP) technique has shown some promising results in previous urinary HPV 
screening studies. Tanzi (2013) reported a very high relative sensitivity of detecting HPV in 
cervical versus urine samples 98.6% (93.1– 99.9%) and a relative specificity of 97.4% (87.7– 
99.9%), with a very high NPV of 97.4% (87.7–99.9%) for HPV DNA detection in urine versus 
38 
 
cervix samples,. Another highly sensitive and quantitative general HPV DNA real-time PCR 
method reported an excellent (93%) kappa agreement for HPV DNA between cervical and urine 
specimens (Payan, Ducancelle et al. 2007). The relative sensitivity of urine versus cervical 
sampling for HPV detection was 90.5% (79.3-96.9) when a highly sensitive PCR method had 
been used (Cuschieri, Nandwani et al. 2011). The relative specificity was 67.6% (50.2–82.0%). 
Fambrini (Fambrini, Penna et al. 2008) reported the relative sensitivity of 96.6%.  
 
A pilot study in France (Payan, Ducancelle et al. 2007) showed that the response rate of women 
who had been invited for a cervical smear examination substantially increased when they were 
offered the option of urine sampling for HPV screening. Whilst 312/5781(5.4%) participants in 
this study accepted cervical smear invitation, 1169/4036 (29%) accepted urine sampling for 
HPV screening.  
 
Although it appears that HPV testing in urine sample has the potential to be a surrogate marker 
of cervical HPV infection, more applied research is required before it can be offered as a 
primary screening tool. Moreover, DNA extraction and testing appears more complex than 
modern, automated, high throughput assays. Two studies that reported very high relative 
sensitivities (91.5% and 98.6%) of detecting HPV between the urine and cervix seem promising 
 
 
2. Could self-sampling increase cervical screening participation in 
high income countries?  
 
Since 2007 a number of applied research studies have been carried out – these are 
summarised in Table 1.2.3. The primary aim of most of these studies was to see if offering self-
sampling to screening programme defaulters would increase the screening attendance.  
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Table 1.2.3 Population-based clinical research on self-sampling in high-income countries 
N
o 
Study  Country 
(screening 
coverage 
%) 
n (age) 
Not 
screened 
for* 
Self-
sampling 
Device  
HPV 
test  
Self-test 
uptake 
(%) 
HPV 
positiv
ity (%) 
HG-
CIN 
(%) 
1 (Stenvall, 
Wikstrom et 
al. 2007) 
Sweden 
(Uppsala)  
(70) 
369  
(35-50) 
6 years 
Qvintip HC2 31.7 26 3 
2 (Bais, van 
Kemenade 
et al. 2007) 
Netherlan
ds 
(63) 
2,546  
(30-50)  
2 invita* 
Viba 
brush+ 
UCM 
PCR 31.3 8 1.7 
3 (Sanner, 
Wikstrom et 
al. 2009) 
Sweden 
(39-60) 
2,829  
(30-58) 
6 years 
Qvintip HC2 39.1 6.7 1.2 
4 (Gok, 
Heideman et 
al. 2010) 
Netherlan
ds 
(77) 
28,073 
(30-60)  
2 invita* 
Delphi 
Screener  
HC2 27.5 10.3 1.3 
5 (Gok, 
Heideman et 
al. 2012) 
Netherlan
ds 
(77) 
26,409 
(30-60)  
2 invita* 
Viba 
brush 
 
HC2 30.8 8.3 2.5 
6 (Georgi 
Rossi, 
Marsili et al. 
2011) 
Italy 
(67-70) 
2,480  
(35-64)  
2 invita* 
Pantarhei 
sampler 
HC2 ‘Letter’= 
5.8 
‘Clinic’= 
12.5 
‘Kit’= 
16.7 
3.6 0.0 
7 (Wikstrom, 
Lindell et al. 
2011) 
Sweden 
(39-60) 
(70) 
4,060  
(39-60)  
6 years 
Qvintip HC2 39.0 7 1 
8 (Lindell, 
Sanner et 
al. 2012) 
Sweden 
(39-60) 
(70) 
3,618  
(50-65) 
6 years 
Qvintip HC2 39.4 4.6 0.7 
9 (Gyllensten, 
Sanner et 
al. 2011) 
Sweden 
(39-60) 
(70) 
7,331 
(30-65)  
6 years 
Qvintip HC2 39 6.6 1.5 
10 (Virtanen, 
Anttila et al. 
Finland   
(70) 
1,130  
(30-60)  
Delphi 
Screener   
HC2 29.8 No 
data 
No 
data 
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2011) 5 years 
11 (Virtanen, 
Nieminen et 
al. 2011) 
Finland   
(70) 
2,397  
(30-60)  
5 years 
Delphi 
Screener  
HC2 31.5 12 1 
12 (Piana, 
Leandri et 
al. 2011) 
France  
(60) 
4,400  
(35-69)  
1 invita* 
?flocked 
swab 
PCR 26 6.2 0.4 
13 (Szarewski, 
Cadman et 
al. 2011) 
UK 
(London) 
(68) 
1,500  
(25-64)  
2 invita* 
Dacron 
swab 
HC2 6.4 5.2 2.0 
14 (Castle, 
Rausa et al. 
2011) 
USA 
(Mississip
pi Delta) 
119  
(25-65)  
3 years 
Fournier 
device 
HC2 52.1 14.5 No 
data 
15 (Tamalet, Le 
Retraite et 
al. 2013) 
France 
(60%) 
3767 (35-
65) 
1 invita* 
flocked 
swab 
PCR 25.1 6.6 0.3 
16 (Darlin, 
Borgfeldt et 
al. 2013)  
Sweden 
(Lund)  
(75%) 
1000  
(32-64)  
9 years 
Cotton 
swab  
PCR 14.7 6.9 0.0 
PCR= polymerase chain reaction, invita= invitation, *these women had not been screened for at 
least (number of) years or did not respond after (number of) Invitations to attend screening, 
‘letter’= letter was sent to order a kit, ‘clinic’= a clinic appointment was sent to discuss screening 
choice, ‘kit’= a self-sampling kit was directly mailed to the woman.  
 
The effectiveness of detecting HPV infected cervical cells may vary between samplers, and 
different populations. Therefore, the heterogeneity of results in Table 1.2.3 should not be 
surprising.   
 
All except one (the USA) of these high-income countries have established cervical screening 
programmes (Anttila, Ronco et al. 2004). The cervical screening coverage in countries that 
these studies were conducted is between 60% (France) and 77% (The Netherlands) although 
the mode is 70%. Although there is no programme in the USA, coverage is estimated to be as 
great (i.e. over 70%).  
 
Two very large scale, population based RCTs were conducted in the Netherlands, including 
28,000 defaulters in 2010 and 26,000 in 2012 by Gök.  
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The most frequently used self-sampler was the Rovers Viba brush. Other self-samplers used in 
order of frequency were: Qvintip, swab (Dacron/flocked/cotton), Delphi Screener, Pantarhei 
sampler and Fournier device. The Darlin study (Darlin, Borgfeldt et al. 2013) described the 
device used as a “cotton swab”. The prevalence of hrHPV was 10/145 (6.9%) and no HSIL was 
found in 7 out 10 HPV+ women who attended cervical cytology, although the cytology of one 
woman who had had a hysterectomy was reported as LSIL. If the swab was indeed made from 
cotton, it could potentially have inhibited HPV DNA detection which may have contributed 
towards not finding any cervical dyskaryosis in this cohort of 147 women. The main author of 
this study, Lotten Darlin, was contacted to clarify this. She confirmed that they had used a 
cotton swab.  
 
The self- sampling uptake rate in 16 studies is summarised in Table 1.2.3.  It varied between 
5.8% and 39.4%. The uptake rate (52.1%) of a study by Castle (Castle, Rausa et al. 2011) has 
been excluded from analysis as researches asked eligible women’s consent in their homes, 
which may have influenced women’s choice. The mean is 26.3% (95%CI, 20.4-32.0). The 
median was 29.8% with IQR=15.7-35.4%. The self-sampling uptake rates (31.7%-39.4%) were 
highest in Swedish studies where Qvintip had been used (Stenvall, Wikstrom et al. 2007; 
Sanner, Wikstrom et al. 2009; Gyllensten, Sanner et al. 2011; Wikstrom, Lindell et al. 2011; 
Lindell, Sanner et al. 2012). By contrast, the only Swedish study that did not use Qvintip (Darlin, 
Borgfeldt et al. 2013) reported one of the lowest uptake rates in self-sampling (6.9%). Two 
studies conducted in Finland reported self-sampling uptake rates around 30% (Virtanen, Anttila 
et al. 2011; Virtanen, Nieminen et al. 2011). The uptake rates were 27.5% (Gok, Heideman et 
al. 2010), 30.8% (Gok, van Kemenade et al. 2012) and 31.3% (Bais, van Kemenade et al. 2007) 
in 3 Dutch studies.  The uptake  rate was 26%  in one French study (Tamalet, Le Retraite et al. 
2013). The UK study (Szarewski, Cadman et al. 2011) reported the lowest self-sampling uptake 
rate of 6.4%. Many factors account for the variance of self-sampling uptake observed in these 
studies. It appears that the self collection uptake rate depends on the type of self-sampling 
device, geographical location of the study population and the way that self- sampling has been 
offered.  
 
High risk HPV positive rate in self collected vaginal samples was reported in all but one study. It 
varied between 3.6% and 26.0%. The mean was 8.8% (95%CI, 5.8-11.9), the median was 6.9% 
with IQR=6.2-10.3%. Of the four studies with over 10% positive for hrHPV, two used the Delphi 
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screener 10.3% (Gok, Heideman et al. 2010), 12% (Virtanen, Nieminen et al. 2011); one used 
the Fournier device 14.5% (Castle, Rausa et al. 2011) and the one used Qvintip 26%. 
Prevalance of hgCIN, which was reported in all but the last study, was 1.3%, 1.0% and 3.0%, 
respectively. 
 
The prevalance of hgCIN was reported in 14/16 studies.. It varied between 0.0% and 3.0%. The 
mean was 1.2% (95%CI, 0.7-1.7). The median was 1.1% with IQR=0.4-1.8%. There was a 
significant correlation between the hrHPV positive rate and the prevalance of hgCIN (Pearson 
Correlation 0.634, P=0.014 two-tailed) The prevalance of hgCIN in these studies is comparable 
with that of the cervical cytology based population screening in England (Health and Social Care 
Information Centre 2013) 
 
HPV screening in self-collected samples appears to be a pragmatic method of increasing 
cervical screening coverage. Authours of an Italian self-sampling study (Giorgi Rossi, Marsili et 
al. 2011) predicted that self-sampling could have the potential to increase cervical screening 
coverage in urban areas such as Rome and Florence up to 90%, if self-sampling increased the 
overall coverage by 5%. Increasing the screening coverage by 5% appears to be somewhat 
optimistic as some interventions were able to increase cytology screening coverage only by 
1.3% (95%CI= -3-2.9) (Eaker, Adami et al. 2004); 0.4%-1.3% (Corkrey, Parkinson et al. 2005) 
and 0.94% (95% CI 0.21% to 1.67%) at 6 months (Jensen, Svanholm et al. 2009). However, 
studies conducted in high income countries with organised screening programs reported that 
providing self-sampling kits to defaulters, particularly when in addition to a reminder letter, may 
improve their screening attendance (Gok, Heideman et al. 2010). All nonparticipants in 
organized cervical cancer screening in Espoo, Finland were randomized to receive a self-
sampling kit (1,130 women) or a reminder letter (3,030 women) (Virtanen, Anttila et al. 2011). 
Participation rate in the self-sampling arm, 30%, was significantly higher than in the reminder 
letter arm, 26% (adjusted relative risk for participation= 1.13). Total participation in Espoo in 
2008 rose significantly after the two interventions from 64.0 to 75.4%.  
 
A randomized controlled study compared screening uptake rates between 4 different 
approaches (Giorgi Rossi, Marsili et al. 2011). In defaulters aged 35–64 years two control 
groups received standard recall letters to perform either a Pap-test (first group) or a HPV test 
(second group) at the clinic, a third arm was sent letters offering a self-sampler for HPV testing, 
to be requested by phone; a fourth group was directly sent the self-samplers to their homes. 
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The screening uptake with standard recall was 13.9% (n=619). Offering HPV testing at the clinic 
had a non-significant effect on uptake (n=616, relative risk (RR) =1.08; 95% CI=0.82–1.41). A 
self-sampler on request had the poorest compliance, 8.7% (n=622, RR=0.62; 95% CI=0.45–
0.86), whereas direct mailing of the self-sampler registered the highest compliance: 19.6% 
(n=616, RR=1.41; 95% CI=1.10–1.82). In a study of 369 women, 179 (49%) ordered a Qvintip 
self-sampling device, of whom 117 (32%) performed self-sampling at home and sent the sample 
to the laboratory for analysis (Stenvall, Wikstrom et al. 2007): a third of the samplers (35%) 
were not returned.  
 
 
3. Reasons for non-participation in cervical screening programmes 
 
Reasons for non-participation in cervical screening depend on many factors. They are largely 
dependent on the accessibility and robustness of the programme. Within a well-established 
cervical screening programme, the reasons for non-participation can be categorised into 
attitudinal and non-attitudinal, although they are often multi-factorial.  
 
Factors that negatively affect cervical screening uptake have been categorised into 3 areas by 
Waller (Waller, Bartoszek et al. 2009).  
a) Demographic factors such as age, marital status and ethnic group 
b) Structural/ health-care factors such as appointment times, female practitioners and 
‘friendly treatment’ 
c) Attitudinal factors like embarrassment, trust and concerns about discomfort.   
 
a. Demographic factors  
Demographic factors often correlate with each other. Socio-demographic and attitudinal 
correlates of self-reported cervical screening uptake were investigated among 1307 women in 
the target age group who participated in two national surveys conducted in Britain (Sutton and 
Rutherford 2005). Uptake was highest among married and separated women and lowest among 
single and widowed women. The strong effects of car ownership and housing tenure showed a 
robust positive association with uptake.  
 
In one study, ethnicity was the most important predictor for participation in cervical screening 
(Moser, Patnick et al. 2009); white British women were significantly more likely to have had a 
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cervical smear than were women of other ethnicity with odds ratio 2.20, (95% CI: 1.41-3.42). 
Uptake of cervical screening was greater among more educated women but was not 
significantly associated with cars, housing tenure, or region. 
 
In a population based survey in Britain examining socio-demographic predictors of HPV testing 
and vaccination acceptability, (Marlow, Waller et al. 2008), the screening attendance was 
associated with education level (odds ratio [OR] = 1.66, confidence interval [95% CI]: 1.07-2.56) 
and being married (OR = 2.04, 95% CI: 1.37-3.03).  
 
b. Healthcare factors  
A telephone-based questionnaire about future attendance at cervical cancer screening which 
included 400 defaulters in Sweden (Oscarsson, Wijma et al. 2008) assessed their requirements 
for attendance and potential ways of improving attendance. 120 considered having a cervical 
smear taken, and 50 of them wanted help to accomplish this. When meeting the women's 
requirements, such as being assured of friendly treatment and a suitable appointment time, the 
numbers of registered cervical smears were higher for the study group compared with a control 
group. Still, the most hard-to reach defaulters did not attend screening. 
 
A postal questionnaire survey was used (Olowokure, Caswell et al. 2006) to compare preferred 
appointment times with those given for cervical screening. Although 33% of respondents 
received appointments between 10h00 and 11h55, only 17% wanted an appointment at that 
time. Nineteen per cent of respondents wanted appointments between 18h00 and 20h00, but 
only 4% received them. Saturday appointments for cervical screening are not given; however, 
overall approximately 13% of those surveyed would have preferred a Saturday appointment. 
 
Women's lack of knowledge of cervical screening appears to be an important factor accounting 
for non-attendance at cervical screening (Neilson and Jones 1998). The response rate to this 
questionnaire- based survey conducted in Edinburgh was 72/187 (38%). The majority of women 
showed preference in a female professional taking the smear. Practical problems of time and 
venue were not considered insurmountable. The main reasons cited for non-compliance were 
the fear and dislike of the test itself. Although the majority of women felt the invitation to attend 
screening was clear and easy to understand, there was a lack of knowledge with regard to both 
the screening itself and the possible causes of cervical cancer.  
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c. Attitudinal factors  
Attitudinal factors can be categorized into embarrassment, trust and concerns about discomfort. 
 
Women who reported that their last test had been painful or embarrassing held more negative 
views of a future test, but a prior positive result was not implicated in women's expectations 
concerning future screening. Orbell and colleagues (Orbell 1996) interviewed 276 women who 
had recently undergone the cervical smear test concerning their screening experience, the 
screening test and their future screening expectations. Anticipated embarrassment and other 
negative attitudes towards screening for example, "There's no point going for screening if you 
don't have any symptoms" were significant independent negative predictors of uptake (Sutton 
and Rutherford 2005).  
 
Lack of trust regarding healthcare professionals who collect the sample and/or the test itself is 
another attitudinal factor that affects screening attendance. A study (Blomberg, Ternestedt et al. 
2008) was conducted to explore how women who actively declined participation in cervical 
screening in Sweden reasoned regarding their choice. Factors related to women's decisions not 
to participate in screening at all included a lack of confidence in the benefits of screening, a 
previous bad experience, a belief in one's own ability to pick up any changes or a belief that one 
was not at risk of cervical cancer, as well as a number of unconventional standpoints on social 
and political issues. Authors recommended the use of Jepson et al.'s ethical framework to 
peruse the evidence-base underlying women's 'informed decision-making' about CCS, which 
was suggested to be more constructive than discussing potential participants' knowledge versus 
lack of knowledge. 
 
A study conducted by tape-recorded interviews of a sample of 14 women in southeast Sweden 
who had chosen not to attend CCS during the previous 5 years was analyzed by qualitative 
inductive content analysis. These women reported various degrees of lack of trust in health-
care. ‘I do not need to’, ‘I do not want to’ and ‘I do not give it priority’ themes were recognized. 
The women had a positive attitude to screening but as long as they felt healthy, they chose not 
to attend. A negative body image, low self-esteem, feelings of discomfort and fear of the results 
also influenced their non-attendance.  
 
Concerns about discomfort were other reasons for non-attendance. Four hundred Swedish 
women were randomized from a population based register (Oscarsson, Benzein et al. 2008), of 
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which 133 non-attendees answered the Cervical Screening Questionnaire in telephone 
interviews.  Previous negative experience (feelings of discomfort with the gynecologic 
examination) was one of the top 3 reasons for non-attendance. Non-attendees who reported 
non-attendance due to experiences of discomfort associated with the gynecologic examination, 
estimated that they would experience great discomfort during their examination. A history of 
sexual abuse was reported by 16.5%. By contrast, discomfort was one of the many reasons for 
non-attendance in Britain (administrative failures, unavailability of a female screener, 
inconvenient clinic times, lack of awareness of the test's indications and benefits, considering 
oneself not to be at risk of developing cervical cancer, and fear of embarrassment, pain, or the 
detection of cancer) according to Fylan (Fylan 1998).  
 
 
4. Different sampling methods 
Over 16 different vaginal self-sampling devices could be found. Some self-collection devices 
attempted to simulate the gold standard cervical sampling technique to a certain extent. 
Therefore, a brief overview of the conventional and standard cervical sampling technique will be 
given first.  
 
(a) The conventional cervical smear collection technique 
The primary purpose of the conventional cervical smear technique is to make a Papanicolaou 
smear on a glass slide, to be examined under a light microscope by a pathologist. Although the 
sampling technique has been slightly evolved since it was first introduced by George 
Papanicolaou between 1928 and 1948 (Papanicolaou and Traut 1997), cytopathological 
principles which underpin the smear test remain unchanged.  
 
(b) The standard cervical smear collection technique 
The standard cervical screening sample in UK is liquid based cytology. The specimen is 
deposited in a 20mL preservative liquid. This is facilitated by collecting the cervical sample with 
brushes and brooms made out of plastic (Fig 1.2.3), a spatula can be used as an alternative.  
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Fig 1.2.3: Standard cervical sampling technique 
 
 
 
(c) Self-collection devices  
It is reasonable to assume the best self-sampler will be capable of collecting a cervical sample 
which is similar to the gold standard clinician collected sample. However, this may not be a 
realistic expectation, considering the complex mechanics involved in cervical cytology sample 
collection. A self-sampler which gets closer to the clinician’s technique could be the best 
alternative to the gold standard.  
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Table 1.2.1: Comparison of different vaginal self-sampling devices  
 Name  Type of 
device  
Liquid 
transport 
medium 
needed  
Potential strengths  Potential limitations  
1 Qvintip Modified 
flocked 
swab 
No Looks simple, 
sampling is easy 
Detachment of the 
flocked tip may 
cause problems  
2  
&  
3 
1st gen. 
Delphi/ 
Pentarhei 
Lavage  Yes It looks like a syringe 
which may be user-
friendly 
Lavage may be 
perceived ‘messy’ 
4 2nd gen. 
Delphi 
Lavage Yes Relatively smaller, 
sampling is easy 
Premature suction 
mechanism may 
yield a less cellular 
sample 
5 Viba brush  Brush 
(100% 
plastic)  
May be Looks simple, 
sampling is easy, 
large surface area 
catches a large 
sample, inexpensive  
Improper use could 
be painful 
6 Viba 
brush+ 
FTA elute  
Brush 
(100% 
plastic) 
with a 
fixative 
cartridge 
No Colour change of the 
cartridge may be 
reassuring to the 
woman 
The whole sample 
may not be placed 
on the cartridge by 
the woman 
7 Genipap Brush with 
a short 
plastic 
sleeve 
May be The sample is 
‘protected’ by the 
device sleeve  
Sampling could be 
very difficult  
8 
&  
9 
QIAGEN/ 
Digene 
cervical 
brush 
Brush 
(nylon 
bristles+ 
metal rod) 
Yes  Looks simple, 
sampling is easy, 
large surface area 
and nylon bristles 
catch a good sample 
Disposal of the 
metal rod of the 
brush can be difficult  
10 Flocked/ 
Dacron 
swab 
Vaginal 
swab  
Yes  Looks very simple, 
sampling is very 
easy, inexpensive 
The small surface 
area limits the 
volume of the 
sample  
11 Cotton 
swab 
Vaginal 
swab 
No Looks very simple, 
sampling is very 
easy, inexpensive 
Cotton may inhibit 
HPV DNA detection  
12 POI/NIH 
sampler 
Modified 
flocked 
swab with 
a short 
sleeve 
Yes Sleeve enhances 
upper vaginal 
sampling  
Sampling is 
complicated and 
could be difficult  
13 Fournier Modified, 
ejectable 
tampon 
May be Long sleeve 
enhances upper 
vaginal sampling 
Tampon part could 
be inadvertently 
ejected inside the 
49 
 
with a long 
plastic 
sleeve 
vagina, sampling 
may be complicated 
14 Pad  Sanitary 
Pad  
No Sampling is easy Shipping and 
processing could be 
difficult 
15 Tampon  Vaginal 
tampon 
No Sampling is easy for 
women who used to 
use tampons 
May not be 
universally 
acceptable 
16 Evalyn 
brush 
Modified 
Viba brush 
with a 
short 
plastic 
sleeve 
No Sleeve enhances 
upper vaginal 
sampling, large 
surface area 
enhances volume of 
the sample  
Appears large and 
complicated 
 
 
(d) The main characteristics of an ideal self-collection device 
It appears that development and improvement of self-sampling devices is still an ongoing 
process (Schmeink, Bekkers et al. 2011). The majority of the studies assessing self-sampling 
have used liquid based storage and transport media. The use of liquid based self-samples has 
the impractical consequence that fluids may leak, and special precautions have to be taken for 
transport. This potentially hampers the large scale introduction of cervico-vaginal self-sampling 
methods as the sampling kit must be suitable for posting. The use of dry transport methods may 
eliminate these disadvantages. Samples may be transported and stored using a ‘dry’ test tube. 
However, over-drying may reduce the number of HPV infected cells available for DNA testing.  
 
Above all, the overall cost for sample collection should be cheaper.  
 
Although self-sampling brushes with long, multiple bristles (Viba brush) collected cellular sample 
representative of the cervix (Yoshida, Sano et al. 2011), vaginal lavage samples are less able to 
do this.  A self-sampling study which used the Delphi Screener (Jentschke, Lange et al. 2013) 
found that 27/140 (19%) physician-collected samples were p16 (INK4a) ELISA positive. In 
contrast, p16 (INK4a) ELISA was positive in only 1/140 (1%) of vaginal lavage samples.  
 
Evidence suggests that ‘wet’ self-samplers have a better HPV yield than the ‘dry’ ones (Please 
refer to the table 2.2.1). HPV positive rates were 10.3-15.3% with the Delphi Screener whereas; 
it was 6.0-6.6 with Qvintip which appears to collect a good sample (Darlin, Borgfeldt et al. 2013). 
Issues in relation to the dryness could be rectified by not letting the sample dry out. Although the 
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time interval between sample collection and testing could be shortened, protecting the mucous 
sample from evaporation until it is placed in the liquid medium is the best way forward.  
 
Collection of HPV infected cells from high in the vagina with no contamination from the lower 
vaginal flora is desirable for the specificity of the screening test. However, it can be argued that 
a test that will detect any hrHPV infection will have an excellent negative predictive value for 
cervical dysplasia.  Intuitively, development of cervical dysplasia is less likely in a woman whose 
lower genital tract is free from hrHPV infection, than a woman who has no hrHPV in the cervix 
but when it is present in the vagina.  
 
Most of these self-sampling studies were small and non-population based. Large scale-
community based studies have been carried out more recently in the Netherlands (Gok, 
Heideman et al. 2010), China (Belinson, Du et al. 2011) and Mexico (Lazcano-Ponce, Lorincz et 
al. 2011). Swab based devices have been used in most of these studies except in 2: the Delphi 
Screener and Viba brush. This can be a main confounding factor between these studies as the 
HPV positivity largely depends on the quality of the sample that is being collected.  
 
Most self-sampling studies used different sampling devices for self-collection and clinician 
collection, which could affect the number of HPV infected cells sampled. This should affect the 
HPV result, its sensitivity and concordance. By contrast, a study conducted in Taiwan (Chang, 
Tseng et al. 2002) used the same sampling device (cotton swab) for self as well as clinician 
sampling. A total of 1194 women were prospectively registered from 1997 to 1999. A vaginal 
swab was self-collected 3 days before a physician collected a cervical swab. Samples were 
analyzed using HC 2 assay. Among them, 144 (12%) of self-test samples and 155 (13%) of 
physician-obtained samples were hrHPV positive. No significant differences were observed in 
the screening rate for cervical cancer using either the self-collected samples or the physician-
collected samples. The sensitivity of cervical pre-cancer or cancer detection using self-obtained 
HPV testing was higher (96.3%) as compared with the Pap smear (79.2%) (p< 0.02). There is 
no doubt that a cervical swab is not the best cervical sampler for cytology screening. It is 
unlikely to be the best sampler even for HPV screening. Using sub-standard devices cannot be 
justified for screening purposes. However, this study suggested that if the same sampler was 
used to collect both cervical and vaginal samples, both samples could be equally good for HPV 
screening.  
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Evalyn brush  
The Evalyn brush which is made of plastic was manufactured in 2011. The head of the Evalyn 
brush is identical to Rovers Viba brush (Fig 1.2.4). 
 
Fig 1.2.4: Evalyn brush self-sampling device     
 
 
Fifty women in Japan self-collected a vaginal sample with the Viba brush, one month after a 
clinician collected sample (Yoshida, Sano et al. 2011). LBC identified high-grade squamous 
intraepithelial lesions in 11 (22%) and 7 (14%) patients, low-grade squamous intraepithelial 
lesions in 19 (38%) and 16 (32%), atypical squamous cells of undetermined significance in 2 
(4%) and 0 patients, in clinician collected and self-collected samples, respectively. A total of 
37/50 (74%) of clinician collected and 41/50 (82%) of self-collected cases were positive for 
HPV, indicating that the Evalyn brush head should be able to collect a rich cellular sample for 
HPV screening.  
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The Evalyn brush is made of plastic. Its sleeve bypasses the lower half of the vagina, simulating 
the speculum of the standard cervical smear technique. The design of the sleeve aids easy 
insertion which should not cause any pain. The Evalyn brush is capable of collecting a rich 
cellular sample from the higher vagina, possibly from the ectocervix from its 3 cm long 14 flat 
bristles made of firm plastic. It is easy to use. It creates clicking sounds when the bristles are 
fully extended in the vagina as well as after each rotation. The manufacturer advises that it 
should be rotated five times, which is keeping in line with the cervical sampling technique. Its 
safety cap prevents the sample from drying out. Its plastic housing prevents accidental 
extensions of bristles. All of these eventually go inside a self-seal, tough plastic bag which 
protects the sample from drying as it prevents leakage of humidity/ moisture from the sample 
container. Hence, almost all samples that we received arrived in a near new condition. They 
were moist and appeared cellular when dissolved in the PreservCyt medium.  
 
The Evalyn device together with the sample collected is sent to the laboratory so that the 
woman doesn’t have to move the sample from the device to another container. Self-collection 
with the Evalyn® brush has shown a high level of concordance of 86% (kappa 0.72) with the 
clinician-collected sample for HPV testing and a good acceptability in 134 participants (van 
Baars, Bosgraaf et al. 2012).  
 
In my opinion, some limitations of the Evalyn brush are that the sleeve is a little short, only 4.5 
cm in length and the size of the cap is large 2.3 cm in width. The length of the vagina is 6-11 
cm. If the length of the sleeve was another 2 cm long, it would overcome this problem, although 
bristles touching the cervix can cause some discomfort to some women. A large cap can be 
intimidating to some women. Moreover, a smaller size would make postage much cheaper. A 
small pen clip like cap would overcome this issue.  
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CHAPTER 2 
 
Aims, objectives and study design  
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2.1. AIMS & OBJECTIVES 
 
Aims 
1. To explore potential methods of increasing cervical screening coverage.  
2. To explore reasons for defaulting.  
 
Primary objectives 
1. To examine the screening attendance to see if it could be improved by offering more flexible 
smear (cervical cytology) options to defaulters. 
2. To examine the screening attendance to see if it could be improved by offering self-sampling 
to defaulters older than 30 years. 
3. To explore barriers to cervical screening and to find out what is acceptable to this cohort of 
defaulters.  
 
Primary endpoints 
1. A woman declinnig participation in the study 
2. A woman accepting a screening test 
3. No response after the screening reminder letter 
4. No attendance at the second appointment at the hospital smear clinic 
 
Secondary endpoints 
1. An HPV+ woman with a cytological abnormality referred to colposcopy 
2. An HPV+ woman with normal cytology attending at the annual follow-up visit 
3. No attendance at the second appointment at the annual follow-up clinic  
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2.2. STUDY DESIGN 
 
According to the Dumfries & Galloway Cervical Screening 2012 Annual Report (based on the 
statistics on 01/01/2012), there were 6106 defaulters out of 36,903 screening eligible population 
in the Health Board. The total population of the Health Board was approximately 151,000.  
 
Although we were aiming to include the whole population of defaulters into various research 
studies, defaulters outwith the normal screening age group were excluded. Remaining 
defaulters were recruited to different studies as per the following flow chart (Fig 2.2.1). 
 
Fig 2.2.1: Main study design 
 
Key: numbers within boxes represent number of women belonging to each category.  
 
 
All defaulters in Dumfries & Galloway in 2012 
20-29 years 
(COHORT 2, 
N=1443)  
720 
721 
- 2 
30-55 years 
(COHORT 1, 
N=3498)  
1246 
1000 
1000 study 
- 246 
221 
200 
200 study 
 - 21 
2031 
2031 
2000 study 
- 0 
56-60 years 
(COHORT 3, 
N=649) 
292 
292 
64 
- 1 
- Defaulters <20 years >60  
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Recruitment of above 5 studies took place during following time periods in 2012: 1= 15 March-
20 April; 2=18-22 June; 3=9-13 July; 4=3 Sep-29 Oct; 5=29-31 Oct (please see Fig 2.2.2).  
 
Fig 2.2.2: Recruitment plan  
 
The first taget of our studies was the 30-55 year old defaulters (cohort 1). They were recruited 
into 3 different studies (1000, 200 and 2000). Cohort 2 was recruited next, followed by cohort 3. 
Research conducted in each of these 3 main age groups will be presented separately as slightly 
different methodologies were tested in each. These are the main five intervenational studies. 
Some smaller studies carried out along with these main studies are described seperately to 
improve clarity.  
 
The main reason why we had to ‘space out’ the study population was to accommodate 
screening positives smoothly to colposcopy without breaching waiting time standards. Other 
reasons were mainly logistical. The PI had to do numerous tasks during this period apart from 
recruitment.  
 
The first database was generated in early March 2012. This included 3498 defaulters. The 
second database included 1441 defaulters aged between 20 and 29 years. This was received in 
early September (cohort 2- younger defaulter study). The third database included 565 defaulters 
aged between 56 and 60 years. This was received at the end of October 2012 (cohort 3- older 
defaulter study). All defaulters belonging to the whole screening population in Dumfries and 
Galloway were included in the above 3 databases. 
 
Mar Apr May Jul Jun Aug Sep Oct 
20-29 database  
1000 
study 
30-55 database   
2000 
study 
56-60 database  
200 
study 
Nov Dec 
Younger 
study 
Older 
study 
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The data were extracted using BOXI (Business Objects Interrogation Tool) associated with the 
SCCRS data by the Screening Services Manager, NHS Dumfries and Galloway.  The data 
extracted were copied to an Excel spreadsheet which was sent to the Research and 
Development Department ordered by CHI number.  It is known that the CHI number is not 
related to name, date of birth or address. Samples of this Excel spreadsheet were carefully 
examined by the Data Manager of the Research and Development Department and two main 
investigators. It appeared that any given large sample of it represented a full spectrum of age 
distribution of the 30-55 year old cohort.  Hence, it was decided to allocate the first 1000 (1246-
246 excluded) CHI numbers to the first study (1000 defaulter study), the second 200 (221-21 
excluded) would be assigned to the second study (200 defaulter study) and the remaining 2031 
to the final study (‘2000’ defaulter study) using this Excel sheet. The analysis of the age 
distribution of each cohort will be presented under each study.   
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CHAPTER 3 
 
Validation studies and research methodology  
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VALIDATION STUDIES 
 
3.1 Can women self-collect an adequate sample for HPV screening? 
 
Study question 
Can women self-collect an adequate sample with the Evalyn brush for Hologic Cervista 
HPV-HR testing? 
 
Summary answer 
All 14 vaginal samples were positive for genomic human DNA, which is deemed adequate 
samples. Some vaginal samples deposited in a larger volume of ThinPrep were falsely 
negative, probably due to dilution effect.  
 
What is known and what this study adds 
Women can self-collect adequate vaginal samples for HPV screening. But no previous study 
has used the Evalyn brush as a ‘dry’ self-sampler. Performance of the Hologic Cervista 
HPV-HR test with such an Evalyn sample was not known. Results of this study suggest that 
women could self-collect an adequate sample with the Evalyn brush for Hologic Cervista 
HPV testing. It appears that increasing the ThinPrep sample concentration reduces false 
negative results. Based on these results, a sample concentration method was adapted.  
 
Limitations  
Samples were collected from 7 subjects only; a larger number would have increased the 
validity of this study. Quantification of HPV DNA and co-testing of samples with a reference 
HPV test would have been useful.  
 
Background 
We wanted to demonstrate concordance between the clinician and self-collected samples 
regarding levels of gDNA (genomic human DNA) internal control within the Hologic Cervista® 
HR assay as well as the HPV DNA. In turn this will allow us to determine the suitability of the 
off-label assay for a self-sampling study. 
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Methods 
A prospective, ethics approved study at Dumfries & Galloway Royal Infirmary’s colposcopy 
clinic between 23/09/2011 and 07/10/2011. Patients who were eligible for the study were 
identified by going through the clinic list and clinical records. The sample size was aimed at 
between 5 and 10 as this was a proof of concept study, mainly to see if the Evalyn brush could 
collect a sample that would pass the internal control of the Cervista test.  
 
Eligible patients were approached by the colposcopy nurse who briefly explained the study and 
they were provided with participant’s information leaflet. Subsequently, patient consent was 
obtained. Women who consented to take part in the study were provided with two sterile Rovers 
Evalyn® brushes, along with verbal and written instructions for a sample collection. Women self-
collected two samples with pre-labelled Evalyn® brushes in the bathroom next to the colposcopy 
clinic, immediately before they were seen. A standard cervical smear was obtained by the 
colposcopist before the colposcopy examination, using a Cervex® brush into a pre-labelled 
20mL ThinPrep® vial. This was used as the HPV reference test material.  
 
Evalyn® brushes with self-collected material were kept in the specimen package at room 
temperature (mimicking the postage time) at least for 48h (range 48-50 hours). The head of the 
Evalyn® brush was pulled out by a new, clean pair of disposable, plastic tweezers provided by 
the manufacturer and was put into a pre-labelled ThinPrep® vial before the cap was shut. Each 
pair of Evalyn® brushes were put into two different vials (one brush head per vial). One vial of 
ThinPrep® contained the standard volume of 20mL whilst other contained 5 mL. The sample 
was vortexed and the brush head was removed from ThinPrep® vial by a new, clean pair of 
tweezers. These ThinPrep® vials were kept at room temperature until they were despatched to 
the Scottish HPV Reference Laboratory (SHPVRL) in Edinburgh on 31st October 2011. Samples 
were subsequently tested for gDNA and HPV DNA with the Cervista® HR-HPV assay.  
 
Results 
The Cervista® HR-HPV assay has an internal control which detects genomic human histone 
DNA (gDNA) in the sample. It would not give a valid HPV result without passing the internal 
control. Please find results of the internal control (gDNA) in Table 3.1.1 and hrHPV DNA results 
in Table 3.1.2. Relevant history which includes the most recent cytology result and the diagnosis 
is recorded in the second column (diagnosis). The order that the self-taken vaginal sample was 
collected (first or second) is in the brackets in the last two columns.  
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All 10 Evalyn samples passed the internal control. All but one of the cervical samples passed 
the internal control. A woman who had been referred to the colposcopy clinic with post-coital 
bleeding with a recent normal smear had passed the internal control of self-collected samples, 
but failed in the cervical sample.  
Table 3.1.1: Genomic human histone DNA results of the proof of concept study  
Patient Diagnosis  Smear for 
gDNA  
Self-collected*  Self-collected* 
5mL ThinPrep®  
gDNA 
20mL ThinPrep®  
gDNA 
1 Moderate dysk- CIN3 Pass Pass  [2] Pass [1] 
2 Post-coital bleeding- smear 
negative 2 years ago 
Fail Pass  [1] Pass [2] 
3 Previous CIN3- smear negative Pass Pass  [1] Pass [2] 
4 Previous CIN1- current CIN3  Pass Pass  [2] Pass [1] 
5 Severe dysk- CIN2 Pass Pass  [2] Pass [1] 
6 Previous CIN1- biopsy normal Pass Pass  [1] Pass [2] 
7 Previous adenocarcinoma- smear 
unsatisfactory 
Pass Pass  [2] Pass [1] 
Table 3.1.2: HPV DNA results of the proof of concept study  
Patient Diagnosis  Smear for 
HPV  
Self-collected*  Self-collected* 
5mL ThinPrep® 20mL ThinPrep® 
1 Moderate dysk- CIN3 Positive  Positive   [2] Positive   [1] 
2 Post-coital bleeding- no smear Negative  Negative  [1] Negative  [2] 
3 Previous CIN3- smear negative Negative  Negative  [1] Negative  [2] 
4 Previous CIN1- current CIN3  Positive Positive   [2] Negative  [1] 
5 Severe dysk- CIN2 Positive Positive   [2] Negative  [1] 
6 Previous CIN1- biopsy normal Negative  Negative  [1] Negative  [2] 
7 Previous adeno ca-smear unsatis Negative  Negative  [2] Negative  [1] 
*[1]=first sample; *[2]=second sample; Pass = sufficient gDNA; Fail= insufficient gDNA 
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hr-HPV was positive in 3/7 cervical samples. All 3 cervical HPV positive samples had current 
hgCIN. HPV results of vaginal samples which were deposited in 5mL ThinPrep matched the 
cervical counterparts. The Evalyn sample which was deposited in 20mL of ThinPrep was 
collected by the woman who was referred with severe dyskaryosis had a negative HPV result. 
All other vaginal samples in 20mL ThinPrep had the same result as in the cervical counterpoint 
 
Discussion  
All self-collected vaginal samples contained an adequate amount of genomic DNA, indicating 
that samples were cellular enough for the internal control of the Cervista test to give us a valid 
result. The test cannot differentiate cervical cells from other types. However, this is unlikely to 
cause any issue, as exfoliated abnormal cervical cells have been found in adequate amounts in 
self-collected samples in other studies (Yoshida, Sano et al. 2011; Yoshida, Sano et al. 2011; 
Jones, Mansukhani et al. 2013) when the Viba brush and sampler have been used. The brush 
head of the Viba brush and the Evalyn brush are virtually identical as they are manufactured by 
Rovers Medical Devices, The Netherlands. Moreover, vaginal self-sampling for HPV testing is 
known to collect a sample which is similar to the cervical counterpart. However, it is best 
practice to ‘test drive’ the methodology before it is used in mass scale.  
 
Conclusions 
Self-collected vaginal samples in 5ml or 20ml of collection fluid with the Evalyn® brush showed 
an excellent agreement with their cervical counterparts for adequacy of the sample as defined 
by genomic DNA. However, two samples placed in 20mL vials were falsely negative despite 
being collected first by the woman, suggesting that the HPV DNA concentration plays an 
important role. Based on this proof of concept study results, industry experts suggested 
concentrating the ThinPrep sample before DNA extraction. After senior level discussion 
between the Hologic Limited and the SHPVRL, the following approach was adapted to process 
ThinPrep samples for our study.  
 
Method of sample concentration 
1. The whole 20mL PrecervCyt sample is transferred from the ThinPrep pot to a 50mL 
Falcon tube. 
2. It is then centrifuged at 1,110g for 10 min to pellet the cells. 
3. All but 5 mL of the PreservCyt solution is removed and the cells are re-suspended in the 
remaining 5mL of solution before being returned to the original ThinPrep pot 
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3.2 The storage study 
 
Study question 
How long will ‘dry’ Evalyn samples remain viable for HPV screening? 
 
Summary answer 
It appears that a vaginal sample self-collected with the ‘dry’ Evalyn® brush remains viable for 
HPV testing for 2 weeks when a PCR based test is used for testing.  
 
What is known and what this study adds 
Performance of the Evalyn brush as a ‘dry’ self-sampling device was unknown. It appears 
that a vaginal sample self-collected with the ‘dry’ Evalyn® brush remains viable for HPV 
testing for 2 weeks when a PCR based test is used for testing. There is a good agreement 
between the clinician-collected cervical sample and self-collected vaginal sample for HPV 
screening in subjects with hgCIN.  
 
Limitations  
Samples were collected from 10 subjects only; a larger number would have increased the 
validity of this study. It would be impossible to divide the Evalyn sample into 2 identical 
portions by cutting the brush head into 2 halves. This process increases the risk of 
contamination and loss of sample. Ideally, half of the sample should have been suspended 
in half of ThinPrep volume (10mL rather than 20mL).  
 
 
Background 
The Evalyn brush is a dry sampling device which does not require liquid/alcohol based medium 
for specimen transportation. This makes a considerable difference to the transportation cost as 
alcohol based media cannot be posted. Although non-alcohol based transport media can be 
sent in the post, it can cost about £5.60 (Royal Mail Special Delivery 2012), whereas postage 
for the dry Evelyn brush costs only £0.10 (RoyalMail pre-paid First Class 2012). Cost-
effectiveness plays the biggest role when choosing a good screening tool. If the dry Evalyn 
sample sent through the post is as good as the gold standard sample for HPV screening, the 
cheaper option can be adapted.  
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Methods 
Ten women attending at the colposcopy clinic with an abnormal cervical cytology test were 
asked to self-collect a vaginal sample with the Evalyn® device, in the patients’ toilet in the clinic. 
A cervical smear was taken with a Cervex® brush, as usual, just before the colposcopy 
examination.  
 
The Evalyn® brush kit was sealed in its plastic bag and was kept in a cardboard box at room 
temperature, simulating a postal sample. The temperature of the room was recorded daily, both 
day and night. Temperatures recorded (n=8) were between 20ºC and 21 ºC. On day 7, the distal 
half (tip) of the Evalyn® brush head was cut into ThinPrep® 20mL vial with a sterile pair of 
scissors, vortexed for 2 minutes and the bristles were removed using a sterile pair of plastic 
tweezers. Utmost care was taken to prevent potential contamination. The Evalyn® device was 
stored again as explained before. The remaining sample was deposited in ThinPrep® 20mL on 
day 14.  
 
Seventeen samples of 3mL of each ThinPrep® pot were tested with Cobas® 4800 test first. The 
remaining 13 were run subsequently. We had to use a qPCR test for this study. Roche Cobas 
4800 is a qPCR based test for simultaneous detection of 14 high-risk HPV types that can be 
used to specifically identify HPV16 and HPV18 DNA 
 
Results 
Women from 3 consecutive colposcopy clinics were recruited to participate in this study. Ten 
women consented to take part in the study. They were aged from 23 to 38 years.  Half of the 
women had high grade smear abnormality. The colposcopy diagnosis was a high grade CIN in 
all but one. Histology confirmed colposcopy diagnosis in all except one case of CIN1 of which 
the colposcopy diagnosis was high-grade CIN. Please see the results summary in table 3.2.1.  
 
All ten cervical samples tested positive for hrHPV on Cobas. HPV 16 was found in 7 samples 
and HPV (other) were found in 7 samples; six samples had both HPV16 and another high risk 
HPV types HPV (other). 
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Table 3.2.1: Storage study results  
No Age Smear  Colpo Histo/  
Specimen 
Cx 
HPV 
0wk 
Cx 
CT 
0wk 
Vag 
HPV 
1wk 
Vag 
CT 
1wk 
Vag 
HPV 
2wk 
Vag 
CT 
2wk 
1 24 Sev hgCIN  CIN3 
LLETZ 
16 
Other 
24.7 
24.6  
16     
Other 
29.1 
29.2 
16 
Other 
32.4 
35.5 
2 23 Mod hgCIN  CIN3 
LLETZ 
16 
Other 
27.6 
27.4  
16 
Other 
32.8 
36.5  
16 
Other 
31.8 
35.9 
3 27 Mild  
x2 
lgCIN  CIN1  
Punch Bx 
16 
Other 
26.8 
29.8  
16 
Other 
31.3 
33.7  
16 
Other 
29.8 
34.3 
4 36 Mild+ 
bnc 
hgCIN  CIN2 
LLETZ 
Other 31.3 Other 38.4 Other 39.0 
5 38 Sev hgCIN  CIN2 
LLETZ 
Other 28.5 Other 35.4 Other 37.9 
6 36 Mod hgCIN  CIN2 
LLETZ 
16 25.3 16 27.3 16 27.3 
7 31 Mild+ 
bnc 
hgCIN  CIN3 
LLETZ 
Other 31.1 Other  33.6 Other 37.1 
8 30 Mild+ 
referr
al 
hgCIN  CIN3 
LLETZ 
16 
Other 
25.8 
26.3 
16 
Other 
30.6 
28.7 
16 
Other 
32.2 
31.0 
9 24 Mod hgCIN  CIN2 
LLETZ 
16 24.3 16 30.5 16 34.0 
10 28 Mild+ 
bnc 
hgCIN  CIN1 
LLETZ 
16 38.3 Neg  Neg  
CT= cycle threshold, 16=HPV 16, other= a high-risk HPV type other than HPV 16.   
 
The CT value of the patient number 10 has been excluded from the analysis as it did not have 
any CT values for the vaginal sample. All other 13 sets of CT values were analysed using a 
linear regression model with the difference in cycle numbers as the outcome, and allow for 
clustering (so the standard errors are calculated using a clustered sandwich estimator). There is 
a significant difference between the cycle numbers needed for cervical week-0 and vaginal 
week-1 (Fig 3.2.1.a). There is a significant difference between the cycle numbers needed for 
cervical week-0 and vaginal week-2 (Fig 3.2.1.b). There is not a significant difference between 
the cycle numbers needed for vaginal week-1 and vaginal week-2 (Fig 3.2.1.c). 
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Fig 3.2.1: Analysis of the storage study data 
(a) diff1= cervical ct at 0 week - vaginal ct at 1 week 
 
(b) diff2= cervical ct at 0 week - vaginal ct at 2 weeks 
 
 
(c) diff3= vaginal ct at1week - vaginal ct at 2 weeks 
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Discussion 
Vaginal samples self-collected with the ‘dry’ Evalyn® brush remain viable for HPV testing for 2 
weeks. In a real time PCR (qPCR) assay a positive reaction is detected by an accumulation of a 
fluorescent signal. The CT (cycle threshold) is defined as the number of cycles required for the 
fluorescent signal to cross the threshold (i.e. exceeds background level). CT levels are inversely 
proportional related to the amount of target nucleic acid in the sample (i.e. the lower the CT 
level the greater the amount of target nucleic acid in the sample). CTs less than 29 are strong 
positive reactions indicative of a good quantity of target nucleic acid in the sample. CTs between 
30 and 37 are positive reactions indicative of moderate amounts of target nucleic acid. CTs 
between 38 and 40 are weak reactions indicative of minimal amounts of target nucleic acid 
which could represent an infection state or environmental contamination (manufacturer’s 
information).  
 
CT values of this PCR test suggest that there is a slight reduction of the viral load between 
weeks 1 and 2, which is unlikely have any clinical significance, as most of our main study 
samples were received within 2 days of collection. There is a good concordance between the 
clinician versus the self-collected samples. Only one discordant sample, participant 10- CIN1 
had the lowest cervical viral load (CT=38.3) and the vaginal samples were negative. We used 
only 3mL out of 20mL in the ThinPrep vial for this PCR assy. No sample concentration step was 
involved. CT values would have been lower, if the method of sample concentration (please see 
study 2.1) of the whole sample had been used. On the other hand, CIN1 has nearly 70% 
chance of regression. This false negative result would probably not cause significant harm.  
 
There is a perfect concordance (in terms of HPV positivity) between the cervical and vaginal 
samples in high grade CIN (all except sample number 3 and 10). A study which investigated the 
use of quantitative real-time PCR (QRT-PCR) which is a detection method that is considered to 
be more sensitive than conventional PCR (Seth, Rippin et al. 2005), measured the viral load 
(copies/ µg DNA) in cervical, vaginal and urine samples grouped according to histological 
classification. The highest viral load was reported in cervical followed by vaginal (Table 3.2.2) 
and urine samples (Daponte, Tsezou et al. 2008).  
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Table 3.2.2: Viral load in different samples  
 Minimum Median Maximum 
A. Viral load—cervix (p <0.001) 
Low grade (n = 49)    2 245 26 366           6 994 554 
High grade (n = 36) 3 077 1 236 781     9 182 746 
Cancer (n = 15) 94 110 7 793 442          7 558 141 
B. Viral load—vagina (p <0.003) 
Low grade (n = 49) 0 16 653                984 650 
High grade (n = 36) 0 20 503 984 650 
Cancer (n = 15) 13 302 78 835              838 045 
 
The CT value of the half of the Evalyn sample is less than the cervical counterpart. It would be 
interesting to know the quantity of HPV (CT values), between the cervical sample and the 
complete Evalyn sample (not half of it). However, using 2 separate Evalyn samples may not be 
ideal for this purpose as the second sample may not catch a cellular sample as well as the first. 
Although cutting may not divide the sample precisely into 2, it would probably be the better of 
two options. This limitation of half of the Evalyn sample may have been overcome if the 
ThinPrep sample had been appropriately diluted. For example, the cervical sample could have 
been diluted x 2 by adding another volume (20mL) of ThinPrep to the smear that had been 
collected. Another study looking at the CT value of the whole of the Evalyn sample in a more 
realistic sample (e.g. a sample stored only for 2-3 days) versus its cervical counterpart would 
also be interesting.  
 
The quantification of HPV DNA in self collected vaginal samples has been researched 
evaluating other self-sampling devices. Similar HPV positive rates between the cervix (13%) 
and the vagina (12%) have been reported in a large study (N=1194) when the same type of 
sampler (Dacron swab) has been used by clinician and for self-collection.  
 
The viral load in a self-collected sample was lower than but comparable to that of the gold 
standard cervical sample; even though the self-collected vaginal sample was stored for 1 to 2 
weeks before testing. These findings would encourage the use of the ‘dry’ Evalyn device for 
HPV screening. We had to limit the number of participants to 10 due to resource limitations. A 
study with the adequate power to calculate concordance between cervical and self-collected 
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vaginal samples and dilution of cervical sample twice to be comparable with the half of the 
Evalyn sample might have strengthened our findings.    
 
Conclusions 
It appears that a vaginal sample self-collected with the ‘dry’ Evalyn® brush remains viable for 
HPV testing for 2 weeks when a PCR based test is used for testing. There is a good agreement 
between the clinician-collected cervical sample and self-collected vaginal sample for HPV 
screening in subjects with hgCIN.  
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3.3 How accurate are the addresses found in the Scottish Cervical 
Call-Recall System (SCCRS)?  
 
Study question 
How accurate are the addresses found in the SCCRS?  
 
Summary answer 
Addresses in the SCCRS are more inaccurate than the Sci Store Live database 
(OR=3.4, 2.3-5.0). 
 
What is known and what this study adds 
Inaccurate addresses in the screening database may adversely affect screening 
participation. There is no published evidence comparing accuracy of addresses 
found in the SCCRS. The odds ratio of an address being wrong in SCCRS relative to 
Sci Store Live database is 3.4 (2.3-5.0). Our data suggest that about 8% of screening 
letters sent by SCCRS may not reach the target, which can be improved. 
 
Limitations 
This study assumed that letters which were not returned undelivered were received 
by the appropriate person. This is not entirely correct as the person may no longer 
living in that address and the mail redirection service could be inactive. Some letters 
may be lost even after it was delivered to the right place. Some people may not read 
the (screening) letter even if it was received safely. Addresses on two databases 
were cross-checked twice, once on the computer, once on the hard copy. But, there 
is still a room for human error of not recognising the mismatch.  
 
 
Background 
No screening database appears to be perfect. A total of 398 (10%) ineligible women, because of 
incorrect addresses or previous hysterectomies were identified in the self-sampling study which 
was conducted in Sweden by Lindell and colleagues (Lindell, Sanner et al. 2012). Around 20% 
addresses in the cervical screening database in London was predicted to be inaccurate or 
‘ghosts’ (letters sent to an inaccurate addresses) by the Szarewski self-sampling study group 
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(Szarewski, Cadman et al. 2011). Inaccurate addresses could be more common among women 
who were categorised as screening programme defaulters. We attempted to evaluate this 
situation in a cervical screening defaulter database in rural Britain (Dumfries and Galloway).   
 
Each participant’s SCCRS address in the 1000 and the study groups were double checked by 
the Research and Development Support Unit at NHS Dumfries and Galloway against the 
TOPAS patient access database, which is believed to be more up-to-date. This revealed some 
inaccuracies of SCCRS addresses, in comparison to the TOPAS. Consequently, a total of 246 
(246/1246=19.7%) addresses that did not tally were removed from the 1000 study group, and 
21(21/221=9.5) were removed from the 200 study group. Still, some letters have been returned 
undelivered. One letter was sent to a lady who had passed away, sometime before. This 
unpredicted situation led us to investigate the accuracy of addresses found in the SCCRS 
database.  
 
We aimed to find the most accurate address for our younger (<30 years old) defaulters study 
where different smear options were offered. We came to know that the Sci Store Live database 
has the most up-to-date addresses of the public/ patients. The Sci Store Live database is a 
national patient access database which is maintained by an organisation in partnership with the 
NHS Scotland. We decided to cross check SCCRS addresses of the younger defaulter study 
group against the Sci Store Live database. 
 
Methods 
Cervical Screening Programme defaulters aged between 20 and 29 years living in Dumfries & 
Galloway were identified in August 2012. There were 1441 defaulters. We checked all of these 
1441 SCCRS addresses on the Sci Store Live database from 2nd to 6th day after pulling the data 
out of SCCRS to create the research database. Addresses were cross-checked twice by the PI.  
 
Addresses that did not match (n=82) were identified. On the 8th day, a non-selected sample of 
10 discrepant addresses (every 8th address) was chosen to confirm their accuracy. Ten phone 
calls were made to the GP of the patient through the hospital switch board to find the correct 
address. Seven different GP practises were contacted. The address that the GP held was 
checked against the address on the database.  
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We could not find a reliable way of finding the accurate address of these 82 defaulters. This 
pushed us to hold on to those addresses for 2 months. These 82 addresses on the database 
were checked against the Sci Store Live database as well as on the SCCRS database in the 9 th 
week.  
 
There is a tab called ‘timeline’ both in SCCRS as well as Sci Store Live. It shows the date and 
the time that the person’s address had been changed. The Sci Store Live has further details on 
this which includes the time and venue that the address has been updated. The timeline of the 
address changes were compared in these 2 databases.  
 
Results 
Of 1,441 addresses 1,359 (94%) matched. A total of 1,359 letters were sent to relevant 
addresses. Thirty four (2%) letters were returned undelivered.  
 
Eighty two addresses did not match. A sample of 10 discrepant addresses was selected. Every 
eighth address of the unmatched address was chosen (numbers 8 16, 24, 32, 40, 48, 56, 64, 71 
and 80). Ten phone calls were made to the GP of the patient though the hospital switch board to 
find the correct address. Seven different GP practises were called. It appeared that the GP had 
the same address as per SCCRS, except in one case.  
 
On week 9, 67 out of 82 addresses matched between the SCCRs and the Sci Store Live 
database. All 82 letters were posted to the address found on the Sci Store Live database. Three 
letters were returned undelivered. 
 
Correlation of the timeline indicated that the Sci Store Live database is more up-to-date than the 
SCCRS database.  
 
Despite being deemed as accurate by 2 databases, 2.6% (34+3)/1441 letters were returned 
undelivered in this cohort of younger (20-30 years old) defaulters. This indicates that no 
database is perfect and 2.6% addresses in the Sci Store Live could be inaccurate.  About 8% 
(119/1441) addresses in the SCCRS could have been inaccurate. The odds ratio of SCCRS 
addresses could be inaccurate in comparison to Sci Store Live is 3.42 (2.3-5.0). 
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Discussion 
The Sci Store Live database has the more up-to-date addresses than the SCCRS. The Sci 
Store Live is expected to have more accurate addresses as it is a ‘live’ database. Six percent 
(1,359/1441) of address in the SCCRS did not match with the Sci Store Live. Despite 
agreement by 2 databases, up to 2% of letters were returned undelivered in this cohort of 20-30 
years old defaulters.  
 
These data also suggest that about 8% of screening invitation letters sent by SCCRS may not 
reach the targeted women. However, such women will probably receive the reminder letter 
which will be sent 2-9 months after the first invitation (prompt letter).  
 
Conclusions 
The Sci Store Live database has more up-to-date addresses than the SCCRS. The odds ratio of 
SCCRS addresses could be inaccurate in comparison to Sci Store Live is 3.42 (2.3-5.0). This 
indicates that about 8% of screening letters sent by SCCRS may not reach the target.  
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3.4 RESEARCH METHODS 
 
Ethical, Caldecott and management approval  
 
The West of Scotland Research Ethics Service approved this study on 7 October 2011 
(Reference No: 11/AL/0333). Please find the main ethical approval and two amendments in the 
Appendix 4. The Caldecott Guardian of NHS Dumfries & Galloway approved the access to the 
Scottish Cervical Call-Recall System database on 12 March 2012. Subsequently, the Research 
and Development and the NHS management approval were granted.  
 
The study population   
 
The population in Dumfries & Galloway is 148,190 (NHS Dumfries and Galloway 2 2013) which 
is scattered over a large geographical area of 2,400 square miles (Fig 3.2.2 and Fig 3.2.3), 
making it a rural population. About 36,500 women between the ages of 20-60 are eligible for 
cervical screening in this county. Of eligible women, 76.6% had been screened in the previous 
3.5 years, and there were 6,109 cervical screening programme defaulters in January 2012.  
 
There were 3498 defaulters between 30 and 55 years on 14 th March 2012.  A total of 1441 
defaulters were found between the age of 20 years and 29 years on 3rd September 2012 and 
648 defaulters between 56 and 60 years on 26th October 2012. 
 
We targeted defaulters in the 30-60 year age group for HPV screening. Cytology screening only 
was offered to the younger 20-29 defaulters.  
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Fig 3.3.1: Geographical area of Dumfries and Galloway (Google Company USA 2014) 
 
 
Fig 3.3.2: Distribution of  NHS Dumfries & Galloway hospitals (NHS Dumfries and Galloway 
2013) 
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Sample size considerations 
 
The reported range of self-sampling uptake rate in eight population-based, large-scale self- 
testing studies was between 6.4% (Szarewski, Cadman et al. 2011) and 39.1% (Sanner, 
Wikstrom et al. 2009). The range of uptake rate of the standard smear (LBC) in those self-
testing studies was between 4.1% (Szarewski, Cadman et al. 2011) and 17.6% (Bais, van 
Kemenade et al. 2007). We were hoping that 10-20% women would accept the HPV self-test 
and 5-10% women would accept the smear test because our target population tends to behave 
more like the population in London than in Sweden. We hypothesized that 15% of the target 
population of the 30-60 age group would accept self- sampling whilst it would be 7% for cervical 
smears.  
 
Assuming 15% HPV self-sampling uptake rate, the width of the 95% confidence intervals based 
on 200, 1000 and 2000 invitations would be +/- 5%, +/- 2.5% and +/- 1.5% respectively. 
 
STATA Version 12.0, SPSS Version 22.0 (Armonk, NY, USA) and Comprehensive Meta-
Analysis Version 2.2.064 (Biostat Inc., NJ, USA) software was used for statistical analysis.  
 
Timetable 
Recruitment to all primary studies was carried out from 15th March 2012 to 31st December 2012. 
The follow up of vaginal HPV positive but, smear negatives (with a repeat smear test and 
colposcopy) was carried out from 17th June 2013 to 31st December 2013. Two women who were 
unable to attend in December re-scheduled for 19th January 2014.  
 
Study design 
The main study design was to offer vaginal self-sampling to defaulters aged between 30 and 60 
years and to offer multiple options to have a smear test for defaulters aged between 20 and 29. 
Such defaulters were identified from the Scottish Cervical Call-Recall System by the Screening 
Services Manager, NHS Dumfries & Galloway. These defaulters were sent an initial letter (Fig 
3.3.4, Fig 8.2.1, Fig 8.2.2), inviting them to consider various options (Fig 3.3.5, Fig 8.2.3) either 
to have a smear test or self-collect a vaginal sample for HPV screening.  
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Fig 3.3.4: The main body of the initial invitation letter (30-60 year old defaulters) 
Your cervical screening test  
 
We are writing to you because our records show that you are not up-to-date with your 
cervical smear test. Cervical screening tests enable us to detect the curable pre-
cancerous stage of cervical cancer.  
 
Around 1000 women die of cervical cancer in UK each year. However, most of those who 
develop it have not been screened regularly. Not going for cervical screening is one of 
the biggest risk factors for developing cervical cancer.  
 
Attendance for a cervical screening test is therefore advised.  
 
We recognise that some women (for a variety of reasons) do not attend the routine smear 
test appointment. We have therefore designed a study to offer women various options for 
getting a cervical screening test.  
 
Fig 3.3.5: Option list (30-60 year old defaulters) 
Options List (please tick the most suitable one for you) 
1. I will make an appointment with my GP Practice or the Sexual Health Clinic 
            to have a routine smear test. 
2. Please give me an appointment at a hospital clinic to have a routine  
smear test. 
3. Please give me an appointment at a hospital clinic. I prefer to collect  
          a vaginal sample myself but under a supervision of a health professional. 
4. I would like to self collect a vaginal sample at home. 
5. I would like a doctor to contact me to discuss how I might get a test. 
6. None of above options suits me.  
 
 Please tell us what arrangements might suit you  or why you do not want a test  
 
     ........................................................................................................... 
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Defaulters could also discuss anything with investigators or opt out. They were asked to inform 
us of their decision by retuning the options list which accompanied the initial letter. All options 
lists were returned to the Research and Development Department, where they were sorted and 
recorded appropriately by the Data Manager of the unit. The women’s choice was facilitated 
appropriately (Fig 3.3.6). Women who wished to self-collect were sent a self-sampling kit with 
an information and consent pack with a pre-paid Royal Mail first class secure envelope. Vaginal 
samples were returned to Dumfries laboratory via the Research & Development Support Unit, 
where they were suspended in ThinPrep and were despatched to the Scottish HPV Reference 
Centre in Edinburgh for Hologic Cervista HPV-HR testing.  
 
Each woman was informed of her HPV status in writing with adequate information. Whilst HPV 
positives were sent an appointment to have a smear test at the hospital smear clinic, which was 
dedicated for this purpose; HPV negatives were strongly advised to accept their next smear 
invitation. Women who were unable to come to the hospital were advised to have a smear test 
locally. In HPV positive women, smear (liquid based cytology, LBC) positives (borderline nuclear 
change or worse, >BNC) were referred to colposcopy as per local and Scottish guidelines. 
Smear negatives were advised to attend the annual follow-up clinic at the hospital. Women with 
any unsatisfactory test were offered a hospital smear clinic appointment to have a repeat 
cervical sample for LBC and HPV testing.  
 
An annual follow-up appointment was sent about 12 months after the first smear test to HPV 
positive women who had at least had one smear test and who had not been referred to 
colposcopy. At the annual follow-up, the cervical smear was repeated and colposcopy was 
carried out according to the BSCCP guidelines and standards. Women diagnosed with CIN on 
punch biopsy were referred to another colposcopy clinic appropriately.  
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Fig 3.3.6: Study flow chart 
 
 
Abbreviations: SCCRS = Scottish Cervical Call-Recall System; HPV =human 
papillomavirus; LBC=liquid based cytology; *Borderline dyskaryosis+ 
Identify defaulters living in Dumfries & Galloway in 2012 from SCCRS  
20-29 years old  
(n=1441) 
Make a choice 
Cervical 
smear  
No reminder  
No questionnaire 
Follow-up 
Facilitate choices 
Offer various 
smear options 
30-55 years old  
(n=3498)  
Make a choice 
Cervical 
smear 
Follow-up  
 Vaginal self-
sampling 
HPV screening 
HPV +  
Smear +  
Colposcopy  
Follow-up 
Smear -  
Colposcopy+ smear 
  in 1 year 
Follow-up  
HPV -  
Accept next smear 
invitation  
Follow-up 
Inadequate  
Cervical sample 
for LBC+HPV  
Follow-up 
Despatch to 
laboratory  
Facilitate choices 
No response 
Reminder + 
questionnaire 
Offer various 
screening options 
56-60 years old  
(n=648) 
’Letter’ (45%) 
‘Kit’ (45%) 
No intervention (10%) 
No reminder  
No questionnaire 
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Contents of the self-sampling kit pack 
1. The sealed, sterile Evalyn device which is placed inside a transparent, ‘peel 
and seal’ type plastic bag which measures (10x25cm). A white colour, 
absorbent pad (12x9cm) is also seen inside the plastic bag (packed according 
to the UN3373 standards packaging instruction P650). 
2. A pre-paid, white colour jiffy bag (170x225cm) with the return address 
(Appendix 3.3) 
3. Evalyn patient information leaflet (Appendix 3.1-3.2) 
4. Questionnire-1 with a check list  
5. Two copies of the consent form 
6. The study’s patient information leaflet 
7. A list of frequently asked questions (Appendix 1) 
8. A letter addressed to the participant  
 
Methods of vaginal self-collection  
The woman was advised to read the Evalyn brush patient information leaflet and our 
check list carefully, before the sample was collected. It is a two page leaflet with 
colorful illustrations (please see appendix 3).   
 
The information leaflet instructs the female to spread the labia with one hand and 
insert the Evalyn brush into the vagina with the other, until the ‘wings’ of the Evalyn 
device come to contact with the labia. Then she is instructed to push the plunger 
(handle) in, hold it firmly and rotate the plunger 5 times clockwise, remove it and pull 
the plunger back, put the cap on and place it back in its plastic housing. This should 
be put in a transparent plastic bag which should be sealed after peeling its sticker off.  
 
This plastic bag and the signed consent form and completed questionnaire were 
dispatched to Dumfries Laboratory in the pre-paid, first class mail jiffy bag provided. 
The woman was asked to put the large size envelope in a post box. 
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Methods of suspending vaginal Evalyn sample in ThinPrep vial  
The Evalyn sample, the questionnaire and the consent form were all pre-labelled with the 
participant’s name, a 10 digit CHI number, reference number and a barcode before the 
Evalyn kit was sent to the woman.  The accuracy of all the patient identifiable data were 
cross-checked and recoded in the laboratory book before the sample was processed. 
The laboratory barcode label which comes in duplicate was placed on the ThinPrep vial 
and the laboratory book. The plastic bag was cut open with a pair of scissors. The seal of 
the ThinPrep vial was broken and the screw of the vial was loosened, but was not left 
open. A new pair of clean gloves was worn before each sample was processed. The cap 
of the Evalyn device was pulled out. The handle of the Evalyn was then pushed in so that 
the head of the Evalyn device would come out. With a new pair of clean, disposable, 
plastic tweezers, provided by Rovers Medical Devices, the plastic head of the Evalyn 
brush was pulled out and immediately put in the ThinPrep vial. The cap of the ThinPrep 
vial was then shut and vortexed for 2 minutes. The floating head of the Evalyn brush was 
then picked up to be discarded by a new pair of tweezers.  
 
Methods of HPV DNA testing 
1. The sample suspended in the PreservCyt solution is transferred from the 
ThinPrep pot to a 50mL Falcon tube. 
2. They are then centrifuged at 1,110g for 10 min to pellet the cells. 
3. All but 5mL of the PreservCyt is removed and the cells are re-suspended in the 
remaining 5mL of PreservCyt before being returned to the original ThinPrep pot. 
4. ThinPrep pots are loaded onto the Hologic Sample Transfer System (STS 5000), 
in which 2mL of each sample are deposited into wells of a deep- well plate. 
5. The deep-well plate (containing the 2mL aliquots of each sample) is loaded onto 
the Hologic HTA with the appropriate reagents to perform the Genfind script (this 
is the DNA extraction step). 
6. The extracted DNA plate (containing the extracted DNA from each of the 
samples) is then reloaded onto the Hologic HTA (for research purposes only) with 
the appropriate reagents to perform the Cervista HPV HR script (this is the actual 
Cervista step). 
7. Results are recorded/ reported appropriately. 
The Cervista™ HPV HR test (Third Wave Technologies, Inc./Hologic Inc., Madison, WI, 
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USA) is a qualitative test for the detection of DNA from 14 high-risk HPV types, namely, 
types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68. A positive result indicates 
that at least one of the 14 high-risk types is present in the DNA sample. The test uses 
the Invader® chemistry, a signal amplification method for detection of specific nucleic 
acid sequences. It has an internal control to detect genomic DNA so that the risk of a 
false negative result is low.  
 
Methods of sample collection for LBC 
Patients were asked to lie in the dorsal position and a plastic disposable Cusco’s bivalve, 
self-retained vaginal speculum was introduced until the cervix was clearly visualized. Any 
profuse discharge or mucous was gently cleared with a large cotton bud. A cervical 
cytology sample was taken with a Rovers Cervex brush and an endocervical brush. The 
Cervex brush was put in the centre of the cervix ensuing that middle longer bristles were 
placed in the endocervical canal. It was rotated clockwise five times, maintaining 
adequate pressure, constantly. The endocervical brush sampler was then introduced 
inside the endocervix with the outermost bristles touching the ectocervix, rotated 1 time 
in a clockwise direction and then placed in the ThinPrep specimen collection tube as 
recommended by the manufacturer. 
 
Methods of diagnostic colposcopy 
Diagnostic colposcopy was carried out by British Society for Colposcopy and Cervical 
Pathology (BSCCP) accredited colposcopists at the Colposcopy Suite, Dumfries & 
Galloway Royal Infirmary. The NHS Cancer Screening Programme’s colposcopy 
guidelines were followed. After application of 3% acetic acid, the entire transformation 
zone, the rest of the cervix and the vagina was systematically examined though the 
colposcope. Colposcopic features of any recognizable lesion were recorded on a 
colpograph. Visualizing the entire squamo-columnar junction and the upper end of the 
lesion, if any found, was always attempted. The Schiller’s test was carried out using 
Schiller’s iodine when indicated. Colposcopic directed punch biopsies were taken when 
the recognizably atypical transformation zone was present.  Multiple biopsies were taken 
from lesions as necessary. No biopsy was taken if the colposcopy examination was 
normal. The colposcopic diagnosis of the lesion  was recorded along with the colpograph 
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Methods of recording findings of diagnostic colposcopy  
In order to explain colposcopic findings in a structured chart for recording colposcopy 
findings, I designed a colpograph (Fig 3.6.7) adhering to the BSCCP guidelines. This 
colpograph would give a reproducible, objective and schematic representation of the 
cervical disease. Aims of designing this colpograph were to precisely explain the extent 
to which HPV+ defaulters would have the HPV disease and to objectively appreciate the 
difference between the HPV screening and the cytology screening.   
 
Fig 3.3.7: A detailed colpograph 
 
Types of transformation zones   
The anatomical junction where the endocervical columnar epithelium meets the 
ectocervical squamous epithelium is the squamo-columnar junction (SCJ). The 
anatomical location of the SCJ in relation to the external cervical os changes during the 
reproductive life mainly due to hormonal effects, giving rise to the original and new SCJ. 
The region (zone) between the original and the new SCJ is by definition is the 
transformation zone (TZ) (Fig 1.1.8). Whilst cells in the SCJ are most susceptible cells to 
HPV attack, TZ is the zone of the cervix where most HPV induced neoplasia (pre-cancer 
and cancer) develop. In other words, TZ (which includes SCJ) is the most vulnerable 
area of the cervix for HPV disease.  
 
 
 
 
Squamous epithilium 
Punch biopsy 
Squamo-columnar junction 
High-grade CIN 
Endocervical canal 
Low-grade CIN 
Columnar epithelium 
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Fig 3.3.8: Different types of transformation zones   
a) Type I TZ- SCJ is fully seen. It is completely ectovervical. 
 
b) Type II TZ- the new SCJ is fully seen. The TZ has an endocervical component 
and may have an ectocervical component. 
 
c) Type III TZ- SCJ is not seen. It recedes within the endocervical canal.  
 
Squamous epithelium 
Endocervical canal 
Opening of the endocervical canal 
Squamo-columnar junction 
Squamous epithelium 
Columnar epithelium 
Opening of the endocervical canal 
Columnar epithelium 
Squamous epithelium 
Squamo-columnar junction 
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Definition of a Scottish Cervical Screening Programme defaulter 
In simple terms, a screening eligible woman who is not up-to-date with her cervical smear test is 
a defaulter. This is, however, difficult to define. 
 
In Scotland, cervical screening is offered to every woman with a cervix between the age of 20 
years +1 day and 60 years and 364 days. The routine recall is every 3 years across the 
screening age group. There are 3 non-routine recalls based on the indication to repeat the test. 
8. 3 months (inadequate smear) 
9. 6 months (immediate post colposcopy or treatment) 
10. 12 months (non-immediate follow-up after the treatment).  
A woman becomes a defaulater if she has not been for testing 3 months after her final reminder. 
Defining a defaulter depends on the woman’s recall advice. Women called routinely for 
screening are sent a prompt and two reminders whereas women requiring follow up are sent an 
additional reminder to attend for screening. A woman who has not attended a routine recall will 
be excluded from the recall and called a defaulter 9 months after being due for a smear (after a 
prompt and 2 reminder mailers at 0, 3 and 6 months, respectively Table 3.3.1). Therefore, a 
woman who has had a routine negative smear but no subsequent test will be called a defaulter 
45 months (36+9) afte her normal test. Similarly, a 20 years and 9 months old woman who 
hasn’t responded to recall letters will be a SCCRS defaulter (see example 1 in table 3.3.2).  
 
Table 3.3.1: The Scottish cervical screening invitation intervals 
 Prompt  Reminder 1 Reminder 2 Reminder 3 Defaulter  
Routine 
Screening  
When 
screening 
is due 
3 months 
after prompt  
3 months 
after 1st 
reminder  
Not 
applicable  
 
Cumulative 
months 
0 3 6 n/a 9-36 
Non-routine 
Screening  
When 
screening 
is due 
2 months 
after prompt  
2 months 
after 1st 
reminder  
8 months 
after 2nd 
reminder  
 
Cumulative 
months 
0 2 4 12 15-36 
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Defining a defaulter status for non-routine recall is more complex. A woman with a non-routine 
recall will be called a defaulter in 15 months of non-respondence (after receiving a prompt 
mailer at 0 months and 3 reminder letters at 2, 4 and 12 months: Table 3.3.1). A women who 
has had her first abnormal smear (e.g. mild dyskaryosis) today and has never attended a in a 
routine recall will be called a defaulter 21 months (6+15) later. If the recall has been 12 months 
(non-immediate follow-up after the treatment), the defaulter status starts at 27 months (12+15). 
If the recall has been 3 months (inadequate smear) the defaulter status starts at 18 months 
(3+15). A woman referred to colposcopy with an abnormal cytology who has failed to attend 
colposcopy clinic appointment/s will be sent reminders by the SCCRS similar to the standard 
non-routine defaulter. A prompt letter will be sent 5 months after the original colposcopy referral 
date and 3 reminders will be sent 2, 4 and 12 months after the prompt mailer.  
 
Routine recall defaulters will be invited for a smear (will receive a prompt letter) 6 years (+0 
months) from the date that woman last had a normal smear test by the SCCRS, A new invitation 
is sent after 4 years for non-routine recalls.  
 
 
Examples of cervical screening recalls 
If a woman in a routine recall (e.g. no previous abnormal smears) did not attend her smear 
which was due on month 36, she will be sent a prompt letter (initial invitation) on the 18 th of the 
month that she was due for a smear. Assuming that she does not respond to any of these 
letters, she willl be sent  the first reminder at 39 months and the second reminder at 42 months. 
She will be excluded from the recalling at 45 months and named a defaulter for the next 27 
months (i.e. month 72). From the time of this invitation until after the reminders (72 to 81 
months) she will not be considered a defaulter even though she does not go for screening (Fig 
3.3.9a).  
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Fig 3.3.9a: Screening recall - routine 
  
 
Fig 3.3.9b: Screening recall - non-routine 
 
 
If a woman in a non-routine recall (e.g. a woman who has been up-to-date with her smears but 
the last smear test was reported as borderline dyskaryosis) has not attended her smear which 
was due in 6 months, she will be sent a prompt letter (initial invitation) in the month that she was 
due for a smear. Assuming that she does not respond to any of these letters, she willl be sent 
the first reminder at 8 months, the second reminder at 10 months and the third reminder at 18 
months. She will be excluded from the recalling at 21 months and named a defaulter for the next 
21 months. After 42 months since her last smear test, she will be sent the second batch of 
recalls (another prompt letter at 42 months followed by 3 reminders at 44, 46 and 54 months) 
(Fig 3.3.9b). 
0 12 24 48 36 60 72 84 
Reminder  
Defaulter (21) 
Abnormal smear 
Defaulter (21) 
Exclusion  Prompt  
(15) (15) (15) 
Key: numbers represent number of months   
0 12 24 48 36 60 72 84 
Reminder  
Screening interval (36) 
Normal smear   
Defaulter (27) 
Exclusion  Prompt  
(9) (9) 
Key: numbers represent number of months   
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The interval between the abnormal smear test and the prompt letter depends on the type of 
abnormality and whether or not she has been treated.  If it has been an inadequate test, the 
interval will be 3 months (example 3, table 3.3.2). For any other smear abnormality, including 
the ones who have failed to attend colposcopy, it is 6 months (example 5). For post treatment it 
can be either 6 months (immediate post treatment) or 12 months (long term follow-up until they 
get back to routine screning).  
 
Table 3.3.2: Examples of different types of defaulters  
 Description of the 
defaulter 
Prompt 
letter 
First 
remind
er 
Second 
remind
er  
Third 
remind
er  
Exclusi
on 
started 
Projecte
d recall 
1 20 year old (DOB 
03/10/91) who has 
never had a smear 
(RR) 
18/10/ 
2011  
(0) 
18/01/ 
2012  
(3) 
18/04/ 
2012  
(6) 
n/a 18/07/ 
2012  
(9) 
18/10/ 
2014  
(36) 
2 30 year old who has 
had a negative smear 
12/11/08  
(RR) 
18/11/ 
2011  
(0) 
18/02/ 
2012  
(3) 
18/05/ 
2012  
(6) 
n/a 18/08/ 
2012 
(9) 
18/11/ 
2014  
(36) 
3 30 year old who has 
had a unsatisfactory 
smear 31/01/08  
(NR) 
18/05/ 
2011  
(0) 
18/07/ 
2011  
(2) 
18/09/ 
2011  
(4) 
18/05/ 
2012 
(12) 
18/08/ 
2012 
(15) 
18/05/ 
2014  
(36) 
4 28 year old who had 
CIN2 21/11/06 & 
negative smear 
12/05/10  
(NR) 
18/05/ 
2011  
(0) 
18/07/ 
2011  
(2) 
18/09/ 
2011  
(4) 
18/05/ 
2012 
(12) 
18/08/ 
2012 
(15) 
 
18/05/ 
2014  
(36) 
5 32 year old who had 
moderate dysk  on her 
3rd smear 07/07/09 
 (NR) 
18/12/ 
2009  
(0) 
18/02/ 
2010  
(2) 
18/04/ 
2010  
(4) 
18/12/ 
2010 
(12) 
Had a 
smear 
01/03/ 
2011 
severe 
Attended 
colposco 
14/04/ 
2011 
Only the last cycle of recall is illustrated. The number of months since the screening has been 
due is in brackets. RR= routine recall. NR= non-routine recall. 
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CHAPTER 4 
 
Interventional studies to offer screening to defaulters  
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4.1: The 1000 defaulter study 
 
Study question 
Can cervical screening participation be improved by sending multiple screening options letters 
to defaulters aged 30-55 years?  
 
Summary answer 
The total positive response rate was 24% (21%-26%) (236/1000). Whilst 129 (13%) defaulters 
opted-in for self-sampling, 92 (9%) samples were received.  
 
What is known and what this study adds 
Sending a self-sampling kit to defaulters is known to increase the screening participation. This 
study showed that sending a letter offering multiple screening options which includes self-
sampling increases cervical screening uptake rate.  
 
Limitations  
It was not possible to check the screening status of defaulters 6 months after the intervention so 
the total number of defaulters screened is unknown.  
 
Methods 
The aim of the three studies in defaulters aged 30-55 was to investigate whether it was possible 
to increase cervical screening participation in screening defaulters by increasing their options for 
screening. In particular to see whether defaulter aged 30-55 years would choose to provide a 
self-sample for HPV testing. Rather than inviting all defaulters in one go, it was decided to invite 
them in stages so as to ensure that we would be able to deal with all requests for screening 
promptly and so that if necessary the protocol could be modified in response to lessons learnt 
from the first wave of invitations. The first study aimed to offer 1000 defaulters several options 
for cervical screening.  
 
The addresses and vital status of all women in the 30-55 year old defaulter database were 
cross-checked against the hospital database (TOPAS Patient Administrative System) by the 
data manager of the Research & Development Support Unit. The database was ordered by the 
community health index (CHI) number. We continued cleaning the database until we had 1000 
valid live subjects with addresses that were the same in the two databases. We examined 1246 
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women in order to identify 1000 to invite. Five women were found to be deceased; two had left 
the country; and 239 were excluded either because the addresses in the two databases did not 
match or because no address was found in the TOPAS database.  
 
All of these 1000 women were sent the initial invitation letter (Fig 3.3.4) inviting them to select 
one option from a list of six (Fig 3.3.5). Invitations were posted by second class mail between 15 
March 2012 and 20 April 2012. Those who did not respond within 3 months were sent a 
reminder letter with the same options. 
 
Women requesting to do HPV testing at home were sent a self-sampling kit. Women who have 
asked for an appointment at a hospital clinic for a HPV test (option-3) were counselled at the 
clinic. They were offered two options: to self-collect a vaginal sample with the Evalyn brush 
under direct supervision of the clinician or to allow clinician to collect a vaginal sample with the 
Evalyn brush adhering to manufacturer’s self-sampling steps [please see details in chapter 3]. 
All women requesting a hospital HPV test asked the clinician to collect the sample. Women 
requesting a cervical smear test at a hospital clinic were offered an appointment and those who 
attended had a speculum examination and a cervical sample taken by a clinician.  
 
Women testing HPV positive on their self-sample were encouraged to have a smear taken at 
the hospital clinic. All women who came to the hospital smear clinic were offered dual testing: 
LBC with HPV testing of the residual. The clinician-collected cervical samples were first used to 
prepare a LBC slide, and residual material was used for HPV testing (reflex HPV testing). All 
HPV tests used the Cervista assay [please see details of laboratory methods in chapter 3] 
 
Women who returned the option questionnaire consented to being following in the SCCRS 
database and details of any subsequent cervical screening in these women were noted. We did 
not have permission to access the screening records of women who did not return their options 
list. 
 
The age of the woman, the time since her last smear test and the type of defaulter (previously 
routine, previously early recall following borderline changes, etc.) were recorded. 
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Results 
A total of 258 option lists were returned (Table 4.1.1). The first option (to have a routine 
screening at the GP practice) was ticked by 63 (6%), the second (to be screened at a hospital 
clinic) was ticked by 23 (2%), the third (HPV testing at a hospital clinic) was ticked by 5 (1%), 
the fourth (HPV testing of a self-sample) by 129 (13%), the fifth (discuss) by 16 (2%) and the 
sixth (opt out) by 22 (2%). According to the number of option lists returned, the total positive 
response rate (excluding those who opted out) was 209 (21%). I was unable to determine the 
number of women who had smears at their GP practice without returning the option list.  
 
Table 4.1.1: Response in the 1000 defaulter study at 6 months 
Option  Description  n % 
1 Smear at GP 63 6 
2 Smear at hospital clinic 23 2 
3 HPV testing at hospital clinic 5 1 
4 HPV testing at home 129 13 
5 Wanted to discuss 16 2 
6 Opt out 22 2 
 Total positive response 236 24  
 
About a third (40/129=31%) of those requesting a self-sampling kit (option 4) did so only after 
receiving the reminder letter. In other words, 89/1000 requested a kit within the first 3 months. 
Only two requests for the option-2 were received after the reminder and there were no option-3 
or option-5. About a dozen of option-1 and a similar number of option-6 were returned after 
receiving the reminder. 
 
Women in the 1000 defaulter study who opted to self-collect (n=129) had median age of 44 
years with inter quartile range 39-52 years. The mean duration for which these defaulters had 
not been screened (duration since the last smear test, if any, or from 20 years of age otherwise) 
was 9.0 years, standard deviation 5.6 years. The median was 8 years with IQR of 5-11 years.  
Fourteen (11%) had never been screened. There were 5 women on the non-routine recall 
category with a previous non-normal smear. Times since last smear test of these 5 women were 
2 years (unsatisfactory), 3 years (borderline dyskaryosis), 3 years (borderline dyskaryosis), 3 
years (unsatisfactory) and 7 years (borderline dyskaryosis).  
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Fig 4.1.1: HPV screening and follow-up summary of the 1000 defaulter study 
 
Abbreviations: HPV+= HPV positive; HPV-= HPV negative; smear+= smear positive; smear-= 
smear negative; <CIN2= low-grade CIN or less; CIN2+= high-grade CIN or worse; F/U= follow-
up. The number of women is indicated within brackets.  
 
 
Pre-screened  
(1246) 
Excluded  
(246) 
Options letters sent  
(1000) 
Kits requested 
(129) 
Samples received  
(92) 
HPV - (50) 
Had a smear (4/31) 
Smear + (0) 
HPV + (42) 
Had a smear (40) 
Smear – 
(33) 
Annual F/U smear & 
colposcopy (23) 
<CIN2 (3) 
CIN2+ (2) 
No annual F/U smear & 
colposcopy (10-2) 
Smear - (1) 
Smear 
unsatis (2) 
Smear + 
(5) 
Repeat smear (3+2) 
Smear - (1) 
Smear + (0) 
Colposcopy (3+1)  
<CIN2 (0) 
CIN2+ (2) 
No smear (2) 
No sample  
(37) 
No reminder 
Had a smear (0/20) 
Smear + 
( 0) 
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Of the 129 women who requested a self-sampling kit, 92 (71%) returned a sample (Fig 4.1.1). 
Fifty (54%) of them were HPV negative, 42 (46%) were HPV positive. Almost all (40/42= 95%) 
HPV positives subsequently had a smear test. One woman who did not come for a smear test 
informed us that she would have it at her new GP practice in England as she was planning 
move away from Scotland at the end of 2012.  
 
A total of 40 smears were carried out in women who were HPV positive on their self-sample. 
Whilst the majority (n=38) came to the hospital smear clinic, two HPV positive women had 
smears at their own GP Practice. All were within 12 months of self-sampling.  
 
Thirty-three (83%) smear tests were reported as negative. There were 2 severe dyskaryosis, 2 
mild (low-grade) dyskaryosis, 1 borderline changes and 2 unsatisfactory smears. Two women 
with severe dyskarysis, one HIV positive woman with borderline dyskaryosis and one woman 
with persistent unsatisfactory smears were referred to colposcopy. Whilst the former 2 patients 
had CIN3, the latter woman had genital atrophy (no CIN detected). The HIV positive woman 
failed to attend her colposcopy appointment twice. Follow-up smears were arranged for all 
women.  The HIV positive woman had borderline changes 4 months after the first smear test. As 
of 10 June 2014 she hadn’t had any further smears. Both women with 2 unsatisfactory smears 
have had 2 satisfactory and negative smears, subsequently. One sample was not retained (after 
LBC) for HPV testing by error. Of 35 smear residuals with a valid HPV result, 14 (40%) had a 
positive HPV result (Table 8.1.1, Appendix 1). Residual samples of 2 smears which were taken 
in the community were not tested for HPV. 
 
Women with high grade CIN were referred to the Clinical Supervisor’s colposcopy clinic 
immediately. Women with low-grade CIN were referred to the same clinician to be seen at the 
colposcopy clinic in 6 months, keeping with local management guidelines. Women with hgCIN 
have had LETTZ treatment.  
 
Women who have had a negative smear following a positive vaginal HPV result in 2012 were 
invited to attend the annual follow-up clinic in 2013, approximately 12 months after the first 
smear test. Women who were referred to colposcopy in 2012 (n=4) and HPV positive women 
who did not attend the smear test in the first round in 2012 (n=2) were not invited to the annual 
follow-up. A total of 33 HPV positive were invited to the annual follow-up clinic. The majority, 
23/33=70% have attended the annual follow-up clinic. One of them decided to have a smear 
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test at the GP. At the annual follow-up clinic, the woman’s informed written consent was 
obtained for a repeat cervical smear test, diagnostic colposcopy ±punch biopsy. Colposcopic 
diagnosis was low grade CIN in 3 women, high grade CIN in 2 and suspected low grade CIN in 
one case. Punch biopsy confirmed above diagnosis except in the woman with suspected lgCIN, 
who was found to have cervicitis.  
 
Of the 50 women who tested negative for HPV, 31 were invited for a smear test by SCCRS by 
31 December 2013 (Fig 4.1.1). Four women (13%) have had a smear test. Although 20 women 
in the group that did not return a sample were called by SCCRS for a smear, none of them have 
had a smear test during the same period of time. This is simply an observation made by 
checking individual’s screening status in the SCCRS which is passive follow-up rather than any 
intervention.  
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4.2: The 200 defaulter study 
 
Study question 
Can cervical screening participation be improved by sending a self-sampling kit with multiple 
screening options letter to defaulters aged 30-55 years?  
 
Summary answer 
The total positive response rate was 32% (25%-38%) [63/200]. A total of 40 (20%) self-collected 
samples were returned.  
 
What is known and what this study adds 
Sending a self-sampling kit to defaulters is known to significantly increase the screening 
participation. Evalyn self-sampling device was not previously used for community based self-
sampling studies. Evalyn brush was well accepted by defaulters in this study.  
 
Limitations  
Sample size was limited to 200.  
 
Methods 
This second study aimed to offer 200 defaulters several options for cervical screening, which 
included sending a self-sampling kit with the initial invitation letter.  
 
The addresses and vital status of women in the 30-55 year old defaulter database were cross-
checked against the hospital database (TOPAS Patient Administrative System) by the data 
manager of the Research & Development Support Unit. The database was ordered by the 
community health index (CHI) number [please see details in chapter 1.3]. We continued 
cleaning the database until we had 200 valid live subjects with addresses that were the same in 
the two databases. We examined 221 women in order to identify 200 to invite. One woman was 
found to be deceased and 20 were excluded either because the addresses in the two databases 
did not match or because no address was found in the TOPAS database.  
 
All of these 200 women were sent a self-sampling kit with the initial invitation letter (Fig 3.3.4) 
inviting them to select one option from a list of six (Fig 3.3.4). Invitations were posted by second 
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class mail between 18 June 2012 and 22 June 2012. Those who did not respond within 3 
months were sent only a reminder letter with the same list of options (without a kit). 
 
Management of women was identical to that used in the 1000 women study. Women requesting 
a cervical smear test at a hospital clinic were offered an appointment and those who attended 
had a speculum examination and a cervical sample taken by a clinician. Women testing HPV 
positive on their self-sample were encouraged to have a smear taken at the hospital clinic. All 
women who came to the hospital smear clinic were offered dual testing: LBC with HPV testing 
of the residual.  
 
Results 
A total of 72 (36%) option lists were returned. The first option (to have a routine screening at the 
GP practice) was ticked by 8 (4%), the second (to be screened at a hospital clinic) was ticked by 
5 (3%), the third (HPV testing at a hospital clinic) was ticked by 0, the fifth (discuss) by 4 (2%) 
and the sixth (opt out) by 3 (2%). A total of 35 samples (option four) were received within 3 
months of being sent out (the first round). The fourth option (HPV testing of a self-sample) was 
ticked by a further 11 (6%) after receiving the reminder at 3 months (in the second round).  
Consequently, 11 Evalyn kits were sent in the second round, but only 5 were returned with a 
sample (Fig 4.2.1).  According to the number of self –samples received or the number of option 
lists returned, the total positive response rate (excluding those who opted out) was 63 (32%, 
including 4 ‘discuss’ and 6 who requested a kit but did not return a sample). I was unable to 
determine the number of women who had smears at their GP practice without returning the 
option list. Therefore, the total screening uptake rate of this cohort is unknown.  
 
Table 4.2.1: Response in the 200 defaulter study at 6 months 
Option   n % 
1 Smear at GP 8 4 
2 Smear at hospital clinic 5 3 
3 HPV testing at hospital clinic 0 0 
4 HPV testing at home 46 23 
5 Wanted to discuss 4 2 
6 Opt out 3 2 
 Total positive response 63 32 
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Fig 4.2.1: HPV screening and follow-up summary of the 200 defaulter study 
 
 
 
Abbreviations: *Women who ticked option-4 only after receiving the reminder letter were sent a 
second kit; HPV+= HPV positive; HPV-= HPV negative; smear+= smear positive; smear-= 
smear negative; <CIN2= low-grade CIN or less; CIN2+= high-grade CIN or worse; F/U= follow-
up. The number of women is indicated within brackets.  
 
Pre-screened  
(221) 
Excluded  
(21) 
Included  
(200) 
Kits sent  
(200 + 11*) 
Samples returned  
(35 + 5*) 
HPV - (16) 
Had a smear (3/10) 
Smear + (0) 
HPV + (24) 
Had a smear (23) 
Smear – (20) 
Annual F/U colposcopy 
(10) 
<CIN2 (0) 
CIN2+ (0) 
No annual F/U colposcopy 
(10-2) 
Smear – (0) 
CIN+ (0) 
Smear 
unsatis (1) 
Smear + (2) 
Repeat smear (1+1) 
Smear - (1) 
Smear + (1) 
Colposcopy (1)  
<CIN2 (0) 
CIN2+ (1) 
No smear (1) 
No sample 
(165 + 6*) 
No reminder 
Had a smear (0/6) 
Smear + 
( 0) 
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A majority of samples returned (35/40=88%) were from the first round, i.e. within the first 3 
months. Twenty (10%) samples were received within a week. Another 11 samples were 
received in next 3 weeks. Only two requests for the option-1 were received after the reminder 
and there were no option-2, option-3 option-5 or option-6. The research team received 7 
telephone calls after defaulters received the kit with the initial invitation letter. Whilst screening 
was not indicated for 3 of them, 4 women wished to get a smear test. The research team 
received 6 telephone calls after defaulters receiving the reminder letter. Whilst screening was 
not indicated for 4 of them, 2 women wished to get a smear test.  
 
Women in the 200 defaulter study who either self-collected (n=35) or wished to do so (n=11) 
were all aged 32-55: the median age was 45 years with inter quartile range 39-52 years. The 
mean duration for which these defaulters had not been screened (duration since the last smear 
test, if any, or from 20 years of age otherwise) was 7.8 years, standard deviation 3.9 years. The 
median was 6.0 years with IQR of 5-9 years.  Four (9%) had never been screened. There were 
5 women on the non-routine recall category with a previous non-normal smear. Times since last 
smear test of these 5 women were 3 years (unsatisfactory), 4 years (borderline dyskaryosis), 4 
years (borderline dyskaryosis), 8 years (borderline dyskaryosis) and 11 years (unsatisfactory). 
That is, none of them had been screened within the last three years. 
 
Thirty five out of 200 kits which were sent in the 3rd week of June were returned with a sample. 
Of the 11 women who requested a self-sampling kit, 5 (45%) women returned a sample (Fig 
4.2.1). Sixteen (40%) of the 40 were HPV negative, 24 (60%) were HPV positive. All except one 
23/24 (96%) HPV positives subsequently had a smear test. Whilst the majority (n=18) came to 
the hospital smear clinic, 5 HPV positive women had smears at their own GP Practice. All were 
within 12 months of self-sampling.  
 
Twenty of 23 (87%) smear tests were reported as negative. There was 1 severe dyskaryosis, 1 
borderline dyskaryosis and 1 unsatisfactory smears. The woman with severe dyskaryosis was 
referred to colposcopy. She was diagnosed with CIN2 on LEETZ biopsy. Of 16 smear residuals 
with a valid HPV result, 6 (38%) had a positive HPV result (Table 8.1.2, Appendix 1). 
 
Women who have had a negative smear following a positive vaginal HPV result in 2012 were 
invited to attend the annual follow-up clinic in 2013, approximately 12 months after the first 
smear test. The woman who was referred to colposcopy in 2012, the woman who has had a 
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total abdominal hysterectomy and the HPV positive woman who did not attend the smear test in 
the first round in 2012 were not invited to the annual follow-up. A total of 21 HPV positive were 
invited to the annual follow-up clinic. About half, 11/52=52% have attended the annual follow-up 
clinic. Two of them decided to have a smear test at the GP. At the annual follow-up clinic, 
woman’s informed written consent was obtained for a repeat cervical smear test, diagnostic 
colposcopy ±punch biopsy.  
 
A total of 11 women had both cervical smear and diagnostic colposcopy. The colposcopic 
diagnosis was high grade CIN in 1 case and low grade CIN in 1 case and normal in the other 9 
cases. Whilst a LLETZ biopsy was taken from the woman with the high-grade CIN, multiple 
punch biopsies were taken from the woman with low-grade CIN. Histology confirmed the hgCIN. 
Suspected lgCIN was diagnosed to have cervicitis.   
 
Of the 16 women who tested negative for HPV on self-sample, 10 were invited for a smear test 
by SCCRS by 31 December 2013 (Fig 4.1.1). Three women (30%) have had a smear test. 
Although 6/11 women in the group that did not return a sample were called by SCCRS for a 
smear, none of them have had a smear test during the same period of time. This is simply an 
observation made by checking individual’s screening status in the SCCRS which is passive 
follow-up rather than any intervention.  
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4.3: The 2000 defaulter study 
 
Study question 
Can the screening participation be improved by sending multiple screening options letter to 
defaulters aged 30-55 years?  
 
Summary answer 
The total positive response rate was 16% (14%-18%) [325/2031]. Whilst 158 (8%) opted for 
self-sampling; only 108 (5.3%) samples were received.   
 
What is known and what this study adds 
Sending a self-sampling kit to defaulters is known to significantly increase the screening 
participation. If the self-sampling kit could be supplied on-demand, it could be cost-effective. 
Defaulters’ response was relatively low in this study in comparison to 1000 defaulter study 
where ‘list cleaning’ was carried out, which may adversely affect the cost-effectiveness of this 
method.  
 
Limitations  
No ‘list cleaning’ may have contributed to the lower response rate.  
 
Methods 
This third study aimed to offer 2000+ defaulters several options for cervical screening, which 
included the option of ordering a self-sampling kit for HPV screening. We allocated all remaining 
(2031) defaulters in the 30-55 year old database of 3498 without list cleaning.  
 
Addresses of these women had NOT been cross-checked against the hospital database 
(TOPAS). Women who did not respond were sent a reminder and the Questionnaire in 2 
months. Methodology of this study was otherwise similar to that of the study 4.1.  
 
First batch of invitation letters were sent 7-20 July 2012. Reminder letters were sent 5-9 
September.  
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Results 
A total of 371 (18%) option lists were returned. The first option (to have a routine screening at 
the GP practice) was ticked by 108 (5%), the second (to be screened at a hospital clinic) was 
ticked by 40 (2%), the third (HPV testing at a hospital clinic) was ticked by 3 (0%), the fourth 
(self-sampling at home) by 158 (8%), the fifth (discuss) by 16 (1%) and the sixth (opt out) by 46 
(2%). A total of 107 samples (option four) were received within 3 months of being sent out (the 
first round). I was unable to determine the number of women who had smears at their GP 
practice without returning the option list.  
 
Table 4.3.1: Response in the 2000 defaulter study at 6 months 
Option   n % 
1 Smear at GP 108 5 
2 Smear at hospital clinic 40 2 
3 HPV testing at hospital clinic 3 0 
4 HPV testing at home 158 8 
5 Wanted to discuss 16 1 
6 Opt out 46 2 
 Total positive response 325 16 
 
A small proportion (22/158=14%) of those requesting a self-sampling kit (option 4) did so only 
after receiving the reminder letter. Twenty six women chose the option-1 in response to the 
reminder letter. Only two requests for the option-2 were received after the reminder and there 
were no option-3. Three women selected the option-5, 18 women selected the option-6 in 
response to the reminder. The research team received 19 telephone calls in the first round. 
Screening was not indicated for 14 of them, 5 women wished to get a smear test at the 
community. The research team received 10 telephone calls in the second round. Whilst 
screening was not indicated for 6 of them, 4 women wished to get a smear test at the 
community. Two emails from the 2000 study group were received during the first round, 
clarifying if they should be screened. Screening was not indicated for either of them.  
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Fig 4.3.1: HPV screening and follow-up summary of the 2000 defaulter study 
 
 
Abbreviations: HPV+= HPV positive; HPV-= HPV negative; smear+= smear positive; smear-= 
smear negative; <CIN2= low-grade CIN or less; CIN2+= high-grade CIN or worse; F/U= follow-
up. The number of women is indicated within brackets.  
 
Kits requested(158) 
Kits sent (158) 
Sample returned 
(107+1) 
HPV - (60) 
Had a smear (3/33) 
Smear + (1) 
No result 
(1)  
Smear+ 
CIN2+ (1) 
HPV + (47) 
Had a smear (40) 
Smear – 
(39) 
Annual F/U colposcopy 
(22+2) 
<CIN2 (3) 
CIN2+ (1+1) 
No annual F/U  
colposcopy (15-3) 
Smear- (1) 
Smear 
unsatis (0) 
Smear + (1) 
Repeat smear (1) 
Smear - (1) 
Smear + (0) 
Colposcopy (0)  
<CIN2 (0) 
CIN2+ (0) 
No smear (7) 
No sample 
(50) 
No reminder 
Had a smear (3+4/27) 
Smear + 
( 1) 
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Women in the 2000 defaulter study who wished to self-collect (n=158) were aged 30-55: the 
median age was 43.0 years with inter quartile range 37-50 years. The mean duration for which 
these defaulters had not been screened (duration since the last smear test, if any, or from 20 
years of age otherwise) was 8.1 years, standard deviation 5.0 years. The median was 7.0 years 
with IQR of 5-10 years.  Fourteen (11%) of these women had never been screened. There were 
5 women on the non-routine recall category with a previous non-normal smear, who should 
have been screened 3-12 months after the previous smear test. The duration since the last 
smear test of these 5 women was 2 years (unsatisfactory), 3 years (BNC), 3 years (BNC), 3 
years (unsatisfactory) and 7 years (BNC) years. 
 
One hundred and eight out of 158 kits which were sent were returned with a sample. One 
sample was returned a long time after the study had stopped. She has subsequently had a 
smear test. Out of 107 self-collected samples, 60 of them were HPV negative, 47 were HPV 
positive. A vast majority 41/47 (87%) HPV positives came for a smear test. Whilst the majority 
(n=34) came to the hospital smear clinic, 7 HPV positive women had smears at their own GP 
Practice. All were within 12 months of self-sampling. It was not possible to do a cervical smear 
in one woman because her cervix was covered with enlarged fibroids.  
 
All except one (39/40) smear tests were negative. A 51 year old woman had a borderline 
dyskaryosis in September 2012, but she has had 2 negative (normal) smears in June and 
December 2013.  
 
Residuals of 7 smears which were taken in the community were not tested for HPV. Four smear 
residuals were not retained for HPV testing by error. Of 26 smear residuals with a valid HPV 
result, 3 (12%) had a positive HPV result (Table 8.1.3, Appendix 1).  
 
Women who have had a negative smear following a positive vaginal HPV result in 2012 were 
invited to attend the annual follow-up clinic in 2013, approximately 12 months after the first 
smear test. A total of 33 HPV positive were invited to the annual follow-up clinic. A majority, 
24/33=73% have attended the annual follow-up clinic. Two of them decided to have a smear 
test at the GP, after receiving the annual follow-up colposcopy invitation. At the annual follow-up 
clinic, the woman’s informed written consent was obtained for a repeat cervical smear test, 
diagnostic colposcopy ±punch biopsy.  
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A total of 24 women had both cervical smear and diagnostic colposcopy. The colposcopic 
diagnosis was high grade CIN in 4 cases, low grade CIN in 4 cases, suspected low-grade in 3 
cases and normal in the 11 cases. Two colposcopies were deemed unsatisfactory (inadequate) 
as the entire transformation zone was not visualised, but colposcopy examinations were normal 
otherwise. Whilst a LLETZ biopsies were taken from the woman who has had colposcopy under 
general anaesthesia (please see below) and the woman with moderate dyskaryosis, women 
with the high-grade CIN, multiple punch biopsies were taken from the woman with low-grade 
CIN. Histology confirmed hgCIN in 3 out of 4 colposcopic diagnoses. Histological diagnosis was 
available for 3 out of 4 lgCIN. Histology confirmed the diagnosis in 2 out of 3 cases.  Histological 
diagnosis was available for 2 out of 3 suspected cases of lgCIN. None of them had any CIN.  
 
Of the 60 women who were tested negative for HPV, 33 were invited for a smear test by 31 
December 2013. Three women (9%) have had a smear test. Three women in the group that did 
not return a vaginal sample have been to a smear test during the study period in 2012. Of the 
remaining 48 women, 27 have been called by SCCRS for smears in 2013, 4 of them have had 
smear tests by 31 December 2013. One of them was a borderline nuclear change, she is due 
for a repeat smear in 6 months.  
 
There were 4 interesting cases in this cohort which are worth reporting in detail.  
 
A 41 year old individual who underwent gender re-assignment was one of our study 
participants. This person disclosed that he is genetically a female who underwent subtotal 
hysterectomy 1 year ago. Although a total hysterectomy was planned, gynaecologists had to 
leave the cervix as it was technically very difficult to remove it. This person would not allow GP 
or Practice Nurse to take a smear. He stated that self-sampling would be the only way that a 
transgender person can get screened. Self-collected sample was HPV positive. He refused to 
come to the smear clinic as he did not want to attend a female clinic. He would not even come 
to the female ward to have a smear test. He will never get this done at the GP practice. In the 
meantime, he was referred to Gynaecology by his GP as he was requesting the remaining 
cervical stump to be removed for various reasons. This has since been carried out in the theatre 
under general anaesthesia. A cervical smear was taken prior to diagnostic colposcopy which 
was subsequently reported as negative. Colposcopy diagnosed a type 2 transformation zone 
and high grade CIN. LETTZ confirmed CIN2.  
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A 53 year old defaulter asked for a self-sampling kit and also for us to contact her. This person 
had multiple unsuccessful attempts of getting a smear test. The last 2 smear tests had been 
reported unsatisfactory in 2009. She explained that there are vaginal ‘tumours’ obstructing the 
cervix, which make taking a smear impossible. This anxious patient who was worried about this 
was seen at the colposcopy clinic by the clinical supervisor, but smear could not be taken as the 
cervix was not seen. It was completely obliterated with a growth which was assumed to be a 
fibroid. A MRI scan had been arranged. The MRI scan in April 2013 has been reported as 
follows: “there is a large mass measuring 5.5 x 4.3 x 4 .5 cm, occupying most of the upper 
vagina and continuous with the cervix. There is no evidence of soft tissue extension into the 
parametrial tissues.  There is no significant pelvic or inguinal lymphadenopathy. On histological 
confirmation, the suggested stage is TIIa”. However, staging is not relevant without histological 
confirmation. Multiple attempts to offer her treatment have been unsuccessful.  
 
A 43 year old defaulter requested a self-sampling kit after receiving the reminder letter. Her last 
smear test was 13 years ago which was normal. She had a borderline smear in 1992. She had 
2 normal smears afterwards. She contacted us in March 2013 asking HPV test results, after we 
have stopped testing samples for HPV. She said that although she has sent a sample for HPV 
testing before, she hasn’t received the result of it. This sounded very unusual, because no 
previous sample had been lost. We checked our database which confirmed that she was sent a 
kit on 5 October 2012, but no sample received. Participant was adamant that she posted the 
sample that she self-collected. We immediately offered her an appointment for a smear test, for 
which she attended. Smear was reported to be moderate dyskaryosis. Colposcopy revealed a 
HGCIN. LETTZ histology confirmed CIN3.  
 
A 34 year old defaulter who had 2 borderline smears in 2001 and another 2 borderline smears 
in 2006 had a normal smear in March 2007. She had not been to a smear since then. Vaginal 
HPV screening was negative. She had been to a smear test in August 2013, soon after 
receiving the second reminder letter. This smear was reported as BNC was referred to 
colposcopy by SCCRS. Colposcopy in early October revealed possible lgCIN. Two punch 
biopsies taken 2x3mm each. Histopathological diagnosis was squamous metaplasia.  
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4.4 The older defaulters study.  
 
Study question 
Can the screening participation be improved by offering multiple screening options to defaulters 
aged 56-60 years?  
 
Summary answer 
The total screening uptake rate in the ‘letter’ group (14%) was not significantly increased in 
comparison to the control group (6%). The total screening uptake rate in the ‘kit’ group (17%) 
was significantly increased (RR=2.7, 1.0-7.2) in comparison to the control group. The difference 
between the kit group and the letter group was not significant. 
 
What is known and what this study adds 
Sending a self-sampling kit to defaulters is known to significantly increase the screening 
participation. The total screening uptake rate in the ‘kit’ group (17%) was significantly increased 
(RR=2.7, 1.0-7.2) in comparison to the control group.  
Limitations  
This defaulters list did not undergo any ‘list cleaning’ process to exclude screening ineligible 
women.  
 
 
Methods 
Defaulters aged between 56 and 60 years were identified from the Scottish Cervical Call-Recall 
System (SCCRS) in November 2012. I had the access to this database. A total of 649 defaulters 
were identified. One woman’s address was not found and was excluded from the study. 
Remaining 648 defaulters were randomised into 3 arms using the www.statisticssolutions.net 
website. Controlled arm was consisted of 64 (10%) defaulters. The second and the third arms 
were consisted of 292 (45%) defaulters each. Controlled arm had no intervention. Whilst the 
second arm was sent the multiple options letter, the third arm was sent a self-sampling kit with 
the initial invitation letter. Screening status of women who were in the control arm and those 
who haven’t had a self-sampling test were checked at 3 times points- 3, 6 and 12 months since 
the randomisation.  
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Results 
Women who wished to self-collect had not been screened for varying duration of time. The 
median duration for which these 50 defaulters had not been screened (duration since the last 
smear test, if they had any or from 20 years of age) was 7.3 years and the median was 7 years 
with IQR of 4-10 years. Two (4%) of them had never been screened. There were 3 women on 
the non-routine recall category with a previous unsatisfactory smear. The duration since the last 
smear test of these 3 women was 2, 5 and 10 years. 
 
Table 4.4.1: Response in the ‘older’ defaulter study at 6 months   
Opti
on  
 Letter group (n=292) Kit group  
(n=292) 
Control group  
(n=64) 
Ticked (%) Done (%) Ticked (%) Done (%) Done (%) 
1 Smear at GP 15 (5%) 9 (3%) 6 (2%) 4 (1%) 4 (6%) 
2 Smear-hospital clinic 4 (1%) 4 (1%) 3 (1%) 2 (1%) 0 
3 HPV- hospital clinic 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 
4 HPV- home 24 (8%) 17 (6%) 26 (9%) 26 (9%) 0 
5 Want to discuss 1 (0%) 0 (0%) 1 (0%) 1 (0%) 0 
6 Opt out 4 (1%) 0 (0%) 6 (2%) 0 (0%) 0 
 Smear at GP without 
informing us 
0 (0%) 11 (4%) 0 (0%) 16 (5%) 0 
 Total positive 
response 
44  
(15%) 
41  
(14%) 
36  
(12%) 
49 
(17%) 
4  
(6%) 
 
A total of 44 option lists were returned by women in the letter group (Table 4.4.1). The first 
option (to have a routine screening at the GP practice) was ticked by 15 (5%), the second (to be 
screened at a hospital clinic) was ticked by 4 (1%), the third (HPV testing at a hospital clinic) 
was ticked by 0 (0%), the fourth (HPV testing of a self-sample) by 24 (8%), the fifth (discuss) by 
1 (0%) and the sixth (opt out) by 4 (1%). According to the number of option lists returned, the 
total positive response rate (excluding those who opted out) was 44 (15%). A total of 42 option 
lists were returned by women in the kit group. The first option (to have a routine screening at the 
GP practice) was ticked by 6 (2%), the second (to be screened at a hospital clinic) was ticked by 
3 (1%), the third (HPV testing at a hospital clinic) was ticked by 0 (0%), the fourth (HPV testing 
of a self-sample) by 26 (9%), the fifth (discuss) by 1 (0%) and the sixth (opt out) by 6 (2%). 
According to the number of option lists returned, the total positive response rate (excluding 
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those who opted out) was 36 (12%). Four women (6.4%) in the control group have had smears 
in these 6 months.  
 
We received 8 phone calls in relation to this study as they wanted to discuss and decide about 
their screening. Screening was not indicated for 4 of them, 3 decided to have a smear at GP 
and one has self-collected. If these 8 phone calls also counted under the option-5, the positive 
response rate would go up by another 1%. 
 
Among the women who opted out, 5/11 (45%) have had a total hysterectomy, 1 (9%) woman 
has had a cervical surgery, after which collecting smears was not apparently possible.  Another 
woman was diagnosed with a stage 1b cervical cancer 2 years ago. Another 2 women had 
previous bad smear experiences and only one didn’t give any reason.  
 
All but one of the defaulters who asked for a hospital smear clinic have had smears, five at the 
hospital smear clinic, and one at the GP as she thought that the smear clinic would be at the 
Stranraer Hospital. She then, decided to go to local GP for a smear.  The Galloway Community 
Hospital in Stranraer is located 73 miles west of Dumfries & Galloway Royal Infirmary, which 
takes 1h 40min to 2h journey.  
 
Screening uptake rate in each arm of the trial has been measured at three time points, 3, 6 and 
12 months. Please find the total combined screening uptake rates at 6 months in Fig 4.4.1.  
 
Total screening uptake rate 3 months after randomisation was 39/292 (13.4%), 40/292 (13.7%) 
and 2/64 (3.1%) in the ‘letter’, ‘kit’ and the control group; respectively. Smear uptake rate 3 
months after randomisation was 15/292 (5.1%), 14/292 (4.8%) and 2/64 (3.1%) in the ‘letter’, 
‘kit’ and the control group; respectively.  
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Fig 4.4.1: Combined HPV screening data of both groups at 6 months 
 
Abbreviations: HPV+= HPV positive; HPV-= HPV negative; smear+= smear positive; smear-= 
smear negative; <CIN2= low-grade CIN or less; CIN2+= high-grade CIN or worse; F/U= follow-
up. *=number of samples received from the ‘letter’ group; the number of women is indicated 
within brackets.  
 
Kits requested(24*) 
Kits sent (24*) 
Sample returned  
(26+17*+1) 
HPV - (26) 
Had a smear (0/13) 
Smear + (0) 
No result 
(1) 
Smear – (1) 
HPV + (17) 
Had a smear (15) 
Smear – (15) 
Annual F/U colposcopy 
(10) 
<CIN2 (0) 
CIN2+ (1) 
No annual F/U (5) 
Smear (0) 
Smear 
unsatis (0) 
Smear + (0) 
Repeat smear (0) 
Smear - (0) 
Smear + (0) 
Colposcopy (0)  
<CIN2 (0) 
CIN2+ (0) 
No smear (2) 
No sample 
(5*) 
No reminder 
Had a smear (0/3) 
Smear + 
( 0) 
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Total screening uptake rate 6 months after randomisation was 41/292 (14.0%), 49/292 (16.7%) 
and 4/64 (6.2%) in the ‘letter’, ‘kit’ and the control group, respectively. Smear uptake rate 6 
months after randomisation was 24/292 (8.2%), 22/292 (7.5%) and 4/64 (6.2%) in the ‘letter’, 
‘kit’ and the control group, respectively.  The total screening uptake rate of the interventional 
cohort at 6 months was 89/584 (15.2%).  
 
Total screening uptake rate 12 months after randomisation was 57/292 (19.5%), 55/292 (18.8%) 
and 6/64 (9.4%) in the ‘letter’, ‘kit’ and the control group; respectively. Smear uptake rate 12 
months after randomisation was 33/292 (11.3%), 29/292 (9.9%) and 6/64 (9.4%) in the ‘letter’, 
‘kit’ and the control group; respectively.  
 
Out of 50 women who wished to self-collect, 44 samples were received. One woman’s sample 
was returned after the samples testing had ceased. She was offered a smear test which was 
been carried out in April 2013. The majority, 26/43= 60% were HPV negative, 40% were 
positive. A majority of HPV positives 15/17= 88% have had smear tests, all of them were 
negative.  
 
Ten women had colposcopy and a cervical smear at the annual follow-up clinic (please see 
table 9.4 in Appendix 1). Colposcopic diagnosis was a high grade CIN in one case which was 
confirmed by biopsy as CIN2. All other colposcopies did not reveal any abnormality although 
one was unsatisfactory due to type 3 transformation zone. All cervical smears have been 
reported negative.  
 
One woman who requested a self-sampling kit decided to have a smear test, which was carried 
out in January 2013. Of the 26 women who were tested negative for HPV, 13 were invited for a 
smear test from 1 January to 31 December 2013. None (0%) have had a smear test. Although 3 
women in the group that did not return a sample (n=6) were called by SCCRS for a smear, none 
of them have had a smear test during the same period of time.  
 
It was possible to check the screening status of each of these 648 defaulters. The relative 
screening uptake rates in each of these interventional arms in comparison to no intervention are 
presented in Fig 4.4.2a and Fig 4.4.2b.   
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Whilst 292 (45%) defaulters in the ‘letter’ arm were sent the multiple screening options letter, the 
defaulters in the ‘kit’ arm (n=292, 45%) were sent a self-sampling kit with the multiple screening 
options letter. No intervention was done for the 64 (10%) defaulters in the control arm (Fig 
4.4.2a and Fig 4.4.2b). There were no ‘list clearance’ or ‘reminder’ interventions in this study.  
 
Fig 4.4.2: Relative screening uptake in the older defaulter study  
(a)  between the self-sampling ‘letter’ and smear options against no intervention  
Self-sampling ‘letter’ + smear options  
(intervention group) 
No intervention 
(control group) 
Number of 
defaulters 
screened (n) 
Total number of 
participants (N) 
Screening 
uptake rate 
[% (95%CI)] 
Number of 
defaulters 
screened (n) 
Total number of 
participants (N) 
Screening 
uptake rate 
[% (95%CI)] 
41 292 14 (10-19) 4 64 6 (2-13) 
 
(b) between the self-sampling ‘kit’ and smear options against no intervention 
Self-sampling ‘kit’ + smear options  
(intervention group) 
No intervention 
(control group) 
Number of 
defaulters 
screened (n) 
Total number of 
participants (N) 
Screening 
uptake rate 
[% (95%CI)] 
Number of 
defaulters 
screened (n) 
Total number of 
participants (N) 
Screening 
uptake rate 
[% (95%CI)] 
49 292 17 (13-22) 4 64 6 (2-13) 
 
The relative increase in the positive response between the self-sampling and multiple smear 
options is presented in Fig 4.4.3 Defaulters in the ‘kit + no reminder’ study group were 2.7 (1.0-
7.2) fold more likely to be screened in comparison to the no intervention arm. This difference is 
marginally statistically significant as the lower limit of the confidence interval is 1.005.  
Defaulters in the ‘letter + no reminder’ arm were 2.2 (0.8-6.0) folds more likely to be screened in 
comparison to the no intervention arm. This difference is not significant. 
 
Fig 4.4.3: Analysis of the older defaulter study 
  
N  
screened 
N 
 not screened 
Risk 
Ratio 
95% Confidence 
Interval 
control 4 60 1 reference 
kit+ no reminder 49 243 2.685 (1.005, 7.173) 
letter+ no reminder 41 251 2.247 (0.834, 6.048) 
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4.5 The younger defaulter study.   
Study question 
Can the screening participation be improved by sending multiple smear options letter to 
defaulters aged 20-29 years?  
 
Summary answer 
The multiple smear options letter has significantly increased the cervical smear uptake among 
defaulters in comparison to controls.   
 
What is known and what this study adds 
Offering more flexible screening options to defaulters does increase the screening participation. 
The screening uptake was significantly increased after the intervention of sending a multiple 
options letter. Only 27% of those who opted for a hospital smear test came to the hospital clinic. 
Whilst 66 informed us that they will have a smear at the GP, 194 had had a smear test at the 
community, indicating that sending a different letter to defaulters itself could be effective in 
raising the screening participation.   
 
Limitations  
Pre-intervention ‘control’ period could have been longer than 1-2 months. Many confounding 
factors may have contributed increasing the screening uptake by defaulters during the 
intervention period, such as the radio advertisement, social media and this study was preceded 
by other self-sampling studies in this small community etc. A formal randomisation may have 
strengthened the evidence developed.  
 
Methods 
We offered various opportunities to have a smear test to screening programme defaulters aged 
between 20 and 29 years.  
 
We selected all under and unscreened women (defaulters) aged between 20 and 29 years, 
living in Dumfries & Galloway Health Board in August 2012 from the Scottish Cervical Call-
Recall System (SCCRS) database (Fig 4.5.1). This database was generated at the end of 
August 2012. Addresses of all these women were cross-checked against the Sci Store Live 
database by the PI. A total of 1359 out of 1441 addresses were matched. These 1359 
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defaulters were contacted first. The remaining 82 were written to 2 months later. Eventually, all 
of these 1441 women were sent a letter (Fig 8.2.3, Appendix 2) inviting them to select one 
option from a list of six (Fig 4.5.2) (Fig 8.2.4, Appendix 2). 
  
A list of 1441 defaulters was sent to the Principal Investigator on an Excel data sheet by the 
screening services manager. It was apparent on the Excel datasheet that these defaulters were 
listed according to their CHI numbers. A 10 digit CHI number begins with the date of birth 
followed by 4 random numbers.  The database was arranged in the order of age in years. 
Women with the same year of birth were ordered according to the 4 digits at the end of the CHI 
number. Even rows of the Excel sheet were allocated to the Group A, odd rows were allocated 
to the Group B. There were 720 defaulters in Group A and 721 in Group B.  
  
At the end of September, women in Group A were sent the standard screening letter with the 
standard cervical screening information leaflet, exactly the same as it would be sent by the 
Screening Services Department of NHS Dumfries & Galloway. Group B did not receive any 
intervention at the end of September. One month later, the screening status of all women in 
Group A and Group B were checked on the SCCRS and was recorded in the database. Women 
in both groups who hadn’t had a smear test were sent the multiple options letter (Fig 8.2.3, 
Appendix 2) at the end of October. A radio advert was broadcast (on 14 days) in the 3rd and 4th 
weeks of October (Fig 4.5.1).  
  
The multiple smear options letter was accompanied by a list of frequently asked questions about 
cervical screening (Fig 8.2.11, Appendix 2) and a pre-paid C5 size envelope addressed to the 
Screening Services Manager, NHS Dumfries and Galloway. There were two sheets in the letter. 
Returned letters were sorted and recorded by the Screening Services Manager’s secretary and 
then passed on to the PI who facilitated the woman’s choice. The Screening Services Manager 
dealt with opt outs and ‘addressee left the area’ replies.  
  
In order to receive defaulters’ requests, a secure email address (dg.smear@nhs.net) was 
generated by the IT Services Department, NHS Dumfries and Galloway, keeping with the local 
policy. A dedicated, password protected mobile phone with an activated tracker device was kept 
in the Ward 4 office to collect text messages from defaulters. The ‘hotline’ mobile phone contact 
number (07799 666 909) was displayed prominently in the letter.  
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Fig 4.5.1: Younger defaulter study flow chart 
 
Fig 4.5.2: Options list 2 (smear option list): not including an option for self-sampling 
Options List (please tick the most suitable one for you) 
 
1. I will make an appointment with my GP Practice or the Sexual Health Clinic. 
 
2. Please give me an appointment at a hospital evening smear clinic. 
 
3. Please give me an appointment at a hospital weekend smear clinic. 
 
4. Please give me an appointment at a hospital lunch time smear clinic.                
 
5. I would like a doctor to contact me to discuss how I might get a test. 
 
6. None of above options suits me.  
 
 Please tell us what arrangements might suit you  or why you do not want a test  
 
     ........................................................................................................... 
 
8 wks 4 wks 
8 wks 4 wks 0 wks 
0 wks 
Group A 
n= 720 
Group B  
n= 721 
Options letter 
Advert 
Database  
Database  
Standard letter Options letter 
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Results 
 
Whilst 12/720 (1.7%) women in the Group A (two letters group) have been to a smear test; 
10/721 (1.4%) in Group B (one letter group) have had a smear test by the 30th of September.  
 
A sharp rise of smear uptake per month was seen in the 2nd to 4th months (Fig 4.6.3). The same 
trend is seen here as well as the two letters group. In the one letter group, where the 
intervention was carried out at the end of the 2nd month, a sharp rise is seen from the 3rd to 5th 
months (Table 4.5.1). A total of 218 smears were carried out in the intervention period of 6 
months.  
 
Fig 4.5.3: Number of smear tests per month in one (n=721) and two (n=720) letters groups 
 
Key: The time point that the standard screening letter was sent to the two letters group is maked 
with a shorter, blue arrow. The time point that the mutiple smear options letter was sent to both 
groups is marked with a longer, red arrow. 
 
The cumulative smear uptake, rate 6 months after the intervention (circled in Table 4.5.1) in the 
Group A was 115/720= 16.0% and 100/721= 13.9% in group B. Hence, the total cumulative 
smear uptake rate at 6 months after the intervention in this cohort was 218/1441= 15.1%. The 
cumulative smear uptake rate of the control (no intervention) group of the older (56-60 years) 
defaulter’s study was 4/64= 6.2%. 
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Over the seven months either before the intervention or more than 6 months after the 
intervention 135 (of 1441) women were screening, corresponding to 1.34% per month. Over the 
six months following the intervention 225 were screened corresponding to 2.6% per month. 
Thus over six months an extra 7.6% of women were screened. 
 
Table 4.5.1: Smear uptake per each month in the ‘younger’ defaulter study  
month total 
two 
letters 
 one 
letter 
1 (Sep 2012) 
22 12 10 
2 (Oct 2012) 
43 29 14 
3 (Nov 2012) 
72 36 36 
4 (Dec 2012) 
35 
18 17 
5 (Jan 2013) 
28 15 13 
6 (Feb 2013) 
24 10 14 
7 (Mar 2013) 
16 7 9 
8 (Apr 2013) 
24 13 11 
9 (May 2013) 
17 8 9 
10 (Jun 2013) 
21 8 13 
11 (Jul 2013) 
12 4 8 
12 (Aug 2013) 
20 13 7 
13 (Sep 2013) 
16 9 7 
total 
350 182 168 
Key: Considering circled six months as the intervention and remaining 6-7 months as the 
control. The intervention began at the end of month 1 in the ‘two letters’ group (A). It began at 
the end of the month 2 in the ‘one letter’ group (B).  
 
Please see the Table 4.5.2 for the response rate and screening status at 2, 6 and 12 months 
since the first intervention (end of Sep 2012). At the end of the 2nd month (on 30 Nov 2012), the 
total positive response rate was 8% (112/1359). At the end of the 6 th month (on 31 Mar 2013), 
the total positive response rate was 10% (133/1441).  
 
Eighty two addresses which did not match when cross-checked against the Sci Store Live 
database were recruited after one month (end of October). A small proportion (3/82= 4%) of 
women have positively responded at the end of 6 months. 
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Table 4.5.2: Results of younger defaulters study at 2, 6 and 12 months (N=1441) 
  2 months 6 months 12 months  
Opti
on  
 Wishe
d (%) 
Actually 
smeared 
(%) 
Wishe
d (%) 
Actually 
smeared 
(%) 
Wishe
d (%) 
Actually 
smeared 
(%) 
1 Smear at GP 55 (4) 13 (1) 66 (5) 33 (2) 66 (5) 43 (3) 
2 Smear at hospital 
evening clinic  
24 (2) 8 (1) 26 (2) 10 (1) 26 (2) 12 (1) 
3 Smear at hospital 
weekend clinic  
18 (1) 5 (0) 23 (2) 6 (0) 23 (2) 8 (0) 
4 Smear at hospital 
lunch time clinic  
12 (1) 4 (0) 15 (1) 5 (0) 15 (1) 6 (0) 
5 Wanted to discuss 3 (0) 0 (0) 3 (0) 0 (0) 3 (0) 0 (0) 
6 Opt out 39 (3) 0 (3) 49 (3) 0 (0) 49 (3) 0 (0) 
 Smear at GP w/o 
informing us 
 92 (7)  164 (11)  281 (20) 
 Total positive 
response   
112  
(8) 
122  
(8) 
133 
(10) 
218  
(15) 
133 
(10) 
350  
(24) 
 
Six months after the first intervention, option 1 (smear at GP) was selected by 66 women, option 
2 (evening hospital clinic) was selected by 26, option 3 (weekend hospital clinic) was selected 
by 23, option 4 (lunch time hospital clinic) was selected by 15 and option 5 (wanted to discuss) 
was selected by 3. The screening services manager and the principal investigator received 10 
phone calls, 3 emails, 2 text messages and 2 letters to discuss screening options from this 
cohort of 1441 younger defaulters. It appeared that 164 women who never replied to our 
correspondence have had smears at the community. However, a good proportion of these 
defaulters might have had smears regardless of our letter/s.  
 
On 30 September 2013 (12 months after the first intervention), about a quarter 350/1441 
(24.3%) of these younger defaulters have had smears. Nineteen (19/350=5.4%) smears were 
abnormal. Of the 19 abnormal smears, 11 (58%) smears had a high grade abnormality. There 
were 16 colposcopy referrals. All referred women attended the colposcopy clinic. Eleven (3%) 
high grade CIN (CIN2+) were diagnosed in this younger cohort of 350 defaulters. Please find 
these results in Table 4.5.3.  
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Table 4.5.3: Results and diagnosis of not-normal results of 350 smears  
Smear abnormality n Number of women 
referred to colposcopy 
Number of histological 
diagnosis 
Unsatisfactory  4 0 0 
Borderline  3 0 0 
Mild (low-grade ) 5 1 1x CIN2 
Moderate (HG- moderate) 5 5 2x CIN2 
3x CIN3 
Severe (HG-severe) 5 5 1x CIN1 
2x CIN2 
2x CIN3 
Glandular abnormality 1 1 1x CGIN 
Invasion  0 0 0 
Total  23 16 11xCIN2+ 
 
Assessment of the relative effectiveness of interventions of the ‘younger’ defaulter study was 
carried out by comparing the first 6 months following the intervention (intervention period) to the 
months before and after this time (control period). Whilst the two letters group was not 
intervened in the first month, one letter group was not intervened in the first 2 months. These 1-
2 months along with the remaining 4-5 months after the end of the intervention period (6 months 
in total) were considered as the ‘control’ period (Table 4.5.1). Note that month 13 data are not 
considered in this analysis in order to have 6 months in both the intervention and the control 
periods. 
 
Whilst 12/720 (1.7%) women in the two letters group (A) have had a smear test prior to the 
intervention; 24/721 (3.3% in two months) in the one letter group (B) have had a smear test prior 
to the intervention. A sharp rise of smear uptake per month is seen in the first 2 months after the 
intervention in both groups. The cumulative smear uptake rate in the intervention period in the 
two letters group (A) was 115/720= 16.0% and 100/721= 13.9% in the one letter group (B). 
Whilst 46 smear tests were carried out from the months 8 to 12 in the two letters group (A), 37 
smear tests were carried out from the months 9 to 12 in the one letter (B) group, after the end of 
the intervention period which was considered as the ‘control’ period. (Fig 4.5.4a and Fig 4.5.4b).  
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Fig 4.5.4: The relative screening uptake in ‘younger’ defaulter study  
(a)  The screening uptake between the two letters group (A) against no intervention  
Two letters group (A) 
(cases) 
No new intervention 
(control) 
Number of 
defaulters 
screened (n) 
Total number of 
participants (N) 
Screening 
uptake rate 
per 6 months 
[% (95%CI)]   
Number of 
defaulters 
screened (n) 
Total number of 
participants (N) 
Screening 
uptake rate 
per 6 months 
[% (95%CI)] 
115 720 16 (13-19) 58 720 8 (6-11) 
 
(b)  The screening uptake between the one letter group (B) against no intervention  
Two letters group (B) 
(cases) 
No new intervention 
(control) 
Number of 
defaulters 
screened (n) 
Total number of 
participants (N) 
Screening 
uptake rate 
per 6 months 
[% (95%CI)] 
Number of 
defaulters 
screened (n) 
Total number of 
participants (N) 
Screening 
uptake rate 
per 6 months 
[% (95%CI)] 
100 721 14 (11-17) 61 721 8 (6-11) 
 
Defaulters in the two letters intervention group were 2.0 (1.5-2.7) fold more likely to be screened 
than its control group. This difference is statistically significant. Defaulters in the one letter 
intervention group were 1.6 (1.2-2.2) fold more likely to be screened than its control group. This 
difference is statistically significant.  
 
In order to further analyse the relative effectiveness of the younger defaulter study which offered 
multiple smear options, data from a historical control group was also used. A new list of 
defaulters aged between 21 and 30 years was generated on 27 September 2013, one year after 
recruiting women to the younger defaulter study. Their screening status was checked on 28 
March 2014. Of the women who have had a smear test, duration from the last screening recall 
(reminder) letter to the current smear test was recorded.  
 
The mean age of the historical control group (N=1732) was 25 years with SD of 3 years. A total 
of 119 smears (6.9% of the group had a smear) were carried out in 6 months. Number of 
smears carried out in each month from October 2013 to March 2014 was 17, 18, 13, 20, 27 and 
24 (Fig 4.5.5).  
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Fig 4.5.5: Number of smears per month in the historical control group 
Month 
Smears 
per month 
1 (Oct 2013) 17 
1 (Nov 2013) 18 
3 (Dec 2013) 13 
4 (Jan 2014) 20 
5 (Feb 2014) 27 
6 (Mar 2014) 24 
Total (6 months) 119 
 
The time interval between the last screening recall letter to the smear test (letter to smear 
interval) of these 119 smears is illustrated in Fig 4.5.6. The mean letter to smear interval is 14 
months with SD of 8 months.  
 
Fig 4.5.6: The last screening recall letter to the smear test (letter to smear interval in months) 
 
If this historical group was considered as the control group of the one letter group of the younger 
defaulter study (who received a multiple smear options letter), the risk ratio of the smear uptake 
can be calculated. A total of 66 women ticked the option-1 indicating that they wish to have a 
smear at the GP practice. A similar number of women wished to have a hospital smear. 
However, only about a third (21/64=33%) came to the hospital smear clinic. Although 66 women 
informed us that they will have a smear at the GP, 194 have been to a smear test by 6 months. 
This indicates that the hospital smear clinic didn’t play a big role in increasing the smear uptake 
rate. A total of 115 (16%) in the 2 letters group 100 (14%) in the one letter group and 119 (7%) 
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in the historical control group and 119 (8%) in the two contemporaneous control groups had 
smears in 6 months (Fig 4.5.7). The smear uptake rate at 6 months in the interventional group 
was roughly twice as high as in the historical control group (n=1732). This difference was more 
clearly seen at 3 months where 66/721 in the one letter group and 48/1732 have had smears 
(RR=3.3, 2.3-4.7).  
 
The defaulter’s response in the younger defaulters study was quicker than other studies. Whilst 
a vast majority (122/133=92%) responded within 2 months, 11 women responded in the third 
month. Therefore, the screening uptake rate at 3 months was calculated. A total of 66 defaulters 
in the one letter group (n=721) had smears in 3 months. In comparison, 48/1732 defaulters in 
the historical control group had smears in 3 months. At 3 months, the smear uptake rate of the 
one letter group was 3.3 (2.3-4.7) times higher than the historical control group, which is 
statistically significant.  
 
Fig 4.5.7: Screening summary of ‘younger’ defaulter study at 6 months 
  
 
 
 
20-29 year old defaulters (intervention) 
(Sep 2012- Mar 2013) 
n=720  
Routine reminder letter 
+ options letter 
GP smear 
wished=35 
Had a GP 
smear=103 
14% 
Hospital smear 
wished=36 
Had a hospital 
smear=12 
2% 
n=721 
Options letter 
GP smear 
wished=31 
Had a GP 
smear=91 
13% 
Hospital smear 
wished=28 
Had a hospital 
smear=9 
1% 
21-30 year old defaulters 
(historical control) 
(Sep 2013-Mar 2014) 
n=1732 
No 
intervention 
GP  
smear =119 
7% 
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Trends in seen in the smear uptake rates between the one letter group and the historical control 
group are illustrated in Fig 4.5.8. Intervention was carried out at the end of the second month.  
 
Fig 4.5.8: Trends seen in smear uptake rates per 1000 defaulters 
 
 
 
4.6 Annual follow-up of vaginal HPV positives.    
 
Methods 
All women testing positive for HPV on a self-collected sample were invited for clinician sampling 
in a hospital clinic in 2012. Those who attended had a liquid based sample collected which was 
used for both cytology and HPV testing (the smear residual was tested for HPV).   
 
All women who have had a positive vaginal HPV test; except the ones that were referred to 
colposcopy with an abnormal smear test, were invited for an annual follow-up clinic in 2013. 
These annual follow-up clinics were run by the PI who is a British Society of Colposcopy and 
Cervical Pathology Society’s (BSCCP) accredited colposcopist. The PI was assisted by a 
female Gynaecology/ Colposcopy Nurse Specialist.  
 
Participants were appropriately counselled and informed written consent was obtained for a 
cervical smear sample and for diagnostic colposcopy ±biopsy. After collecting the cervical 
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cytology (smear) sample using 2 brushes (Cervex brush and endocervical brush), a diagnostic 
colposcopy was performed according to the BSCCP standards (NHSCSP 2010). All acetowhite 
areas suggestive of CIN were biopsied.  
 
All biopsy positive for CIN1+ were referred to the Clinical Supervisor, Dr Heather Currie’s 
colposcopy clinic for further assessment and/or treatment.   
 
These follow-up colposcopy clinics were run from 18 June 2013 to 31 December 2013. 
Cytology, colposcopy and histology results were recorded and correlated.  
 
Results 
Sixty seven women attended the annual follow-up clinic. Colposcopic findings of each of these 
vaginal HPV positive women with a lesion are presented in the Fig 8.1.5 in the Appendix 1. 
Please find the analysis of these lesions in the section 4.7.  
 
About 30 women did not attend the annual follow-up clinic. Six women were unable to come due 
to the distance (60-70 miles from Dumfries hospital). They were happy with the reassurance 
they got from the last smear test. They were advised to attend their future smears, regularly. 
One person has had a total abdominal hysterectomy in April 2013. One person is currently 
undergoing breast cancer treatment. One person informed that she is currently pregnant. One 
person has severe motion sickness so would rather not travel from Stranraer (73 miles). One 
busy healthcare professional has been sick and never attended both appointments.  
 
Two persons could not attend the clinic as the follow-up (colposcopy) clinics were not run in 
evenings. One defaulter didn’t come this time as her last smear test that she has had at the 
hospital smear clinic was painful. Two persons opted out by sending emails, but not reason was 
stated. All other women did not attend without giving any reasons.  
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4.7 Analysis 
 
Response rates 
The total response for each study group at 6 months is presented in Table 4.7.1 and Fig 4.7.1. 
 
Table 4.7.1: Screening data of all defaulters at 6 months 
Outcome 
at 6 
months 
1000 
study 
(letter)  
200 study 
(kit)  
2000 
study 
(letter)  
Older 
study 
(letter)  
Older 
study 
(kit)  
Younger 
study  (2 
letters) 
Younger 
study (1 
letter) 
Control 
(none)  
n  1000  % 200  % 2031  % 292  % 292  % 720 % 721 % 64  % 
Age range 30-
55 
 30-
55 
 30-
55 
 56-
60 
 56-
60 
 20-
29 
 20-
29 
  56-
60 
  
Mean age 
(SD)  
43 
(7.5)  
 43 
(7.7)  
 43 
(7.5) 
 58 
(1.4)  
 58 
(1.4)  
  24 
(2.7) 
 24 
(2.7) 
  58 
(1.4) 
  
Smear GP  63  6  8  4  108  5  15  5  6  2  35 5 31 4 4  6  
Sm.  hosp 23  2  5  3  40  2  4  1  3  1  38 5 29 4 - - 
HPV hosp  5  1  0  0  3  0  0  0  0  0  - - - - - - 
HPV home  129  13  46  23  158  8  24  8  26  9  - - - - - - 
Discuss  16  2  4  2  16  0  1  0  1  0  2 0 1 0 - - 
Positive 
response  
236  24  63  32  325  16  44  15  36  12  73 10 60 8 4  6  
95%CI   21-
26  
 25-
38 
 14-
18  
 11-
20  
 9-
17  
 8-
13 
 6-
11 
  
Actual 
screened 
232* 23* 61* 31* 342* 17* 41 14 49 17 115 16 100 14 4 6 
95%CI        10-
19 
 13-
22 
 13-
19 
 11-
17 
 2-
13 
Opt out  22  2  3  2  46  2  4  1  6  2  27 4 22 3 - - 
*estimated figures based on the sensitivity analysis (Table 4.7.3) 
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Fig 4.7.1: Positive response rates of all defaulters at 6 months 
 
The positive response rate of each study group is presented in Table 4.7.1. The positive 
response percentage (rate) and the 95% confidence interval of the 1000 letter + reminder study 
group was 23.6% (21-26), of the 200 kit + reminder study group was 31.5 (25-38), of the 2000 
letter + reminder study group was 15.8 (14-18), Older letter + no reminder study group was 15.1 
(11-20), Older kit + no reminder study group was 12. (9-17), Younger 2 letters study group was 
10.1 (8-13) and Younger 1 letter study group was 8.3 (6-11).  
 
The total screening uptake rate at 6 months is known in the Older and Younger defaulter 
studies. It was 14 (10-19) in the Older letter + no reminder study group, 17 (13-22) in the Older 
kit + no reminder study group, 16 (13-19) in the Younger 2 letters study group and 14 (11-17) in 
the Younger 1 letter study group. Four defaulters in the non-intervention arm of the ‘older’ 
control group have had smears in 6 months, making the screening uptake rate of 6.3% (2-14).  
 
The 1000, 200 and 2000 defaulter studies 
Defaulters aged between 30 and 55 years were offered self-sampling, in addition to multiple 
smear options. Data relating to the total number of self-samples returned between the self-
sampling letter + reminder group versus the self-sampling kit + reminder group is presented in 
Fig 4.7.2. A total of 3031 participants were sent a letter and a reminder, 200 participants were 
sent a self-sampling kit and a reminder. Whilst 200 samples were returned in the letter+ 
reminder group, 40 samples were returned in the kit + reminder group.  
 
Cervical screening defaulters living in Dumfries & Galloway in 2012  
20-29 years 
Younger  
2 letters  
n=720 
10% 
Younger  
1 letter  
n=721 
8% 
30-55 years 
1000 letter 
24% 
200 kit  
32% 
2000 letter  
16% 
56-60 years 
Older letter 
n=292 
15% 
Older kit 
n=292 
12% 
Older control 
(n=64) 
6% 
127 
 
Fig 4.7.2: The relative self-sampling uptake rate between the ‘letter’ and the ‘kit’ method. 
 
Self-sampling ‘letter’ + reminder  
(intervention 1) 
Self-sampling ‘kit’ + reminder  
 (intervention 2) 
Self-samples 
returned (n) 
Total number of 
participants (N) 
Returns rate 
[% (95%CI)] 
Self-samples 
returned (n) 
Total number of 
participants (N) 
Returns rate 
[% (95%CI)]  
200 3031 7 (6-8) 40 200 20 (16-23) 
 
Participants in the self-sampling kit + reminder group were 3.5 (2.4-5.1) fold more likely to return 
a self-collected sample than the self-sampling letter + reminder group. This difference is 
statistically significant (p<0.001). Note however that the difference in the Older women study 
between women sent a kit initially and those who had to request one was relatively much less. 
Overall the screening uptake rates were 49/292 compared with 41/292: an additional 3% were 
screened risk ratio 1.20. 
 
Age related trends seen in the 30-55 year age gruop 
Potential age related trends in relation to the positive response rate, choosing to self-sample 
(option 4) or choosing to have a smear at the GP (option 1) have been examined in 1000, 200 
and 2000 study groups (Table 4.7.2). Respondents were divided into 3 age groups 30-38, 39-47 
and 48-55. The positive response rate remained similar across all 3 age groups in all 3 study 
groups with no statistically significant difference. The probability of choosing self-sampling 
remained similar across all 3 age groups in all 3 study groups with no statistically significant 
difference. The probability of choosing to have a smear test at the GP remained similar across 
all 3 age groups in all 3 study groups with no statistically significant difference.  
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Table 4.7.2: Age related trends in choosing different options- n (%) and 95%CI of the % 
 
Abbreviations: Propor= proportion  
 
Sensitivity analysis 
Whilst some defaulters who wished to have smear test were never able to do it, others who 
didn’t let us know their intentions have had it. It was not possible to check the screening status 
of those who did not let us know their screening intentions in the 30-55 year old cohort of 
defaulters. In the ‘Younger’ defaulter study, although 130 out of 1441 defaulters informed us that 
they wish to have a smear test, 218 have actually had smears at 6 months. Similarly, in the 
‘Older’ defaulter study, although 28 out of 584 defaulters informed us that they wish to have a 
smear test, 47 have actually had smears at 6 months. Based on these figures, the smear uptake 
rates were estimated for the 30-55 year age group (Table 4.7.3).  
129 
 
Table 4.7.3: Actual and estimated smear uptake at 6 months among defaulters who wished to 
have a smear (sensitivity analysis) 
 Study group (method 
of intervention) 
n/N (%) who 
wished to have a 
smear 
n/N (%) who 
actually had a 
smear 
n/N (%) estimated 
smear uptake 
1 1000 (letter+remind) 86/1000 (9%) ? 140/1000 (14%) 
2 200 (kit+remind) 13/200 (7%) ? 21/200 (11%) 
3 2000 (letter+remind) 148/2031 (7%) ? 234/2031 (12%) 
4 ‘Older’ letter+ no remind 19/292 (7%) 24/292 (8%) n/a 
5 ‘Older’ kit+no remind 9/292 (3%) 23/292 (8%) n/a 
6 ‘Younger’ 2 letters 73/720 (10%) 115/720 (16%) n/a 
7 ‘Younger’ 1 letter 60/721 (8%) 100/721 (14%) n/a 
 Total  408/5256 (8%) 264/2025 (13%) 405/3231 (13%) 
 
The total screening uptake rate in the 1000, 200 and 2000 studies can be estimated using these 
estimated smear uptake numbers, as checking their screening status was not possible. It would 
be (92+140)/1000= 24% in the 1000 defaulter study. It would be (40+21)/200= 31% in the 200 
defaulter study. It would be (107+234)/2031= 17% in the 2000 defaulter study. The total 
screening uptake rate in the older defaulter study is 15% and the younger defaulter is 15%. The 
estimated total screening uptake rates appear similar to the total positive response rate in the 
1000, 200 and 2000 study groups. Therefore, it is reasonable to conclude that trends seen in 
positive response rates in the 1000, 200 and 2000 study groups are comparable to the 
estimated screening uptake rates.  
 
The sum of the estimated and actual number of smears carried out in defaulters who did not do 
HPV screening was 669. Furthermore, a total of 137 defaulters who wished to self-collect 
(118xHPV+, 10xHPV-, 2xNo HPV result, 7xNo sample) have had smears (Table 4.7.3). This 
indicates that about 800 defaulters may have had smears during the study period.  
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HPV screening 
A condensed summary of defaulters who wished to self-sample is presented in the Fig 4.7.3. A 
total of 322 primary kit requests have been received. Sixty one kits were retuned with a sample 
by women in study groups who received a kit with the initial invitation (n=200+292=492). A total 
of 284 samples were returned by women although a sample was returned after the HPV testing 
has ceased and one was lost. These two women had no HPV result. Both of them were offered 
a hospital smear appointment. One of them had a high-grade smear and hgCIN. A small 
proportion 3/282 (1%) of samples didn’t give a valid HPV results in the first run due to problems 
in the internal control, but all of these 3 gave a valid result in the second run. Whilst 152 (54%) 
were HPV negative, 130 (46%) were HPV positive.  
 
A vast majority (118/292=91%) of HPV positives have had smears. Eight (6.8%) were positive, 
107 (90.7%) were negative and 3 (2.5%) smears were unsatisfactory (inadequate sample). Of 8 
abnormal smears, 3 met the criteria for colposcopy referral. All of these 3 were diagnosed to 
have CIN3. Repeat smears were indicated for other 5 abnormal smears. All of these 5 women 
had smears, 3 were and 2 were abnormal. Both of these women were referred to colposcopy. 
Whilst one of them had CIN1, the other woman did not attend. Colposcopy was indicated for 
one of the 3 women who had unsatisfactory smear result due to 3 consecutive unsatisfactory 
results. She was diagnosed to have vaginal atrophy. All 3 women with unsatisfactory smears 
had subsequently had negative smears. The majority (67/107=62.6%) of smear negatives (but 
vaginal HPV positives), came to the annual follow-up clinic. Whilst 7 women opted out giving 
reasons, 33 women did not attend. Of 67 women who had a repeat smear test and colposcopy 
approximately 1 year (range 11-14 months, median=mode= 12 months) after they collected the 
vaginal sample. Tissue diagnosis was available for 17/67 colposcopies carried out. There were 
6xCIN1 and 5xCIN2 out of which only 3 had an abnormal smear in 2013 (Fig 4.7.3).  
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Fig 4.7.3: HPV screening and follow-up data of the whole 30-60 year old defaulters 
 
Abbreviations: *Women who ticked option-4 only after receiving the reminder letter were sent a 
second kit; HPV+= HPV positive; HPV-= HPV negative; smear+= smear positive; smear-= 
smear negative; <CIN2= low-grade CIN or less; CIN2+= high-grade CIN or worse; F/U= follow-
up. The number of women is indicated within brackets.  
Kits requested (383) 
Kits sent (383) 
129+ (35+11*)+158+ (26+24*) 
Sample returned  
(282+2) 
HPV - (152) 
Had a smear  
(10/87) 
Smear- (9) 
CIN+ (0) 
No result 
(2) 
Smear + (1) 
CIN2+ (1) 
HPV + (130) 
Had a smear 
 (118) 
Smear – (107) 
Annual F/U 
colposcopy  
(67) 
<CIN2 (6) 
CIN2+ (5) 
No annual F/U 
colposcopy  
(40-7) 
Smear- (3) 
CIN+ (0) 
Smear 
unsatis (3) 
Repeat smear  
(2) 
Colposcopy (1) 
Smear - (3) 
CIN+ (0) 
Smear + (8) 
Repeat smear  
(5) 
Smear +(2) 
Smear - (3) 
CIN+ (0) 
Colposcopy  
(3)  
<CIN2 (0) 
CIN2+ (3) 
No smear  
(12) 
No sample  
(99) 
No reminder 
Had a smear  
(7/56) 
Smear-(6) 
CIN+ (0)  
132 
 
Diagnostic outcomes of HPV screening  
Histological diagnosis of a cervical lesion is considered to be the gold standard. However, the 
natural histories of two different CIN2 can take two different pathways; whilst one may 
spontaneously regress, other may develop into a carcinoma, which will be hard to predict. The 
extent to which these neoplastic lesions affect the cervix should be one such surrogate marker, 
which at least indicates the severity of HPV disease on the cervix. Comparison of colpographs 
between the lesions diagnosed by HPV screening alone versus lesions diagnosed after an 
abnormal smear test following HPV screening (Fig 4.7.4) would give us some clue regarding 
their clinical relevance. Lesions spread extensively tend to have more clinical significance than 
small focal lesions, although they have the same histological diagnosis.  
 
Fig 4.7.4: Comparison of colposcopy findings of cytology detected lesions versus those were 
not 
lgCIN   hgCIN   Punch biopsy site  
 
HPV+ with an abnormal smear HPV+ with a normal smear  
 
33 years, severe- CIN3 
 
41 years, CIN2 
 
45, years, severe- CIN3 
 
57, years, CIN2 
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44 years , severe- CIN2 
 
41 years, CIN2 
 
51 years, moderate- CIN2 
 
45, years, CIN2 
 
30 years, bnc- CIN1 
 
39, years, CIN1 
 
46 years, bnc-CIN1 
 
32 years, CIN1 
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49 years, CIN1 
 
 
 
55 years, CIN1 
n=6 (2xCIN3, 2xCIN2, 2xCIN1) n=8 (0xCIN3, 4xCIN2, 4xCIN1) 
 
It appears that lesions associated with abnormal cervical cytology in these 14 CIN diagnosed in 
30-60 year old age group are generally larger than their HPV-only counterparts.  
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Other research to complement interventional studies  
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5.1 Trends seen in colposcopy referrals during the study period  
 
Study question 
Were more defaulters referred to colposcopy during the study period when multiple 
screening options had been offered to them? 
 
Summary answer 
The number of new defaulters referred to colposcopy was significantly increased by 
three fold in during June-December 2012, in comparison to the same time period in 
2011. Consequently, 15 extra cases of CIN2 or worse were diagnosed in 2012.  
 
What is known and what this body adds 
It is difficult to measure the real impact of our study on cervical screening outcomes. 
The number of new defaulters referred to colposcopy was significantly increased 
during June-December 2012, in comparison to the same time period in 2011. Our 
study may have contributed to bringing significantly more defaulters back to 
screening in the last 7 months in 2012 in comparison to the same period in 2011.  
 
Limitations 
Screening outcomes (diagnoses) of all new colposcopy referrals were not assessed 
in this retrospective audit. Therefore, it is not possible to estimate the relative impact 
of the study on total screening outcomes.  
 
Background 
All abnormal smear tests are referred to NHS Dumfries & Galloway colposcopy services. 
Therefore all participants of our studies are referred to colposcopy, if they have had an 
abnormal smear which meets the referral criteria. This gave us the opportunity to get some idea 
about the number of women who had had a smear test in the community without informing us. 
This was used as a surrogate marker of how effective our interventions were in terms of 
motivating defaulters to attend screening.  
 
A small audit has revealed that the number of defaulters referred to colposcopy increased 
fourfold between early and mid- 2012. It was noted that the only defaulter with an abnormal 
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smear in March was seen in the third week of May at the colposcopy clinic.  Similarly, most 
defaulters who came forward for screening may have been seen at colposcopy before 31 
December 2012. Therefore, all new colposcopy referrals during (June- Dec 2012) and the 
comparable time in the previous year have been included in this audit. 
 
Methods 
A retrospective audit was carried out including colposcopy referrals made in Dumfries & 
Galloway in June to December 2012 and 2011. The primary aim of the audit was to find out the 
number of new defaulters referred to colposcopy in each year.  
 
Hard copies of colposcopy clinic lists from March 2012 to January 2013 and from March 2011 to 
January 2012 were retrieved from two different sources: the appointments centre and 
Gynaecology secretaries. Both sets of clinic lists were cross-checked to ensure completeness. 
The screening history of each individual was checked in the SCCRS, in order to differentiate 
defaulters from regular screening attendees.  The histological diagnoses of defaulters were 
checked in the Sci Store Live database. All findings were recorded on the clinic list as well as an 
Excel database. Care was taken to identify women who had been in the clinic list more than 
once due to various reasons. This audit was approved by the Clinical Governance Department.  
 
Results 
A total of 51 defaulters were referred to colposcopy from 1 June 2012 to 31 December 2012 out 
of 182 new SCCRS referrals. During the same period in 2011, 17 defaulters were referred to 
colposcopy out of 183 new SCCRS referrals (Table 4.5.1). A considerable proportion (51/182= 
28%) of new colposcopy referrals were defaulters in 2012, in comparison to 2011 (17/183= 9%).  
 
There were 28 CIN2+ (7xCIN2, 16xCIN3, 3xCGIN and 2xcacinoma) diagnosed in these 51 
defaulters in 2012. There were 13 CIN2+ (8xCIN2, 5xCIN3, 0xCGIN and 0xcacinoma) 
diagnosed in these 17 defaulters in 2011. The number of new defaulters diagnosed with CIN2+ 
during June-December 2012 significantly increased in comparison to the same time period in 
2011 (RR=2.2, 1.2-4.1).  The number of CIN2+ was 15 less in the same period in 2011 (Fig 
4.5.1).  
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Table 5.1.1: New colposcopy referrals in Dumfries & Galloway June-Dec 2012 & 2011 
Year  2012 2011 
Month clinics new def cin2+ clinics new def cin2+ 
June 7 22 3 1 6 20 3 2 
July 10 42 15 10 10 36 3 3 
Aug 5 21 3 2 4 20 2 2 
Sep 7 22 6 4 8 32 4 3 
Oct 8 26 11 5 8 23 1 1 
Nov 7 22 6 2 8 26 1 0 
Dec 8 27 7 4 6 26 3 2 
Total 52 182 51 28 50 183 17 13 
Key: clinics= number of colposcopy clinics per month; new= number of new colposcopy referrals 
per month; def= number of new defaulters referred to colposcopy per month; cin2+ histological 
diagnosis of high grade CIN or worse amongst defaulters.  
 
Fig 5.1.1: Details of hg-CIN or worse (CIN2+) cases diagnosed amongst defaulters in each year  
Histology 2012 2011 
CIN2 7 8 
CIN3 16 5 
CGIN 3 0 
Cancer 2 0 
 
The number of new defaulters referred to colposcopy (Fig 4.5.2) during June-December 2012 
significantly increased in comparison to the same time period in 2011 [OR=3.8 (2.1-6.9)].   
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Fig 5.1.2: Comparing number of new defaulters referred to colposcopy between June and Dec 
2012 and the corresponding period in 2011.  
 
 
 
Discussion 
The number of new defaulters referred to colposcopy increased 3 folds (OR=3.8, 2.1-6.9) during 
the study period in comparison to the same period (June-Dec) in 2011.  
 
The extra number of CIN2+ cases diagnosed in June-Dec 2012 was 15, in comparison to the 
same period in 2011. Assuming that all of these extra 15 cases were a consequence of the 
study, we attempted to estimate the number of defaulters diagnosed with CIN2+ after having 
been to a smear test (without HPV testing). We clearly know that two CIN3 diagnosed between 
June and December 2012 were participants who were first found to be HPV positive in vaginal 
samples. Therefore, up to 13 CIN2+ may have been diagnosed as a consequence of extra 
smear tests which were carried out in the community, because no abnormal smears (from 
women who ticked option-2) were referred to colposcopy from the hospital smear clinic.  
Prevalence of CIN2+ in women attending for cervical screening in England is about 1% (Health 
and Social Care Information Centre 2013). If the above assumption is correct, up to 1300 
defaulters in Dumfries & Galloway might have had cervical smears in the community. This 1300 
figure could be a little over-estimation, as the relative risk of CIN2+ in defaulters is higher than 
the general population.  
 
There were 2 defaulters in May 2012. However, both of them had been to cytology just before 
15 March, indicating that study participants were referred to colposcopy after May 2012. Whilst 
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most defaulters had been recruited before November, all recruitments were completed by mid-
November.  
 
The methodology of this audit limited its potential to measure the total screening outcome. Its 
focus was on the number of new defaulters referred colposcopy during the study period, in 
comparison to the same period in the previous year. Screening outcomes (diagnoses) of 
remaining new colposcopy referrals were not assessed. Therefore, it is not possible to estimate 
the relative impact of the study on total screening outcomes.  
 
Conclusions 
The number of new defaulters referred to colposcopy was significantly increased in during June-
December 2012, in comparison to the same time period in 2011. Whilst the odds of diagnosing 
CIN2 or worse diagnosis in a defaulter was increased twice during the study, a marked increase 
in CIN3 or worse diagnosis was seen.  
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5.2 Cost analysis of offering multiple screening options to defaulters 
within 2 studies 
Study question 
What is the estimated cost of offering multiple screening options to defaulters in the 
1000 and 200 defaulter studies? 
 
Summary answer 
If £2,200 extra money was spent offering multiple screening options to 1000 
defaulters in two cycles, the total estimated number of defaulters screened over 6 
months would be 230 (90 HPV tests + 140 smear tests) in the ‘letter’ method. If 
£4,300 extra money was spent offering multiple screening options to 1000 defaulters 
in two cycles, the total estimated number of defaulters screened over 6 months would 
be 300 (200 HPV tests + 100 smear tests) in the ‘kit’ method. The ‘kit’ method 
appears to be more cost effective than the ‘letter’ method in terms of the cost per 
self-sample collected and cost per one defaulter tested for HPV. In terms of total 
number of defaulters screened, the ‘letter’ method appears to be more cost effective. 
 
What is known and what this body adds 
About 60/1000 defaulters will go back to screening without any intervention over 6 
months. If defaulters were offered multiple screening options which include self-
sampling, this can be significantly increased. The relative cost-effectiveness between 
the ‘kit’ and ‘letter’ method is unknown. Based on the estimated screening uptake 
rates of the 1000 and 200 defaulter studies, the ‘letter’ method appears to be more 
cost effective than the ‘letter’ method in terms of the total number of defaulters 
screened. This evidence may be useful in developing self-sampling based screening 
models.  
  
Limitations 
All of our studies were not included in this analysis. Laboratory sample handling 
(human) costs were not included in this cost analysis, which should increase the 
amounts estimated to an extent. Estimated positive gains of screening outcomes 
(prevention of cancer morbidity and mortality) were not included in this analysis.  
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Background 
The cost of testing using a smear test was £7.19 and the cost of HPV testing was £12.83 when 
the sentinel study was carried out in 2009, according to its report published in 2012. The cost of 
a HPV test kit and reagents (excluding laboratory handling costs) is currently about £9.00. 
However, a sample collection for a smear test can cost substantially more (Fig 5.2.1) than a 
sample collection for a self-collected vaginal HPV tests (Table 3.6.2). It appeared that supplying 
a self-sampling kit on-demand could be cost-effective as postage of a self-sampling kit was 
thought to be high. 
  
Fig 5.2.1: Cost of sample collection for a smear test 
cost of making an appointment 
woman’s time 
travelling costs 
clinician’s time 
chaperone’s time 
hand washing 
hand towels 
gloves 
speculum 
brushes 
lubricant 
gown for the woman (sometimes) 
paper drapes to cover the couch  
paper to cover for woman’s privacy (sometimes a cloth) 
absorbent (incontinent) pad 
wipes 
sanitary towel 
disposal of this clinical waste 
cost of running the clinic (estate costs) 
cost of specimen transport 
other costs 
 
Methods 
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Costs of each step of screening were calculated. The number of women screened may be found 
from the study database.  Calculations used in this analysis were based on methods and 
outcomes of the 1000 defaulter study which sent a multiple options letter to defaulters (‘letter’ 
method) and the 200 defaulter study which sent a self-sampling kit to defaulters (‘kit’ method).  
 
Results 
The cost of sample collection for a self-collected vaginal HPV test (2012) in the ‘letter’ method 
was £2.52. The ‘kit’ method costs less (£1.98) (Table 5.2.2). Of note, the franking price for 1000 
Royal Mail First Class pre-paid envelops is £10 (10p each). 
 
Table 5.2.1: Cost of one vaginal sample collection, ‘letter’ method 
Item  £ p 
Invitation letter (printing & sorting)  20 
Postage  31 
return postage    8 
Kit letter (printing & sorting)                15 
Rovers Evalyn brush kit 1 00 
Jiffy bag  10 
Kit sending letter envelope  5 
Sending postage  53 
Return first class pre-paid postage  10 
Total  2 52 
 
Table 5.2.2: Cost of one vaginal sample collection, ‘kit’ method 
Item  £ p 
Invitation & kit letter (printing & sorting)                20 
Rovers Evalyn brush kit  1 00 
Jiffy bag  10 
Kit sending letter envelope  5 
Sending postage  53 
Return first class pre-paid postage  10 
Total  1 98 
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The total extra cost (apart from the staff costs for HPV testing) of offering HPV screening to 
1000 defaulters in a single cycle using the letter method would have been £1354, assuming 9% 
kit requests in a single cycle (Table 5.2.3). At the end of this, we predicted that about 60 women 
would have had HPV testing. The total cost (apart from the staff costs for HPV testing) of 
offering HPV screening to 1000 defaulters in a single cycle of the letter method would have 
been £1555, inclusive of the costs for 28 smear tests (28x7.19= £201.32) that HPV positives 
would have needed to have.  
 
Estimating costs per 2 cycles is slightly more difficult as it depends on the total response rate of 
the first cycle, which varies. The total extra cost (apart from the staff costs for HPV testing) of 
offering HPV testing to 1000 defaulters in 2 cycles of the letter method would be £2220, 
assuming 15% total response (total number of defaulters choosing options 1 to 6), at the end of 
the first cycle. At the end of 2 rounds, about 130 women would request self-samplers, out of 
which 90 women would actually do it. The total cost (apart from the staff costs for HPV testing) 
of offering HPV testing to 1000 defaulters in 2 cycles of the letter method would be £2507, 
including the costs for 40 smear tests (287.60) that HPV positives would need to have. 
 
Table 5.2.3: Cost differences between different self-sampling models 
 Method  £ p Num
ber*  
(£) Per 
head$  
1 Collection of 1 vaginal sample, ‘letter’ 2 52 - - 
2 Collection of 1 vaginal sample, ‘kit’ 1 98 - - 
3 Sample collection from 1000 in one cycle, ‘letter’  772 16 62 12.45 
4 Sample collection from 1000 in one cycle, ‘kit’ 1980 00 175 11.31 
5 Offering HPV screening to 1000 in one cycle, ‘letter’ 1354 10 62 21.84 
6 Offering HPV screening to 1000 in one cycle, ‘kit’  3633 75 175 20.76 
7 Offering HPV screening to 1000 in two cycles, ‘letter’ 2177 78 92 23.67 
8 Offering HPV screening to 1000 in two cycles, ‘kit’  4275 50 200 21.38 
Note: These costs are based on methods and outcomes of our studies, conducted in 2012. *Number of 
self-samples returned. 
$
Cost per sample collected/tested.  
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Cost per one self-sample collected between the ‘letter’ model and the ‘kit’ model in a single 
cycle can be compared as follows: The total cost for the sample collection (£772) was lower in 
the ‘letter’ group in comparison to the ‘kit’ group (£1980). However, the proportion of self-
samples received in one cycle (without a reminder) was less (6%) in the ‘letter’ model in 
comparison to the ‘kit’ model (17%). Hence, the cost per one sample collected in the ‘letter’ 
model (772/62= £12.45) was 10% more than that of the ‘kit’ model (1980/175= £11.31) [a total 
of 35 out of 200 kits which were sent in the first cycle in the 200 defaulter study have been 
returned]. Moreover, the total cost for sample collection in the kit model would be £1980, even if 
all 1000 defaulters or none of them decided to self-collect. This varied in the letter model.  
 
Cost per one defaulter tested for HPV would be (1354/92=£21.84) in the ‘letter’ method, 1 cycle 
(Table 5.2.3). Cost per one defaulter tested for HPV would be (3633/200=£20.76) in the ‘kit’ 
method, 1 cycle.  
 
Cost per one defaulter tested for HPV would be (2177/62=£23.67) in the ‘letter’ method, 2 
cycles (Table 5.2.3). Cost per one defaulter tested for HPV would be (4275/200=£21.38) in the 
‘kit’ method, 2 cycles.  
 
Although there has been a marked rise in general postage seen between 2012 (£1980) and 
2014 (£2030), the rise in franking prices is not very high. The stationery cost is unchanged. 
Therefore, the total cost difference is only £50.  
 
Discussion 
The number of new defaulters referred to colposcopy during the study period (June-December 
2012) was significantly higher than the same period in 2011. Although 8-9% women informed us 
that they wished to get a smear test, the actual number that had smears could have been 
higher. Although it is not possible to find the number of defaulters who had smears without 
informing us in the 1000 and 200 and 2000 defaulter studies, it was possible in the ‘Older’ and 
‘Younger’ defaulter studies (Table 4.7.3). Although 28 out of 584 defaulters informed us that 
they wished to have a smear test at 6 months by ticking the option-1 and option-2, 47 had 
smears in the ‘Older’ defaulter study.  Although 133 out of 1441 defaulters informed us that they 
wished to have a smear test at 6 months, 218 had smears in the ‘Younger’ defaulter study. This 
indicates that if 161 defaulters inform us that they wish to have a smear, 265 will actually have it 
(x1.65).  
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This is almost the opposite trend of self-sampling, where 284/383 (74%) actually returned a 
sample. A total of 86 women in the 1000 defaulter study wished to have a smear test. It could 
be estimated that 142 (86x1.65) might have had smears at 6 months. A total of 13 women in the 
200 defaulter study wished to have a smear test. It could be estimated that 21 (13x1.65) might 
have had smears at 6 months.  
 
A total of 92 (9%) in the 1000 defaulter study, 40 (20%) in the 200 women study did HPV self-
testing.  
 
Summary  
Cost per one self-collected sample returned for HPV screening in the ‘kit’ method is £1.14 
cheaper than the ‘letter’ method (Table 5.2.3). Two cycles of ‘kit’ method is 1.2 times more 
expensive than a single cycle, which increased the self-sampling uptake by 1.1 times. Two 
cycles of ‘kit’ method is 1.6 times more expensive than a single cycle, which increased the self-
sampling uptake by 1.5 times. Therefore, a second cycle (reminder) appears to be equally cost-
effective in collecting self-samples in the ‘kit’ as well as in the ‘letter’ method.  
 
The ‘kit’ method (£11.31) appears to be more cost effective than the ‘letter’ method (£12.45) per 
one self-collected sample returned. The ‘kit’ method (£20.76) appears to be more cost effective 
than the ‘letter’ method (£21.84) per one defaulter tested for HPV in a single cycle. A similar 
trend is seen in the ‘two cycles’ model (Table 5.2.3).  
 
If £2,178-£4,276 extra money is spent offering multiple screening options to 1000 defaulters in 
two cycles, 90-200 of them may have HPV testing. It can be predicted that additional 100-140 of 
them might have smears. This means that total estimated percentage of defaulters screened 
would be 23% (£9.47 per defaulter screened) in the ‘letter’ method and 30% (£14.25 per 
defaulter screened) in the ‘kit’ method. If £1,354-£3,634 extra money is spent offering multiple 
screening options to 1000 defaulters in one cycle, 62-175 of them may have HPV screening. It 
can be predicted that additional 75-100 of them might have smears. This means that total 
estimated percentage of defaulters screened would be 16% (£8.46 per defaulter screened) in 
the ‘letter’ method and 25% (£14.54 per defaulter screened) in the ‘kit’ method. In terms of total 
number of defaulters screened, the ‘letter’ method appears to be more cost effective.  
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Conclusion 
If £2.2-4.3k extra was spent offering multiple screening options to 1000 defaulters in two cycles, 
230-300 of them could be brought back to screening over 6 months. If £1.4-3.6k extra was 
spent offering multiple screening options to 1000 defaulters in one cycle, 160-250 defaulters 
could be brought back to screening. This will significantly increase the number of new defaulters 
referred to colposcopy. 
 
The ‘kit’ method (£11.31) appears to be more cost effective than the ‘letter’ method (£12.45) per 
one self-collected sample returned. In terms of total number of defaulters screened, the ‘letter’ 
method appears to be more cost effective. 
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CHAPTER 6 
 
Surveys  
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Introduction to chapter 6 
The chapter 6 includes surveys conducted as a part of this study. There were two main methods 
of data collection- 3 questionnaires, free text boxes of option lists and the content analysis of the 
consultation when defaulters presented at the hospital smear clinic.  
 
6.1 Acceptability of Evalyn brush as a self-sampling device.  
 
Study question 
How acceptable is the Evalyn brush for vaginal self-sampling to cervical screening 
programme defaulters?  
 
Summary answer 
The Evalyn device was fairly well accepted (217/311=70%) by those who requested 
self-sampling. Self-sampling experience was highly rated (86-97%) by 272 women 
who self-collected. 
 
What is known and what this body adds 
Almost all (98%) participants who were 134 patients visiting the gynaecology 
outpatient clinic in The Netherlands rated their Evalyn brush experience as good or 
excellent. Its acceptability in other settings, especially by non-attendees, is unknown. 
It appears that Evalyn brush was fairly well accepted by defaulters who decided to 
self-collect. It was highly rated by those who have self-collected, which encourage its 
use in non-attendees.  
 
Limitations 
The questionnaire had only ‘yes’ and ‘no’ answers. It did not have a ‘don’t know’ or 
‘unsure’ column which may have changed the shape of the survey outcome. Our 
study was not designed to compare the acceptability between different samplers that 
the relative acceptability of Evalyn brush is unknown. Evalyn brushes were provided 
free of charge by the Rovers medical devices. However, the company did not play 
any role in this study apart from being a valued sponsor.  
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Background 
According to the manufacturer, the Evalyn brush has been well accepted for self-sampling in a 
limited number of women in The Netherlands. There was no published evidence on its feasibility 
when we started our study. Our aim was to see if the device was acceptable to a sample of 
British women. We wanted to collect both objective and subjective evidence about this self-
sampling kit.   
 
Methods 
We designed a simple questionnaire (Questionnaire 1 Fig 8.2.7, Appendix 2,) which was sent 
with the Evalyn brush to women who wished to self-collect. We advised them to fill the feasibility 
questionnaire after self-collecting a sample and return it with the sample in the pre-paid 
envelope.  
 
The last objective question of this feasibility questionnaire was “If you had the option of self-
sampling, is it more likely that you would regularly participate in future cervical screening?” This 
question was repeated in Questionnaire 2 (Fig 8.2.8, Appendix 2), which was administered 
when HPV positives came to the hospital smear clinic for a cervical cytology (smear) test, 
approximately 2 months after they had self-collected the sample.  
 
Results 
A total of 284 Evalyn samples were returned. All except 8 women returned the completed 
questionnaire along with the sample. All of these 8 women subsequently retuned the 
questionnaire with the consent form, after a reminder letter. No one returned the questionnaire 
alone (without a sample). Four questionnaires were lost (could not be found for analysis). The 
remaining 272 questionnaires were analysed.   
 
The analysis of these 272 questionnaires is as follows (Table 6.1.1). Almost all (264/272=97%) 
said that the information provided was clear enough to self-collect a sample. They did not wish 
any additional information (97%). They found that self-sampling was easy (97%) and acceptable 
(96%). Whilst 11% found that self-sampling was uncomfortable, it was painful for 4%.  
 
 
 
 
151 
 
Table 6.1.1: Results of 272 feasibility questionnaire (Questionnaire 1) analysis 
 Yes  % No  % No 
answer  
% 
Was the information clear enough to self-collect a sample? 264  97 4  1 4 1 
Did you wish more information? 2  1 265 97 5 2 
Was self-sampling easy? 265  97 4 1 3 1 
Was self-sampling uncomfortable? 30  11 235 86 7 3 
Was self-sampling painful? 12  4 256 94 4 1 
Is self-sampling acceptable to you? 261  96 8 3 3 1 
If you had the option of self-sampling, is it more likely that 
you would regularly participate in future cervical screening?  
265  97 4 1 3 1 
Please add any comments you may have below 
 
 
 
A total of 265 (97%) women said (at the time of self-sampling) that if they had the option of self-
sampling, they would regularly participate in future cervical screening. A similar intention was 
noted when HPV positives came to the smear clinic where 99/105 (94%) answered ‘yes’ to the 
above question (Fig 6.1.1).  
 
Fig 6.1.1: Results of 105 Questionnaire-2 analyses (answer to the second last question) 
Question  Yes No No 
answer 
If you had the option of self-sampling, is it more likely that you 
would regularly participate in future cervical screening? 
99 
(94%) 
4 
(4%) 
2   
(2%) 
 
Subjective comments made in the free text box of the Questionnire-1 were analysed separately 
(Fig 8.1.6, Appendix 1). Comments were categorised into ‘practical reasons’, ‘attitudinal 
reasons’, ‘screening is not indicated’ or ‘the information is not clear’ to put into one of above 4 
categories. For descriptive purposes, some (26/68) of comments written by defaulters are 
categorically presented in the Fig 6.1.2.  
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Fig 6.1.2: Free comments made in questionnaire-1 
(a) practical reasons 
  “I suffer from IBS so I don’t like to have people prodding at me at times when it 
flares up.” 
 “I suffer from agoraphobia so it makes it difficult to get to surgery” 
 “I suffer from a very unpleasant vaginal discharge, too embarrassed to allow a 
doctor to perform a smear” 
 “I have some memory problems” (56 years) 
 “I have very painful hips & this form of screening was much more comfortable”  
 “I personally know my GP and the practise nurse I have had a bad smear 
experience at my practice”  
 “I have been sexually abused”  
 “Self sampling may be the only way transgender persons will have screening”  
 “Fibroids obstructing the cervix - taking a smear was unsuccessful in 4 different 
days”  
  “I find it extremely painful to have a normal smear test and this was painless, 
easy & quick.” (43 years, last smear 2008) 
  “Previously the nurse had a problem due to the position of the cervix- is this 
sample adequate?” (HPV positive, 48 years, 2006) 
 “This way of screening is much more private and so much easier to fit into your 
life ” (41 years, last smear 2008) 
 “Nice to be able to do it at home when you are free and relaxed. Thank you.” (44 
years, last smear 2001)  
 
(b) attitudinal reasons 
 “I have made it to 32 years old without having a smear- ridiculously avoided 
because of embarrassment. If this self sampling was an option, I would 
participate and get tested regularly.” (32 years, never had a smear) 
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(c)  screening was not indicated 
 “Declined last smear invite as I work in NHS England ad for me invite would be 
given not 3 years as NHS Scotland”. 
 “This was easy to do, as I never had one before as I am not sexually active and 
I have not had sex yet”. 
 
(d) the reason is not clear 
 “I would do this every year rather than go to doctor, even though my doc is 
great!” (36 years, last smear 2000) 
 “No lasting after effects, but didn’t expect spotting.” (54 years, last smear 2007) 
 “Slightly uncomfortable, noted small spot of blood after taking sample.” (56 
years, last smear 2006) 
 “I was sore on insertion but the test was easy and once inside was OK” (57 
years, last smear 2008) 
  “I don’t think I should have to take part in a study to have this option.” (56 years, 
last smear 2003) 
 “So much paper to work through may put people off participating in this study.” 
(55 years, last smear 2006) 
 “Needed translation” (Eastern European, never had a smear) 
 “I did struggle with trying to work out how to seal the bag!” (46 years, last 2005) 
 “It would have been better (for the kit) to come in a Jiffy bag.” (60 yr, last 2003) 
 “No mention about the absorbent paper in the instruction leaflet.” (this has been 
removed by the participant, 55 years, last smear 2006) 
 
Free comments were written by 25% (68/272) defaulters who completed the Questionnaire-1. 
Whilst 11/ 37 (30%) defaulters over the age of 55 wrote some comments, younger defaulters did 
so less often (57/235=24%). The reason was not clear in 59% (40/68) statements (Fig 6.1.2). 
According to written information, screening did not appear to be indicated for 3% who made free 
comments. When the reason for defaulting is clearly stated, it appeared to be a practical reason 
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for a majority (23/26=88%) of respondents and attitudinal reason for 12%. General attitude of 
the comments appeared positive in 60%, negative 22% and not very clear in 18% (Fig 6.1.3).  
 
Fig 6.1.2: Reason for not going for smears 
 Category  N % 
a Practical 23 34 
b Attitudinal  3 4 
c Not indicated  2 3 
d Not clear 40 59 
 Total  68 100 
  
Fig 6.1.3: General attitude of the comment made  
 Category  N % 
1 Positive  41 60 
2 Negative 15 22 
3 Not clear 12 18 
 Total  68 100 
 
 
Discussion 
The majority (70%) of women who requested the kit have returned a sample. It was well 
accepted for those who had done the test. Most women who self-sampled may have hoped that 
they would be tested negative, as they had to come for a smear test if they were tested positive. 
Therefore, our aim was to check if they still accepted this even if they had to come for a smear 
test in consequence. We administered Questionnaire-2 whilst the HPV positives were waiting 
for the smear test at the hospital smear clinic. Still, almost all of them said that they would 
regularly participate in future cervical screening, if they had the option of self sampling. This was 
a surprise answer for us.   
 
A recently published study (Darlin, Borgfeldt et al. 2013) collected data in a way that is similar to 
ours by sending a questionnaire for those who failed to respond 1 month since the first contact. 
This detailed questionnaire covered their reasons for not attending the organized cervical 
screening programme, their sexual history, parity, smoking habits and educational level. The 
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most common reason given for nonattendance by non-attendees was “Uncomfortable with 
vaginal examination” (37%) followed by previous negative experiences of gynaecological 
examinations (25%). The same trend was seen in the smear group. Other common reasons 
were “Feel healthy”, “Lack of time” and “Experience of unfriendly health workers” indicating that 
a vast majority were practical reasons for non-attendance. These Swedish findings are 
comparable to ours.  
 
Conclusions 
The Evalyn device was fairly well accepted (70%) by those who requested self-sampling. It was 
highly rated and commended by women who have actually self collected a sample and returned 
it. Furthermore, 97% of them said that they would regularly participate in future cervical 
screening, if they had the option of self-sampling, soon after the self-collection. A similar 
intention was noted when HPV positives came to the smear clinic about 2-3 months after the 
self-collection. When the reason for defaulting was clearly written by those who self-collected, it 
appears to be a practical reason for a vast majority (88%).  
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6.2 What are the barriers to cervical screening? Results of 2 surveys 
 
Study question 
What are the barriers to cervical screening?  
 
Summary answer 
Practical barriers to cervical screening appear to have more effect than attitudinal 
barriers to the HPV positive defaulters who came to the hospital smear clinic.  
 
What is known and what this study adds 
Practical barriers to cervical screening appear to have more effect than attitudinal 
barriers in the UK. The survey of 105 HPV positive defaulters who came to the 
hospital smear clinic supported the above evidence. According to the free comments 
provided by 20% of women who returned an  option list, screening was not indicated 
for 86% (98/114) defaulters who opted-out (but still returned a questionnaire), 
compared with 19% (12/62) of those who opted-in. Precise reasons why most of 
defaulters were screened may never be undestood (due to lack of engagement). 
However, reasons that we explored may be representative of them. 
 
Limitations 
Opinion of defaulters who opted in for self-sampling could be biased. Only 695 (20%) 
defaulters responded to the initial invitation letter so the opinion of the majority is 
unknown. 
 
Background 
The coverage of smear tests within the recommended screening interval (usually 3 or 5 years) 
was above 80% in only three European countries in 2004 (Anttila, Ronco et al. 2004)  
 
Factors that negatively affect cervical screening uptake has been categorised into 3 by Waller 
(Waller, Bartoszek et al. 2009).  
a) demographic factors such as age, marital status and ethnic group 
b) structural/ health-care factors such as appointment times, female practitioners and 
‘friendly treatment’  
c) attitudinal factors like embarrassment trust and concerns about discomfort.  
 
157 
 
However, when both women who attended and did not attend for screening were interviewed 
(Waller, Bartoszek et al. 2009), practical barriers to cervical screening seem to have affected 
more than the negative attitudes for non-attendance. Pain (68%) and embarrassment (79%) 
were the two main issues associated with smears for working women in China who had ever 
attended screening (Holroyd, Twinn et al. 2001).  
 
The aim was to describe and interpret why women with no cervical smear taken during the 
previous recommended interval chose not to attend the national cervical screening programme. 
 
Methods 
Data was collected using two sources: Questionnaire 2 and the free text comments made in the 
options list.  
 
Vaginal HPV positives of our main study came for a hospital smear test. The clinic receptionist 
requested the participant to fill in Questionnaire 2 when they handed in the appointment letter. 
Women filled the questionnaire whilst they were waiting for their smear test and put them in the 
questionnaire box sitting on the waiting area desk.  
 
All defaulters aged between 30 and 55 were sent a multiple options list along with each 
screening letter (both initial invitation as well as the reminder). Many wrote free text comments 
when they returned the option list (requesting a kit, requesting a hospital smear clinic 
appointment etc.). In very small number of cases, defaulters or someone else on behalf of the 
defaulter contacted us, usually by telephone explaining their circumstances. Such comments 
were prospectively recorded by the Data Manager of the Research & Development Department. 
These subjective comments are presented in (Fig 8.1.7, Appendix 1).  
 
These free text comments were categorised into one of the following 4: ‘practical’, ‘attitudinal’, 
‘not indicated’ and ‘not clear’. If the comment written did not clearly explain the reason why the 
defaulter had not had screening, it was categorised as “not clear” (NC). When screening was 
not indicated for a clearly defined reason or on other reasonable grounds, it was categorised as 
“not indicated” (NI). When the reason for non-attendance was more likely to be an attitudinal it 
was categorised as “attitudinal” and practical as “practical”. These were individually categorised 
by the PI and Dr Gwen Baxter (co-investigator). Any disagreements were discussed to come to 
a consensus.  
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Results 
1. Analysis of Questionnaire 2 
A total of 105 Questionnaire-2 were analysed (Table 6.2.1a - Table 6.2.1c).  
 
Table 6.2.1a: Results of Questionnaire-2 analysis, the number of defaulters endorsed ‘yes’ to 
each question 
No Statement 
 
Yes No No 
answer 
1 Smear tests are embarrassing 72  31  2 
2 I intend to go when I am due, but I don’t always get 
round to it straight away 
73 29 4 
3 I worry that a smear test will be painful 45 58 2 
4 I’m scared of what a smear test might find 61 39 5 
5 I’ve had a bad experience of a smear test in the past 31 72 2 
6 It is difficult to get an appointment to fit in with 
work/childcare commitment 
41 62 2 
7 I don’t feel at risk of cervical cancer 26 71 8 
8 I’m not sexually active so I don’t need to go for a 
smear test 
9 90 6 
9 I do not trust the smear test 16 85 4 
10 I do not need a test if I do not have any symptoms 
 
12 88 5 
12 If you had the option of self sampling, is it more likely 
that you would regularly participate in future cervical 
screening? 
99 4 2  
13 I have never had a smear test 
 
9 85 56 
14 My last smear was …. years ago (number of times a 
figure is written) 
75 n/a 30 
15 Please write any other reason/comments you may 
have, below (number of comments written) 
14 n/a 91 
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Table 6.2.1b: Results of Questionnaire-2 analysis- attitudinal barriers  
No Statement 
 
Yes No No 
answer 
1 Smear tests are embarrassing 
 
72  31  2 
3 I worry that a smear test will be painful 
 
45 58 2 
4 I’m scared of what a smear test might find 
 
61 39 5 
7 I don’t feel at risk of cervical cancer 
 
26 71 8 
8 I’m not sexually active so I don’t need to go for a 
smear test 
9 90 6 
9 I do not trust the smear test 
 
16 85 4 
10 I do not need a test if I do not have any symptoms 
 
12 88 5 
 
Table 6.2.1c: Results Questionnaire-2 analysis- practical barriers  
No Statement Yes No No answer 
2 I intend to go when I am due, but I don’t always get 
round to it straight away 
73 29 4 
5 I’ve had a bad experience of a smear test in the past 31 72 2 
6 It is difficult to get an appointment to fit in with 
work/childcare commitment 
41 62 2 
 
Questions were sorted into two categories: attitudinal barriers (statement numbers 1, 3, 4, 7, 8, 
9 & 10) or practical barriers (2, 5 & 6). The number of women answered ‘yes’ to each question 
was analysed. Practical barriers to cervical screening affected more than attitudinal barriers 
(RR=1.4, 1.20-1.64).  
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2. Analysis of free comments made in the screening option lists  
Many (183/695=26%) defaulters wrote free text comments when they returned option lists. They 
were categorized into 4 categories: practical, attitudinal, not indicated and not clear. Analysis of 
these 4 categories is presented in the Table 6.2.2. Five (3%) women who didn’t choose any 
option were removed from analysis. 
 
Table 6.2.2: Analysis of free comments made by respondents 
Category  1 
GP smear 
2 
Hospital 
smear 
3 
HPV 
hospital 
4 
HPV home 
5 
Discuss 
6 
Opt out 
Total  
Practical 6 6 0 7 2 7 28 
 21.43 50.00 0.00 36.84 100.00 6.14 15.73 
Attitude 2 0 1 7 0 3 13 
 7.14 0.00 33.33 36.84 0.00 2.63 7.30 
NI 11 1 0 0 0 98 110 
 39.29 8.33 0.00 0.00 0.00 85.96 61.80 
NC 9 5 2 5 0 6 27 
 32.14 41.67 66.67 26.32 0.00 5.26 15.19 
Total  28 
100.00 
12 
100.00 
3 
100.00 
19 
100.00 
2 
100.00 
114 
100.00 
178 
100.00 
Abbreviations: NI= not indicated; NC not clear 
 
Whilst defaulters who opted-out chose the option 6, those who opted-in chose options 1 to 4. 
Screening was not indicated for 98 out of 114 those opted-out (86%) than those who opted-in 
(12/62=19%). This difference was significantly different OR=25.5 (11.2-58.1). However, only 
20% (695/3498) of defaulters returned the options list (624 defaulters selected options 1-5 and 
71 selected option number 6).  A total of 2803 (80%) defaulters did not respond. These 2803 
non-responders’ opinion is unknown which could totally change this result.  
 
Discussion  
It could be argued that if question number 5: “I’ve had a bad experience of a smear test in the 
past” belongs to ‘practical barriers’. A bad experience when getting a smear test can be caused 
by various factors. It could depend on a woman’s menopausal status, menstrual status, pelvic 
anatomy, sensory (pain) syndromes and attitude, as well as healthcare factors, such as 
available resources (e.g. an adjustable examination couch that is designed for this purpose, 
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appropriate lighting, and different types of specula), together with the skill, behaviour and 
attitude of the smear taker. This may not recur. The woman’s attitude is only one of many 
factors. A woman with a normal attitude towards screening could also experience a bad smear 
test. Therefore, it is categorised under practical reasons. However, “I am worried that my 
previous bad smear experience could occur again” is better categorised as an attitudinal barrier.   
 
It could be argued that embarrassment is a neutral attitude rather than a negative attitude. It is 
possible that embarrassment would be similarly endorsed by regular attendees and defaulters. 
The questionnaire survey was anonymous. Women attending at the hospital smear clinic could 
pick a questionnaire from the clip board. They knew that it will be put into a big box which was 
kept on the middle desk of the clinic waiting area. The questionnaire did not have any reference 
number or space to write down a name. Hopefully, this gave them some reassurance that the 
information that they put down would be anonymous. This was clearly stated in the 
questionnaire too.  
 
Conclusions 
Practical barriers to cervical screening had more effect than attitudinal barriers to 105 HPV 
positive defaulters who came for a hospital smear test. One in five (n=695) of the target 
population returned the options list. Screening was not indicated in 98 out of 114 defaulters who 
opted-out (86%) than those who opted-in (12/62=19%). 
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6.3 What is acceptable for defaulters who refused our multiple 
screening options? 
 
Study question 
What form of screening would be acceptable for defaulters who refused our multiple 
screening options? 
 
Summary answer 
The response rate to this survey is 1-2% (38/2419). All 38 respondents stated that if 
they could be screened using a sample of urine, they will accept that offer. Half of 
them made some suggestions about how the testing could be made more acceptable 
to them. They appeared to have a positive attitude toward screening and suggestions 
were generally constructive.  
 
What is known and what this body adds 
Although much research has explored reasons why women did not attend routine 
screening, no study has been conducted to see what is appropriate for women who 
declined the offer of multiple screening options which included self-sampling. The 
response rate to this survey was very low, indicating that the answer is still unknown. 
Questionnaire surveys do not appear to be an effective method in exploring this 
research question.   
 
Limitations 
The poor response rate 1-2% is the main limitation of this survey. However, 
overcoming this limitation may not be easy in accessing this hard-to-reach group of 
people.  
 
Background 
Despite our best efforts, the majority of defaulters in Dumfries and Galloway still remain 
unscreened. The aim of questionnaire 3 was to explore this. The maximum screening uptake of 
any community based self sampling study was 39%. Further improvement of the screening 
uptake may have been achieved by answering the question: what can make them accept a 
cervical screening test?  
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Methods 
All defaulters aged between 30 and 55 who did not respond to the initial invitation (n=2714) 
were sent Questionnaire 3 and a reminder, 3 months  (2 months in the 2000 women study) after 
the first invitation letter. There were 2 text boxes in view to collect qualitative data and only one 
objective question in this simple questionnaire (Fig 6.3.1). Questionnaires retuned intact, for 
example, a woman retuning an empty Questionnaire 3 with the option list ticked in any given 
box, was not included in the analysis.  
 
Fig 6.3.1: Questionnaire-3 
Reasons why I declined the testing. 
....................................................................................... 
....................................................................................... 
....................................................................................... 
Suggestions about how the testing could be made more acceptable for me. 
........................................................................................ 
........................................................................................ 
........................................................................................ 
If you could be tested using a sample of urine would you accept that offer?   
Please answer yes or no 
YES             NO 
 
Thank you for completing this questionnaire.  
 
 
Results 
Although 2714 questionnaires were sent, it was not relevant to women who had been to a 
smear test without informing us, which are about 295 according to the sensitivity analysis.  
 
A total of 45 (1.7%) questionnaires were returned, of which 7 were returned blank with a 
completed options list. It could be assumed that these 7 questionnaires may not have been 
returned, unless the option list was returned. Remaining 38 questionnaires were filled, at least 
partially.  
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All those who attempted to fill the questionnaire (38/38=100%) answered yes, to the urine 
sample question.  
Subjective comments were written in 31 questionnaires. Reasons for not having any screening 
test so far are listed in Fig 8.1.9 in the Appendix 1. These reasons were categorised into 4 
different categories: ‘practical’, ‘attitudinal’, ‘screening is not indicated’ or ‘not clear’. Their 
suggestions to make screening acceptable to them are listed in Fig 8.1.10 in the Appendix 1. It 
was categorised whether their suggestions were positive or not.  
 
A total of 31 (86%) women wrote something in free text boxes. Screening was not indicated for 
5 (16%) out of 31 of them. Whilst 15 (48%) were practical reasons 11(35%) were attitudinal 
reasons (Fig 6.2.1).  
 
Half of them (19/38= 50%) made some suggestions about how the testing could be made more 
acceptable to them. All of them appeared to have a positive attitude toward screening and 
suggestions were generally constructive.  
 
Fig 6.3.2: The main categories of reasons for not accepting screening 
Category  n % 
Practical  15 39 
Attitudinal  11 29 
Not indicated  5 13 
Not relevant 0 0 
Not stated 7 18 
Total  38 99 
 
 
Discussion 
The response rate is very low [38 ÷ ((total list=3498) – (list clearance=267) – (responded to the 
initial letter=517) – women who had smears without informing us))]. According to the sensitivity 
analysis, it is estimated that about 295 women might have had smears without informing us. 
Therefore, the response rate is calculated to be 38/2419=1.6%.  
 
According to the findings of the 1996-97 Canadian National Population Health Survey which 
included 33,817 women (Maxwell, Bancej et al. 2001), for those who hadn’t had a smear test 
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during the last screening interval; most (53%) reported that they did not think it was necessary. 
This fact may be applicable to our cohort of defaulters who did not accept any method of 
screening, despite having multiple options. Screening was not indicated for a vast majority of 
those who opted out by choosing option 6 of our intervention.  
 
Conclusion 
The response rate to this survey was very low (1-2%), indicating that a questionnaire survey is 
an ineffective research tool to explore this question.  All 38 respondents answered ‘yes’ to the 
question ‘if you could be tested using a sample of urine would you accept that offer?’ Half of 
them (19/38= 50%) made some suggestions about how the testing could be made more 
acceptable to them. All of them appeared to have a positive attitude toward screening and 
suggestions were generally constructive.  
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6.4 What was the main barrier to cervical screening? A content 
analysis of the smear clinic consultation 
 
Study question 
What was the main barrier to cervical screening for women who defaulted?  
 
Summary answer 
According to the content analysis of the smear clinic consultation, practical barriers to cervical 
screening appear to have more effect than negative attitudes for non-attendance to this cohort 
of 155 defaulters. 
 
What is known and what this study adds 
Practical barriers to cervical screening appear to have more effect than attitudinal barriers in the 
UK. This qualitative study conducted amongst 155 defaulters strengthens the current evidence.  
 
Limitations  
Opinion of defaulters who opted in for screening could be biased. Interview with the defaulter 
was not tape recorded which limits the reproducibility of the data. Most of these HPV positive 
defaulters took part in more than one survey.  
 
Background 
It has been highlighted that non-attendance is due more to the practical barriers than attitudinal 
barriers. Reasons may vary in different geographical locations.  
 
Methods 
A content analysis of the smear clinic consultation where either under or unscreened women 
were seen. HPV positives of our main study came for a hospital smear test. Each woman was 
properly counselled by the PI before the smear test was taken. At the end of counselling, each 
participant was asked one clear question: what was the main reason why you didn’t go to your 
last smear test? We waited for the woman’s reply, for as long as it took. However, most women 
gave a quick answer. A few of them gave various reasons, of which the first answer was 
recorded on the data sheet. Care was taken not to facilitate their answer. The PI decided 
whether it was a practical or attitudinal reason there and then and recorded it next to the reason.  
167 
 
Some came to a hospital smear clinic without having a HPV test. For those who had previously 
provided a self-sample, the result (HPV negative or positive) was known by the time they 
attended the hospital smear clinic.  
 
Results 
Prospectively collected data are presented in Fig 8.1.8 in Appendix 1. The main reason for non-
attendance is categorised into 4- ‘practical’, ‘attitudinal’, ‘screening not indicated’ and ‘not clear’. 
 
A total of 142 out of 155 reasons were recorded. They were categorised into 4. The main 
reasons for ‘not clear’ were ‘no spontaneous answer’ and ‘forgot to record’. Please find the 
analysis of data in Fig 6.4.1. These cohort of defaulters faced practical barriers to cervical 
screening more than negative attitudinal barriers [RR=4.9 (3.3-8.0)]. Practical barriers to 
cervical screening appear to be similarly affecting both defaulters who opted for self-sampling 
and had a positive test as well as for those who did not wish to self-collect (Fig 6.4.2). 
 
Fig 6.4.1: The main categories of reasons for not going for the previous smear 
Category  n % 
Practical  113 73 
Attitudinal  22 14 
Not indicated  7 5 
Not recorded 13 8 
Total  155 100 
 
 
Fig 6.4.2: Analysis of the main reason for not going for the previous smear between HPV 
positive defaulters versus defulters who did not wish to self-collect 
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The main reason for non-attendance could be grouped as follows (Fig 6.4.3): 
 
Fig 6.4.3: The main reasons for non-attendance 
(a) Practical  
1. Busy at work or with the family or both 
2. A regular attendee experiencing a bad smear test  
3. Illnesses such as dementia, IBS, arthritis, bipolar disorder and genital atrophy 
4. Personal problems  
5. I want to avoid my practice’ smear taker 
6. Received appointment letter, but didn’t get round to it 
7. Received an appointment letter, but I was pregnant then 
8. Didn’t receive a letter 
9. Change of address 
10. Lack of understanding  
11. Lack of communication or poor care by the healthcare staff  
 
(b) Attitudinal  
1. Embarrassment 
2. Anxiety and phobia 
3. Didn’t want to know 
 
Many defaulters thought that screening was not necessary as they were either not sexually 
active at that time or had not been sexually active for a long time (for example, widows and 
women who were not in a relationship). Only a few women said it was for no apparent reason.  
 
Discussion 
Some defaulters believed that they didn’t have to go for screening, if they were not at risk of 
getting a sexually transmitted infection (STI). Consequently, they took screening less seriously 
either since they had been in a stable, monogamous relationship for a long time or since they 
had ceased sexual activity completely. This was not an attitudinal reason. It was mainly lack of 
understanding for which the National Screening Programme and healthcare professionals 
should have taken some of the responsibility. I am yet to find a patient information leaflet that 
clearly states that the HPV infection has the potential to stay in the genital tract forever 
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(although 90% women who are exposed to HPV are likely to clear the infection within a few 
years). Perhaps, this knowledge gap should be closed by educating the public. The defaulter 
reminder letter and the screening information leaflet should be amended appropriately.   
 
A few factors may have biased this information: 
1. The background of these women who came for a smear test. Whilst most came after 
being tested positive for HPV, others came for a smear test because they did not want to 
go to the place that they usually go or were supposed to go. Hence, there was a natural 
tendency that they would praise us or our study. In order to reduce this bias, we asked 
this question at the very beginning of the consultation, soon after a rapport had been 
built. We tried to create a neutral environment and adopt a neutral behaviour. We did not 
patronise anyone’s (community smear takers) behaviour nor did we incriminate it whilst 
collecting this information.  
2. The professional role of the PI (Gynaecologist in the NHS) and the gender (male). 
However, most women seemed to be genuine about their opinion. The PI was always 
accompanied by a senior healthcare assistant. 
3. The defaulter’s state of mind; i.e. some were self-blaming, some were blaming the setup, 
some were slightly concerned, some were neglecting and a few were seriously worried, 
some or all of which may have attributed to it.  
 
It could be argued that embarrassment is a neutral attitude rather than a negative attitude.  
 
“How do women who choose not to participate in an organised screening programme reason 
about their decision?” was the research question of a qualitative research conducted in Sweden 
(Blomberg, Ternestedt et al. 2008). Women contacting the central organization, who neither 
wished to participate in the organised cervical screening programme at that time nor in the 
future, were the subjects of the study. Qualitative telephone interviews and fax messages from 
women who actively declined participation were analyzed inductively. Factors related to the 
women's decisions not to participate in screening at all include:  
1. lack of confidence in the benefits of screening 
2. previous negative health care and preventive experiences 
3. a belief in the individual's own ability to discern health changes 
4. a belief that the individual was not at risk for cervical cancer 
5. a number of unconventional standpoints on social and political issues 
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Our study findings were somewhat similar to these findings, although the method of sampling 
varied significantly. A cohort of women who contact the central organization expressing their 
unwillingness to participate was quite different from that of the woman who wished to do it in a 
different way. However, the research question is almost the same: ‘what was the main reason 
why you haven’t been to your last smear test?’ Keeping with the difference in women being 
interviewed, the Swedish cohort appears to have had more attitudinal barriers than our cohort. 
This can be interpreted as women who wished to accept alternative screening being more likely 
to have practical barriers to cervical screening than women who totally declined screening.  
 
A qualitative study examined the barriers to cervical screening in an urban setting in Canada 
(Fitch, Greenberg et al. 1998). Focus group methodology was used to explore the perspectives 
of socioeconomically disadvantaged women regarding their access to health care. The study 
revealed four broad themes:  
1. being able to talk with doctors is important 
2. being treated as a person is important 
3. finding answers to many questions about cancer is important 
4. having a Pap test is uncomfortable 
 
Data collected from nine focus group discussions with 62 women from diverse socio-economic 
backgrounds in Serbia (Markovic, Kesic et al. 2005) identified that the interplay of social and 
personal barriers influenced poor screening attendance. A series of focus groups among African 
Caribbean, African, Gujarati, Pakistani, Greek and Arabic groups living in Brent and Harrow in 
the UK, which consisted of 85 women and 50 men were conducted to discover their perceptions 
of cancer screening and the barriers to effective uptake (Thomas, Saleem et al. 2005). Analysis 
of focus group data revealed that interplay of practical and attitudinal factors affected screening 
participation. It was revealed that poor knowledge, underlying health and cultural beliefs, 
attitudes, language and unhelpful attitudes of health professionals were all important barriers. 
 
Women who reported that their last test had been painful (bad experience) or embarrassing 
held more negative views of a future test (Orbell 1996). These were the reasons for non-
attendance for many women in our cohort. The ways in which cervical screening discourses 
were negotiated, accepted and resisted by British women appears complex (Bush 2000).  
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Conclusions 
Practical barriers to cervical screening appear to have more effect than negative attitudes for 
non-attendance [RR=4.9 (3.3-8.0)] to this cohort of defaulters. Defaulters who opted for self-
sampling (and had a positive test) as well as those who opted for a smear test alone (without 
doing self-sampling) were similarly affected by practical barriers.  
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6.5 Patient experience survey at the hospital smear clinic 
 
Study question 
What was the overall experience of women attending at the hospital smear clinic 
when screening programme defaulters were offered multiple smear options? 
 
Summary answer 
The hospital ‘out of normal working hours’ smear clinic was highly rated by patients. 
 
What is known and what this body adds 
Hospital smear clinics are no longer available within the NHS. Hence, its acceptability 
and necessity is unknown. This survey shows that the hospital smear clinic was 
acceptable to those defaulters who attended. The hospital ‘out of normal working 
hours’ smear clinic was highly rated by its service users. All 3 smear clinics were 
equally rated. No serious adverse comments were made by clinic attendees. 
Running a hospital smear clinic at a frequency which is governed by its demand (e.g. 
first Wednesday and/or first Saturday of the month) may be recommended. This may 
widen women’s choice.  
 
Limitations 
User surveys can be biased due to various reasons. Although we attempted to 
minimise such, there was room for bias.  
 
Background 
Previous bad smear test experience was one of the main practical reasons for non-attendance 
for under-screened women. The aim was to evaluate the patient experience of women attending 
the hospital smear clinic by administering a simple questionnaire in view of exploring the things 
that we do better and not as well. These findings could be used for service development.  
 
Methods 
All patients attending at the hospital smear clinics from October to November 2012 were 
requested to complete a simple patient experience survey questionnaire as they left the smear 
clinic. This was requested by the nurse or healthcare assistant on the smear clinic. Patients 
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filled it in outside the smear clinic and put in the ‘Patient Feedback’ box in the waiting area. 
Women didn’t know about the questionnaire until they left the clinic. The nurse was supposed to 
say “Can you please fill this questionnaire about this clinic and put it in this box?” Care was 
taken not to influence patient’s decision making. 
 
Separately coloured questionnaires (Fig 6.5.1) were administered for lunch time (green), 
evening (yellow) and weekend (pink) clinics.  
 
Fig 6.5.1: User survey questionnaire of the hospital smear clinic 
Smear Clinic (please tick) Yes No  Unsure 
Did we meet your expectations? 
 
   
If this service was available in the future, 
would you use it again? 
   
 
How would you rate this service?  
1 
 
2 
 
3 
 
4 
 
5  1 = poor, 5 = excellent (please circle) 
Any suggestions for improvement  
 
Thank you for your feedback.  
 
Results 
Feedback of smear clinics is illustrated in Fig 6.5.2.a to Fig 6.5.2.f. Fifty five women attended 
the hospital smear clinic during the survey period. A total of 55 slips were found in the box. All of 
them were filled. Almost all 54 (98%) said that their expectations were met. A similar proportion 
(53/55=96 %) said that if this service was available in the future, they would use it again. The 
overall rating of the smear clinic experience was very positive with no one rated 1 or 2. Three 
(5%) rated 3, 9 (16%) rated 4 and 43 (78%) rated 5. Some suggestions for improvement were 
written by 11 women Fig (6.5.2.f). Whilst 9 were happy with the current service, one patient 
wished the appointment time not to be breached, other women preferred to have a female 
smear taker.  
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Fig 6.5.2: Results of the hospital smear clinic user survey  
(a) Lunch-time smear clinic feedback 
 8 women Yes No Unsure 
Did we meet your expectations? 
 
8 0 0 
If this service was available in the future, 
would you use it again? 
8 0 0 
How would you rate this service? 1 2 3 4 5 
1 = poor, 5 = excellent 0 0 0 1 7 
(b) Evening smear clinic feedback 
23 women Yes No Unsure 
Did we meet your expectations? 
 
22 1 0 
If this service was available in the future, 
would you use it again? 
22 0 1 
How would you rate this service? 1 2 3 4 5 
1 = poor, 5 = excellent 0 0 2 5 16 
(c) Weekend smear clinic feedback 
 24 women Yes No Unsure 
Did we meet your expectations? 
 
24 0 0 
If this service was available in the future, 
would you use it again? 
23 0 0 
How would you rate this service? 1 2 3 4 5 
1 = poor, 5 = excellent 0 0 1 3 20 
(d) Overall summary of the smear clinic feedback 
55 women  Yes  No  Unsure  
Did we meet your expectations?  54  1  0  
If this service was available in the future, 
would you use it again?  
53  0  1  
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(e)  Overall rating of the smear clinic experience 
 
                                                                                                                                                                                                   
(f) suggestions for improvement  
 Any suggestions for improvement  
1 Excellent – would be great if this could continue.  
2 Comment- much easier than I anticipated. Doc/Nurse excellent.  
3 Smaller instrument.  
4 Would have been nice to have been given the option of a female 
nurse testing smear test.  
5 Staff was very understanding. 
6 Appointments on time! 
7 Exceptional service. 
8 Doesn’t need improving it works perfect.  
9 None.  
10 None. 
11 No. 
 
Discussion                                                       
The size of the questionnaire slip was limited to a 1/3rd of an A4 sheet. The number of questions 
was limited to 4, designed in this way to keep the woman’s focus on the main points. This was 
also to improve compliance. The main objective of the questionnaire was to use its outcomes for 
service development.                                                                                                                                                   
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Most defaulters who asked for a hospital smear clinic appointment in the younger defaulter’s 
study were included in this sample. Some women who selected option 2 in other studies also 
came to these clinics along with a small number of HPV+ women who came for their smear test.  
 
The hospital smear clinic met all except one out of 54 service user’s expectations. All except 
one would use this service in the future (one person did not answer this question). All except 3 
rated this service 4-5 out of a scale of 5, where 5 was ‘excellent’ and 1 was ‘poor’. No serious 
adverse comment was made by clinic attendees although one woman who was seen on time 
was not happy about it and another woman would have preferred a female smear taker. 
 
The effectiveness of flexible smear appointments was tested in a population-based randomized 
trial in western Sweden (Broberg, Jonasson et al. 2013). Telephone contact with non-attendees, 
offering an appointment to take a smear, was compared with a control group. Of 8,800 cervical 
screening defaulters, 4,000 were randomized to a telephone arm, another 800 were offered 
HPV self-sampling and 4,000 constituted a control group. Participation during the following 12 
months was significantly higher in the telephone arm group than in the control group, 718 
(18.0%) versus 422 (10.6%) (RR: 1.70, 95%CI, 1.52-1.90). However, the difference over a one 
year period was small (7.4%). ‘Out of normal working time appointments’ were endorsed by a 
similar proportion (17%) of 290 women who were likely to be eligible for breast screening when 
the research focus was to explore aspects of the service likely to increase participation 
(Richardson 1990). In our studies between 1% and 4% of defaulters chose a hospital clinic for 
their smear and of those opting for a hospital appointment only 71% actually attended. 
 
Conclusions 
The hospital smear clinic was acceptable to defaulters. The hospital ‘out of normal working 
hours’ smear clinic was highly rated by its service users. All 3 smear clinics were equally rated. 
No serious adverse comments were made by clinic attendees.  
 
Running a hospital smear clinic at a frequency which is governed by its demand (e.g. first 
Wednesday and/or first Saturday of the month) may be recommended. This may widen 
women’s choice.  
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7.1 DISCUSSION  
 
7.1.1. High HPV prevalence  
Clinical application of vaginal self-sampling for HPV screening was evaluated in most of these 
studies. We explored potential reasons for not going for the smear test. We also explored what 
was acceptable for those who did not accept these options to be screened by using 
Questionnaire 3.  
 
The HPV prevalence in vaginal samples is very high in all of our studies (Table 7.1.1.1), in 
comparison to the cervical residual samples of those who were tested positive in self-collected 
samples (Table 7.1.1.2).  
 
Table 7.1.1.1: HPV test results of vaginal samples 
  1000 study 200 study 2000 study Older study Total 
HPV + (%) 46% 60% 44% 40% 46% 
HPV – (%) 54% 40% 56% 60% 54% 
Total (n) 92 40 107 43 282 (100%) 
 
Table 7.1.1.2: Valid HPV test results of cervical smear residual samples in women who were 
HPV positive in vaginal samples 
  1000 study 200 study 2000 study Oder study Total 
HPV + (%) 43% 38% 12% 50% 33% 
HPV – (%) 57% 63% 88% 50% 67% 
Total  (n) 35  16  25  8  84 (100%) 
 
All cervical smears were taken adhering to the standard procedure (NHSCSP 2006). 
Inadequate cervical residual samples giving an invalid HPV result has never been an issue in 
the 30-56 year age group. However, it caused problems when smear residuals were tested for 
HPV. It was apparent when smears were collected from older defaulters that the cellular 
material obtained on the sampling brushes (Cervex brush and endocervical brush) was scanty. 
Hence, we took extra care to make sure that we suspended as much sample as possible in the 
ThinPrep vial.  
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First, the Cervex brush (Fig 7.1.1.1a) was agitated in the ThinPrep vial according to the 
manufacturer’s instructions- the brush head was pushed against the bottom of the vial 10 times, 
forcing the bristles to bend apart. Finally, it was swirled vigorously to release any additional 
cellular material. However, this technique was not applicable to the endocervical brush which 
has very fine, short nylon bristles attached to a metal central helix (Fig 7.1.1.1b) Even though 
the manufacturer’s instructions were followed (the cytobrush was immersed and agitated in the 
vial containing the liquid medium to release cells), about half of the specimen was left on the 
brush head due to the thick mucous nature of the specimen. This problem was overcome by 
rubbing the endocervical brush with the Cervex brush within the PreservCyt medium of the 
ThinPrep vial (using the Cervex brush to comb the bristles of the endocervical brush). Finally, 
both brushes were swirled in the liquid medium, before being put into the disposal bin. This 
technique appears to have left little specimen on bristles.  
 
Fig 7.1.1.1: The cervical sampling technique  
(a) with Rovers Cervex® brush 
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(b)  with the endocervical brush 
 
 
 
  
 
Despite this technique to transfer the sample to the liquid medium, the resulting cervical sample 
did not appear to be as cellular as the pre-menopausal cervical sample.  
 
A similar trend was seen with samples obtained using an Evalyn brush. Evalyn samples 
received from pre-menopausal women appeared to contain a rich cellular material. Mucous, 
cellular material was seen not only on the bristles, but also on the sleeve of the Evalyn brush. 
However, we did not include material on the sleeve in the PreservCyt medium to minimise 
contamination. This heavily cellular material which is probably only available with the Evalyn 
brush (in comparison to other self-sampling devices) may partially explain higher HPV 
prevalence in these vaginal samples. A good sample is vital for a good result. Not only did the 
Evalyn sampler collect arguably a very good sample, we also concentrated it to make it even 
better. Based on results of our first validation study- ‘can women self-collect an adequate 
sample for HPV screening?’ it was decided that the ThinPrep samples should be concentrated 4 
fold (p.62).  
 
Unlike other nucleic acid amplification tests, the Hologic Cervista HR-HPV invader technology 
apparently requires a rich cellular sample in order to give a valid result. This appears to be an 
adaptation to prevent picking up clinically insignificant HPV infections. However, this is less 
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relevant when it comes to self-sampling, where detection of any high-risk infection may be 
necessary due to a less cellular nature of the self-collected sample. We wanted to find women 
with any important high-risk genital HPV infection during the primary screening step. We did not 
want to compromise the sensitivity of the HPV screening to get reasonable positive predictive 
value (PPV) as HPV positives were cytology triaged for colposcopy. 
 
We thought that the approach of picking up any significant high-risk genital HPV infection may 
not do any harm as we would not treat anyone based on the HPV result alone. We considered 
HPV positivity as a marker of women who would require a smear test, nothing else. We labelled 
the HPV home test as the ‘pre-screening test’ and the smear test as the ‘proper screening test’. 
We counselled our study participants accordingly.  
 
The hrHPV prevalence could have been reduced by increasing the cut-off values of the Cervista 
test. A higher cut-off value may have picked up fewer HPV infections. It is possible that women 
who have done self-sampling (282/3498=8%) were indeed at a higher risk of having the HPV 
infection or at least these women might have perceived that. However, lower HPV prevalence in 
cervical counterparts suggests that other factors may have confounded this result. It can be 
argued that some HPV results of cervical residuals were falsely negative. It is theoretically 
possible that Hologic ThinPrep LBC slide absorbs all infected cells in the ThinPrep pot and 
leaves the residual with an inadequate sample. For example, cervical smear of the patient 
number 2 of the proof of concept study (Table 3.1.1.) did not have any genomic human DNA 
and failed the internal control. Presence of inhibitors is another possibility. The answer to this 
question could have been found, if we had collected a separate cervical sample and tested it. 
However, we did not originally plan to do this, mainly due to resource implications.  
 
High HPV prevalence was reported in other studies. In their cohort study involving the whole of 
Scotland, (Kavanagh, Sinka et al. 2013) estimated the HPV prevalence in young women in 
Scotland in view to monitoring the vaccination impact. The weighted prevalence of any HPV in 
young women aged 20–21 was 32.2% for the urine, 39.5% for the self–taken swab, and 49.4% 
for the residual LBC samples. They had used a vaginal swab for self-sampling which might have 
been the reason for discrepancy of prevalence between the cervix and the vagina. Although this 
was a younger cohort of women than ours, the estimated HPV prevalence was high.  
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A self-sampling study that included 878 sexually active women, aged 15-69 (Holanda, Castelo 
et al. 2006), reported 34% hrHPV prevalence when a brush was used as the self-sampler. The 
same type of brush was used for clinician a sample which was tested only for HPV (without 
using it for cytology). The cervical hrHPV prevalence was 29%. The Hybrid Capture II DNA 
positivity (relative light units in relation to a 1-pg/mL positive control ≥1) was significantly more 
common in vaginal samples. The hrHPV prevalence remained higher even if the threshold of 
positivity was raised to RLU/PC≥3. Although we do not have access to such DNA quantification 
cut-off data, this may well have been the case in our study samples.  
 
Vaginal self-collected samples had slightly higher HPV rates than cervical counterparts, 
irrespective of the age among the 307 women aged 15-49 years in Canada. (Karwalajtys, 
Howard et al. 2006). The prevalence of HPV was (64/307= 20%) and (54/307=18%) in the 
vaginal and cervical specimens, respectively. Among the women aged 50 years and older, 
prevalence was (15/152=10%) and (13/152=9%), respectively. 
 
A Swedish study (Stenvall, Wikstrom et al. 2007), reported a mean hrHPV prevalence of 26% 
(30/117) in a population based study conducted in Sweden. Participants were women aged 
between 35 and 50 years, who had not had a smear test for 6 years. The self-sampling device 
used was Qvintip. The HC2 was used for HPV testing, which can detect HPV DNA 
concentrations over 1 pg/mL. The hrHPV prevalence was 31% in women aged 35-42.  
 
Contamination of samples during the initial processing at Dumfries laboratory or during the 
testing in Edinburgh HPV Reference Centre was also possible. However, this was discussed 
within the research team soon after the first set of results was available. Although no evidence 
for contamination was found, potential ways of contamination were discussed and utmost care 
was taken to prevent contamination. But still, high prevalence was noted throughout the 10 
month study period. In some days, only one sample was processed in Dumfries laboratory, 
making the contamination from another sample virtually impossible.  
 
Most cervical smears were collected 2-3 months after self-sampling. Although up to third of HPV 
infections may have been overcome by host immune system during such a short period, it 
cannot be attributed to this major difference in HPV positivity.  
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Even if every contributing factor was accounted for, the exact reason for very high HPV 
prevalence seen in these vaginal samples cannot be fully explained. Hopefully, future evidence 
on the Evalyn brush will inform us more about this.  
 
7.1.2. Response rates   
Self-sampling for HPV screening was offered in all except the younger defaulter study. 
Defaulters who chose options 1 to 5 were considered as positive responses. Defaulter’s 
response depended on many factors.  
 
The 1000 defaulter study was the first study group. Participants were recruited between 15 
March and 20 April 2012. The total positive response rate was 24% (236/1000) at six months. 
About a third (40/129=31%) who did not respond requested a self-sampling kit only after 
receiving the reminder letter, 3 months after the first invitation letter.  
 
The 200 defaulter study was the second study group. Participants were recruited between 18 
and 22 June 2012. The key feature of this study in comparison to the other three was the fact 
that a self-sampling kit was sent with the initial invitation letter. The total positive response rate 
was 32% (63/200) at six months. Twenty (10%) samples were received within the first week. 
Another 11 samples were received in next 3 weeks. The vast majority (34/40=85%) of returned 
samples were returned within 3 months. Whilst 11 new kit requests were received after sending 
the reminder letter, one person retuned the kit with a sample in October, which was 4 months 
after it had been sent to her. Although 11 women responded after the reminder, about 15% 
(6/40) samples were received after the reminder letter. Most of other options (1, 2, 5, & 6) were 
ticked and received in the first 2 weeks of sending the initial invitation letter. Basically, the 
response was immediate and it was comparatively good.  
 
The 2000 defaulter study was the third study group. Participants were recruited between 9th 
and 13th July 2012 which was 4 months after the database was generated. The total positive 
response rate was 16% at six months. This cohort of women was sent the reminder letter 2 
months after the initial invitation, rather than 3 months in the previous 2 studies. Only 22 out of 
158 (14%) requested self-sampling after receiving the reminder letter in the second week in 
September. Basically, the overall response rate as well as the response to the reminder letter 
was poor in this cohort.  
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The majority (57%) of those who indicated they were willing to take up the smear test did not do 
so within a one-year period (Orbell and Sheeran 1998). This longitudinal test of the association 
between motivation to undertake a precautionary health action and subsequent behaviour was 
conducted on women's uptake of the cervical screening test in 166 women who had never been 
screened.  
 
The older defaulter study was the fifth study group. Participants were recruited between 29 th to 
31st October. Twenty six samples were received from the letter + kit group and 24 kit requests 
were received from the letter only group at 2 months. No reminder was sent. 
 
Table 7.1.2.1: Self-sampling response to the initial invitation and the reminder  
 1000 defaulter 
study 
200 defaulter 
study 
2000 defaulter 
study 
older defaulter 
study 
Kits requested 
first round  
89 (69%) 34* (76%) 136 (86%) 50 (100%) 
Kits requested 
second round  
40 (31%) 1*+11 (24%) 22 (14%) N/A (0%) 
Total (n/N%) 129/1000  
(13%) 
46**/200 
(23%) 
158/2031  
(8%) 
50/584 
(9%) 
*kits sent in the first cycle, ** number of kit requests received from the first cycle + 11 samples 
that were requested in the second cycle.  
 
A significant heterogeneity with two degrees of freedom is observed between 3 response rates 
in these three studies (1000, 200, 2000 studies) conducted in the same 30-55 year age group 
database (X2
2=54.7, p<0.001). It appears that the self-sampling response to the initial invitation 
was 2% lower than its comparable counterparts. The self-sampling response rate to the 
reminder was lowest (14%) in the 2000 defaulter study group. Several factors may have 
affected the lower response rate seen in the 2000 women study group.  
 
Addresses of the 1000 and 200 women study groups were cross-checked against the hospital 
database, TOPAS. When in doubt, telephone calls were made by the data manager of the 
Research and Development Department. Consequently, 246 out of 1246 in the 1000 study 
group and 21 out of 221 in the 200 study group were removed from the list. About 18% that 
were found on the SCCRS appeared to be inaccurate. Documented reasons for removing 
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defaulters from the list were numerous. The most common category was not living at the current 
address, which was explained as ‘untraceable’, not living in Dumfries & Galloway, not living in 
Scotland, living in elsewhere in UK, living in a foreign country, not registered, change of address 
and ‘no fixed abode’. There were names of 5 deceased women in that list of 1467. According to 
the younger defaulter study, up to 8% addresses of younger defaulters found in the SCCRS 
could have been inaccurate.  
 
Finally, members of the research team who ran the smear clinic observed that screening uptake 
was poor during school holidays and during the time that London 2012 Olympic and Para-
Olympic games were being held. I believe that these activities in the summer might have 
negatively impacted the screening uptake rate of the 2000 defaulter study which was conducted 
at the same time. This trend was seen nationally. 
 
A total of 3.3 million cervical smears were carried out in England in 2012-13 (N=3,334,052)   
(Fig 7.1.2.1). The number of smears carried out in the second quarter (July to September, 
n=840,525) was significantly less than that of the first three months (n=902,426) [RR=0.9, 0.9-
0.9]. It dropped by another 10% in the third quarter from October to December (n=777,594) 
[RR=0.9, 0.9-0.9]. Interestingly, the reduction of screening uptake rate seen in our studies over 
the time follows the same pattern.  
Fig 7.1.2.1: Number of smear tests carried out in each quarter in 2012-13 in England 
 
Source: Health and Social Care Information Centre. (2013) 
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The average monthly smear uptake rate among defaulters (without any intervention) may be 
considered as 1% across our study population.  It was 0.78% per month, in the control group 
older (56-60 years) defaulters (6÷12÷64). It was 1.15% (119÷6÷1732) in the historical control 
group. It would have been 1.38% per month (58÷6÷720) (61÷6÷721) in the younger (20-29) 
defaulters predicted control groups. The mean monthly smear uptake in the middle-aged (30-55 
years) group (n=3498) of defaulters is likely to have been in between these two figures, which 
can be rounded up to 1% per month.  
 
Self-sampling uptake rates in different study groups  
The self-sampling uptake rate of our studies (Table 7.1.2.2) can be put in to perspective when 
other population based studies are considered. It is best to compare the self-sampling uptake 
rate, as it was the measured primary outcome in most of the other studies (Table 1.2.3).  
 
Table 7.1.2.2: Self-sampling uptake rate to the initial invitation and the reminder  
 1000 defaulter 
study 
200 defaulter 
study 
2000 defaulter 
study 
older defaulter 
study 
Samples received after 
the initial invitation 
71 (77%) 34 (85%) 95 (88%) 43 (100%) 
Samples received after 
the reminder 
21 (23%) 1*+5 (15%) 13 (12%) N/A (0%) 
Total n/N (%) 92/1000 
(9.2%) 
40/200 
(20.0%) 
107+1/2031  
(5.3%) 
43+1/584 
(7.4%) 
*a kit which was sent out after the initial invitation 
 
In many aspects, our study is best compared with the London study (Szarewski, Cadman et al. 
2011). The main differences between these two studies were population, self-sampling kit and 
the approach. The population in Westminster is multi-cultural and more mobile in comparison to 
Dumfries & Galloway. Whilst these factors are not in favour of higher screening uptake by 
defaulters, the lower smear coverage (68% in London, 77% in Dumfries) should have been in 
favour of taking up self-sampling. The London study (Szarewski, Cadman et al. 2011) used a 
small Dacron swab as a self-sampling kit with the invitation letter and other paperwork. Apart 
from the self-sampling kit, list clearing, multiple options list and the reminder, the method of 
intervention of the London study appears similar to our 200 defaulter study. However, self-
sampling uptake rate in London was lower (96/1500=6.4%) than our 200 defaulter study 
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(20.0%). Even if the first cycle alone is considered, the self-sampling uptake rate of the 200 
study group was 35/200= 17.5%. But, the self-sampling uptake rate of the 56-60 age group in 
our study was lower (26/292=8.9% in the ‘kit’ method) than that of the 200 defaulter study 
group. Confounding factors for lower screening uptake in the older defaulter study could have 
been the extreme end of the screening age group and the time of year that the study was 
conducted (winter 2012). Perhaps, differences in approach may have made a difference to 
outcomes. Whilst we made an open invitation for defaulters to come back to screening by giving 
them as many options as possible, one arm of the London study offered self-sampling only. 
However, the overall self-sampling (which mostly includes the ‘letter’ method) uptake rate of our 
study’s total population 7.4% (284/3815) is similar to the London study.  
 
A recently published study (Darlin, Borgfeldt et al. 2013), targetted 1500 defaulters aged 
between 32 and 64 to be randomised 2:1 to self-sampling and a flexible no-fee appointment for 
a cervical smear. The study design of this study was similar to that of our 200 defaulter study. 
However, there were some differences. Participants had not been to a screening in over 9 
years. The self-sampling kit was a cotton swab. One month after the invitation, a reminder was 
sent to non-responding women with another self-sampling kit.  
 
A total of 147 (15%) samples were received, of which two thirds (93) were received after the 
reminder. Only 10/147 (7%) were hrHPV positive. A very low number of women (21=4%) opted 
for a smear test, of which two thirds (14/21) requested it after receiving the reminder letter. The 
screening uptake rate in the first round of this study was surprisingly low (5%), in comparison to 
many Swedish studies which reported self-sampling uptake rates of 31.7%, 39.0%, 39.0, 39.1% 
and 39.4% (Table 7.1.2.2). The mean self-sampling uptake rate of our study groups which were 
sent a reminder was 7.4% (240/3231). The longer interval between the last screening test and 
the current multiple screening choices offer should have been the most important negative 
factor affecting screening uptake of the (Darlin et al. 2013) study. However, the mean duration 
since the last smear test our 200 defaulter study showed was 7 years, with 3 women who had 
never been to screening. This duration was 9 in the 1000 defaulter group and 8 years in the 
2000 defaulter group. Perhaps the appearance of the Evalyn brush which appears to simulate 
the smear collection technique may have given women better reassurance than a cotton swab.  
Only 3 out of 249 Evalyn brush users in our study were unsure if they had collected an 
adequate sample.  
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7.1.3. Effectiveness of HPV screening methods   
The relative effectiveness of HPV self-sampling against the routine cytology screening was 
measured in some self-sampling studies. A Swedish study by Lindell recruited 3,618 women 
aged 50-65 years for self-sampling and they used 6,048 women of the same age as controls. 
Whilst 15 CIN2+ were diagnosed in controls (0.25%), HPV self-sampling for HPV screening arm 
diagnosed 10 CIN2+ in 1426 self-samples (0.70%).  The odds ratio for using self-sampled 
vaginal smear and a high-risk HPV test for detection of CIN2+ when compared with Pap smear 
for detection of the same lesion was 2.84 (95%CI, 1.14–6.77, P = 0.0174).  
 
The London study Szarewski et al. (2011) diagnosed 3 CIN2+ (CIN2, CIN3 and cancer, each) in 
96/1500 (6.4%) self-samples, whereas one CIN2+ was found in 68 (4.5%) women who attended 
for smears out of 1,500 controls, indicating that the HPV screening appears more sensitive than 
LBC in detecting CIN2+, although numbers are too low to draw any reliable conclusions.  
 
The MARCH Trial demonstrated an odds ratio of 3 between HPV screening in self-collected 
samples and the conventional Pap smear. About 10% (884/9202=9.6%) who self-collected were 
HPV positive. There were 108 (1.2%) CIN2+ in this unscreened Mexican cohort. HPV testing 
identified 117·4 women with CIN 2 or worse per 10 000 (95·2–139·5) compared with 34·4 
women with CIN 2 or worse per 10 000 (23·4–45·3) identified by cytology; the relative sensitivity 
of HPV testing was 3·4 times greater (2·4–4·9). Similarly, HPV testing detected 4·2 times (1·9–
9·2) more invasive cancers than cytology did (30·4 per 10 000 [19·1–41·7] versus 7·2 per 10 
000 [2·2–12·3]). 
 
Although 383 defaulters opted to self-collect, only 284 (74%) samples were received. Almost all, 
118/130 (91%) HPV positives had smear tests. Three of them were high-grade smears. They 
were referred to colposcopy.  All of them were diagnosed to have CIN2+ on LLETZ        (2x 
CIN3 and 1x CIN2). HPV positive but smear negative 67 defaulters had colposcopy and a 
repeat smear 12 months after the first. Whilst 1 woman had a high grade smear result (one 
CIN2+) at the annual follow-up, 4 defaulters had hgCIN on colposcopy (four CIN2+) despite 
negative smears. HPV screening in self-collected samples appears to be more sensitive than 
cytology screening in detecting CIN2+. Findings of this annual follow-up were consistent with 
previous self-sampling evidence (Lindell, Sanner et al. 2012; Tamalet, Le Retraite et al. 2013).  
 
189 
 
The HPV prevalence in our 30-60 year age group was 130/282=46%. There were 3 CIN2+ in 
the first round and 5 CIN2+ in the annual follow-up of HPV+, with a total of 8/282=2.7%. 
Reported rates of CIN2+ in 11 population-based self-sampling studies were between 0% and 
3% (Table 7.1.2.2), indicating that the effectiveness of our self-sampling methods is comparable 
to other self-sampling studies. A pooled analysis of 5 self-sampling studies conducted in China 
reported a higher percentage (507/13,004= 3.9%) CIN2+ (Zhao, Lewkowitz et al. 2012). 
However, participants of these studies were referred to colposcopy, if any of the multiple 
cervical screening tests (self HPV, cervical HPV, LBC, VIA) were positive. Four random biopsies 
were taken from each quadrant of the cervix from everyone who attended colposcopy, which 
tended to increase the number of CIN2+ cases diagnosed.  
 
Most women (51/77=71%) who ticked option 2 came for a smear test at the hospital smear 
clinic, two of them had a borderline smear result and 1 smear had to be repeated due to an 
unsatisfactory result (inadequate sample). One woman who requested a self-sampling kit could 
not be HPV screened, as no kit was received. She eventually came for a smear test, which was 
reported as moderate dyskaryosis and was diagnosed as CIN3 on LLETZ. A total of 350/1441 
(24%) in the younger defaulters’ study had been to cervical smears in 13 months. Five percent 
19/350 of them had had an abnormal (BNC+) smear result. All 12 women who were referred to 
colposcopy had attended colposcopy.  A total of 11 (3.1%) CIN2+ (five CIN2, five CIN3 and one 
CGIN) were diagnosed in these 350 defaulters aged between 20 and 29 years of age.      
 
Of the 153 HPV negative women, 12 had cervical smears in the community, in the following 12 
months. One of them had an abnormal smear result.  
 
7.1.4. Communication of results   
Results were sent to participants in writing within 2 days by first class mail after being made 
available (please see the results letters in Appendix 2). Multiple identifiers such as community 
health index (CHI) number, date of sample collection, date that the sample was received and 
the lab reference number were included to make it more reliable (trustworthy) to the participant. 
It was assumed that mistakes could be minimised by adopting this strategy. We are very 
pleased to report that no mistakes were made in communicating results.   
 
We were very careful when drafting the results letter, in order to make it clear, concise and 
simple. Whilst emphasising the importance of follow-up, we wanted to make sure that the letter 
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would not cause unnecessary anxiety. We included several ways that participants could contact 
different levels of healthcare professionals for any further information or advice. This letter was 
reviewed by several healthcare professionals and appropriate changes were made.  
 
We wanted to make the HPV positive letter (Fig 8.2.15) clear and straightforward. It is a dual 
purpose letter- to deliver the result and offer the follow-up appointment, which is similar to a 
colposcopy clinic appointment. We decided not to include the word cancer, which could cause 
unnecessary anxiety. We made the concepts of HPV and cytology screening simpler by 
phrasing “positive for HPV infection means that you need to have a smear test”.  This letter was 
accompanied by a comprehensive 2 page list of frequently asked questions (Fig 8.2.15, 
Appendix 2).  
 
Drafting the HPV negative results letter was much harder than its positive counterpart. It was 
difficult to find the right balance between being honest about the HPV negative result and 
emphasising the importance of accepting the next smear test which was due in 0 days to 2 
years after receiving this letter. However, we adopted a pragmatic strategy. First, we said that 
this result may be falsely negative. Second, although a woman could be negative today, she 
may acquire the disease in due course. Thirdly, a smear would give more reassurance. We 
developed this letter (Fig 8.2.16, Appendix 2) based on the content of the National Screening 
Programme’s screening negative result letter.  
 
Four Evalyn samples did not give a valid result in the Cervista first run, and therefore had to be 
re-tested. Consequently, the HPV result of a 31 year old woman was delayed more than 6 
weeks, which caused significant anxiety. This woman’s sample was received the day after one 
batch of samples had been despatched to Edinburgh. This sample had to wait another 13 days 
in Dumfries. The sample gave an invalid result due to a problem with the internal control, which 
had to be repeated. Soon after, the Scottish HPV Reference Laboratory was physically shifted 
to Edinburgh Royal Infirmary from the medical school building. When they re-established on the 
new site, the sample was retested. However, it was not possible to test samples due to 
technical failure of the new Cervista platform until industry experts eventually repaired it. In the 
seventh week, the participant contacted us. A big apology was rendered. The patient was 
offered an immediate smear test for which she attended the following morning. The HPV result 
(negative) was available in the same afternoon, and was communicated over the phone 
followed by a letter (with a written apology). This is the only result that breached the 6 week 
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agreed target. Almost all other results were sent to participants within 4 weeks. It was a mistake 
not to communicate with the patient regarding this delay, which may have alleviated her anxiety.  
 
7.1.4 Communication with participants   
We received about 30-40 telephone calls relating to the study. Most informed us that they didn’t 
need cervical screening as either it has not been indicated or they had been to a smear test 
recently. 
 
Some women were not happy that they received the reminder letter even after they had been to 
a smear test at their GP practice recently. Some such women became angry when they read 
the first question of the Questionnaire 3- “Reasons why I declined the testing”. The Clinical 
Governance Department received some phone calls complaining about this, as they had not 
declined testing. Some women were worried that their smear result or sample may have been 
lost and that they would have to go for another smear test. Fortunately, these women called 
either their GP or us.  
 
A person who was sent 2 reminders made a complaint about this study. We were advised by 
the NHS authorities not to send more than one reminder and to objectively reflect on that 
incident and learn from it.  
 
7.1.5 Reasons for defaulting    
Reasons for defaulting were gathered in various forms at different stages of the study. Reasons 
for defaulting were mainly collected from women who had opted for screening. These defaulters 
were more likely to have a practical barrier to overcome, in order to come back to screening. 
Such reasons were reflected in the questionnaire survey as well as in the qualitative study.  
 
We were able to gather reasons not only from defaulters who wished to come back to 
screening, but also from those who declined it. Exploring reasons for non-attendance from 
defaulters who refused further screening despite these multiple, flexible options were possible in 
4 ways:  
a) as they returned the pre-paid options list 
b) when they contacted us through telephone, email and mobile text 
c) as they returned the pre-paid questionnaire-3 
d) through their carers or healthcare professionals 
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Gathering and reporting this information was useful for service development. Whilst most of 
these defaulters did not need cervical screening (e.g. total hysterectomy, disabled who has 
never been sexually active), some needed it.  
 
A wrong address or the woman no longer being eligible for cervical screening at that address 
(e.g. women who is living abroad) belong to a separate ‘iatrogenic’ category. These women 
were wrongly labelled as defaulters. Deceased individuals also belong to this category. Though 
the cancer risk of this category would not be reduced by these smear recalls, they are not 
necessary. It appears that some system should be put in place to clean the call-recall database. 
This will not only save resources, but also build public confidence in the screening programme, 
as it would ensure clean and accurate statistics.        
 
7.1.6 Analysis of the written content of the hospital smear clinic consultation     
Direct quotations of ‘the main reason for not having the last smear test’ was recorded in the 
clerking sheet of the hospital smear clinic. This question was asked soon after women had 
competed the questionnaire-2, which contained objective questions regarding non-attendance. 
This may have ‘primed’ and ‘probed’ these women’s minds to determine the main reason. 
Hence, most women gave the main reason, promptly. Some women required more time to 
provide a response. Only a few need to be prompted. No one said “I’ve never thought about it”. 
 
This question was asked by a male gynaecologist (PI), which might have confounded the 
answer to a minor degree in some women. However, most women gave their reason without 
any hesitation. Even when embarrassment was the reason, it was more due to a ‘familiar health 
professional’ rather than a ‘male doctor’.  
 
7.1.7 Annual follow-up   
It was agreed that HPV positive women who attended the smear test in the first round would be 
called to attend the annual follow-up clinic.   
 
7.1.8 Passive follow-up  
Will HPV negative defaulters attend future cervical smears? To find the answer for this 
important question, screening histories of all study participants who were tested negative for 
HPV (n=153) have been checked on 27 December 2013, 12-18 months since they have 
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received a negative HPV result. The control group was women (n=99) those who have asked 
for a kit, but no sample was returned.  
 
A total of 37 women who have had a negative HPV result have been recalled by the SCCRS, 5 
(14%) of them have had smear tests. By contrast, 6/34 (18%) in the control group have had a 
smear test.  
 
This 14% figure looks very positive. These defaulters have been to smears despite the fact that 
they had a negative screening test within 6-12 months. Furthermore, they were told that they 
were tested negative for the virus that can cause cervical disease. Even then, 14% were 
motivated to have the smear test, which testifies the quality of the participant education 
component of our study. This indicates that this proportion is likely to grow with time as most 
women believe that they don’t have to undergo screening, not more frequent than every 3 
years. We promoted screening, not HPV testing. Consequently, women appear to have 
received a clear, positive message about screening, which may have motivated these HPV 
negative defaulters to accept the screening recall. If we were to randomise HPV only arm (50%) 
and smear only arm (50%) for a RCT, we could have struggled to counsel participants properly. 
Although we wanted to conduct our studies as robust as possible, as clinicians, we were 
ethically bound to select the right balance for our population. 
 
After receiving the self-sampling kit, 12 women have contacted me to discuss the most suitable 
cervical screening test for them. Based on the discussion, more than half of them have decided 
to get a smear test. This may have contributed towards slightly high rate of smear uptake in the 
control group.  
 
It may be argued that defaulters who decided to self-collect vaginal sample with the Evalyn 
brush may not participate in future cervical screening. This argument makes sense as most of 
defaulters who accepted self-sampling did so, as they did not like the smear test in the first 
place. However, this is not entirely true. We were very conscious about this fact at the beginning 
of our study. Therefore, we focused on this matter in our participant education component. We 
emphasised the importance of regular screening and stated that this is a one-off study; hence 
they may not get the chance to self-sample again. We warn them that if they did not accept the 
cervical screening recall invitation, they will be put back to the defaulter state, which will result in 
no recall for another 2½ years. They were told in the results letter that no screening test is 100% 
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accurate, but, if you were tested negative repetitively, your chance of developing cervical cancer 
will be very low. The primary aim of our effort was to bring defaulters back to regular screening.    
 
About 1 in 7 defaulters who were tested negative for HPV had responded to their next cervical 
screening recall, even when they were called within a few months of receiving a HPV negative 
result. This proportion is likely to grow over the time. This indicates that our efforts of bringing 
defaulters back to regular screening have been successful.  
 
We will be monitoring this screening uptake rate in the future.  
 
7.1.9 Things which we would have done differently 
In our multiple screening options studies, if participants did not respond by 2-3 months, one 
further reminder letter was sent.  However, we were unable to check the screening status of 
participants before the reminders were sent due to logistical reasons. This sometimes clashed, 
if the person had been for a smear independently and had not informed us (the research group).  
 
Conducting a second run of main studies in 2013, which is one year after the first intervention, 
in the same population would have been interesting. However, we were given a target of 31 
December as the final date for these studies. If these multiple screening options were offered 
until 31 March (when national statistics are calculated), the screening coverage in the region 
could have been much better.  
 
I now feel that we should have included a larger non-intervention (control) group, representative 
of the whole population, in order to demonstrate robust statistically significant difference. I 
believed that everyone should be given an equal opportunity to know the potential risk 
associated with not being screened and have the privilege of make use of using these 
alternative screening options. Therefore, we limited the control group to a minimum (1% of the 
total population).  
 
7.1.10 Limitations of these studies  
It was difficult to foresee every potential issue that may arise within the study when the study 
was planned in early 2011. Available resources were another main limitation, as it was virtually 
nothing at the beginning apart from the support received from the Research & Development 
Department. Some more interventions, if planned, would have given better answers. One of 
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them is to offer colposcopy for a representative sample of HPV negatives. This should have 
given the evidence to support the true negative predictive value of HPV screening.  
 
The high HPV positivity seen in the self-collected material and the discrepancy of HPV positivity 
that was seen between the self-collected material and cervical smear residual of the same 
population could have been explained, if a reference HPV test (e.g. HC2 or a highly sensitive 
PCR-based test) was used for all samples head to head with the Cervista test. However, the 
Scottish HPV Reference Centre has an excellent quality control programme. Not knowing the 
cervical HPV status at the annual follow-up visit was another limitation. If a separate cervical 
sample was taken for HPV testing, it would have given us better answers for some questions 
such as, high prevalence of HPV in vaginal samples and explaining smear negative but CIN 
positive cases. However, the associated cost was an issue, as we did not have any funding for 
this research. Our valued sponsors kindly recognised the importance of this study and 
supported the essential work proposed.  
 
Despite all of our efforts to get defaulters engaged, the majority of them have not responded. 
Views, attitudes and behaviours of those defaulters could not be assessed; which was the main 
limitation of our survey carried out amongst defaulters who did not respond to our options. This 
has always been the case in other research conducted in this area. It is very important that we 
understand this limitation as overenthusiastic efforts of getting defaulters into screening may 
affect patient’s/ individual’s autonomy. Individual’s autonomy must be respected all the time 
which is a fundamental ethical principle.  
 
The positive response rate in the 2000 study group is less than that of the 1000 and 200 
defaulter studies (24-32%) although they are from the same age group (30-55 years). Figures 
are much lower when it comes to the proportion of self-collected samples received. It was 5.3% 
(108/2031) in the 2000 study, 9.2% (92/1000) in the 1000 study and 20.0% (40/200) in the 200 
study. It could be argued that the self-sampling uptake rate is low in 1000 and 2000 studies. 
However, the method of recruitment to 1000 and 2000 studies was a letter, whilst it was a kit in 
the 200 study, which explains some of these differences. The only one previous study which 
adapted this ‘letter’ method where a self-sampling needs to be ordered (Giorgi Rossi, Marsili et 
al. 2011) reported a self-sampling uptake rate of 5.8%. Moreover, there was no ‘list clearing’ in 
the 2000 study. This is not a normal cohort of the general population. This is a minority of the 
population which did not accept screening in the first place. These uptake rates need to be put 
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in to perspective. Without any intervention, about 1% of these defaulters would go back to 
screening per month (6/64 per year, 21/1441 per month), according to our controls.   
 
We could have randomised the whole target population into four different intervention arms as 
Giorgi Rossi and colleagues did (Giorgi Rossi, Marsili et al. 2011), which could have enabled 
calculate the relative effectiveness of each method. However, I was concerned that such 
approach could cause issues when getting the ethical approval. For example, encouraging 
women to take up self-sampling without putting due emphasis on cervical smears may put some 
members in the ethical committee off.  
 
The non-interventional (control) group consisted only of women aged between 56 and 60 years, 
which is not ideal. I did not have access to the database that was used to recruit women for the 
1000, 200 and 2000 defaulter studies. However, databases that I had access to (older and 
younger defaulter studies) were randomised appropriately. 
 
Three women who attended smear clinic following a positive HPV test were found to be 
significantly anxious, which we recorded in the notes. However, it would have been better to 
formally assess the level of anxiety of these women which will aid planning future research and 
making some remedies to reduce it.  
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7.2 IMPLICATIONS 
 
7.2 Translation of this research into practise 
How can these results be used to improve patient care, delivery of services and/or population 
health? 
 
7.2.1 Potential ways of increasing the screening attendance 
We hope that more flexible cervical screening options will be welcomed by non-attendees. We 
believe that the HPV self-testing gives women privacy and autonomy, empowering and making 
them full partners of their gynaecological health.  
 
The Scottish Cervical Screening Programme makes an annual estimation of cervical screening 
coverage based on screening statistics on 31 March in each year. Out of 15 Health Boards, 
Dumfries and Galloway was the 4th best cervical screened health board in Scotland in 2012 and 
it is the 3rd in 2013. It became the best cervix screened health board amongst all the mainland 
boards. 
 
The Scottish cervical screening coverage dropped almost by 2% from 73.0% in 2012 to 71.2% 
in 2013 (Table 7.2.1.1). The lowest drop is seen in Orkney (0.4%). Second best is Dumfries and 
Galloway (0.5%) The screening coverage in Dumfries and Galloway was 76.6% in 2011 and 
76.1% in 2012. Therefore, Dumfries and Galloway recorded the second best screening uptake 
rate in Scotland in 2012-13.  
 
Screening coverage is the proportion of the balance between screening attendance and the 
non-attendance out of the total eligible population. Whilst many non-attendees were going back 
to screening, more number of usual attendees may have defaulted which has caused this 
national drop of screening coverage by 1.8% in just one year. The difference between these two 
was second lowest in Dumfries and Galloway (0.5%) and lowest in both Lothian (2.1%) and 
Greater Glasgow (2.1%). Although our study interventions may have had some positive impact 
on these screening outcomes, it cannot be attributed to all of it.  
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Table 7.2.1.1 Scotland’s cervical screening coverage in the last decade (ISD Scotland 2013) 
 
 
 
Fig 7.2.1.1 Scotland’s cervical screening coverage (%) in the last decade 
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Developing more flexible and convenient cervical screening options will be a continued process, 
based on findings of this study. We hope that other screening programmes may adapt this 
flexible approach which tends to improve the compliance and hence, the coverage.  
At the end of this study, we designed a ‘screening service model’ (please see Fig 7.2.1.2) that 
could be replicated among other health boards. We may be able to increase the cervical 
screening coverage and hence, to reduce the cancer incidence, morbidity & mortality. Offering 
self-testing may be cost-effective. This may be the introduction of dual method testing for 
cervical screening within the NHS so as to include a defaulter screening programme.  
 
Fig 7.2.1.2: Proposed screening model 
 
 
Women eligible for cervical screening  
Standard Programme Defaulter Programme 
HPV Screening in a self collected sample 
HPV + 
Cervical sample for co-testing 
Cyto + 
HPV  ± 
Colposcopy 
+FU 
Cyto – 
HPV + 
Cervical sample for co-testing in  1 year 
Cyto + 
HPV ± 
Colposcopy 
+FU 
Cyto – 
HPV + 
Colposcopy 
+FU 
Cyto – 
HPV –  
HPV  Screening 
every 3 years+ FU 
Cyto – 
HPV –  
HPV Screening  
every 3 years+ FU 
HPV –  
HPV Screening 
every 3 years + FU 
200 
 
Recognising self-sampling for HPV screening as a primordial screening test (a test which tells 
you who should be further screened) will be an important step forward, at least for getting 
defaulters back to the standard screening programme. Over 90% of vaginal HPV positives in 
our study have come for the smear test, which they would have refused otherwise. A gold 
standard primary screening test which will have an excellent sensitivity and specificity can be 
carried out subsequently using a proper sample. It is not very realistic to expect the same 
sensitivity and specificity from a woman collected sample from currently available self-sampling 
devices. However, evidence suggests (Arbyn, Verdoodt et al. 2014) that current methodologies 
are good enough to recognise women with genital HPV infection. Once women find that they 
are at higher risk of developing disease, they will come forward for further testing.  Recognising 
self-sampling for HPV screening as a primordial cervical screening test will reduce unnecessary 
anxieties about screening, which may enhance compliance. We adapted this approach in our 
study which has been accepted by almost all of participants.  
 
Other medical screening programmes use various samples other than the gold standard 
screening test. Such examples are: 
1. saliva and urine sample for HIV screening rather than serum 
2. identifying fecal occult blood in bowel screening rather than sigmoidoscopy  
 
Some screening programmes use a combined risk score in defining individuals at risk. Such 
examples are: 
1. Pregnancy’s Down syndrome (DS) risk is usually calculated using woman’s 
demography (age), several serum markers and some ultrasound markers, in 
combination. For example, maternal age at the expected date of delivery; serum β 
human chorionic gonadotropin (βhCG), alpha feto protein (AFP), unconjugated 
estriol (uE3), Inhibin A in the second trimester (15 weeks); pregnancy associated 
plasma protein-A (PAPA) at 10 weeks and nuchal translucency scan 11-14 weeks 
gestation are all included in the integrated screening for DS. The risk of DS is 
calculated by multiplying the background maternal age and gestation related risk by 
likelihood ratio derived from the nuchal scan and blood test results of two stages.  
 
Such a complex integrated test for Down syndrome screening has been deveoped mainly for 
one purpose- to increase the accuracy of the screening test. This test seems to be cost-effective 
(Wald, Bestwick et al. 2006) considering the the lowest false positive rate (1-2%) and higher 
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sensitivity (85-90%) amongst 6 screening tests which have sensitivities between 60% and 90% 
(Gekas, Gagne et al. 2009; Wald, Huttly et al. 2009). Whilst many NHS organisations offer this 
to the public (Wald, Bestwick et al. 2006), others still offer the double test which has the 
sensitivity of 60% for a given false positive rate. Considering the seriousness of the cervical 
cancer, it would be reasonable to make the HPV self sampling as a primordial screening test.  
 
 
 
Therefore, it is necessary give the self sampling for HPV screening the place that it deserves- 
primodical screening test. If we attempted to replace the current primary screening test, it may 
not work. It appears that using HPV status of the self test in combination with the cervical 
cytology ±HPV testing may lead to confusing results. Therefore, it is best to consider the self 
collected HPV test as the test to tell whether or not a defaulter needs a cervical smear test (Fig 
7.2.3). This approach may reduce any conflicting opinion and build good public understanding 
about it.  
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7.2.2 Proposed colposcopy management pathway   
There is no established professional consensus on how to manage HPV screen positive 
women. For the management of women with persistent cervical HPV infection, the following 
colposcopy management pathway (Fig 7.2.2.1) can be suggested.  
 
Fig 7.2.2.1: Proposed colposcopy management pathway for HPV screen positives 
 
 
Abbreviations: Cyto- = normal liquid based cytology; Cyto+= BNC+; TOC= test of cure.  
 
Women eligible for cervical screening  
Standard Programme Defaulter Programme 
HPV Screening in a self collected sample 
HPV + 
Cervical sample for co-testing 
Cyto + 
HPV  ± 
Colposcopy 
Cyto – 
HPV + 
Cervical sample for 
co-testing in1 year 
Cyto + 
HPV ± 
Colposcopy 
Cyto – 
HPV + 
Cervical samples for    co-
testing every 3 years 
Cyto –  
HPV + 
Family is completed / 
informed choice 
Consider removing the 
transformation zone 
Follow-up as per 
TOC protocol 
Family is not 
completed yet 
Cervical sample for co-
testing in every 3 years 
Cyto – 
HPV –  
HPV self testing 
every 3 years 
Cyto – 
HPV –  
HPV self testing 
every 3 years 
Cyto – 
HPV –  
HPV self testing 
every 3 years 
HPV –  
HPV self testing 
every 3 years 
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Women with cervical cancer in the post-screening age group present relatively late with more 
advanced disease than the screen-detected cancer, which is the most apparent reason for 
increased risk of mortality observed in the elderly. However, it is possibly associated with poor 
immunity, with consequent reactivation of HPV infection contributing to this sharp rise in the age 
specific mortality rate. The cause of poor immunity may be associated with lack of estrogen. 
One randomised controlled trial (Sawaya, Grady et al. 2000) and a case control study 
(Parazzini, La Vecchia et al. 1997) found that there is no increase in relative risk from the use of 
systemic HRT. This highlights the importance of studies examining effects of HRT, both 
systemic and locally administered estrogen, on cervical neoplasia which may suggest a novel 
way of cervical cancer prevention.  
 
 
7.3 Public Engagement in Science 
 
Some questions in relation to public engagement in science have also been explored during this 
project. These are not scientific studies, but are some activities carried out and observations 
made during the project. Hence they are explained here.  
 
7.4.1 How to educate the public on a new cervical screening test? 
As a part of our main study, self-sampling for HPV screening was introduced to Scotland 
(Dumfries and Galloway Health Board) for the first time. Introducing a new screening test was 
challenging, even though it was offered within the research domain. We had to educate the 
public carefully, on this new cervical screening test, as we never wanted to disregard the 
existing screening test, cervical cytology (smear) test. In fact, our aim was to bring the 
defaulters back to the standard cervical cytology screening programme, exploiting the benefits 
of self-sampling.  
 
We used public media, a website, patient information leaflets, letters and education of health 
professionals for this purpose. We adhered to the principle of encouraging screening as a 
whole. Whilst the smear test finds the stage of the cervical HPV disease that can be treated, the 
HPV test finds the cause of it. We told women that if they were tested positive for HPV, then 
they need come for a smear test.     
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First, we asked one objective question using the Questionnaire 1: “Did you wish more 
information?” This questionnaire was filled soon after they have self-collected a sample.  
 
Then, we asked HPV positive women when they came for a smear test, if they understood 
about the HPV testing and this process.  
 
We developed a dedicated, website with over 10 pages which included multiples resources for 
our study. The number of website hits to www.hpvscreening.co.uk was checked on 1 November 
2012. Also, we have often asked women attending at the hospital smear clinic between April 
and May 2012, if they had visited our website.  
 
It would be difficult to measure outcomes of these interventions. But, surrogate markers suggest 
that our interventions were effective at least for women those who have responded.  
 
Fig 7.3.1.1: Questionnaire-1 analysis 
 Yes No No answer 
Did you wish more information? 2 265 5 
 
Almost all (265/272=97%) of those who filled the Questionnaire 1 (Fig 7.3.1.1) answered ‘no’ to 
the question: “Did you wish more information?” Only two persons answered ‘yes’.  
 
We asked women who came for a smear test, after being tested positive for HPV, if they 
understood about HPV testing process. This question was asked from about 90 participants. 
The immediate answer was yes for most (approximately 70%) of them. About 20% didn’t come 
up with an instantaneous answer, suggesting that they understood some of it. About 10% would 
like to know about it again. However, this data is based on observation and not on formally 
collected data. Most of them understood screening principles much better after counselling. 
Some participants were very grateful for explaining things in detail to them.  
 
Forty five out of 674 total numbers of visits were from Dumfries. Only 17 new visits were from 
Dumfries out of which 4 were investigators. Despite the reference to this website was made in 
every letter that was sent to 4146 defaulters in the region, it was visited only by a small number 
of people in Dumfries. The real number of defaulters who visited should be about 13. We 
understood this trend from the inquiries that we made at the smear clinic.  
205 
 
 
We took utmost care neither to disregard nor to discourage the current screening tool- cervical 
smear test. However, it was difficult to convince women who were tested negative for HPV to 
accept their next cervical smear test for which some of them will be called in a few months’ time.  
 
About 3 in 1000 targeted defaulters have actually accessed our study website. This indicates 
that the website played almost no role in influencing defaulter’s decision of getting screened.  
 
Women do not appear to be confident in accepting a new screening test. A study conducted in 
Cameroon to assess the feasibility of self-collected HPV test in place of the cytology screening 
(Berner, Hassel et al. 2013) revealed that most of the women were more comfortable and less 
embarrassed with the self-HPV. However, most participants thought that clinician collected 
samples are more reliable than self-collected samples. Whilst (125/217= 57%) felt ‘‘moderate’’ 
or ‘‘high’’ confidence when self-collecting a sample, virtually all (216/217=99%) felt the same for 
the physician sampling. Similar attitudes was observed in the UK in a Manchester based 
questionnaire survey (Forrest, McCaffery et al. 2004) which included 200 women of Indian, 
Pakistani, African-Caribbean and white British origin. Although the willingness to try to use the 
test was high, and women did not foresee religious or cultural barriers to self-sampling, a large 
proportion of women were concerned about doing the test properly. This concern was greatest 
in the Indian and African-Caribbean groups. It appears that these women had not had an 
adequate understanding cervical cancer, its prevention and also about the accuracy of self-
sampling. A qualitative study involving 28 Muslim women living in north-east London 
(Szarewski, Cadman et al. 2009) reported that women were generally positive about cervical 
screening, but they were concerned about not doing the self-test correctly. Although women's 
willingness to try self-sampling for HPV is encouraging, worries about carrying out the 
procedure correctly may be counterproductive (Waller, McCaffery et al. 2006). These studies 
highlighted the importance of educating women in order to build confidence on self-sampling, 
before it is offered. 
 
Virtually all women who self-collected (245/249= 98%) in our study answered ‘no’ to the 
question: “Did you wish more information?” Only two persons answered ‘yes’. Whilst this 
indicates that information provided was sufficient to collect the sample, it may also be a 
surrogate marker of information overload. Giving the right amount of information in a form that is 
suitable to every individual is difficult, particularly when new, complex pieces of information 
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should be delivered in printed format.  However, written information appears to be the most 
accessed mode of information.  
 
Although 902 women were able to carry out the test alone, using simple written instructions 
(Waller, McCaffery et al. 2006), multiple approaches should provide a better outcome than just 
one way of educating the target population.  
 
7.3.3. Improving public awareness on cervical screening  
Clear understanding of the pros and cons of cervical screening is important for women to make 
the right decision in taking part in it. A good public education should help overcoming attitudinal 
barriers to cervical screening. Our main aim was to raise the public awareness of the potential 
benefits of cervical screening.  
 
We have used public media, a website, patient information leaflets, letters and education of 
healthcare professionals for this purpose. We highlighted the importance of screening, without 
emphasising the ‘attractiveness’ of the home testing method.  
 
We broadcast a 20 seconds radio ‘advert’ on cervical screening in parallel to our penultimate 
study (offering multiple smear options to defaulters younger than 30 years) on the most popular 
local radio station- Westsound. This message was broadcast 8 times a day over 2 weeks. 
Content of the message which was delivered by Dr Hannah Smith (Foundation Year 2 Trainee) 
is as follows (Fig 7.3.3.1):  
 
Fig 7.3.3.1: Westsound radio cervical screening message (20 seconds) 
Hi, I am Doctor Hannah Smith. Routine screening can prevent cervical cancers 
from developing. So, if you haven't had a smear test in the last 3 years, please 
call us on (Dumfries) 241 241 to attend one of our weekend or evening clinics 
at Dumfries & Galloway Royal Infirmary. Please remember, cervical screening 
could save your life! 
 
The Dumfries & Galloway Health Board’s did a news release on 18 June. News about our 
research project was published on 3 local newspapers, Reporting Scotland segment of the BBC 
News at ten (pm), BBC local radio and two other local radio stations. It can be found on BBC 
online http://www.bbc.co.uk/news/uk-scotland-south-scotland-18476882 
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It would be difficult to measure outcomes of the interventions. But, surrogate markers suggest 
that our interventions were somewhat effective. Although one-off public awareness campaign is 
always better than nothing, an ongoing public awareness programme should be much more 
effective. Dumfries and Galloway’s Screening Programme Co-ordinator was surprised to see 
such a good response (122/1311=9% have had a smear test at 2 months) from this ‘hard to 
reach’ younger defaulters cohort. The radio ‘advert’ may have contributed to it.  
 
Although a personal approach based on providing information and individual counseling 
appears to be successful in encouraging non-attendees to reconsider their decision and 
participate in the cervical screening (Campbell, MacDonald et al. 1996), this strategy may not be 
easily executed. Furthermore, evaluation of the effectiveness or cost-effectiveness of methods 
that we have used to raise the public awareness on screening remains difficult.  
 
7.4 Recommendations 
 
1. Sending a letter which is different to the routine recall letter when defaulters are recalled 
could be recommended. The content of which may be similar to the main body (without 
multiple options) of our letter-1 (Fig 3.3.4). Such a pilot project could be implemented 
without spending any extra money in a Health Board. According to the national cervical 
programme publication number 26 (NHSCSP 26), “Since the publication of the 1997 
report, very little research evidence has been produced that specifically addresses 
questions related to the content cervical screening programme letters and the 
information needs of women receiving these materials.” We believe that the evidence we 
developed based on the initial invitation letter (which was sent to 5256 defaulters in 
Dumfries & Galloway) justifies this recommendation.   
2. Replication of methodology of some of our studies in another health board in Scotland 
as a pilot project is suggested. In our overall experience, one cycle of the ‘kit’ method 
could be recommended.  
3. It appears that more effective system/s should be put in place to identify and remove 
women who are not eligible for screening (e.g. deceased, total hysterectomy, living 
abroad or another area) from the call-recall database. This will not only save resources, 
but also build the public confidence on screening programme, as it would ensure clean 
and accurate statistics. 
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4. Recognise self-sampling for HPV screening as a primordial screening test (a test which 
tells you who should be further screened), for defaulters. The lay term could be ‘a pre-
screening test’. This test will tell whether or not a defaulter needs to come for a smear 
test. About 90% of pre-screening positives will take the next (primary) screening test.  
5. It may be worthwhile considering re-commencing hospital smear clinics. Frequency of 
the clinic could be little as once a month. This may help small proportion of defaulters to 
come back to screening. However, this intervenation may not significantly increase the 
screening coverage. A fair proportion of women attending at our hospital smear clinic 
verbally requested us to continue the hospital smear clinic.  
 
7.5 Questions for future research 
 
1. I believe that examining the feasibility of offering more flexible screening options to 
defaulters e.g. urine testing is really valuable. Although the sensitivity of such methods 
could be far from ideal, getting defaulters back to any form of screening is a positive 
behavioural change. Such defaulters may ultimately accept better screening tests.  
2. Further research into accuracy of the SCCRS database would strengthen the findings of 
our study. It may be worth examining how accurate are the cervical screening databases 
in other areas in the UK.  
 
 
 
7.7 CONCLUSIONS 
Whilst about 6% defaulters had smears in 6 months without any intervention, about 14%-31% 
were screened 6 months after our interventions. Offering the option of self-sampling along with 
the cervical smear to defaulters may significantly increase the number of new defaulters 
referred to colposcopy. Practical barriers are often the cause of women not attending for 
cervical screening and offering more options, particularly the option of self-sampling at home, 
increases screening coverage.  
 
This project has shown that by adopting a flexible approach with regards to the sensitivity of this 
test and the needs of women, a great deal can be achieved. We should continue to examine 
what is most suitable for individuals rather than sticking to a traditional method and adapt 
accordingly. 
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Appendix 1 (GROSS DATA) 
Gross data of all defaulters who requested self-sampling, in the order that they were requested 
 
Table 8.1.1: Gross data of all 129 kit requests (1000 study) in the order that they were 
requested 
No Age 
Last 
smear 
HPV 
vagina 
HPV of 
Smear1 
Smear1 
(2012) 
Smear2 
(2013) Colp TZ Histology 
1 41 6               
2 54 never               
3 48 12               
4 35 14               
5 31 9 pos neg neg         
6 47 5 pos pos neg neg normal 1   
7 41 17 pos neg neg neg normal 1   
8 55 9 pos neg neg neg unsat 3   
9 55 8               
10 34 14 pos pos severe   hgCIN 1 CIN3 
11 54 8 pos pos neg neg normal 1   
12 50 never               
13 55 9               
14 54 6     neg**         
15 31 never pos neg neg  pregna       
16 53 7 pos neg neg         
17 55 6               
18 44 11               
19 52 10 pos neg neg         
20 45 5               
21 37 bnc-3* pos pos bnc         
22 33 never               
23 39 9 pos pos neg         
24 55 6               
25 45 8 pos neg neg neg hgCIN 1 CIN2 
No Age 
Last 
smear 
HPV 
vagina 
HPV of 
Smear1 
Smear1 
(2012) 
Smear2 
(2013) Colp TZ Histology 
26 52 6               
27 31 never pos neg neg neg normal 1   
28 42 5 pos pos neg         
29 50 5 pos neg neg neg normal 1   
30 55 8               
31 55 6               
32 44 6     neg**         
33 51 10 pos pos neg moder hgCIN 2 CIN2 
34 40 4               
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35 43 5 pos neg neg neg normal 1   
36 46 16               
37 35 9               
38 32 5 pos neg neg neg lgCIN 1 CIN1 
39 43 24 pos pos neg         
41 43 7 pos pos neg         
41 46 5 pos neg neg bnc lgCIN 1 CIN1 
42 55 5 pos neg neg neg normal 2   
43 41 8               
44 47 5               
45 44 5               
46 36 bnc-3*               
47 55 8               
48 52 5     neg**         
49 53 8               
50 44 5               
No Age 
Last 
smear 
HPV 
vagina 
HPV of 
Smear1 
Smear1 
(2012) 
Smear2 
(2013) Colp TZ Histology 
51 52 13               
52 37 12               
53 53 9               
54 37 never               
55 36 8 pos   neg         
56 39 6 pos neg neg neg normal 1   
57 33 never               
58 53 4               
59 50 12               
60 33 never               
61 47 9               
62 55 unsat3* pos neg unsat neg normal 2   
63 53 12               
64 44 9 pos pos severe   ?invasio 2 CIN3 
65 41 19               
66 40 8               
67 44 9 pos neg neg         
68 43 5               
69 31 5               
70 45 never pos neg neg         
71 45 12               
72 44 9  pos             
73 43 5 pos pos neg neg normal 1   
74 51 5 pos neg neg neg normal 1   
75 54 6 pos pos neg neg normal 2   
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No Age 
Last 
smear 
HPV 
vagina 
HPV of 
Smear1 
Smear1 
(2012) 
Smear2 
(2013) Colp TZ Histology 
76 51 6               
77 45 9               
78 47 9               
79 52 6 pos neg neg neg normal 1   
80 32 9               
81 40 6               
82 50 17 pos na neg         
83 37 13               
84 54 8 pos neg unsat neg 
 
    
85 46 5               
86 49 unsat2*               
87 49 12               
88 49 9 pos pos neg neg ?lgCIN 1 cervicitis 
89 52 never               
90 31 5               
91 49 9               
92 37 4               
93 50 5               
94 44 6 pos na neg neg 
 
    
95 41 never               
96 55 5               
97 39 6 pos pos neg neg normal 1   
98 41 8               
99 41 12               
100 42 8               
No Age 
Last 
smear 
HPV 
vagina 
HPV of 
Smear1 
Smear1 
(2012) 
Smear2 
(2013) Colp TZ Histology 
101 31 6               
102 41 9               
103 48 6               
104 49 10               
105 34 never               
106 43 13               
107 41 never               
108 31 6               
109 42 7               
110 53 7               
111 43 13 pos   neg         
112 36 5               
113 44 6     neg**         
114 52 6               
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115 51 4               
116 36 5               
117 33 bnc-7*               
118 47 4               
119 54 11               
120 48 4               
No Age 
Last 
smear 
HPV 
vagina 
HPV of 
Smear1 
Smear1 
(2012) 
Smear2 
(2013) Colp TZ Histology 
121 52 10               
122 35 never               
123 47 17               
124 35 9 pos na mild         
125 54 7               
126 30 9 pos pos mild bnc lgCIN 1 CIN1 
127 40 4               
128 48 5               
129 32 5               
      pos=42 pos=15 pos=5 pos=3 pos=7   pos=7 
 
Table 8.1.2: Gross data of all 45 kit requests (200 study) 
No Age 
Last 
smear 
HPV 
Vagina 
HPV of 
Smear1 
Smear1 
(2012) 
Smear2 
(2013) Colpos TZ Histology 
1 31 never               
2 39 8     unsat**         
3 37 6 pos neg neg          
4 38 8               
5 54 5 pos neg neg  neg ?lgCIN 1 cervicitis 
6 38 6               
7 39 5               
8 55 5 pos pos neg  neg normal 1   
9 51 12 pos pos neg          
10 45 6 pos neg neg  neg normal 1   
11 50 10 neg             
12 41 4* pos na neg          
13 41 6 pos neg neg  TAH 2013     normal 
14 33 5 pos na bnc bnc       
15 44 8               
16 52 6     neg**         
17 48 9     neg**         
18 52 5 pos pos neg          
19 47 13 pos neg neg          
20 48 7 pos neg neg  neg normal 2   
21 52 9 pos neg neg  neg normal 2   
22 55 9 pos neg neg  neg normal 2   
23 39 never pos pos neg          
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24 31 never pos na neg          
25 55 6               
No Age 
Last 
smear 
HPV 
Vagina 
HPV of 
Smear1 
Smear1 
(2012) 
Smear2 
(2013) Colpos TZ Histology 
26 52 5               
27 54 6 pos na neg          
28 33 unsat3* pos na neg  neg normal 1   
29 46 6 pos na neg          
30 45 5 pos neg neg  neg normal 1   
31 52 5 pos neg neg  neg unsat 3   
32 39 4 pos pos neg  neg normal 1   
33 52 4               
34 55 6               
35 33 unsat11* pos             
36 43 5               
37 45 9               
38 50 17               
39 37 4*               
40 52 5               
41 40 16               
42 38 never               
43 53 4               
44 44 13 pos pos severe   hgCIN 1 CIN2 
45 36 8*               
46 54 6 pos na unsat  neg       
      pos=24 pos=6 pos=2 pos=1 pos=2   pos=1 
 
Table 8.1.3: Gross data of all 158 kit requests (2000 study) 
No Age 
Last 
smear 
HPV 
Vagina 
HPV of 
Smear1 
Smear1 
2012 
Smear2 
2013 Colpos TZ Histology 
1 37 4 pos             
2 30 4 pos 
no 
result neg         
3 32 4 pos neg neg         
4 33 7 neg             
5 31 never neg             
6 36 4               
7 30 5 pos 
no 
result neg         
8 38 6 neg             
9 52 8 pos neg neg neg normal 2   
10 37 4 neg             
11 53 11 pos             
12 45 11 neg             
13 55 22 neg             
14 33 3* neg     bnc** ?lgCIN** 1 metapla** 
15 48 never pos 
no 
result neg         
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16 43 4 pos na neg neg       
17 41 7 neg             
18 50 8 neg             
19 42 9 neg             
20 43 6 pos unsat neg neg normal 2   
21 34 5               
22 38 6               
23 53 
unsat 
2* pos neg neg         
24 39 4               
25 33 6               
26 41 10 pos    neg         
27 31 never neg     neg**       
28 45 never pos neg neg neg lgCIN 1 cervicitis 
29 55 7 pos neg neg neg lgCIN 1 CIN1 
30 31 4 pos neg neg neg normal 1   
No Age 
Last 
smear 
HPV 
Vagina 
HPV of 
Smear1 
Smear1 
2012 
Smear2 
2013 Colpos TZ Histo 
31 39 4     unsat neg       
32 35 5 neg             
33 30 6 pos pos neg neg normal 1   
34 48 4 neg             
35 36 5 pos  na neg         
36 35 4 neg             
37 43 22               
38 49 7 pos neg neg neg lgCIN 1 CIN1 
39 33 13               
40 39 4 pos pos neg         
41 45 9               
42 39 4 neg             
43 54 12 neg             
44 47 bnc3* pos neg neg neg metapla 1   
45 46 4 neg             
46 41 7 pos neg neg neg hgCIN 1 CIN2 
47 54 5 pos neg neg neg normal 1   
48 48 5 neg             
49 45 7               
50 37 11 pos neg neg neg ?lgCIN 1 normal 
51 48 5     neg         
52 55 6 pos             
53 53 13 neg             
54 44 15 neg             
55 53 5 pos na neg         
56 45 never               
57 48 5               
58 45 4               
59 53 7 pos neg neg neg metapla 1   
60 40 7 pos neg neg neg ?lgCIN 1 No biopsy 
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No Age 
Last 
smear 
HPV 
Vagina 
HPV of 
Smear1 
Smear1 
2012 
Smear2 
2013 Colpos TZ Histo 
61 53 12 neg             
62 33 5 neg             
63 44 5 neg             
64 53 14               
65 34 4               
66 55 7 neg             
67 47 8 neg             
68 50 9 pos neg neg neg normal 2   
69 37 12 pos             
70 37 bnc5* pos neg neg         
71 53 
unsat 
2* pos   imposi       (1b1) 
72 38 8               
73 43 5 neg             
74 43 7 pos neg neg         
75 51 never neg             
76 41 4 neg             
77 50 5               
78 34 4 neg             
79 43 4 pos neg neg         
80 42 10               
81 38 4 neg             
82 31 5 neg             
83 53 7               
84 54 7 neg             
85 48 17               
86 40 8 neg             
87 44 7 neg             
88 33 11               
89 55 6               
90 52 6 pos   neg neg unsat 3   
No Age 
Last 
smear 
HPV 
Vagina 
HPV of 
Smear1 
Smear1 
2012 
Smear2 
2013 Colpos TZ Histo 
91 51 6 pos neg bnc neg lgCIN 1  No biopsy 
92 32 5 pos pos neg         
93 40 5 neg             
94 52 9 pos unsat neg         
95 45 12 neg             
96 45 8 pos neg neg neg normal 1   
97 32 never neg             
98 31 8               
99 31 6               
100 43 4 pos neg neg neg normal 1   
101 39 5 pos neg neg neg hgCIN 1 CIN1 
102 46 4 neg             
103 54 5               
104 35 never neg             
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105 49 7 neg             
106 42 5     neg         
107 54 9               
108 49 7 neg             
109 49 11               
110 43 4 neg             
111 38 8 neg             
112 51 8 neg             
113 37 6       neg***       
114 32 never pos  na neg         
115 53 9               
116 39 10 neg             
117 45 5 neg             
118 30 4 neg             
119 55 4 neg             
120 50 5               
No Age 
Last 
smear 
HPV 
Vagina 
HPV of 
Smear1 
Smear1 
2012 
Smear2 
2013 Colpos TZ Histo 
121 31 4 pos na neg         
122 52 10       neg***       
123 39 3* neg             
124 46 8               
125 43 13 na na   moder hgCIN 1 CIN3 
126 45 12               
127 44 12               
128 47 8 neg             
129 39 never               
130 44 never neg             
131 44 bnc10* neg             
132 34 12               
133 37 16               
134 40 9 neg             
135 49 5 neg     neg**       
136 40 4 neg             
137 43 9               
138 54 7 neg             
139 48 4               
140 35 6 neg             
141 43 6 pos neg neg         
142 54 6               
143 38 8 neg             
144 43 5       bnc***       
145 31 never               
146 38 never       neg***       
147 50 10 neg             
148 46 5 neg             
149 32 5               
150 41 7               
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No Age 
Last 
smear 
HPV 
Vagina 
HPV of 
Smear1 
Smear1 
2012 
Smear2 
2013 Colpos TZ Histo 
151 50 4 pos unsat neg imposi unsat 3   
152 46 5               
153 41 8 pos 
 
  neg hgCIN 1 CIN2 
154 51 5               
155 55 4 pos neg neg         
156 53 12               
157 50 13 pos na neg neg normal 1   
158 39 6 neg             
      pos=47 pos=3/26 pos=1/41 pos1/3 pos=12/24   pos=6/9 
 
 
 
 
Table 8.1.4: Gross data of all 50 kit requests (Older study)  
Kit group 
No Age 
Last 
smear 
HPV 
Vagina 
HPV of 
Smear1 
Smear1 
2012 
Smear2 
2013 Colpos TZ Histology 
1 57 4 pos pos  neg neg normal 1   
2 58 8 neg             
3 59 4 pos pos  neg neg normal 1   
4 56 4 neg             
5 60 14 neg             
6 57 4 pos   neg         
7 59 5 pos pos  neg neg normal 2   
8 60 12 neg             
9 59 16 neg             
10 56 4 neg             
11 56 8 neg             
12 58 8 neg             
13 60 5 neg             
14 59 19 neg             
15 60 7 neg             
16 59 7 neg             
17 60 8 neg             
18 60 4 pos unsat neg neg normal 1   
19 60 4 pos unsat neg neg normal 1   
20 60 unsat5* pos unsat neg neg normal 1   
21 60 4 pos neg neg         
22 60 4 neg             
23 60 unsat10* neg             
24 57 5 neg             
25 60 4 pos neg neg neg normal 2   
26 59 6 neg             
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Letter group 
No Age 
Last 
smear 
HPV 
Vagina 
HPV of 
Smear1 
Smear1 
2012 
Smear2 
2013 Colpos TZ Histology 
1 60 14 neg             
2 58 21 neg             
3 60 7 neg             
4 56 7 neg             
5 59 5 neg             
6 60 unsat2* neg             
7 57 13 pos neg neg         
8 60 4 neg             
9 57 10 pos   neg neg unsat 3   
10 58 4     neg         
11 60 7 neg             
12 56 never               
13 57 8 pos 
no 
result neg neg hgCIN 1 CIN2 
14 59 7               
15 56 4 pos neg neg         
16 60 7 neg             
17 58 4 pos             
18 59 11 pos pos  neg neg normal 1   
19 60 4               
20 60 10 pos             
21 59 9               
22 56 6       neg**       
23 58 4 pos   neg         
24 56 never               
      pos=17 pos=4/8 pos=0 pos=0 pos=110   pos=1/1 
Key: Last smear= duration since the last smear test in years; HPV of Smear1= HPV result of the 
smear residual of the first smear test; Smear2= smear which was taken at the annual follow-up, 
12 months after the first smear test; Colp= colposcopic diagnosis; TZ= type of the cervical 
transformation zone; bnc= borderline nuclear changes; mild= mild dyskaryosis; moder= 
moderate dyskaryosis; severe= severe dyskarysis; *woman on non-routine recall; **woman who 
had been to a smear test after having a negative smear test; ***women who had been to a 
smear test after being called by SCCRS in 2013; never= never had a smear test; unsat= 
unsatisfactory; pos= positive; neg=negative; na= not available; pregna= pregnant; ?lgCIN= 
suspected low grade CIN; metaplas= squamous metaplasia; TAH= total abdominal 
hysterectomy; ?invasio= suspected invasive cervical cancer. A woman with a negative HPV test 
is highlighted in green and a positive HPV test is orange. A positive smear test is highlighted in 
yellow and CIN is red.  
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Fig 8.1.5: Screening pathway of HPV positive defaulters with abnormal colposcopic diagnosis.  
lgCIN   hgCIN   Punch biopsy site  
  
Case  Description  Year   Finding  Colpograph  
1000 
/10 
Age  (2013) 33 
 
Previous treatment  No   
Last smear  1998 Neg  
Vaginal HPV Apr 2012 Pos  
Cervical HPV June 2012 Pos  
Smear  June 2012 Severe  
Annual F/U smear  n/a   
Diagnostic 
colposcopy 
July 2012 T1TZ 
hgCIN 
Histology of punch 
bx 
No   
Histotogy of LLETZ July 2012 CIN3 
 
Case  Description  Year   Finding  Colpograph  
1000 
/64 
Age   45 
 
Previous treatment  No  
Last smear (non-
UK) 
2003 Neg 
Vaginal HPV Pos Pos 
Cervical HPV July 2012 Pos 
Smear  July 2012 Severe  
Annual F/U smear  n/a  
Diagnostic 
colposcopy 
Oct 2012 T2TZ 
?Cancer  
Histology of punch 
bx 
Oct 2012 CIN3 
Histotogy of LLETZ 
(GA) 
Nov 2012 CIN3 
 
Case  Description  Year   Finding  Colpograph  
200 
/44 
Age   44 
 
Previous treatment  No  
Last smear  1999 neg 
Vaginal HPV Oct 2012 Pos 
Cervical HPV Dec 2012 Pos  
Smear  Dec 2012 Severe 
Annual F/U smear  n/a  
Diagnostic 
colposcopy 
Jan 2013 T1TZ 
ghCIN 
Histology of punch 
bx 
no  
Histotogy of LLETZ Jan 2013 CIN2 
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Case  Description  Year   Finding  Colpograph  
2000 
/153 
Age   41 
 
Previous treatment  No  
Last smear  2004 neg 
Vaginal HPV Dec 2012 Pos  
Cervical HPV Not avail  
Smear  Apr 2013 Neg 
Annual F/U smear  n/a  
Diagnostic 
colposcopy 
Apr 2013 T2TZ 
hgCIN 
Histology of punch 
bx 
no  
Histotogy of LLETZ Apr 2013 CIN2 
 
Case  Description  Year   Finding  Colpograph  
2000 
/125 
Age   43 
 
Previous treatment  No  
Last smear  1999 neg 
Vaginal HPV Dec 2012 Not 
avail 
Cervical HPV Not avail  
Smear  Aug 2013 Modera 
Annual F/U smear  n/a  
Diagnostic 
colposcopy 
Sep 2013 T1TZ 
hgCIN 
Histology of punch 
bx 
no  
Histotogy of LLETZ Nov 2013 CIN3 
 
Case  Description  Year   Finding  Colpograph  
1000 
/33 
Age  2012 51 
 
Previous treatment  1995 CIN3 
Last smear  2002 Neg  
Vaginal HPV May 2012 Pos  
Cervical HPV June 2012 Pos   
Smear  June 2012 Neg  
Annual F/U smear  Jun 2013 Modera 
Diagnostic 
colposcopy 
July 2013 T2TZ 
hgCIN 
Histology of punch 
bx 
No  
Histotogy of LLETZ Aug 13 CIN2 
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Case  Description  Year   Finding  Colpograph  
2000 
/101 
Age   39 
 
Previous treatment  No  
Last smear  Apr 2007 Neg 
Vaginal HPV Aug 2012 Pos 
Cervical HPV Oct 2012 Neg  
Smear  Oct 2012 Neg 
Annual F/U smear  Dec 2013 Neg 
Diagnostic 
colposcopy 
Dec 2013 T1TZ 
hgCIN 
Histology of punch 
bx 
Dec 2013 Unstis 
?CIN1 
Histotogy 2 Feb 2014 CIN1 
 
Case  Description  Year   Finding  Colpograph  
Older 
/d17 
Age  2012 57 
 
Previous treatment   No 
Last smear    
Vaginal HPV Dec 2012 Pos 
Cervical HPV Not avail  
Smear  Feb 2013 Neg 
Annual F/U smear  Jan 2014 Neg 
Diagnostic 
colposcopy 
Jan 2014 T1TZ 
hgCIN 
Histology of punch 
bx 
Dec 2013 CIN2 
Histotogy of LLETZ   
 
Case  Description  Year   Finding  Colpograph  
2000 
/46 
Age   41 
 
Previous treatment  no  
Last smear  2005 Neg  
Vaginal HPV Oct 2012 Pos 
Cervical HPV Nov 2012 Pos 
Smear  Nov 2012 Neg  
Annual F/U smear  Dec 2013 Neg  
Diagnostic 
colposcopy 
Dec 2013 T1TZ 
hgCIN 
Histology of punch 
bx 
Dec 2013 CIN2 
Histotogy of LLETZ   
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Case  Description  Year   Finding  Colpograph  
1000 
/25 
Age   45 
 
Previous treatment  no  
Last smear  2004 Neg  
Vaginal HPV Apr 2012 Pos 
Cervical HPV May 2012 Neg  
Smear  May 2012 Neg  
Annual F/U smear  June 2013 Neg  
Diagnostic 
colposcopy 
June 2013 T1TZ 
hgCIN 
Histology of punch 
bx 
June 2013 CIN2 
Histotogy of LLETZ   
 
Case  Description  Year   Finding  Colpograph  
1000 
/38 
Age   32 
 
Previous treatment  2004 CIN1 
Last smear  2007 Neg  
Vaginal HPV Apr 2012 Pos 
Cervical HPV May 2012 Neg 
Smear  May 2012 Neg 
Annual F/U smear  June 2013 Neg 
Diagnostic 
colposcopy 
June 2013 T1TZ 
lgCIN 
Histology of punch 
biopsy 
June 2013 CIN1 
Histotogy of LLETZ   
 
Case  Description  Year   Finding  Colpograph  
1000 
/41 
Age   46 
 
Previous treatment  no  
Last smear  2007 Neg  
Vaginal HPV Apr 2012 Pos  
Cervical HPV May 2012  Neg 
Smear  May 2012  Neg  
Annual F/U smear  June 2013 bnc 
Diagnostic 
colposcopy 
June 2013 T1TZ 
lgCIN 
Histology of punch 
biopsy 
June 2013 CIN1 
Histotogy of LLETZ   
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2000 
/38 
Age   49 
 
Previous treatment  No   
Last smear  2005 Neg  
Vaginal HPV Aug 2012 Pos 
Cervical HPV Sep 2012 Neg 
Smear  Sep 2012 Neg 
Annual F/U smear  Nov 2013 Neg 
Diagnostic 
colposcopy 
Nov 2013 T1TZ 
lgCIN 
Histology of punch 
biopsy 
Nov 2013 CIN1 
Histotogy of LLETZ   
 
Case  Description  Year   Finding  Colpograph  
2000 
/ 29 
Age   55 
 
Previous treatment  No   
Last smear  2005 Neg  
Vaginal HPV Aug 2012 Pos  
Cervical HPV Sep 2012 Neg 
Smear  Sep 2012 Neg 
Annual F/U smear  Nov 2013 Neg 
Diagnostic 
colposcopy 
Nov 2013 T1TZ 
lgCIN 
Histology of punch 
biopsy 
Nov 2013 CIN1 
Histotogy of LLETZ   
 
Case  Description  Year   Finding  Colpograph  
1000 
/126 
Age   30 
 
Previous treatment  No  
Last smear  2003 Neg 
Vaginal HPV Nov 2012 Pos 
Cervical HPV Dec 2012 Pos 
Smear  Dec 2012 mild 
Annual F/U smear  Dec 2013 bnc 
Diagnostic 
colposcopy 
Dec 2013 T1TZ 
lgCIN 
Histology of punch 
biopsy 
Dec 2013 CIN1 
Histotogy of LLETZ   
1000 
/88 
Age   49 
 
Previous treatment  No   
Last smear  2003 Neg  
Vaginal HPV Jul 2012 Pos 
Cervical HPV Aug 2012 Pos 
Smear  Aug 2012 Neg  
Annual F/U smear  Oct 2013 Neg  
Diagnostic 
colposcopy 
Oct 2013 T1TZ 
?lgCIN 
Histology of punch 
biopsy 
June 2013 Cervicitis 
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Case  Description  Year   Finding  Colpograph  
200 
/5 
Age   54 
 
Previous treatment  No   
Last smear  2007 Neg  
Vaginal HPV June 2012 Pos 
Cervical HPV Aug 2012 Neg 
Smear  Aug 2012 Neg 
Annual F/U smear  Oct 2013 Neg 
Diagnostic 
colposcopy 
Oct 2013 T1TZ 
?lgCIN 
Histology- punch bx Oct 2013 Cervicitis 
Histotogy of LLETZ   
 
Case  Description  Year   Finding  Colpograph  
2000 
/60 
Age   40 
 
Previous treatment  No   
Last smear  2005 Neg  
Vaginal HPV Aug 2012 Pos  
Cervical HPV Oct 2012  Neg 
Smear  Oct 2012  Neg  
Annual F/U smear  Dec 2013 Neg 
Diagnostic 
colposcopy 
Dec 2013 T1TZ 
?lgCIN/  
Histology- punch bx Dec 2013 Cervicitis 
Histotogy of LLETZ   
 
Case  Description  Year   Finding  Colpograph  
2000 
/38 
Age   49 
 
Previous treatment  No   
Last smear  2005 Neg  
Vaginal HPV Aug 2012 Pos 
Cervical HPV Sep 2012 Neg 
Smear  Sep 2012 Neg 
Annual F/U smear  Dec 2013 Neg 
Diagnostic 
colposcopy 
Dec 2013 T1TZ 
?lgCIN 
Histology- punch bx Declined   
Histotogy of LLETZ   
 
Case  Description  Year   Finding  Colpograph  
2000 
/ 91 
Age   51 
 
Previous treatment  No   
Last smear  2006 Neg  
Vaginal HPV Aug 2012 Pos  
Cervical HPV Sep 2012 Neg 
Smear  Sep 2012 bnc 
Smear Mar 2013 Neg 
Annual F/U smear  Dec 2013 Neg 
Diagnostic 
colposcopy 
Dec 2013 T1TZ 
lgCIN 
Histology- punch bx Declined   
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Fig 8.1.6: Free comments written in the Questionnaire-1 by women after self-collecting a vaginal 
sample  
No Age Comment  Cat Co 
  56-60 year old defaulter comments=11/37 (30%)   
2 57 Declined last smear invite as I work in NHS England ad for me 
invite would be given not 3 years as NHS Scotland. So much paper 
to work through may put people off participate in this study.  
Ni  - 
3 57 Very simple and straightforward. Only question why can I not turn 
the device without having to hold and click 
Nc + 
5 60 I have always attended for smears, but recently the practice nurse 
couldn’t get the smear. I went to two different nurses.  
P + 
6 60 Having  a very retroverted womb & tilted side wards self sampling 
enabled me to position the device correctly to minimise pain & 
discomfort – despite informing ‘collectors’ of a smear, this does not 
happen- the result being I will not have smears in the future BUT 
happily use this device 
P + 
7 59 Due to menopause, I suffer from vaginal dryness. Reason I found it 
very painful to have a smear test carried out.  
P  
8 59 Normal screening is very painful, the speculum used are too large. I 
am in pain for much of the day. This is OK.  
P + 
10 59 There was a lot of paper to read, which might off putting for many!  Nc - 
11 56 It would have been better to come in a jiffy bag as mine (envelope) 
had got wet & torn exposing the content to my postman.  
Nc - 
13 59 I have ceased to attend because it is so painful. Self sampling isn’t 
any less painful and I don’t think I have attained an adequate 
sample. I could insert it as instructed, but could not push the 
plunger sufficiently or twist it. I can still feel discomfort.  
P - 
17 58 Less anxiety experienced and less painful Nc + 
30 58 There were slight traces of blood on the brush after taking the 
sample. 
Nc - 
  30-55 year old defaulter comments =57/235 (24%)   
39 55 I felt that this is much more comfortable than having the usual 
equipment inserted which always hurts and bleeds me.  
Nc + 
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40 42 I am distressed being called a madam- I am transgender + male. 
This may be the only way transmen will have smears. I was also 
sexually abused. Both reasons made me this very hard.  
P + 
48 41 Sorry I took long to return Nc  
50 35 Painless and easy to do. Fell less self-conscious and more relaxed 
at home 
Nc + 
51 31 Very easy to use and much more comfortable than a smear Nc + 
54 55 I was sore on insertion but the test was easy and once inside was 
OK.  
Nc  
55 49 Self sampling was not uncomfortable unlike my last smear test at 
the doctors 
P + 
63 33 Sorry I couldn’t find these sheets when I sent in my sample this 
afternoon, I will post this in the morning 21/9/12. Hopefully you will 
receive them (I endorsed the green form [options list] instead)  
Nc  
64 53 No mention of this (absorbent) paper until the check list before 
sending the sample. Perhaps a warning not to let the ‘paper’ sheet 
out of the polythene bag might be appropriate in the instruction 
leaflet – or somewhere due to be read BEFORE sampling! 
Nc - 
67 35 The instruction say it will click every time. I turned it round 5x inside 
me. It didn’t click.  
Nc - 
74 31 I think self sampling will appeal to many, as if like me with a young 
family finding time and sitters to look after the children while you go 
(for a smear) can be difficult. Also getting appointments at your 
local GP surgery that fit in with your plans of free time really is 
difficult.  
P + 
77 53 Previously cervical smear tests were very painful, this test was 
great- was not uncomfortable or painful.  
P + 
79 52 This is the first time I have not attended my routine smear test due 
to various reasons – on a temporary work contract with no time off 
& an elderly relative requiring significant time commitment. If this 
self sampling works, I will certainly use it for any tests in the future.  
P + 
81 32 I have made it to 32 years old without having a smear – ridiculously 
avoided because of embarrassment. If this self sampling was an 
A + 
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option I would participate and get tested regularly.  
84 43 I find it extremely painful to have a normal smear test & this was 
painless, easy and quick.  
P + 
86 46 Sub-total hysterectomy (one ovary and cervix remain) carried out 
January 2009 @ DGRI.  
Nc  
94 41 Would have never got round to going for a smear. Thank you for 
this option.  
Nc + 
95 55 No lasting after effects but didn’t expect spotting.  Nc - 
96 37 I would do this every year rather than go to doctor even my doc is 
great! 
Nc + 
102 46 The pink cap was off when I took it from the packet Nc - 
104 45 Nice to be able to do it at home when you are free + relaxed. Thank 
you 
Nc + 
113 55 Slightly uncomfortable, noticed small spot of blood after taking 
sample. No periods / have had hysterectomy in past but left with 
cervix.  
Nc - 
116 33 Very easy and not painful in the slightest Nc + 
124 37 I was far more relaxed before me self collect & the instructions 
were easy to follow. I would definitely participate in future cervical 
screening if I could self collect.  
Nc + 
125 39 Simple and easy to do. No problems at all. Nc + 
128 39 Going to the nurse for a smear test can be a daunting experience 
for some. The self test is a brilliant idea. 
P + 
132 41 Used test kit four days before menstruation due to start, but some 
blood on test. If test invalid, I will be happy to do another test.  
Nc - 
134 50 I found this method to be quick, easy and so much less painful, it is 
also so much more convenient than trying to arrange and 
appointment for screening.  
P + 
135 37 Absolutely great way of doing smears, I wouldn’t change anything 
about doing the smear this way and wouldn’t hesitate to do it again.  
Nc + 
151 33 Very simple to perform- I think if the test is proved to be accurate/ 
reliable this would be a very good option for those reluctant to 
cervical screening.  
Nc + 
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152 54 It is very convenient way. As time constrains sometimes make it 
difficult to attend clinic.  
P + 
154 55 I have an anteverted uterus. It is unlikely that endocervical cells will 
be present. Even professionals have struggled to get them in the 
past! 
P  
156 39 Needed translation Nc - 
157 55 I do not think that access to my medical records should be 
necessary. I do not think I should have to take part in a study to 
have this option. 
Nc  
164 41 I have spoken to a few women and they all agreed they would 
rather use this method. It is less intrusive and more chance off 
woman being screened. Thanks  
Nc + 
167 45 I did feel some discomfort after taking the sample but it wasn’t 
painful.  
Nc - 
168 51 I’ve never had a screening test for any disease.  Nc  
169 54 I found this self sampling easy to do and don’t have to leave the 
house. 
Nc + 
170 55 Previously nurse has had problem due to position of cervix ?this 
sample adequate  
P  
174 39 I had a smear test done 6 months ago, but doctor had to stop as I 
was in a lot of pain. I have since been sent for a scan and I am 
waiting on another appointment for colonoscopy.  
P  
175 36 Less invasive and done at suitable time for me, no pain after self 
sample, smear tests always hurt! No more having to face a nurse 
regardless of reassurance. Best idea yet, thank you! 
P + 
176 38 Less embarrassing than going to GP or clinic & also convenient as 
you don’t have to make an appointment organise kids etc to attend. 
Impressed!! 
Nc + 
178 31 This was easy to do, as I never had one before as I am not sexually 
active and I have not had sex yet. 
Ni + 
183 44 I suffer from agoraphobia so it makes it difficult to get to surgery P  
187 33 I have avoided smear tests for years as I have been suffering from 
a very unpleasant vaginal discharge. Too embarrassed to allow a 
P + 
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Dr to perform a smear as discharge is so unpleasant so self 
sampling has been a good option for me. Is there a self sampling kit 
to test for whatever STI is causing the discharge? My ex-partner 
slept with a few people before I found out and ended it.  
193 42 I have always found the ‘collection of cells’ bit uncomfortable/ 
slightly painful- though the brush didn’t seem as bad as last smear 
test. I found everything very easy, straightforward (did struggle 
terribly with trying to work out how to seal the bag!) 
P  
200 49 Did not have an envelope in my pack to return my sample. Nc - 
204 43 Was very easy, unlike getting it done at the doctors, never felt a 
thing.  
Nc + 
205 51 I find this way of screening much more private and much easier for 
fit into your life.  
Nc + 
207 54 I found this method much easier for me as I have very painful hips 
& this form of screening was much more comfortable. 
P + 
211 47 I felt a little uncomfortable after I withdraw the Evalyn device. Nc  - 
219 55 Surprisingly easy to do. Very clear instructions. I’d definitely do this 
again. Thank you.  
Nc + 
236 46 Never liked going for smears. This is great alternative. At + 
438 55 Unsure if I need to have cervical screening since I have not been 
sexually active for over 10 years. 
At  
244 33 I have never had a smear done at my GP’s due to a thing that 
happened in my past was always unable to let it be done. This is a 
way I would rather tested.  
P + 
245 50 So simple to use why do then not do it that way at doctors. Nc + 
247 43 I think this is a great idea. Nc  + 
Abbreviations: Cat= category; Co=Comment (+ positive), (-negative), (blank when not clear); 
At= attitudinal; P= practical; Ni= (screening) is not indicated); Nc=not clear.  
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Fig 8.1.7: Free comments written by respondents in the options list  
(a) 1000 defaulter study  
 1000 defaulter study comments Opt
ion  
Cate
gory 
1 "Not declined just struggle to find time, I also hate the process 
which delays doing something about it. Would use a smear kit 
test at home"  
4 Pract 
2 "Don't feel comfortable". 4 Atti 
3 Adult living with Asperges Syndrome.  Has a key worker.   6 NI 
4  "don't like the uncomfortable feeling"  3 Atti 
5 "FYI, due to a traumatic labour/birth resulting in a 3rd degree 
tare I have been panicked by the thought of a smear test, great 
idea to have other choices and options". 
4 Atti 
6 "Forgot to make appt" 1 Pract 
7 Patient has had a total hysterectomy 6 NI 
8 "Much more preferable! More comfortable - I always found 
sample at doctors rather painful." 
3 NC 
9 "I have not had sex for a long time also I seize up when 
examined it is subconscious.  I do think the test home kit you 
sent me may be the answer but it looks bewildering but if I am in 
charge of carrying out this procedure then perhaps it’s the best 
way forward". 
4 Atti 
10 "I am having a baby due in day! 21st June". 6 NI 
11 “I am currently attending regular check-ups with a gynaecologist, 
surely this information must be on my notes”. 
6 NC 
12 Patient has had hysterectomy - no dates given. 6 NI 
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13 "No need for the test as I have never been "sexually active" 
please leave me alone 
6 NI 
14 "I felt a little uncomfortable after I withdrew the Evalyn device"  4 NC 
15 Patient living in New Zealand for past 10 years.  6 NI 
16 Committed Christian (plus enclosed "10 Reasons to Believe" 
leaflet). 
6 Atti 
17 Lengthy letter received as to why she did not wish to participate. 6 NI 
18 Not to be contacted again for this study.  This patient has had a 
discussion with her GP and does NOT require screening. 
6 NI 
19 "As I have never had a physical relationship with anyone.  So I 
feel that I don’t need to have a "smear test". 
6 NI 
20 "I have had a hysterectomy 8 years ago in New Zealand (so I'm 
not showing that on my UK records).  I have tried several times 
through my GP to be taken off this register but have obviously 
still remained on it". 
6 NI 
21 I find it embarrassing.  If I could do it myself at home and send 
sample to hospital. 
4 Atti 
22 I do not want a test as I am not sexually active and never have 
been.  I will get in touch with my Doctor if things change. 
6 NI 
23 "Kept forgetting to make an appointment. Automatically send me 
an appointment".  
2 Pract 
24 "I will make appointment with my GP… "for the 20th April" 1 NC 
25 A detailed reply received with a summary of her experiences 
and reasons why she has defaulted to attend for smear test. 
(PRACTICAL)   
4 Pract 
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26 “My experiences in the past have not been very positive and feel 
that I was being judged - I have a weight issue which could have 
been handled in a more positive way.  I think the home testing is 
an excellent idea and one I am keen to pursue - I have never 
received this offer before for alternative testing although the 
letter states you have wrote to me in the past.  Thank you for 
this offer. 
4 Pract 
27 "In January 1995 I had a radical hysterectomy for cervical 
cancer; everything was removed. Since then I have had 'vault' 
smears but do not find them very comfortable in any way". 
6 NI 
28 "Your records are incorrect I have had  smear test at my GP 
practice 15/12/11" 
1 NI 
29 "The last smear test I had took ages, I'm overweight and have 
restricted movement in my hips.  Usually the nurse/doctor finds it 
difficult.  I'm embarrassed and upset".  
2 Pract 
30 "Not sexually active - never have been".   6 NI 
31 "Quite simply been putting it off - not an acceptable excuse I 
know". 
1 NC 
32 "Daughter is severely disabled, would like to attempt urine 
sample test" 
6 NI 
33 "X assessed by Ed Psych for another matter and the test has 
been undertaken". 
2 NC 
34 "I am answering on behalf of my daughter who is handicapped 
and suggest that urine testing would be her best option".   
6 NI 
35 Patient has had a total abdominal hysterectomy in the past. 6 NI 
36 "White coat syndrome".  I am not trying to be difficult 
deliberately.  Confession - did not read last letter - I would be 
willing to try self collection kit for HPV testing, also urine sample. 
4 Pract 
37 "I suffer from anxiety, depression and agraphobia.  If I could do it 
at home". 
4 Pract 
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38 "It's painful and most of the time they don’t collect enough cells, I 
bleed afterwards and they said the neck of my womb had 
collapsed". 
5 Pract 
39 "Intrusive, I have never been sexually active. I am under the 
impression from you leaflets that means I don’t have to be 
tested. A self collection kit would be the best option".  
6 NI 
 
(b) 200 defaulter study 
 200 defaulter study comments  opti
on 
categ
ory 
40 "I don’t have a partner and Dr advised me it would be too painful 
so I feel I cannot take part in this study".  
6 NI  
41 Comments on phone- patient has never been sexually active - 
opting out of screening - patients has Down’s Syndrome.  
6 NI 
42 Patient had a hysterectomy in 1989 6 NI 
43 "Very simple to perform, I think if the test is proved to be accurate 
/ reliable this would be a very good option for those reluctant to 
go to cervical screens" 
4 NC 
44 Please find enclosed smear test pack I am returning it as I have 
had a smear done at my Doctors on 30/3/2012 and the results 
came back clear.  Thanks again'. 
1 NC 
45 "Less invasive and done at suitable time for me, no pain after self 
sample, smear tests always hurts! No more having to face a 
nurse regardless of reassurance, best idea yet, THANK YOU". 
4 NC 
46 "OPTING OUT"  6 NC 
47 X has learning difficulties, Practice Nurse decided it would be too 
distressing and didn’t carry out the test. 29/8/12 
6 NI 
48 "Living in England now - no further correspondence please" 6 NI 
49 "I am not, and never have been, sexually active". 6 NI 
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(c) 2000 defaulter study 
 2000 defaulter study comments  opti
on  
categ
ory 
50 Participant's mother called to inform investigators that her 
disabled daughter is opting out of the study. 
6 NI 
51 "I find it very painful".  Suggestions: "A smaller instrument 
possibly?" 
6 Pract 
52  "26 weeks pregnant". 6 NI 
53 "Far too painful procedure". 6 Pract  
54 "Had TAH & BSO 2006"  6 NI 
55 "No cervix! Werthymes Hysterectomy March 2007.  Cancer 
removed by surgery.  No further treatment, 5 year follow up 
completed by at DGRI".  
6 NI 
56 "Never been sexually active so not need it please stop". 6 NI   
57 "Discussed with my GP, I am not sexually active, if my 
circumstances change, I will have a smear",  
6 NI 
58 "My daughter has severe learning difficulties and would not cope 
with the examination". 
6 NI 
59 "I don’t like health professionals poking about simple reason".   Atti 
60 Social Services informed us that this patient has never been 
sexually active and hence would not attend for cervical 
screening.  
6 NI   
61 "Have had smear tests while undertaking other medical 
treatment privately". 
6 NI 
62 "Keep forgetting".  1 Pract 
63 "My daughter has learning difficulties". 6 NI   
64 "Have had other things on my mind".  1 Atti  
65 "Not sexually active - never have been".  6 NI   
66 "NB: Please see medical notes from my visit to Gynaecology 
Clinic a few months ago.  Thanks". (has had a smear) 
6 NI 
67 "Don't like it".   Atti  
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68 "Problems with penetration mean I can't have a smear. It 
distresses me and I have decided not to do it.  I am also sexually 
inactive". 
6  NC  
69 "Really struggle with childcare/work then no dr appointments". 4 Pract  
70 "I am pregnant". 6 NI 
71 "Cannot bend my leg cartridge problem.  No relationships smear 
test is very sore and painful".  
6 Pract   
72 "My daughter, X is presently living in Greece and has paid 
privately to have a smear test carried out in January 2012". 
6 NI   
73 "Fear - do not wish to give any more details".   Atti  
74 "Told by my previous medical practice I no longer required to be 
tested".  
6 NI 
75 "I have problems with my bones and have a lot of pain so it is 
very difficult". "I would be very interested if you could test with 
urine as this would be much more acceptable for myself". 
 Pract  
76 "I have an annual smear test with a private gynaecologist".  6 NI 
77 "I do not want a test as I have never been sexually active" 6 NI 
78 "I have learning disability and do not understand the procedure 
and also have a fear of doctors/nurses with procedures I don’t 
like".   
6 NI 
79 "Absolutely GREAT way of doing smear's, I wouldn’t change 
anything about doing the smear this way and wouldn’t hesitate to 
do it again". 
4 NC 
80 "I haven’t declined the testing; I was pregnant with my 2nd child 
and was advised to wait until after I gave birth, I will be making 
an appointment with my GP ASAP now I have had my baby". 
1 NI 
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81 "I have not yet made an app as I leave home 7-7.30am and 
return 6-7pm Mon-Fri. Surgeries are not open on Saturdays 
when I am at home.  I will make an app when next on annual 
leave in November. Suggested GP Surgeries open on a 
Saturday".  
1 Pract  
82 My daughter, X has down syndrome and a smear test would be 
too much for her". 
6 NI 
83 Participant asked if her records could be amended to reflect the 
fact she had a hysterectomy approx 10 years ago. 
6 NI 
84 "Have had the above done at my practise" 1 NI 
85 "I have had a smear test recently at the Cumberland Infirmary (in 
England)". 
6 NI 
86 "! Am not sexually active, I have discussed it with my family and 
support workers"  
6 NI 
87 "I think I don’t need a smear test as I have been diagnosed with 
terminal cancer". 
6 NI 
88 "I have recently had a smear test on Monday at my GP surgery". 1 NI 
89 "Never had one - too scared". 4 Atti  
90 "I had a hysterectomy in June 2005 at DGRI as far I am aware 
my cervix was removed during surgery therefore I do need 
require to have a smear test". 
6 NI 
91 "I had just had surgery on my groin for an existing condition 
(Hidradenitis) and preferred not to have another procedure at 
this time".  
 Pract  
92 Called to inform us that she has had a total hysterectomy. 6 NI 
93 "X no longer resides in Scotland.  She moved to USA a number 
of years ago and only visits now twice yearly".  Signed by 
mother. 
6 NI 
249 
 
94 X has a learning disability and does not fully understand the 
procedure.  X is not sexually active.  She will not allow invasive 
procedure".  
6 NI 
95 "I am pregnant and will arrange for a smear test after the birth" 1 NI 
96 "I am now pregnant, so not due for a smear test". 6 NI 
97 "I have made an informed assessment of my risk of getting 
cervical cancer and consider it to be significantly lower than the 
risk of a false positive result". 
6 NI 
98 "Had cervix removed years ago, was advised Test was pointless, 
have explained this to hospital but no one is listening to me". 
6 NI 
99 "I have attended my own GP practice for routine smear test but 
was informed that I did not require this as I have never been 
sexually active".  
6 NI 
100 This participant informed us that she has had a total abdominal 
hysterectomy for cervical invasive adenocarcinoma followed by 
radiotherapy.  
6 NI 
101 "I did not decline testing; I have been ill and couldn't get to the 
hospital to have this test done". 
2 Pract  
102 "X in United States of America at the moment".  6 NI 
103 "Any time would be available for a test to be done".  3 NC 
104 "My sister received a smear test for home as like the HPV test 
home kit.  I would rather do this opposed to Dr or FPC". 
4 NC 
105 "I have had a hysterectomy (in Australia) and when I discussed 
smears with my GP said I don’t need cervical screening".  
6 NI 
106 I have never been sexually active and I don’t want the test. 6 NI 
107 "I am very embarrassed about my body and don’t feel 
comfortable with the nurse that was doing the test - to be able to 
do the smear test at home in privacy would be more acceptable".  
4 Atti  
108 "not sexually active" 6 NI 
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109 I have informed my GP that I DO NOT WANT THIS SERVICE.  
Please remove me from your mailing list. 
6 NC 
110 "X has downs-syndrome and will not let anyone touch her down 
below". 
6 NI 
111 "I am scared of people touching me".  4 Atti  
112 "I am currently 23 weeks pregnant.  I was advised during my last 
pregnancy not to undertake a smear until the baby was born.  If 
things have changed then I am happy to undertake a smear in 
my current condition!” 
1 NI 
113 Participant's mother returned documents with note to inform us 
that X now lives in Perth, W. Australia 
6 NI 
114 "I am not sexually active and never have been I have discussed 
not having smear tests with past GPs and would seek an 
appointment should my situation change".  
6 NI 
115 Participant’s mother phoned us to inform that she has never 
been sexually active and hence do not wish to attend for cervical 
screening. 
6 NI 
116 The patient’s mother phoned us to inform that X is now living 
abroad and that her smear test is up to date.  
6 NI 
117 "Have never been sexually active…"  6 NI 
118 "I feel it is embarrassing and there no information before or after 
and medical staff no need side manners or interest in the 
individual patients needs". 
6 Atti   
119 "Have moved back to Poland".  6 NI 
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(d) ‘Older’ defaulter study 
 Older defaulter study comments  opti
on 
categ
ory 
120 I have had a full hysterectomy. 6 NI 
121 Not sexually active, 60 years. 6 NI 
122 I had a hysterectomy 10 years ago at DGRI. 
 
6 NI 
123 Got the neck of the womb frozen years ago and since have been 
unable to get a proper smear test.  
 
6 Pract  
124 Last smear failed as too dry, vagifem caused discharge, 60 next 
year.  
 
6 Pract  
125 I went but it was too painful. They were going to send back for me 
but didn’t so I don’t want one. Thank you.  
6 Pract  
126 I do not wish to participate with the test as I have concerns 
regarding accessing to my medical records. I will have a smear 
test at my GP Practice. 
 
6 NC 
127 I have had a full hysterectomy. 6 NI 
128 Not sexually active, 60 years. 6 NI 
129 I have made an appointment on 28/11/2012 at my GP practice.  1 NC 
130 Apologies for delay in getting the smear test.  1 NC 
131 I have made appointment with nurse at GP Practice for the 20th 
November.  
 
1 NC 
132 Appointment has been made for 03/04/13 at Stranraer (GP).  1 NC 
133 I have ignored previous invitations because I have found smears 
uncomfortable, so this was just the prompt I needed. I have never 
found smears “enjoyable”! I had to return to GP twice because 
she failed to get enough cells. Third time it was managed with a 
metal inserter thing (speculum). I did not find this experience 
comfortable, so it has put me off. I do appreciate that discomfort 
at a smear test is preferable to cervical cancer, so I acknowledge 
that I have been silly. Thank you for the information pack.  
 
4 Pract  
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(e) ‘Younger’ defaulter study 
 Younger defaulter study comments  opti
on 
categ
ory 
134 I am currently pregnant and will arrange an appointment with my 
GP once baby is born 
6 NI 
135 I am in early pregnant and my midwife advised me to do the 
cervical screening test after giving birth 
1 NI 
136 I do not require a smear as I have never been sexually intimate 
with another person. When I have I shall arrange for a smear 
 
6 NI 
137 X is now living in Australia (signed by mother in law) 
 
6 NI 
138 I currently work two jobs with unpredictable and late and early 
shifts whilst also going to college so I don’t have much time free. I 
also have a strong dislike of the doctors and hospitals and I get 
very anxious at the thought of going 
 
6 Pract  
139 At present I am living abroad in Germany and have arranged to 
be tested by a doctor here. Please take me off your list until 
further notice. Many thanks   
6 NI 
140 I thought we had exempted (personally unsuitable) but will check 
SCCRS (note written by GP, signed by father) 
 
6 NI 
141 I do not need one because as it states in the 1st question 2nd line 
in bold writing (Every woman with a cervix who has EVER been 
sexually intimate with another person should go for cervical 
screening) 
6 NI 
142 I can’t have a test done at the moment as I am 37 weeks 
pregnant. I will make an appointment in a few months 
6 NI 
143 Filled in on behalf of X by her mother as X is currently in Australia 6 NI 
144 I was raped and do not like to be touched, I cannot face doing 
this test at the moment, may be in the future but not this year  
6 NI 
145 I have not had intercourse yet   
 
6 NI 
146 Please remove from records as she now lives in Turkey with her 
husband + child. Thank you 
6 NI 
147 X stays in Australia  
 
6 NI 
148 X has severe learning difficulties and has a genetic condition 
Nicolaides Baraister Syndrome. She has never and will never 
have asexual relationship (signed by mother) 
6 NI 
149 I do not require a test at this time but will get one when I do. 
Thanks  
6 NI 
150 X no longer lives in UK. Please remove her from your records 
(signed by grandmother)  
6 NI 
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151 My daughter now lives in Australia. Thank you (signed by mother) 
 
6 NI 
152 Disabled lady, wheelchair bound and mum (carer) doesn’t wish X 
to have a c-smear. Thanks (note written by GP) 
6 NI 
153 I do not want a test because I never been sexually intimate with 
another person before and my periods are normal   
 
6 NI 
154 I am only on the pill for medical reasons and I have not been in a 
relationship  
6 NI 
155 My reason for not having a test is because I am single and have 
never had sexual intercourse, but wish to be reminded of the next 
routine screening  
6 NI 
156 No sexually & got the injection for cervical cancer vaccine  6 NI 
157 I have never been sexually intimate with anyone therefore have 
been advised I don’t need smear tests yet. If this information is 
wrong please let me know 
 
6 NI 
158 X has never been sexually intimate with anyone so was told that 
she didn’t need a test (signed by mother)   
6 NI 
159 I don’t want a test 
 
6 NC 
160 I am living in London & have smear tests there, I am up to date 
with screening (pp signed illegibly)  
6 NI 
161 I am currently pregnant and was advised not to be tested during 
pregnancy. Will gladly make appointment if this is not the case 
1 NI 
162 X has been travelling for the last 20 months, will be returning in 
the new year (signed by mother)   
1 Pract  
163 I have had a smear test done on Tue 23rd October at my GP 
 
1 NI 
164 I am pregnant at was told at my first booking (of pregnancy) that I 
will get one done 6 weeks after giving birth. I will contact my GP 
for this 
6 NI 
165 I don’t believe I need the test at the moment, I could be wrong but 
I’d prefer not to waste anyone’s time  
 
6 NI 
166 I am pregnant so not to be able to attend. I will make appointment 
after my baby is born 
6 NI 
167 I am anxious about the procedure to make an appointment, I 
would be more than happy to carry one at home and return it but 
these letters make me nervous, I feel physically ill when I see 
them. While I understand it is in my best interest to come. I am 
not ready to do so at this time 
6 Atti 
168 Pregnant just now baby due 18/11 arranging with clinic for post 
baby screening  
1 NI 
169 Due to health anxiety I will make an appointment with my GP 
when I feel able to do so 
1 Atti 
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170 I have recently received letters asking me to go for a smear 
check up but as I am currently living away from home for 
University I cannot go for the check-up until Christmas holiday 
period 
1 Pract  
171 I will see my GP 1 NC 
172 I had my last smear in Australia January 2012 1 NI 
173 I’ve just been too busy. Now I have more time. I will go 1 Pract  
174 I have an appointment on 12/11/12 at my surgery 1 NC 
175 I would like a female Dr or Nurse to do the test please  2 Pract  
176 Preferably after 6pm, thanks 2 NC 
177 Please could I have appointment Monday night at 6pm 2 NC 
178 Monday or Tuesday after 7pm 2 NC 
179 I work shifts so weekends 03/11/12 or 17/11/12 would be fine. If 
an evening appt is made I may have to rearrange it  
2 Pract  
180 I am still a virgin and feel i don’t need a cervical smear 2 NI 
181 I am in Australia until the 14th Nov so, it would need to be after 
then 
2 Pract  
182 Preferably Tuesday between 12-1 2 NC  
183 Bad experience last time and also recent problems have led to 
this delay emotional stress  
5 Pract  
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Table 8.1.8: The main reason for non-attendance (reason documented in the smear clinic 
clerking sheet) 
No Ag
e  
H
P
V 
Main reason stated Ot
her  
Categ
ory  
1 54 Y ‘Embarrassment’ N Atti  
2 22 N ‘They took my sample and told me that they can’t 
process it, because I am no longer registered with the 
practice (in Dumfries & Galloway). I had to register 
with a GP in Edinburgh as I go to the Edinburgh 
University’  
N Pract 
3 47 N (No reason recorded)  - NC 
4 45 N (No reason recorded)  - NC 
5 40 N (No reason recorded)  - NC 
6 39 Y ‘I got the first letter, to be honest. I was hoping to go 
after the reminder letter. I changed my address and 
didn’t get the reminder’ 
N Pract 
7 48 N ‘I found smears are painful all the time. The nurse 
struggled to take my last smear and it was really 
painful’ 
N Pract 
8 22 N ‘I have never had sex’ N NI  
9 29 N ‘I don’t want the practise nurse to take it. I would 
rather get it done by a doctor, but it is not an option’ 
N Pract 
10 24 N I came to Scotland recently from Poland. I never had 
it before’ 
N Pract 
11 26 N ‘I had a smear in 2006. I was worried that it may pick 
up anything nasty’ 
N Atti  
12 21 N ‘Didn’t get round making an appointment due to 
various reasons- busy, anxious as I never had it’ 
N Pract 
13 29 N ‘I am busy with my own business. I am free only on 
Thursdays. I tried to make an appointment, but, my 
practice doesn’t do smears on Thursdays’ 
N Pract 
14 29 N ‘I didn’t get round making an appointment’ N  Pract 
15 35 N ‘I’ve got a little child and a toddler, husband is working 
full-time. I could not go for a smear in a weekday’ 
N Pract 
16 22 N ‘Busy with my job’ N Pract 
17 24 N ‘I had a smear in 2008. I busy at work. I tried to fix an 
appointment, but didn’t work out’ 
N Pract 
18 22 N ‘I went to my practice to get a smear test. The nurse 
told me that it can’t be done as I was having a urine 
infection. My practice gives only Wednesday 
afternoon appointments, which I can’t keep as  I work 
in Glasgow’ 
N Pract 
19 25 N I have never been sexually intimate with another N NI  
20 29 N Putting it off, actually for no real reason N Atti 
21 48 N ‘I am a nurse. I know what I am capable of... I don’t 
want a nurse to take my smears. I always had it at the 
Well Women Clinic’ 
N Pract 
22 44 Y I don’t know why I was putting it off N Atti 
256 
 
23 59 N I was due for a smear when have had chemo and 
radiotherapy for endometrial cancer. Oncology nurse 
said it may interfere with the smear result.  
N Pract 
24 59 N I didn’t get round a smear because my last smear in 
2004 was not pleasant  
N Pract  
25 55 N I thought I had my cervix removed at the time of 
hysterectomy (it was a sub-total hysterectomy) 
N Pract 
26 32 Y I don’t know why I didn’t go N Atti 
27 37 Y I had an abnormal smear in the past- I was a bit 
apprehensive  
Y Atti 
28 41 Y My previous bad experience put me off N Pract 
29 57 Y I work shifts and they are busy- I was not able to 
arrange an appointment 
N Pract 
30 22 N Anxious and embarrassed  N Atti 
31 26 N I got 3 smear letters when I was pregnant, nothing 
since 
N Pract 
32 24 N I thought they took a smear when I was an in-patient 
on the Gynaecology was early in this year (it was just 
a swab, not a smear. Her last smear test was in 
2008).  
N Pract 
33 60 N I have been living in my son’s home since 2010. I 
might have missed my letters 
N Pract 
34 31 Y I have been moving my house when I got my last 
smear letter. I was busy with my life and job 
N Pract 
35 26 N Busy travelling around the world N Pract 
36 59 Y My last 3 smears have been painful N Pract 
37 43 Y I know the practice nurse well N Pract 
38 59 Y I have been busy at work and coming to the hospital 
to sort out a problem in my throat 
N Pract 
39 60 Y I’ve been living in Italy in last 5 years N Pract 
40 29 N I had the screening test in Poland in 2010 N NI  
41 60 Y My last test in 2008 was really painful N Pract 
42 30 Y My mum’s got a terminal cervical cancer, which put 
me off going for smears (crying) 
Y Atti  
43 55 Y I had painful smears in the past N Pract 
44 57 Y It is embarrassing  N Atti 
45 56 Y My last smear test was a nightmare- a nurse and two 
doctors took it, yet they haven’t got enough cells 
N Pract 
46 28 N I was due for a smear when I was pregnant N Pract 
47 59 N I have some memory problems Y Pract 
48 56 Y Disabled daughter, grandchild with hyperactive 
disorder, 2 jobs.... (very busy) 
N Pract 
49 59 Y I haven’t got any letter in the recent past  N Pract 
50 59 Y I had a bad experience when I had my last smear N Pract 
51 21 N I have not been sexually active until recently N NI 
52 50 Y Both pain and embarrassment N Atti 
53 27 N (No reason recorded)  - NC 
54 56 N (No reason recorded)  - NC 
55 60 Y I received the letter, but couldn’t get round it N Pract 
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56 52 N I went to my smears in the past. I had several 
personal problems, recently 
N Pract 
57 22 N I went for the smear test, but they couldn’t do it 
because of the pain 
N Pract 
58 43 N I have been going up and down to Latvia N Pract 
59 35 Y Busy with my family and the job N Pract 
60 54 Y I had sex only once in my life. I went to a smear test, 
it was too sore 
N Pract 
61 57 Y I have been ill- stroke, heart disease and COPD N Pract 
62 58 N I have to go to the toilet very often as I have this 
diarrhoea for many years. So, I never leave my home 
N Pract 
63 39 Y Smears are uncomfortable- my last one at doctors 
was painful 
N Pract 
64 55 Y Busy with life- looking after disabled sister, old father, 
3 children whilst working night shifts. 
N Pract 
65 36 N I have no issues with having smears. I never had any 
smear letter since 2008. 
N Pract 
66 60 Y I had suffered from serious emotional problems at the 
menopause, which put me off 
Y Pract 
67 59 Y Busy with job and life, I was not able to fix an 
appointment  
N Pract 
68 54 Y I find it difficult to sit down or lie down due to arthritis N Pract 
69 43 Y I have actually booked an appointment in 2010, but 
never got round 
N Pract 
70 39 Y I never had a smear letter. I am living in 44A, one of 5 
studio flats. Perhaps, my address is wrong (Never 
been screened, the address in the SCCRS was just 
Studio 44) 
N Pract 
71 55 Y I would rather avoid familiar people doing my smear Y Pract 
72 52 Y They tried 3 times when I went for my last smear test. 
I have never been since 
N Pract 
73 30 N Gynaecologists removed a cyst in my ovary. I have 
been sore since 
N Pract 
74 39 N I was pregnant when I got the smear letter N Pract 
75 43 N I (personally) know the smear nurse at the practice- I 
wanted to avoid her 
N Pract 
76 48 N The smear that my GP took (a long time ago) was 
very sore. I didn’t know that I could get it in other 
places 
N Pract 
77 54 Y Embarrassment  N Atti  
78 47 Y I am self employed and work 14 hours a day. N Pract 
79 49 Y Very busy- I run businesses and follow my son’s 
racing in weekends 
N Pract 
80 44 Y I made appointments but cancelled them. I suffer from 
irritable bowel  
N Pract 
81 39 Y I had some bad experiences when having the smear 
test 
N Pract 
82 31 Y (No reason recorded)   NC 
83 47 Y (No reason recorded)   NC 
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84 55 Y (No reason recorded)   NC 
85 39 Y (No reason recorded)   NC 
86 53 Y  I have been busy studying. I know... this is not the 
right age to study  
N  Pract 
87 37 N I didn’t receive any letter. I would have gone, if I did N  Pract 
88 53 N I never received any letter since I had hysterectomy in 
Poland in 2005. Perhaps my cervix is not there (no 
cervix was found) 
N  NI 
89 48 Y Embarrassment  N  Atti  
90 52 N Embarrassment N  Atti  
91 44 N Didn’t get a letter Y Pract 
92 40 N I work in the practice and I they all know me, so I 
didn’t go 
N Pract 
93 38 N Busy with my job and the family  N Pract 
94 38 N Very busy with my job, would have gone otherwise. I 
don’t have anyone to cover me. (Weekend clinics are 
ideal for me) 
N Pract 
95 32 N I had an abnormal smear in the past. I was asked to 
go for it every 6 months, which put me off. (I thought 
you have to get it every 3 years. If I was explained it 
clearly, I would have gone) 
N Pract 
96 48 N I personally know my GP and the Practice Nurse  N Pract 
97 55 Y My last smear test was not pleasant. The nurse was 
not nice. So, decided not to go again 
N Pract 
98 59 N I used to go to the Well Women Clinic for my smears. 
But, they had stopped doing it 
N Pract 
99 37 Y I don’t like smears but, I like the self test N Atti 
100 54 Y My dad died in the year that I was due for a smear. 
Never got round making an appointment 
Y Pract 
101 45 Y Last smear was due when I was pregnant  Y NI 
102 56 Y My smears have always been taken by (one particular 
Gynaecologist). I don’t want others to take it 
N Pract 
103 30 Y I never got a letter N Pract 
104 43 Y I was busy then (when I was due) N Pract 
105 32 Y I have been busy at work, travelling up and down- I 
work in England 
N Pract 
106 45 Y I never-ever had a smear.... due to embarrassment N Atti 
107 52 Y I can’t remember if I got any letter. I run a pub. I must 
have missed it due to busy life 
N Pract 
108 39 Y I have been pregnant each time I received a smear 
letter.... (I know you won’t believe this) 
N NI 
109 45 Y I could not get round making an appointment N Pract 
110 41 Y Embarrassment N Atti  
111 30 Y I am self-employed- can’t leave it- can’t arrange an 
appointment out with normal working hours 
N Pract 
112 50 Y I am very busy with my 4 grandchildren- never got 
round it 
N Pract 
113 53 Y Never got around making an appointment. I was sent 
an appointment, I would have gone 
N Pract 
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114 37 Y I didn’t get a letter after 2009 N Pract 
115 55 Y I didn’t go since my periods stopped  N Pract 
116 39 Y I was OK with my Practice Nurse at Kilmarnock. But, I 
don’t like to my GP Centre in here 
N Pract 
117 52 Y I had a very bad smear last time- 3 people tried to 
take it. Sexual Health doctors eventually got it after 
half an hour 
N Pract 
118 45 Y My last smear result was filed in another woman’s 
notes by mistake. This completely put me off 
N Pract 
119 52 Y I am busy- never managed to arrange an appointment 
(would have gone, if I was sent an appointment as 
you did) 
N Pract 
120 53 Y My last smear was very sore N Pract 
121 52 Y (no reason recorded) - NC 
122 43 Y I am busy at work- I have a full time career  N Pract 
123 48 N I have arthritis of my hips- can’t fully open my legs. I 
was in agony when they took my last smear 
N Pract 
124 52 N I used to come to the well women clinic for my 
smears. It’s been stopped. I don’t want to go to GP 
Y Pract 
125 46 N  I am busy with my job- unable to arrange a 
convenient time  
N Pract 
126 51 Y I have been living with my daughter for a few years, 
since my neighbour’s been bothering me. So, I didn’t 
get any letter (we updated her address) 
N Pract 
127 52 Y I was in agony after my last smear test. I would have 
gone, if I knew that you’ve got smaller instruments 
N Pract 
128 46 N I have had a major operation in England when I was 
last due 
N Pract 
129 51 N They did cone biopsy 20 years ago- since then they 
didn’t get enough cells which put me off 
N Pract 
130 48 N I got some memory problems  N Pract 
131 47 N I have the bipolar disorder N Pract 
132 39 N (no reason recorded) - NC 
133 35 N (no reason recorded) - NC 
134 32 N (no reason recorded) - NC 
135 55 N I always had difficult smears N Pract 
136 40 N Last smear took 20 minutes - I will never go back to 
them 
Y Pract 
137 35 N Busy at work (NHS) N Pract 
138 39 Y I used to go to the well women clinic when I was in 
Edinburgh- here it is my GP who is a man 
N Pract 
139 43 Y Embarrassment   Atti  
140 43 Y I’ve got 3 children- one of them has autism. I can’t 
literally leave home  
Y Pract 
141 51 Y I had treatment to my cervix. I was asked to come to 
colposcopy clinic for a smear. They mixed up the 
appointment. Although I was promised, I never got 
another appointment  
N Pract 
142 42 Y I went to my smears religiously, after my treatment for N Pract 
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3 years. They (GP practice) said that they will send 
me an appointment, but never happened 
143 37 Y I don’t like it  N Atti  
144 50 Y  I am busy Y Pract 
145 46 Y I had a very bad experience last time (pain) N Pract 
146 55 Y I have problems with the health centre staff N Pract 
147 32 Y Childcare problem Y Pract 
148 45 Y I didn’t get round it  N Pract 
149 52 Y Smears are embarrassing N Atti  
150 53 Y I just could not arrange an appointment N Pract 
151 34 Y I don’t like it  Y Atti 
152 31 Y Didn’t get round to it N Pract 
153 43 Y As GP is male and is not comfortable with male doing 
smear 
Y Pract 
154 31 Y It is embarrassing to go for smears N Atti  
155 54 Y I just didn’t go N Atti  
Key: HPV= HPV positive; other= was there any other reason for defaulting; Y=yes; N=no; Not 
indicated (screening was not indicated when she was called last time) 
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Fig 8.1.9: Free comments written in the Questionnaire 3– reasons why I declined testing 
No Ref 
No 
Reasons why I declined testing  Category  
1 2648 “I did not decline testing, I have been ill and couldn’t get to 
the hospital to have this test done” 
Practical  
2 2885 “I am scared, very-very scared, and would like tested for 
sexual health as well please” 
 Attitudinal  
3 1643 “I find when I have had the test in the past (I realise it has 
been a long time) butt the test made me feel a bit scared and 
uncomfortable” 
 Attitudinal  
4 2991 "I am very embarrassed about my body and don’t feel 
comfortable with the nurse who was doing the test" 
 Attitudinal  
5 1880 
“Never had one- too anxious and too scared, would rather not 
know if anything was wrong” 
 Attitudinal  
6 034 
"My daughter X is sexually disabled don’t no how I would be 
able to do the test". 
Not 
indicated  
7 062 “Because I have a vaginal fissure and I am not/ have not 
been sexually active"  
Not 
indicated  
8 065 
“I am a virgin so it is not necessary for me to have the test” 
Not 
indicated  
9 502 "Never had sexual relations and unlikely in future. I am sterile 
with Tuners syndrome and do not menstruate" 
Not 
indicated  
10 915 “Really struggle with childcare/work then no doctors 
appointments  
Practical   
11 269 
“Forgot to make an appointment” Practical   
12 212 
“Don’t like the uncomfortable feeling”  Attitudinal  
13 133 
“I didn’t decline a test – simply took no action to have a test” Practical*    
14 597 
“I found it very painful”  ?Attitudinal  
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15 541 “I was going through very bad menopause symptoms, could 
not even stand the thought of anyone carrying out a test. 
Stress was very high, no explanation other than that 
mentioned” 
Practical*   
16 135 
“Don’t feel comfortable”  Attitudinal  
17 998 “Its painful and most of the time they don’t collect enough 
cells. I bleed afterwards and they said the neck of the womb 
had collapsed” 
Practical   
18 393 “I have not had sex for a long time also I seize up when 
examined. It is subconscious” 
Attitudinal  
19 1108 “‘White coat’ syndrome. I am not trying to be different 
deliberately” 
Practical   
20 009 “Not declined just struggled to find time. I also hate the 
process which delays doing something about it” 
Practical   
21 642 
“I find it embarrassing”  Attitudinal  
22 026 “I did not specifically decline, but never got round to replying. 
I have had a series of medical problems that need treatment 
so I ignored this. I have only had a smear once as I had 
differing advice from GPs. I found the experience painful and 
unpleasant”  
Practical   
23 512 
“Bad experience with some doctors and nurses” Practical*   
24 640 “Very uncomfortable, do not have heterosexual/ penetrative 
intercourse. Work professionally with health staff” 
Attitudinal  
25 040 
“Natural selection!!! May refuse treatment”  Attitudinal  
26 867 “The last smear test I had taken again. I am overweight and 
have restricted movements in my hips. Usually the nurse/ 
doctor find it difficult. I am embarrassed and upset” 
Practical   
27 551 
“Keep forgetting to make an appointment” Practical   
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28 1302 
“Not sexually active ” (never been sexually intimate) 
Not 
indicated*  
29 1434 “I am sorry for not returning my smear test. I put it away and 
forgot about it. I will send it very soon” 
Practical   
30 1318 “I had been for my smear recently. I found it too painful and 
then nurse had to stop. I don’t know if HPV testing would suit 
me better” 
Practical   
31 1319 “Reasons why I declined smear- after failed attempt at sexual 
health clinic” 
Practical   
32 932 “Personally it had been a painful experience resulting in 
Dr......... (Gynaecologist) & colleagues arranging it out at 
DGRI. I was given one option fo Practice Nurse, which 
resulted in her suggesting I go to a ‘drop-in’ clinic at Carigg 
Rd, feel uncomfortable just ‘drop in’. Not keen to do it your 
self-test” 
Practical*   
33 991 
“I suffer agoraphobia” Practical*   
Key: *comments written in the second box has been complementary to categorisation; not 
indicated= screening is/was not indicated  
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Fig 8.1.10: Free comments written in the Questionnaire 3– suggestions to make it acceptable 
No Ref 
No 
Suggestions about how the testing could be made more 
acceptable for me 
Positive 
suggesti
on   
1 2648 “I realise that the full routine smear test is the best way of finding 
the proper results so if I could have an appointment sent out 
please. I would prefer a female member of staff to do the test 
please” 
 Yes  
2 2991 
“To be able to do the smear test at home in privacy”  Yes  
3 034 “I don’t no if I can get a urine test as she is incontinent. But I will 
do my best to try and get one” 
 Yes  
4 062 "At this moment in time and the foreseeable future no testing is 
suitable for me. Thank you for being so interested in my health 
but I can arrange a smear test for myself at a more suitable time 
in my life" 
 Yes  
5 502 
“Discussed with GP ad agreed not necessary as low risk”  Yes  
6 133 "Home test would suit me, as I have young children at home with 
limited childcare options. Taking children to a smear test is not 
appropriate- suggestions - Do 2 members of staff run a clinic ie. 
GP +Nurse, therefore if I had no childcare could a staff member 
supervise a child while the test was taken" 
 Yes  
7 597 
"I would rather use the self collection kit"   Yes  
8 331 “Testing is never the problem. I remember when I get my period 
then forgot to book appt. Stupid I know but simple” 
 Yes  
9 541 "What you have offered now is good. Especially when someone 
could be feeling the way I was at that time, (hopefully 
understood) I have never acted this way until menopause, fully 
agree with screening in any way that suits the individual, but not 
with familiar doctor or nurse (in small towns)" 
 Yes  
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10 393 “I do think the test home kit you sent me may be the answer but 
it looks bewildering but I am in charge of carrying out this 
procedure then perhaps its the best way forward” 
 Yes  
11 1108 “Confession – did not read last letter – I would be willing to try 
self collection kit for HPV testing, also urine sample” 
 Yes  
12 009 
“Would use a smear kit test at home”  Yes  
13 642 
“If I could do it myself at home and send sample to hospital”  Yes  
14 026 “I will happily try the test at home. I am sorry to waste people’s 
time and resources by not acting on this smear” 
 Yes  
15 512 
“for them to be far more gentle”    Yes   
16 512 
“Women’s Clinic- eg. Sandyford in Glasgow, Brooke Advisory”  Yes  
17 040 
“Home testing kits”  Yes  
18 551 
“Automatically send me an appointment”  Yes  
19 1302 “I am unsure about this and feel I might like to talk to someone 
first” 
 Yes 
20 932 “Appointment is preferred, so I can arrange for someone to 
come with me as I nearly passed out after leaving hospital last 
time” 
 Yes 
21 991 
“If I could do it at home”  Yes 
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Appendix 2 (RESEARCH TOOLS) 
Fig 8.2.1: Screening invitation letter (30-60 years old) page 1 
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Fig 8.2.2: Screening invitation letter (30-60 years old) page 2 
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Fig 8.2.3: Options list (30-60 years) 
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Fig 8.2.4: Screening invitation letter (20-29 years old) page 1 
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Fig 8.2.5: Options list (20-29 years) 
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Fig 8.2.6: Participant consent form 
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Fig 8.2.7: Questionnaire 1 (with the check list) 
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Fig 8.2.8: Questionnaire 2 
Please tick ‘Yes’ or ‘No’ for each statement 
Statement 
 
Yes No 
Smear tests are embarrassing 
 
  
I intend to go when I am due, but I don’t always get round to it straight 
away 
  
I worry that a smear test will be painful 
 
  
I’m scared of what a smear test might find 
 
  
I’ve had a bad experience of a smear test in the past 
 
  
It is difficult to get an appointment to fit in with work/childcare commitment 
 
  
I don’t feel at risk of cervical cancer 
 
  
I’m not sexually active so I don’t need to go for a smear test 
 
  
I do not trust the smear test 
 
  
I do not need a test if I do not have any symptoms 
 
  
If you had the option of self-sampling, is it more likely that you would 
regularly participate in future cervical screening? 
  
I have never had a smear test   
My last smear was …. years ago    
Please write any other reason/comments you may have, below    
Thank you for completing this questionnaire. Please put in the box provided. 
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Fig 8.2.9: Questionnaire 3 
 
 
Dear Madam 
We understand that you are not up to date with cervical screening and 
have declined our offer of different ways to get either a smear test or a 
HPV test. 
 
We are keen to find out what would encourage you to take up a screening 
test and kindly ask you to record below why you declined testing and any  
suggestions on how we could make the testing more acceptable for you. 
 
 
Reasons why I declined the testing. 
.................................................................................................. 
.................................................................................................. 
.................................................................................................. 
 
Suggestions about how the testing could be made more acceptable for 
me. 
.................................................................................................. 
.................................................................................................. 
.................................................................................................. 
.................................................................................................. 
.................................................................................................. 
  
If you could be tested using a sample of urine would you accept that 
offer?  Please answer yes or no 
 
           YES            NO  
  
Thank you for completing this questionnaire.  
 
We have enclosed another copy of the options should you now 
choose to be tested. 
 
Please return your response(s) in the enclosed pre-paid envelope. 
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Fig 8.2.10: Participant information leaflet sent to women who opted for self-sampling  
 
Frequently Asked Questions  
Q: What is cervical screening? 
A: The search for cervical disease in women who do not have any symptoms. 
Every woman with a cervix who has EVER been sexually intimate with 
another person should go for cervical screening, even if she has not been 
sexually active or has been in a stable relationship, for many years. Aim of 
cervical screening is to prevent cervical cancer by detecting the condition at the 
pre-cancerous stage. It is not a test for cancer. There are 2 types of cervical 
screening tests. Cervical smear test helps to find the abnormal cell 
changes on the cervix. The HPV test checks for the virus that can cause 
this. HPV test is as good as the smear test in preventing cervical cancer, and 
hence, it has now been incorporated into the NHS Cervical Screening Programme. 
Cervical screening can stop cervical cancer, before it has chance to develop. 
Q: What causes cervical cancer? 
A: Cervical cancer is caused by the persistent HPV infection. Eight out of 10 
women carry HPV at some point in their lives. Most people recover from the 
infection with no consequences. However, 1 in 10 women are unable to get rid of 
it. Persistent HPV infection can damage the genes of the cells on the neck of the 
womb (cervix). Irreversible damage will result in abnormal cells. If these 
abnormal cells are left untreated, over several years, they may develop into a 
cancer. So, any woman who has EVER had sex is at risk of contracting HPV 
and could develop cervical cancer.  
Q: Does HPV infection imply infidelity or promiscuity? 
A: No. Women can contract HPV during a single sexual encounter, but the virus 
could stay there forever, if your immune system is unable to clear it. Hence, a 
woman may still have the HPV infection even if she has not been sexually active 
for many years or decades. It does not require infections with many types of HPV 
from multiple partners to cause the harm, a single type of HPV from just one 
partner is enough. So, HPV infection does NOT imply either infidelity or 
promiscuity. 
Q: Why should women get screened? 
A: HPV can take many years to develop abnormal cells on the cervix. Women who 
have persistent HPV infection or pre-cancer will have no symptoms. Without a 
cervical screening test, they will not know they are at risk of developing cervical 
cancer. Pre-cancer can be easily treated. But, going through treatment for 
cervical cancer is much more difficult. Each day in the UK, 8 women are 
diagnosed with cervical cancer and 3 of those die from the disease, 6 out of 
those 8 who developed cancer have not been screened regularly. Regular 
screening is our best weapon     in the fight against cervical cancer.   
Q: What is the smear test? 
A: It is a test in which a cellular sample is collected from the surface of the 
neck of the womb. It is then examined under a microscope for abnormal cells. 
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The sample is collected from   the neck of the womb with a little plastic brush, 
which gently brushes cells from the neck of the womb. This is an easy outpatient 
procedure which takes only a few minutes. It is not painful in most, but may be 
uncomfortable.  
Q: What is the best time to have a cervical smear test?  
A: Anytime out-with your period is suitable.  
Q: How reliable is the smear test?  
A: It is a very reliable test. Regular smear testing can stop 8 out of 10 cervical 
cancers from developing. So, take the test and cut your risk of cervical cancer. 
Q: What is the HPV test? 
A: The HPV test is a molecular test that detects the genetic material (DNA) 
of the HPV virus. Molecular tests are generally very sensitive and accurate. For 
example, a self collected vaginal swab or a sample of urine is now used for 
Chlamydia testing rather than specimen collected from the cervical canal by a 
clinician. More than 10 well-known HPV tests are currently available. The HPV test 
requires only a few HPV infected cells to detect the virus, whereas the smear test 
requires at least 10,000 cervical cells. HPV can be tested in urine as well as 
vaginal samples.  
Q: How reliable is the HPV test?  
A: It is a very reliable test. HPV test, when negative, almost certainly rule out any 
serious disease of the cervix. HPV self testing based screening could stop 8 out of 
10 cervical cancers from developing.  
Q: How do I know if I collected a sufficient sample for the HPV test?  
A: If you follow the instruction for self-collection given in the leaflet provided, it is 
extremely unlikely that your sample will be insufficient for testing. Fewer than 1 
in 100 self-collected samples may not contain an adequate specimen for the test. 
However, the HPV test has an internal control which is clever enough to pick up 
such samples. Without an adequate sample, it won’t give us any result.  So, 
please don’t worry, just follow the simple, self-collection steps provided in the 
leaflet.  
Q: Where will my sample be tested for HPV?  
A: Your sample will be tested at the National HPV Reference Centre Laboratory in 
Edinburgh.    There is a well-established quality assurance system in place for 
HPV testing. We write to you with your HPV test result in 3-6 weeks with 
necessary advice.  
Q: What happens if I get tested negative for HPV?  
A: A negative HPV test is more reassuring than a single negative smear 
test. Theoretically, you will not get the disease without its cause. However, no 
screening test is 100% accurate. A mild infection could be missed. Moreover, 
there is a theoretical possibility that the woman might be exposed to a new 
human papillomavirus, in the due course. Hence, attending regular cervical 
screening is the best means of reducing the risk of cervical cancer - if you are 
tested repetitively and have negative results, you are much less likely to develop 
cervical cancer. However, having one test is better than doing nothing.  
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Q: What happens if the HPV test is positive?  
A: You will need a smear test. Since treatment is available only for HPV 
affected cells, but not for the virus itself such as anti-viral therapy, the most 
pragmatic second line test available is the routine cervical smear test. Aim will be 
to search for abnormal cervical cells, which can be treated. However, not all HPV 
positive women will have an abnormal smear test as this might be a transient or 
mild (sub clinical) HPV infection. Cervical cells will remain normal until HPV 
causes irreversible damage to their genes (it is not possible to say how long it 
takes). Moreover, HPV can infect any part of the female lower genital tract, not 
just the cervix. Hence, your cervical smear test could still be normal, which is 
good. 
Q: What happens if the smear test is abnormal?  
A: If the smear test is abnormal, you will be referred to the colposcopy clinic. 
Diagnosis made at the clinic is usually confirmed with a tissue sample. Whilst 
most of advanced precancerous cell abnormalities are usually treated at the 
clinic, less advanced disease is just monitored without any treatment. Only the 
severe pre-cancers, such as cervical intraepithelial neoplasia 2 (CIN2) and CIN3 
need treatment. Most women recover from less severe HPV infections with no 
consequences.     With early treatment (removal of abnormal cervical 
cells) cervical cancer can be stopped before it has a chance to develop.  
Q: Should girls who have had HPV vaccine be screened? 
A: Yes. The HPV vaccine is targeted against the 2 commonest high risk types of HPV 
which accounts for 7 in 10 cervical cancers. There are nearly 13 more high risk 
types of HPV, which can cause cancer.                                                                                   
Q: What is the best time to self collect a vaginal sample?  
A: Anytime out-with your period is suitable. However, you should avoid 
douching (washing inside the vagina), using vaginal medicines, lubricants, 
spermicides or tampons within the 2 days before self-collecting a sample.  
Q: Is self-collection with the Evalyn® device painful?  
A: No. Almost all Evalyn brush users in Dumfries & Galloway said that it was not 
even uncomfortable  
Q: Is self-collection with the Evalyn® device safe?   
A: Yes. It is a user-friendly, simple, quality tested device. Evalyn® is a sterile 
device, so carries no risk of infection. It is made of latex-free, high-quality plastic.  
Q: Can my partner, family member, carer or friend assist me collecting a 
vaginal sample?  
A: Yes. Please read the basic steps in the leaflet and follow them to prevent 
contamination.  
Please visit the study website www.hpvscreening.co.uk for more information.  
 
(Version 6:27/10/2012) 
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Fig 8.2.11: Participant information leaflet sent to younger (20-29 years) defaulters along with the 
multiple smear options letter.  
Frequently Asked Questions  
Q: What is cervical screening? 
A: The search for cervical disease in women who do not have any symptoms. 
Every woman with a cervix who has EVER been sexually intimate with 
another person should go for cervical screening. Aim of cervical screening is 
to prevent (stop) cervical cancer by detecting the condition at the pre-cancerous 
stage. It is not a test for cancer. There are 2 types of cervical screening tests. 
Cervical smear test helps to find the abnormal cell changes on the cervix. 
The HPV test checks for the virus that can cause this. However, the HPV 
test is not very useful in women under the age of 30, as most of them will test 
positive for the human papillomavirus (HPV) as it is very common in younger 
people. The cervical smear test is the best and most reliable screening test for 
younger women. Cervical screening can stop cervical cancer, before it has chance 
to develop.  
Q: What causes cervical cancer? 
A: Cervical cancer is caused by the persistent HPV infection. Eight out of 10 
women carry HPV at some point in their lives. Most people recover from the 
infection with no consequences. However, 1 out of 10 women are unable to get 
rid of it. Persistent HPV infection can damage the genes of the cells on the neck of 
the womb (cervix). This may result in abnormal cells. If these abnormal cells are 
left untreated, over several years, they may develop into a cancer. So, any 
woman who has EVER had sex (even once) is at risk of contracting HPV 
and could develop cervical cancer.  
Q: Does HPV infection imply infidelity or promiscuity? 
A: No. Women can contract HPV during a single sexual encounter, but the virus 
could stay there for ever, if your immune system is unable to clear it. Hence, a 
woman may still have the HPV infection even if she has not been sexually active 
for many years. It does not require infections with many types of HPV from 
multiple partners to cause the harm, a single type of HPV from just one partner is 
enough. So, HPV infection does NOT imply either infidelity or promiscuity. 
Q: Why should women get screened? 
A: HPV can take many years to develop abnormal cells on the cervix. Women who 
have persistent HPV infection or pre-cancer will have no symptoms. Without a 
cervical screening test, they will not know they are at risk of developing cervical 
cancer. Pre-cancer can be easily treated. But, going through treatment for 
cervical cancer is much more difficult. Each day in the UK, 8 women are 
diagnosed with cervical cancer and 3 of those die from the disease, 6 out of 
those 8 who developed cancer have not been screened regularly. Regular 
screening is our best weapon in the fight against cervical cancer.   
Q: What is the smear test? 
A: It is a test in which a cellular sample is collected from the surface of the 
neck of the womb. It is then examined under a microscope for abnormal cells. 
The sample is collected from the neck of the womb with a little plastic brush, 
which gently brushes cells from the neck of the womb. This is an easy outpatient 
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procedure which takes only a few minutes. It is not painful in most, but may be 
uncomfortable.  
Q: What is the best time to have a cervical smear test?  
A: Anytime out-with your period is suitable.  
Q: How reliable is the smear test?  
A: It is a very reliable test. Regular smear testing can stop 8 out of 10 cervical 
cancers from developing. So, take the test and cut your risk of cervical cancer. 
Q: What happens if the smear test is abnormal?  
A: If the smear test is abnormal, you will be referred to the colposcopy clinic. 
Diagnosis made at the clinic is usually confirmed with a tissue sample. Whilst 
most of advanced precancerous cell abnormalities are usually treated at the 
clinic, less advanced disease is just monitored without any treatment. Only the 
severe pre-cancers, such as cervical intraepithelial neoplasia 2 (CIN2) and CIN3 
need treatment. Most women recover from less severe HPV infections with no 
consequences.     With early treatment (removal of abnormal cervical 
cells) cervical cancer can be stopped before it has a chance to develop.  
Q: Should girls who have had HPV vaccine be screened? 
A: Yes. The HPV vaccine is targeted against the 2 commonest high risk types of HPV 
which accounts for 7 in 10 cervical cancers. There are nearly 13 more high risk 
types of HPV, which can cause cancer.                                                                                   
Please visit www.hpvscreening.co.uk for more information.                                    
(Version 7: 01/09/12) 
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Fig 8.2.12: Evalyn brush information leaflet (page 1) 
 
Evalyn brush information leaflet (page 2) 
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Fig 8.2.13: Evalyn brush self sampling kit inside its pre-paid return envelope  
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Fig 8.2.14: HPV positive results letter 
Ms E….. M………                                     Sample was collected: 27 Nov 2012  
                                                                  Reference number: 3006 
Date: 10 Dec 2012                                    Code number: P10- 1645 
                                                                  CHI number: 0901003242 
Dear Madam 
 
Your recent cervical screening test  
 
The cervical screening test that you have had recently has tested positive for Human 
Papillomavirus (HPV) infection. This means that further testing is necessary.  
Not all women with HPV infection will have abnormal cells in the cervix. When the 
HPV infection does not clear up, it can cause damage to the cells in the cervix which 
could develop into abnormal cells. It is, therefore, very important that you now 
have a cervical smear test in order to rule out the possibility of abnormal cells on 
the skin of the neck of the womb.  
We have arranged this test for you at our ‘Smear Clinic’ on Ward 4, Dumfries & 
Galloway Royal Infirmary. Please report to the Reception Area which is on your right 
as you enter the Ward 4. The Smear Clinic is just in front of the Reception Area. 
Appointment: Thursday 13 December 2012 at 12:45 
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Fig 8.2.15: The negative results letter 
Ms D….. J………                                        Sample was collected: 27 Nov 2012  
                                                                    Reference number: 3007 
Date: 10 Dec 2012                                      Code number: P10- 1646 
                                                                    CHI number: 0901003243 
Dear Madam 
 
Your recent cervical screening test  
 
We are pleased to say that your recent cervical screening test for HPV is negative. 
This means that our test did not show any evidence of Human Papillomavirus (HPV) 
infection in the sample that you self-collected. 
 
Research evidence shows that if a woman does not carry HPV, then the risk of 
developing cervical cancer is very low indeed. We don’t say ‘no risk’ just ‘low risk’. A 
woman who has ever had sex will probably have come into contact with HPV which 
might cause cervical cancer, so she should attend regular screening. Therefore, we 
advise you to accept your next invitation for a cervical smear, which you will receive 
anytime within the next 3 years. A cervical smear test helps to find pre-cancerous 
cell changes on the cervix whilst the HPV test checks for the virus that can cause 
these cell changes. If you are tested negative for both HPV and cervical smear, it can 
give you excellent reassurance.  
Regular screening reduces the chance of cancer of the cervix developing. Please 
remember it is still important to see a doctor as soon as possible anytime you have 
any unusual discharge or bleeding, including bleeding after sex or between periods.  
 
If you wish to discuss this further, please do not hesitate to contact us. Please find 
the answers for some frequently asked questions, enclosed. You may wish to visit 
our study website www.hpvscreening.co.uk for further information.  
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Appendix 3 (APPROVAL) 
Fig 8.3.1: Main ethical approval 
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Fig 8.3.2: Ethical approval- amendment number 1 
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Fig 8.3.3: Ethical approval- amendment number 2  
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Fig 8.3.4: Caldecott approval 
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Appendix 4 (GLOSSARY OF TERMS) [Edited by PI] 
 
Adenocarcinoma 
Cancer arising from glandular tissue (of the cervix). An adenocarcinoma can develop in the 
glandular lining of the endocervical canal, the narrow passageway that connects the cervix to the 
womb (inside the canal of the cervix). These cancers are often difficult to diagnose using a 
cervical smear alone, since the cells inside the canal of the cervix are not as easily collected 
during the smear test.  
Asymptomatic 
Not having any symptom of a disease. Many cancers may develop and grow without causing any 
symptoms, particularly in early stages. Screening tests, for example, a cervical smear test is able 
to find cervical cancer at the pre-cancer stage of the disease before symptoms start, when the 
chance of cure is usually highest.  
Biopsy 
Collection of a sample of tissue that is then examined under a microscope by a Pathologist. This 
may confirm the presence or absence of abnormal tissue, including cancer. A cervical biopsy 
taken in a colposcopic examination is considered as the diagnostic test where the disease or the 
condition is confirmed (or excluded).  
Cervix 
Neck of the womb. This is the lower, cylindrical end of the womb that connects to the vagina. 
The part which is exposed to the vagina is called the ectocervix. The central cervical canal is 
called the endocervix.  
Cervical cancer 
Cancer of the neck of the womb (uterus). The tumour may spread into surrounding tissue and 
may involve adjacent organs. It may be detected in a pre-cancerous stage of development by a 
cervical screening test.  
Cervical intraepithelial neoplasia (CIN)  
Cellular changes on the surface of the cervix preceding the invasive stages of cervical cancer. 
The CIN grading system distinguishes three stages, CIN1, CIN2 and CIN3. The three grades of 
CIN relate to the thickness of the tissue covering the cervix (skin of the cervix) that is affected. 
CIN 1 means one third of the thickness of the tissue covering the cervix has abnormal cells. CIN 
3 means the full thickness of the tissue covering the cervix has abnormal cells. CIN 2 and 3 are 
collectively termed as high-grade CIN, whereas CIN 1 is called low-grade. All these results 
mean that they (CIN) are pre-cancerous.  
Cervical glandular intraepithelial neoplasia (CGIN)  
Cellular changes that occurs in the glandular epithelial cells (lining of the canal of the cervix) 
preceding the invasive stages of cervical cancer. CGIN is categorised into low and high grade by 
the Pathologist. Both low-grade CGIN and high-grade CGIN are pre-cancerous  
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Cervical smear test (also called smear test, liquid based cytology or Pap test) 
A test in which a sample collected by a clinician form the neck of the womb that is stained and 
examined under a microscope. At least 10,000 cells collected from the ectocervix and some cells 
from the endocervical canal are required for the sample to be deemed adequate for the test  
Colposcopy 
A procedure in which the lining of the cervix and the vagina are examined using a magnifying 
telescope (colposcope) for signs of pre-cancerous lesions or cancer (or otherwise).  
Coverage (of cervical screening) 
The proportion of resident eligible women for cervical screening who have had a cervical 
screening test with a recorded result at least in the previous 3 years (one screening interval). e.g. 
the number of women screened divided by the number of resident eligible population.  
Defaulters 
Eligible women who do not attend following repeat invitations for cervical screening. They are 
not up-to-date with their cervical smears.  
DNA testing 
DNA stands for deoxyribose nucleic acid which makes the genetic blue print of organisms. DNA 
molecules of the Human Papillomavirus (HPV) can be detected using novel technology. This is a 
very sensitive testing method, and most DNA tests require only a small number of HPV infected 
cells for an accurate result. Hence, self collected material is more than adequate for this purpose. 
Research has shown that even a urine sample is also sufficient.  
Dyskaryosis 
Abnormal cells (of the cervix). The appearance of abnormal cells whose nuclei show the features 
characteristic of the earliest stage of malignant change. There are 4 categories borderline, mild, 
moderate and severe. For example, mild dyskaryosis indicates slight cell changes in the cervix, 
severe dyskaryosis indicates severe cell changes in the cervix. Dyskaryosis can also be 
categorised into 2 main groups of lesions, low-grade (borderline + mild) and high-grade 
(moderate + severe). High grade lesions are more likely to develop into cancer, if not treated.  
Ectocervical 
The outer part of the cervix which is opened into the vagina.  
Endocervical 
Inside the canal of the cervix.  
Eligible women (for cervical screening in Scotland)  
Women aged 20 to 60 years who have never had a total hysterectomy.  
False negative test result 
A test result that appears normal, but in reality is not. There is a potential risk that abnormalities 
to progressing unknowingly.  
296 
 
False positive test result 
A test result that appears abnormal, but in reality is not, thus making additional tests necessary 
which can cause anxiety.  
Glandular abnormality 
Abnormality involving the glandular epithelial cells (lining of the canal) of the cervix. Glandular 
cells appear tall and columnar. They secrete mucous which helps protect the entrance to the 
womb.  
Human Papillomavirus (HPV)  
The name for a group of viruses, of which there are more than 100 types  
Hysterectomy 
An operation in which the womb (uterus) is removed. When the neck of the womb is also 
removed at the same time, this is referred to as a total or complete hysterectomy. When the 
cervix is left behind during an abdominal hysterectomy, this is called sub-total. Hence, women 
who have had a sub-total hysterectomy should have cervical screening tests.  
Immodeficiency/ immunosupression 
A state in which the ability of the immune system to respond is reduced  
Intraepithelial 
Within the layer of cells that forms the lining of a part of the body (or a body surface).  
Invasive cancer 
Cancer that has spread from its original site.  
Lesion 
Any abnormal tissue or area, usually caused by disease or trauma.  
Liquid based cytology (LBC)  
It could simply be considered as the medical term for the modern cervical smear test. However, it 
is a technique for processing cervical screening tests for examination in the laboratory. 
Immediate transfer of cells into a liquid preservative when the specimen is collected is 
characteristic of this technique. A sample collected by a clinician form the neck of the womb 
with a little plastic brush, which gently brushes cells from the neck of the womb. The cells are 
rinsed directly into a small jar containing 20 millilitres of preservative fluid. This sample is then 
transported to the laboratory, where it is treated to remove unwanted material. A thin layer of the 
resulting cell suspension is deposited onto a slide and stained. The slide is then examined under 
the microscope by the cytopathologist. LBC reduces the rate of unsatisfactory samples and low 
grade test results, and therefore the need for repeat tests. However, at least 10,000 cells collected 
from the ectocervix and some cells from the endocervical canal are required for the sample to be 
deemed adequate for the test.  
LLETZ 
The acronym for loop electrosurgical excision procedure (Large Loop Excision of 
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Transformation Zone). A fine wire loop (not too large), through which a safe electrical current 
flows to generate heat, is used to remove abnormal tissue of the cervix. It often carried out as an 
outpatient procedure in the colposcopy clinic, under local anaesthesia to numb or freeze the area. 
The LLETZ treatment is different to the laser treatment.  
Neoplasm 
A tumour. It is precisely, an abnormal growth that starts from a single altered cell. A neoplasm 
may be benign (not-cancer) or malignant (cancer). Some benign tumours may be converted into 
a malignant tumours, over time.  
Non-attendees 
Eligible women who do not attend following an invitation for cervical screening. Also called 
defaulters when they failed to respond to repeated screening invitations.  
Pathologist/ Cytopathologist 
A specialised doctor or health professional who diagnoses disease by studying tissue/ cells under 
a microscope.  
Precancerous 
Cells or tissue that is not currently cancerous, but may become so over time.  
Referral 
The process whereby a patient is transferred from one health professional to another, usually for 
specialist advice and/or treatment.  
Risk factor 
Something that increases the chance of developing a disease. In the case of cervical cancer, for 
instance, a woman with a persistent HPV infection is at greater risk of developing cervical 
cancer, particularly if her immunity is poor.  
Satisfactory smear test 
A test that is of sufficient quality for the cytopathologist to issue a valid report.  
SCCRS 
Scottish Cervical Call-Recall System.  
Screening 
The search for disease in people who do not have any symptoms. Screening may refer to 
examination of people with no symptoms, to detect unsuspected disease or condition, such as 
cancer. The same test used for screening may also be used for the diagnosis. For example, the 
HPV test is used as a test of cure after the treatment is completed.  
Screening test 
A means of testing apparently healthy people for presence of a disease or disorder. There are 
more than seven different screening tests available for Down syndrome screening in pregnancy. 
Each test has benefits as well as disadvantages. Combined tests are generally more reliable than a 
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single test. Best suitable screening test/method varies, depending on individual circumstances. 
Liquid based cytology (LBC) and the HPV test are well recognised screening tests available for 
cervical screening.  
Smear 
A cytological preparation made by spreading a specimen (or a part of it) directly onto a glass 
slide.  
Squamous cells 
Flat cells that look like scales or plates through a microscope.  
Transformation zone 
The area (zone) on the cervix where the tall, columnar cell lining of the endocervix undergo 
changes whilst merging with the squamous cell lining of the ectocervix. This is the area which is 
most susceptible to the Human Papillomavirus infection. Hence, it is closely examined during 
colposcopy.  
Under screened women 
Eligible women who do not regularly attend following an invitation for cervical screening 
regularly (e.g. every 3 years). Women whose cervical screening test is overdue.  
Unscreened women 
Eligible women who have never had a cervical screening test.  
Unsatisfactory smear test 
A cervical screening test which cannot be properly assessed microscopically due to poor quality 
or too few cells (less than 10,000 squamous cells and/or no endocervical cells). A repeat test is 
advised.  
Uptake rate (of cervical screening)  
The proportion of women invited to a cervical screening appointment who actually attend.  
 
 
 
 
 
 
 
 
 
 
 
